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Introduction 
The study of genes in health and disease has dramatically increased our understanding of 
human biology. The identification of mutated genes in diseases of the kidney, liver, muscle or 
virtually any other human tissue enabled us to study the function of these tissues at molecular 
and cellular levels. In this dissertation, I describe investigations of the FOXP2 gene, which has 
been found to be mutated in people with speech and language problems. The relation between 
FOXP2 and human language was first discovered nearly 15 years ago (Lai et al., 2001) and 
has been described “as a molecular window into speech and language” (Fisher and Scharff, 
2009). My aim was to change angles and look through that window at the molecular 
mechanisms that precede FOXP2. 
In this chapter I will introduce FOXP2, starting with the discovery of this gene in a family with 
a speech and language disorder. I will describe the expression during development and in 
adult brains and summarize the current knowledge regarding the downstream molecular and 
cellular functions of FOXP2. Next, I will review the current literature on the upstream processes 
that may regulate FOXP2 and show that this aspect of the FOXP2 story is not well understood. 
At the end of this chapter, I will formulate the overarching question and aims of this dissertation.  
Speech and language problems in people with FOXP2 mutations 
In 1990, a large three-generation family was described, of which about 50 percent of the family 
members presented with primary deficits in speech and language (Gopnik, 1990; Hurst et al., 
1990) (Figure 1). A major aspect of the disorder is developmental verbal dyspraxia (DVD), also 
known as childhood apraxia of speech (CAS) (Hurst et al., 1990). The affected members of 
this family, generally referred to as the KE family, have severe problems with articulation, as 
well as poor processing and production of grammatical structures. The articulatory problems 
involve difficulties in performing the rapid coordinated sequences of oral and facial movements 
required for speech (Hurst et al., 1990; Vargha-Khadem et al., 1995). In addition to the orofacial 
motor control problems, the affected members showed problems with language, including 
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reduced ability in applying grammatical rules governing tenses and plurals (Gopnik and Crago, 
1991; Vargha-Khadem et al., 1995) and lower scores on tests for the understanding of 
grammar (Vargha-Khadem et al., 1995). In terms of general cognition, both unaffected and 
affected members scored on the lower side of the normal range of the general population. 
However, a low IQ did not co-segregate with the speech and language disorder (Vargha-
Khadem et al., 1995). It has been argued by some that the speech and language problems in 
this disorder stem from a core deficit affecting the coordination of orofacial motor-movements 
(Vargha-Khadem et al., 2005).  
 
Analyses of the phenotype of the KE family suggested that disrupted cognitive and neural 
motor-control functions underlie the observed problems with speech and language 
development. To identify affected brain regions in the KE family, brain imaging studies were 
performed on healthy and affected members. In structural magnetic resonance imaging (MRI) 
studies the grey matter volumes of the affected family members were compared to the 
unaffected members and an unrelated control group, using voxel based morphometry (Vargha-
Khadem et al., 1998; Watkins et al., 2002; Belton et al., 2003). The volumes of the head of the 
Figure 1: Pedigree of the KE family reproduced from Lai et al. 2001. Affected individuals are indicated by 
filled symbols. Squares are males, circles are females, and a line through a symbol indicates that the person was 
deceased in 2001. 
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caudate nucleus and cerebellar lobule VIIIB were consistently reduced in comparison to control 
groups, whereas the volume of the putamen was increased. In addition, structural differences 
were detected in cortical areas involved in motor control and language processing, including 
increased volumes of the posterior superior temporal gyrus (including Wernicke’s area) and 
angular gyrus, as well as decreased inferior frontal gyrus (including Broca’s area) and 
precentral gyrus. The affected brain structures form cortico-striatal and cortico-cerebellar 
circuits, which are important for planning and exerting motor movements (Middleton and Strick, 
2000). In complementary functional brain studies, the caudate nucleus showed increased 
activity in PET scans performed during word repetition tasks (Vargha-Khadem et al., 1998) 
and the putamen reduced activity in fMRI scans during semantic language tasks, where the 
subjects had to generate verbs in combination to heard nouns (Liegeois et al., 2003; Liegeois 
et al., 2011). In addition, in these studies, under- and over-activation of cortical areas involved 
in orofacial motor control, such as the precentral gyrus, and language-related cortical areas, 
such as the inferior frontal gyrus, were detected (Vargha-Khadem et al., 1998; Liegeois et al., 
2003; Liegeois et al., 2011). Thus, structural and functional aberrations overlap in the basal 
ganglia, cerebellum, motor-control area and language-related cortical areas in the affected KE 
family members. Based on the observed effects in cortico-striatal and cortico-cerebellar 
networks, it has been suggested that the speech and language phenotype result from problems 
in planning and performing sequences of orofacial movements (Vargha-Khadem et al., 2005).  
The mode of inheritance in the KE family suggested that a mutation in a single autosomal gene 
might account for the speech and language disorder of this family. In 1998, the hypothesis of 
an autosomal dominant locus was confirmed by molecular studies, and the location of the 
affected gene was narrowed down to a region on chromosome 7 (Fisher et al., 1998). Using 
genome-wide linkage analysis in the KE family, the authors identified a region on chromosomal 
band 7q31 that perfectly segregated with affection status. Further clues to the location of the 
likely damaged gene came from identification of an unrelated case, referred to as CS (Lai et 
al., 2000), with a strikingly similar phenotype to that seen in the KE family. This child carried a 
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de novo balanced translocation involving reciprocal exchanges between chromosomes 7 and 
5, with one breakpoint directly disrupting a newly identified gene on chromosome 7q31, in the 
region of linkage identified in the KE family. This novel gene, given the name FOXP2, was 
characterized and subsequently sequenced in the KE family, revealing a non-synonymous 
mutation in all fifteen affected family members, which was not present in unaffected members 
or healthy controls (Lai et al., 2001). The disruption of FOXP2 in CS and the KE family strongly 
suggested that disruption of this gene was responsible for their speech and language deficits. 
Indeed, the scientific literature now describes multiple independent cases with speech 
problems and mutations affecting the coding sequence of FOXP2, including deletions of the 
whole gene (Feuk et al., 2006; Zeesman et al., 2006; Lennon et al., 2007; Palka et al., 2012; 
Rice et al., 2012; Zilina et al., 2012), chromosomal rearrangements disrupting the gene (Lai et 
al., 2001; Feuk et al., 2006; Shriberg et al., 2006), missense mutations (Lai et al., 2001; 
MacDermot et al., 2005), a nonsense mutation (MacDermot et al., 2005) and a two-nucleotide 
intragenic deletion that yields a frameshift mutation and premature stop-codon (Turner et al., 
2013). 
Neuronal expression of FOXP2 during development and in adult brains 
The expression of the FOXP2 gene has been described in numerous species. To refer to 
genes and gene products I will use the standardized nomenclature to distinguish between gene 
orthologues and gene products (Wain et al., 2002). Genes, including their mRNA, are generally 
written in italics and the proteins are referred to in non-italic style. Human gene symbols are 
written in all capital letters (eg. FOXP2 gene, FOXP2 protein). According to standard 
nomenclature, I will refer to mouse and rat genes with a starting capital letter (eg. Foxp2), 
zebrafish genes with all lower case letters (foxp2) and zebra finch genes with a starting and 
end capital letter (eg. FoxP2).  
Foxp2 is expressed in multiple tissues including the central nervous system, gut, lung and 
heart (Table 1) (Shu et al., 2001). Expression starts during embryonic development and 
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continues postnatally and into adulthood. Since the speech and language deficits in the KE 
family relate to alterations in the central nervous system (as described above), I focus here on 
reviewing the expression in the brain. First, I describe the expression pattern during embryonic 
development and then continue on to detail the findings for postnatal development and in 
adulthood. In addition I have summarized the findings of the systematic FOXP2/Foxp2 
expression studies in mice and humans in table 1. 
The earliest neural expression of FOXP2/Foxp2 can be detected in the developing medulla 
oblongata at embryonic day 11.5 (E11.5) in mice and at Carnegie stage 23 (CS23) in humans 
(Lai et al., 2003). At later embryonic stages the inferior olives of the medulla oblongata can be 
identified as the FOXP2/Foxp2 positive nuclei. During further embryonic development Foxp2 
mRNA was detected at E12.5 in the lateral ganglionic eminences (GE) and expression 
remained in the GE-derived embryonic and postnatal striatum (Ferland et al., 2003). In 
humans, FOXP2 mRNA can be detected at comparable developmental stages (CS23) in the 
developing striatum (Lai et al., 2003). At E14.5 mRNA is detected in the cortical plate and 
ventricular zone of mice (Ferland et al., 2003; Hisaoka et al., 2010). During embryonic and 
post-natal development cortical mRNA expression can be detected in the cortical plate and 
ventricular zone (Ferland et al., 2003; Lai et al., 2003). However, Foxp2 protein expression 
was only detected in the cortical plate and was absent from the ventricular zone. Similarly, in 
human prenatal brains FOXP2 expression can be detected in the subplate and inner cortical 
plate (Miller et al., 2014). FOXP2/Foxp2 is not expressed in the hippocampal formation 
(Ferland et al., 2003; Lai et al., 2003). Additional forebrain regions that showed strong 
embryonic expression were the developing thalamus and hypothalamus in mouse embryos 
(E13.5) and human foetuses (Ferland et al., 2003; Lai et al., 2003). Further expression was 
detected in the amygdala and olfactory bulb and tubercule of mice (Ferland et al., 2003). In 
addition to forebrain structures, expression was detected in developing mid- and hindbrain 
regions (Ferland et al., 2003; Lai et al., 2003). Midbrain expression was detected in the 
substantia nigra and tectum in mice (E16.5) and human at foetal stage 1 (FS1) (Lai et al., 
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2003). In the hindbrain FOXP2/Foxp2 is expressed in the alar plate of the cerebellum in human 
(CS23) and mice (E13.5) (Lai et al., 2003). With progressing embryonic development the 
strong cerebellar expression was seen to be specific to the Purkinje cell layer in mice (Fujita 
and Sugihara, 2012) and human (Lai et al., 2003). The deeper nuclei of the cerebellum show 
weak FOXP2/Foxp2 expression (Lai et al., 2003; Fujita and Sugihara, 2012). In addition, Foxp2 
expression was found in interneurons of the developing spinal cord (Morikawa et al., 2009).  
Following the developmental expression, FOXP2/Foxp2 remains expressed during adulthood. 
The adult cortical expression is mainly limited to the deeper cortical layer VI (Ferland et al., 
2003; Tsui et al., 2013). In mice, protein expression was also detected in layer V of the motor 
and somatosensory cortex (Hisaoka et al., 2010). Foxp2 expression was absent from the 
hippocampus and the three-layered paleocortex (Ferland et al., 2003). In the basal ganglia 
Foxp2 is highly expressed in the caudate nucleus, putamen and globus pallidus of the striatum 
(Ferland et al., 2003). Adult expression in the thalamus is strong in the auditory relay nucleus 
of mice (Horng et al., 2009) and detectable in neuronal subtypes of the principal visual relay 
nucleus (Iwai et al., 2013). Midbrain expression is detected in the substantia nigra and inferior 
colliculi of the tectum (Ferland et al., 2003). Adult cerebral expression is specifically strong in 
the Purkinje cells with weaker expression in deeper cerebellar nuclei (Ferland et al., 2003; 
Fujita and Sugihara, 2012). Foxp2 expression in the brainstem is limited to the inferior olive 
(Ferland et al., 2003; Fujita and Sugihara, 2012). 
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 Table 1: FOXP2 expression studies in human and mice 
  Structure Detail Species Age Molecule Ref. 
Fo
re
br
ai
n/
te
le
nc
ep
ha
lo
n 
Cortex 
inner intermediate zone of the 
neopallial cortex mouse 
E12.5 to 
E16.5 mRNA 1 
deeper layers of the cortical plate and 
subplate mouse E14.5 to birth 
RNA, 
protein 2 
cortical plate mouse newborn mRNA 3 
restricted to cortical layer VI mouse postnatal 
RNA, 
protein 2 
some layer V expression in very 
medial and posterior aspects of the 
cortex mouse postnatal 
RNA, 
protein 2 
Basal Ganglia 
deep aspects of the ganglionic 
eminence mouse E12.5 
RNA, 
protein 2 
caudate nucleus mouse/human E13.5/CS23 mRNA 3 
caudate putamen mouse/human E16.5/FS1 mRNA 3 
substantia nigra mouse E16.5 mRNA 3 
caudate nucleus mouse newborn mRNA 3 
substantia nigra mouse newborn mRNA 3 
striatum mouse adult 
RNA, 
protein 2 
caudate-putamen, substantia nigra 
and ventral striatum mouse adult 
RNA, 
protein 2 
Olfactory 
system 
olfactory bulb mouse adult 
RNA, 
protein 2 
anterior olfactory nucleus mouse adult 
RNA, 
protein 2 
olfactory tubercule mouse adult 
RNA, 
protein 2 
septal nucleus mouse adult 
RNA, 
protein 2 
Amygdala 
amygdala mouse adult 
RNA, 
protein 2 
Fo
re
br
ai
n/
di
en
ce
ph
al
on
 
Thalamus 
thalamus mouse/human E13.5/CS23 mRNA 3 
thalamus mouse/human E16.5/FS1 mRNA 3 
habenular nucleus mouse E16.5 mRNA 3 
thalamic nuclei mouse newborn mRNA 3 
thalamus (paraventricular, lateral 
posterior, dorsal thalamic nuclei, 
habenula, medial and lateral 
geniculate) mouse adult 
RNA, 
protein 2 
Hypothalamus 
hypothalamus mouse/human E13.5/CS23 mRNA 3 
hypothalamus mouse/human E16.5/FS1 mRNA 3 
zona incerta mouse E16.5 mRNA 3 
hypothalamus, paraventricular 
nucleus mouse adult 
RNA, 
protein 2 
M
id
br
ai
n 
Tectum 
inferior colliculus mouse E16.5 mRNA 3 
inferior colliculus mouse newborn mRNA 3 
superior and inferior colliculli mouse adult 
RNA, 
protein 2 
H
in
db
ra
in
 
Cerebellum 
alar plate of the cerebellar 
primordium mouse/human E13.5/CS23 mRNA 3 
cerebellum mouse E14.5 
RNA, 
protein 2 
developing cerebellum and cerebellar 
nuclei mouse/human E16.5/FS1 mRNA 3 
piriform layer of cerebellum (PCs) mouse newborn mRNA 3 
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PCs of the cerebellum mouse 
mature 
cerebellum 
RNA, 
protein 2 
deep cerebellar nuclei mouse 
mature 
cerebellum 
RNA, 
protein 2 
Brainstem 
precursor of medulla oblongata mouse E11.5 mRNA 3 
midline of the hindbrain human CS18 mRNA 3 
medullary raphe mouse/human E13.5/CS23 mRNA 3 
medulla oblongata mouse/human E13.5/CS23 mRNA 3 
medulla oblongata mouse/human E16.5/FS1 mRNA 3 
lateral lemniscus nucleus mouse E16.5 mRNA 3 
lemniscus nuclei mouse newborn mRNA 3 
inferior olives of the medulla 
oblongata mouse newborn mRNA 3 
inferior olive mouse adult 
RNA, 
protein 2 
  
Spinal cord ventral interneurons of the spinal cord mouse 
E12.5 to 
E16.5 mRNA 1 
  
non-neuronal 
tissue 
intestine mouse 
E12.5 to 
E16.5 mRNA 1 
  heart mouse 
E12.5 to 
E16.5 mRNA 1 
  lung epithelium mouse 
E12.5 to 
E16.5 mRNA 1 
1: Shu et al. 2001 
2: Ferland et al. 2003 
3: Lai et al. 2003 
 
The expression of FOXP2 overlaps with brain regions which have been noted to be structurally 
and functionally aberrant in the KE family, including the basal ganglia, cerebellum and motor 
cortical areas (Lai et al., 2003). Thus, the mutated variant of FOXP2 likely impairs the 
development and function of these brain regions and associated neuronal networks. FOXP2 
expression is present in additional brain regions, which did not show detectable changes in the 
KE family. A single functional copy of FOXP2 may be sufficient for these structures to develop 
and function normally or the influence of FOXP2 mutations may have been undetected by the 
brain imaging studies. In addition, the affected KE family members have no reported problems 
with the lung, heart or digestive tract in which FOXP2 is expressed, suggesting that one 
functional copy of is sufficient in these tissues. In summary, FOXP2 is expressed in neuronal 
subpopulations in multiple distinct brain regions, including the striatum, cerebellum and cortex. 
The affected KE family members show structural and functional aberrations in these brain 
regions, suggesting that mutations of FOXP2 impair the development of cortico-striatal and 
cortico-cerebellar networks. 
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Protein structure and molecular function of FOXP2 
The FOXP2 gene encodes a transcription factor (TF) that binds to DNA and regulates the 
expression of other genes (Lai et al., 2001). The FOXP2 protein contains several known protein 
domains: a glutamine-rich region, a zinc-finger, a leucine-zipper, a forkhead-box (FOX) DNA-
binding domain and a C-terminal acidic tail (Figure 2). The glutamine-rich domain of FOXP2 
contains a short (10 glutamines) and a long (40 glutamines) stretch of contiguous glutamines; 
such polyglutamine tracts are believed to mediate interactions with other proteins (Li et al., 
2004). The leucine-zipper domain of the FOXP2 protein enables it to form homo- and 
heterodimers with other closely related TFs and the dimerized form of FOXP2 binds to DNA 
(Li et al., 2004). Zinc-finger domains can mediate the interaction with a variety of molecules, 
including DNA, RNA, protein and lipids (Laity et al., 2001). The function of the zinc-finger in 
FOXP2 has not been studied in detail and, in one study, the deletion of this domain did not 
affect the regulatory function in vitro (Li et al., 2004). The FOX domain is the defining feature 
of the FOX family of TFs (Katoh and Katoh, 2004; Jackson et al., 2010) and binds to DNA in a 
sequence-specific manner (Stroud et al., 2006; Vernes et al., 2007; Nelson et al., 2013). The 
point mutation identified in the KE family affects the FOX domain and replaces an arginine at 
the amino-acid position 553 with a histidine. The R553H variant of FOXP2 does not bind to the 
consensus target DNA sequence (Lai et al., 2001; Vernes et al., 2006) or alternative motifs 
(Nelson et al., 2013). Therefore, the mutation detected in the KE family disturbs the function 
of the FOXP2 protein.  
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The regulatory effect of FOXP2 on the expression of its direct downstream target genes was 
initially described as repressive (Li et al., 2004). The repressive effect is mediated through 
interactions with histone deacetylase complexes (Chokas et al., 2010). However, accumulating 
evidence shows that FOXP2 protein can act both as repressor and activator of gene 
expression (Vernes et al., 2011; Devanna et al., 2014). The identification of target genes is a 
promising strategy to increase our understanding of the genetic underpinnings of speech and 
language (Vargha-Khadem et al., 1995; Fisher et al., 1998; Lai et al., 2001; Fisher and Scharff, 
2009). Several studies have investigated the target genes of FOXP2 in human neuronal-like 
cells (Vernes et al., 2007; Roll et al., 2010; Walker et al., 2012; Nelson et al., 2013), neuronal 
tissue of mice (Vernes et al., 2011) and foetal human (Spiteri et al., 2007). These studies 
identified hundreds of putative target genes, which partly overlapped between cell type and 
species. Thus, FOXP2 regulates hundreds of genes, which may be regulated in a cell-type 
specific manner. Functional enrichment analysis of the downstream targets identified an 
overrepresentation of genes known to be involved in neurite outgrowth and axonogenesis 
(Spiteri et al., 2007; Vernes et al., 2007; Vernes et al., 2011). To analyse the impact on cellular 
processes, wild-type Foxp2 was compared to aetiological variants in mutant mice. Differential 
Figure 2: Linear protein structure of FOXP2. Schematic representation of the full-length FOXP2 protein 
containing the glutamine-rich region, zinc finger, leucine zipper and forkhead-box domains. The amino acid 
positions of the domains are labelled above the figure. Protein variants, which have been studied in detail, are 
indicated above the schematic representation. The coding change identified in the KE family changes the 
arginine (R) at amino acid position 553 within the FOX domain into histamine (H) (Lai et al., 2001). Another 
aetiological variant, which was identified in another affected family, changes the arginine (R) at position 328 into 
a stop codon (X) (MacDermot et al., 2005). Two amino acid changes at position 303 (T303N) and 325 (N325S) 
occurred in the human genome after the split from the common ancestor with chimpanzees (Enard et al., 2002). 
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analysis of mouse primary neuronal cell cultures, homozygous for the R552H variant, which is 
equivalent to the human R553H variant, revealed that the mutated variant impaired aspects of 
neurite outgrowth, such as the number of branching sites and total neurite length (Vernes et 
al., 2011). The human aetiological variant R328X, which was identified in another family 
(MacDermot et al., 2005) is equivalent to S321X in mice and does not produce a protein 
product, likely due to nonsense mediated-decay at the RNA level (Groszer et al., 2008). In 
utero knock-down in the cortex of mouse embryos revealed that Foxp2 knock-down inhibits 
neuronal differentiation and migration (Tsui et al., 2013). In addition, overexpression of FOXP2 
in human neuronal-like cells increased neurite outgrowth and reduced cell migration (Devanna 
et al., 2014). In conclusion, studies thus far suggest that FOXP2 is able to promote the 
maturation of neurons through the support of neurite growth and reduced mobility. The 
aetiological variants fail to regulate FOXP2 target genes, which results in impaired neuron 
development.  
 
The functions of FOXP2 orthologues in animal communication 
The expression pattern of FOXP2 is highly conserved among vertebrates and has been 
described in fish (Bonkowsky and Chien, 2005; Shah et al., 2006; Bonkowsky et al., 2008; 
Itakura et al., 2008), crocodiles (Haesler et al., 2004), birds (Haesler et al., 2004; Teramitsu et 
al., 2004; Chen et al., 2013), rodents (Ferland et al., 2003; Takahashi et al., 2003; Campbell 
et al., 2009), carnivores (Rowell et al., 2010), monkeys (Takahashi et al., 2008b) and humans 
(Lai et al., 2003). The conserved expression pattern makes animal studies a valuable strategy 
to investigate the neuronal function of FOXP2. Foxp2 knockout and aetiological variants were 
studied in mice to investigate the function of Foxp2 on brain development and behaviour (Shu 
et al., 2005; French et al., 2007; Fujita et al., 2008; Groszer et al., 2008). Mutant mice have 
been generated that carry either a conditional Foxp2 knockout (Foxp2-Flox) (French et al., 
2007), a complete knock-out (Foxp2-KO), a mouse equivalent of the aetiological R553H 
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mutation generated by a transgenic knock-in strategy (Foxp2-R552H-KI) (Fujita et al., 2008) 
or mouse equivalents generated by chemical mutagenesis (Foxp2-R552H-ENU and Foxp2-
S321X) (Groszer et al., 2008). Homozygotes for aetiological mutations and homozygous 
knock-out mice showed delayed development, reduced weight gain, severe motor problems 
and died within 4 weeks after birth (Shu et al., 2005; French et al., 2007; Fujita et al., 2008; 
Groszer et al., 2008). In addition, R552H and S321X homozygous mouse pups and the Foxp2-
flox, after global knock-out, presented with reduced cerebellar volume and intact cerebellar 
cytoarchitecture (Fujita et al., 2008; Groszer et al., 2008). In contrast, the Foxp2-KO 
homozygous mouse pups showed normal cerebellar volume, but abnormal cytoarchitecture of 
the Purkinje cell layer and the external granular layer of the cerebellum (Shu et al., 2005). The 
mouse studies demonstrate that complete loss of wild type Foxp2 is lethal at early post-natal 
ages. In agreement with this finding, only heterozygous FOXP2 mutations have been detected 
in humans.  
Heterozygous mice were fully viable in all studies and did not show gross histological 
anomalies (Shu et al., 2005; French et al., 2007; Fujita et al., 2008; Groszer et al., 2008). 
Heterozygous Foxp2-KO mice presented with mild developmental delay with no differences 
beyond postnatal day 15 (Shu et al., 2005). Mild developmental delay was also observed in 
some Foxp2-R552H-KI heterozygotes (Fujita et al., 2008). However, the Foxp2-R552H-ENU 
heterozygotes did not show developmental delay, but showed impaired long-term depression 
in striatal neurons and reduced motor learning skills in comparison to wild-type littermates 
(Groszer et al., 2008). Because human FOXP2 mutations affect speech and language, the 
vocalizations of the mutant mice have been studied in more detail. Mice vocalize in the 
ultrasonic frequency spectrum and ultrasonic vocalizations of homozygous and heterozygous 
mice have been analysed in neonatal mouse pups, with debated results (French and Fisher, 
2014). The innate nature of neonatal pup calls indicates that differences in mouse pup calls 
are secondary to general developmental delays (Gaub et al., 2010). In male adult Foxp2-
R552H-ENU and Foxp2-S321X mice it was shown that disruption of Foxp2 produced altered 
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ultrasonic vocalizations in response to female/female urine (Gaub et al., 2016). In conclusion, 
mouse studies indicate that heterozygous disruptions of Foxp2 have subtle effects on the 
function and structure of Foxp2 positive brain regions. Furthermore, the aetiological variants 
affect vocalization on cognitive and behavioural levels in adult mice. 
In addition to the expression pattern, the amino-acid sequence of the protein encoded by 
FOXP2 is highly conserved across mammals. The mouse and human orthologues of FOXP2 
vary at three amino acid positions, two of which did arise in the human lineage after the split 
from the chimpanzee (Enard et al., 2002; Zhang et al., 2002) and are present in Neanderthals 
(Krause et al., 2007). The two substitutions are located in exon 7 outside of known protein 
domains (Figure 2). Thus, the impact of the substitutions on protein function is unknown. The 
presence of two amino-acid substitutions in this highly conserved protein suggested that the 
substitutions may be of functional importance to human-specific traits (Enard et al., 2002). To 
test the effect of human FOXP2 on mouse brain development, transgenic mice were generated 
that carried the two human amino-acid changes within the endogenous Foxp2 locus (Enard et 
al., 2009). Heterozygous and homozygous mice were both healthy and fertile. A set of 
phenotypic tests revealed effects only on the explorative behaviour of the homozygous mice. 
In Foxp2 positive brain regions, the dopamine levels were reduced and medium spiny neurons 
in the striatum grew longer dendrites and exhibited increased long-term depression. In a follow-
up study, FOXP2 positive neurons in cortical layer VI and the thalamus also showed increased 
neurite length (Reimers-Kipping et al., 2011). Thus, the human-specific protein-coding 
changes of FOXP2 could have improved the connectivity of cortical basal-networks, which may 
impact on cognition and behaviour. Indeed, it was further shown that the partially humanized 
mice have improved declarative learning, as compared to wildtype littermates, which was 
assessed in a T-maze paradigm with spatial cues (Schreiweis et al., 2014). The humanized 
mice were also faster in switching from declarative to procedural learning. Taken together, the 
findings suggest that the two amino acid changes, acquired during human evolution, alter the 
connectivity of neuronal networks and may have improved sensorimotor learning processes.  
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The conserved expression pattern and protein structure of FOXP2 suggested that FOXP2 
function is not only involved in human speech but may underlie animal communication. Results 
supporting this hypothesis were obtained in studies conducted in zebra finch songbirds. Zebra 
finches learn their songs from a tutor by imitation of the song structure. During the learning 
process, the structure of the produced song varies during acquisition and stabilizes over time 
to mimic the tutor song structure. The zebra finch orthologue of FOXP2, referred to as FoxP2, 
is strongly expressed in striatal nucleus area X, which is important for song learning (Haesler 
et al., 2004; Teramitsu et al., 2004). FoxP2 expression in this area was shown to change during 
the vocal learning period in juvenile zebra finches (Haesler et al., 2004). Knockdown of FoxP2 
in area X disrupted the ability of juvenile zebra finches to copy the tutor song, resulting in 
incomplete and inaccurate production of song syllables (Haesler et al., 2007). To study the 
effects of FoxP2 in adult zebra finches, the expression of FoxP2 in area X was compared 
between males singing to a female (directed singing) and in the absence of a female 
(undirected singing). The expression was found to be downregulated during undirected singing 
of male zebra finches, as compared to non-singing males, indicating the regulation of FoxP2 
expression during vocal behaviour (Teramitsu and White, 2006; Miller et al., 2008). In addition, 
during directed singing the expression levels remained constant, indicating that the regulation 
of FoxP2 also depends on the social context (Teramitsu and White, 2006). Analysis of the 
neuronal song control circuits further indicated that FoxP2 knockdown alters the signalling 
between area X and connected brain regions, which has been shown to be caused by 
decreased dopamine signalling in area X (Murugan et al., 2013). Thus, striatal expression of 
zebra finch FoxP2 is dynamically regulated during vocal communication, dependent on the 
social context, and plays important functional roles in mediating plasticity of song structure.  
Mouse studies investigating the functions of Foxp2 in auditory networks detected differential 
expression in the auditory nucleus of the thalamus in response to auditory input (Horng et al., 
2009). Hence, dynamic expression of Foxp2 can be detected in mammals. Moreover, 
aetiological Foxp2 mutations have been suggested to impair auditory-guided motor learning in 
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mice (Kurt et al., 2012). Taken together, the dynamic regulation of Foxp2 in the thalamus may 
contribute to motor learning in mammals. As no techniques are available to study gene 
expression in a non-invasive way, the active regulation of FOXP2 expression in post-natal 
human brains has not been studied.  
 
Regulation of FOXP2 expression 
Signalling pathways upstream of FOXP2 
FOXP2/Foxp2 can be used as a molecular marker for specific neuronal populations, such as 
for cortical layer VI neurons (Chen et al., 2005; Hisaoka et al., 2010) or neurons derived from 
induced pluripotent stem cells (iPSC) (Bickenbach et al., 2013; Espuny-Camacho et al., 2013; 
Belinsky et al., 2014; Raitano et al., 2015). Consequently, temporal changes in Foxp2/FOXP2 
expression have been described for these neuronal populations. One study investigated the 
effect of histamine and expression of histamine type 1 receptor expression on the developing 
rat cortex (Molina-Hernandez et al., 2013). Histamine-signalling is active during embryonic 
neurodevelopment and regulates the proliferation of neuronal stem cells (Panula et al., 2014). 
Panula et al. used Foxp2 as a marker for postmitotic deep layer cortical neurons and measured 
the expression in cultured neurons isolated from rat embryos. The authors found that after 
histamine treatment the proliferation of Foxp2-positive cells increased and that this effect was 
dependent on histamine receptor 1.  
Cultured neurons derived from human iPSCs can differentiate into FOXP2 positive neuronal 
populations, using specific cell culture conditions and supplements (Bickenbach et al., 2013; 
Espuny-Camacho et al., 2013; Chen et al., 2014; Raitano et al., 2015). For example, treatment 
of cultured neurons with Noggin, a signalling protein important for embryonic development, 
produced neurons with a cortical phenotype and a subpopulation of FOXP2 positive cortical 
neurons (Espuny-Camacho et al., 2013). Thus, the upstream signalling pathways that may 
activate FOXP2 expression can be studied in cultured human neurons. So far, the studies that 
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exploit human iPSC-derived neurons use FOXP2 as a neuronal marker and do not investigate 
the signalling cascades that lead to FOXP2 expression. Accordingly, increased FOXP2 
expression has been described in cultured neurons derived from patients with bipolar disorder 
(Chen et al., 2014) and reduced expression in frontotemporal dementia (Raitano et al., 2015). 
The nuclear factors and transcription factors that may have mediated the differential 
expression, and possibly regulate FOXP2, were not investigated.  
Transcription factors indicated to regulate FOXP2 
Gene regulation in response to developmental programs or environmental cues is mediated 
by TFs. The identification of upstream TFs is, therefore, a valuable approach to identify the 
mechanisms preceding FOXP2 expression. The activation of FOXP2 expression during 
development is of specific importance to understand the complex expression pattern. Co-
expression of TFs, which may indicate positive regulation, has been described in different 
tissues and species. Table 1 shows a selection of co-expression studies, which include the 
FOXP2 gene and other TFs. The co-expression of the listed TFs was determined on mRNA 
and/or protein levels. The co-expression of two TFs can suggest hypotheses about their 
function and relation, but experimental evidence for the interaction is required. The direct 
regulation of FOXP2/foxp2 has been studied in detail for pax6 (Bonkowsky et al., 2008) and 
lef1 in zebrafish (Coutinho et al., 2011) and for POU3F2 in human cell lines (Maricic et al., 
2013).  
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Table1: Co-expression of Transcription factors with FOXP2   
Transcription 
Factor Species Brain structure Molecule Publication 
Atoh1 mouse spinal cord protein (Miesegaes et al., 2009) 
Dlx5 monkey, rat amygdala, striatum mRNA (Kaoru et al., 2010) 
Ebf1 monkey, rat striatum mRNA (Kaoru et al., 2010) 
emx1 zebrafish embryonic telencephalon mRNA (Shah et al., 2006) 
Foxp1 mouse hypothalamus, subthalamic nuclei protein (Skidmore et al., 2008) 
Foxp1 monkey, rat striatum, nucleus accumebens, thalamus 
mRNA, 
protein 
(Takahashi et al., 
2008b; Kaoru et al., 
2010) 
FOXP1 songbird striatum, thalamus, inferior olive mRNA, protein 
(Teramitsu et al., 2004; 
Mendoza et al., 2015) 
Foxp4 rat ganglionic eminence, embryonic thalamus, amygdala, cortex mRNA 
(Takahashi et al., 
2008a) 
FOXP4 songbird 
adult: Purkinje cells, thalamus, 
striatum, inferior olive; embryonic: 
ganglionic eminence, cortical plate, 
thalamus 
mRNA, 
protein (Mendoza et al., 2015) 
Gli1 mouse amygdala protein (Carney et al., 2010) 
lef1 zebrafish embryonic tectum, mid-hindbrain boundary mRNA (Bonkowsky et al., 2008) 
Lhx1/Lhx5 mouse spinal cord protein (Miesegaes et al., 2009) 
Lmx1b mouse hypothalamus, subthalamic nuclei protein (Skidmore et al., 2008) 
Lmx1b rat pons protein (Miller et al., 2012) 
Meis2 monkey, rat amygdala, nucleus accumbens, island of calleja, striatum mRNA 
(Takahashi et al., 
2008b; Kaoru et al., 
2010) 
Pax6 monkey, rat amygdala, striatum mRNA, protein (Kaoru et al., 2010) 
PBX3 monkey, rat amygdala, nucleus accumbens, island of caleja, striatum mRNA 
(Takahashi et al., 
2008b; Kaoru et al., 
2010) 
Pitx1 mouse hypothalamus, subthalamic nuclei protein (Skidmore et al., 2008) 
POGZ human inner cortical plate protein (Willsey et al., 2013) 
Tbr1 mouse cortical layer VI protein (Hisaoka et al., 2010) 
TBR1 human inner cortical plate protein (Willsey et al., 2013) 
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One study investigated the regulation of foxp2 by pax6 in zebrafish (Coutinho et al., 2011). 
PAX6 is a TF involved in early neurogenesis and brain patterning. The TF is expressed in the 
developing neocortex, prethalamus and cerebellum (Osumi, 2001). In the zebrafish genome, 
the foxp2 promoter was predicted to contain pax6 binding sites and Coutinho et al. 
demonstrated the binding of pax6 to these sites (Coutinho et al., 2011). The element drove 
reporter gene expression in foxp2-positive forebrain regions of zebrafish embryos. The in vivo 
activity of this enhancer was dependent on pax6 expression. The results suggested that foxp2 
is a target of pax6 and may suggest a link to the biological functions of pax6. Another study 
investigated a link between lef1 and foxp2 in zebrafish (Bonkowsky et al., 2008). lef1 is a 
transcription factor that regulates gene expression in response to WNT signalling. This 
signalling pathway is important for cell-to-cell communication and the patterning of the central 
nervous system during embryonic development. The authors characterized the expression of 
lef1 and foxp2, and detected temporal overlap in the tectum and mid-hindbrain boundary in 
developing zebrafish embryos, suggesting that lef1 might regulate foxp2. To test if there was 
a direct regulatory effect, the authors ran in silico searches for lef1 binding sites near the foxp2 
gene in the zebrafish genome and then determined if these elements drive gene expression in 
embryonic zebrafish (Bonkowsky et al., 2008). Two of the predicted elements showed in vivo 
enhancer activity and overlapped with foxp2 expression. These findings suggested that these 
two enhancers regulated foxp2. The fact that foxp2 is a direct downstream target of lef1 
suggests that foxp2 may be regulated by WNT-signalling.  
Another regulatory relationship was suggested by investigating genetic changes, which 
occurred in humans during recent evolutionary periods (Krause et al., 2007; Maricic et al., 
2013). Parts of the FOXP2 locus seem to have undergone positive selection after humans split 
from Neanderthals. The positive selection was determined by the presence of modern human 
alleles, which are fixed or occur at high frequency in humans and are absent in the Neanderthal 
genome. Positive selection of these alleles could indicate that they are relevant for FOXP2 
function in humans. One such human-specific substitution, which is located in intron 8 of 
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FOXP2 and occurred at an evolutionary conserved site, was predicted to reduce the binding 
of POU3F2. Indeed, POU3F2 protein was shown to bind stronger to the Neanderthal allele 
than to the human allele. In addition, the putative surrounding regulatory element carrying the 
human allele showed reduced reporter gene expression in response to POU3F2 
overexpression compared to the element carrying the Neanderthal allele. However, the 
measured reporter gene expression was dependent on an additional viral enhancer, 
suggesting that the tested regulatory element does not act as an independent enhancer. In 
accordance to this, the element did not drive gene expression in transgenic mice. The study 
by Maricic et al. suggests that POU3F2 regulates the expression of FOXP2 via an evolutionary 
conserved site and that this regulatory interaction is reduced in humans.  
Genetic variation and the regulation of FOXP2 
Regulatory genomic elements control the timing and levels of gene expression. Consequently, 
genetic changes in regulatory elements may alter gene expression and contribute to normal or 
pathogenic phenotypic variation. The majority of trait-associated single nucleotide 
polymorphisms (SNPs) identified in genome-wide association studies (GWAS) are located in 
non-coding regions of the genome (Welter et al., 2014). Thus, associated SNPs near the 
FOXP2 gene may be located within regulatory regions and affect the expression of this gene. 
GWAS studies have identified associations between SNPs located near the FOXP2 gene with 
a number of phenotypes, for example N-glycosylation of immunoglobin (Lauc et al., 2013), 
Crohn’s disease (Julia et al., 2013), lymphoblast cell viability (de With et al., 2015), obesity 
(Kim et al., 2013) smoking behaviour (Argos et al., 2014; Sung et al., 2015). These phenotypes 
have no obvious link to motor-learning or communication. Thus, if the associated SNPs tag 
regulatory regions, they do not seem to underlie FOXP2 regulation in relation to human speech 
and language. 
Candidate genetic association studies have investigated common genetic variants of FOXP2 
in the context of human traits hypothesized to be related to FOXP2 function. To improve the 
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power to detect associations, most studies focused on a limited amount of genetic variants. 
Studies have investigated associations of FOXP2 to auditory-visual hallucinations (Sanjuan et 
al., 2006; McCarthy-Jones et al., 2014), schizophrenia (Tolosa et al., 2010; Spaniel et al., 
2011), ADHD (Ribases et al., 2012), autism (Park et al., 2014), dyslexia (Wilcke et al., 2012), 
brain activation during reading tasks (Pinel et al., 2012) and enhanced language skills 
(Chandrasekaran et al., 2015). The location of associated variants could indicate the presence 
of regulatory elements. However, the low density of genetic markers would not allow for the 
localization of regulatory elements. One study investigated genetic markers at the FOXP2 
locus at high density, looking for association to brain volumes (Hoogman et al., 2014). 
However, Hoogman et al. did not detect significant associations. In conclusion, candidate 
association studies so far do not suggest the presence of regulatory SNPs near FOXP2. More 
importantly, candidate association studies could benefit from including SNPs within regulatory 
regions to improve the identification of genetic variants linked to normal variation in cognitive 
traits.   
Genetic variants in FOXP2 regulatory elements may also contribute to pathogenic variation. 
Chromosomal rearrangements in the vicinity of FOXP2 have been described in clinical reports 
of people presenting with speech impairments (Feuk et al., 2006; Moralli et al., 2015). These 
genetic variants leave the protein coding sequence intact but may alter endogenous 
expression. Chromosomal rearrangements have been detected in cases with speech 
phenotypes similar to that observed in the KE family (Feuk et al., 2006; Adegbola et al., 2015; 
Moralli et al., 2015). Moralli et al. described a child with late development of speech, who 
carries an inversion of chromosome 7 and a breakpoint 200 kb downstream of FOXP2 (Moralli 
et al., 2015). Feuk et al. described a patient with developmental delay with a deletion reported 
to just start at the telomeric end of FOXP2 (Feuk et al., 2006). However, the authors do not 
report the genomic location of the breakpoint. The assumed cause of the patient phenotypes 
is an aberrant FOXP2 expression, caused by deleted or displaced regulatory elements. 
However, the putative regulatory elements were not identified. The identification of these 
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regulatory sequences would help to clinically define these patients and investigate the 
molecular aetiology of the observed phenotype.  
Question and aims of this dissertation 
Research into the function and the downstream molecular pathways of the FOXP2 gene has 
proven to be highly valuable in investigating cognitive traits from molecule to behaviour. 
Similarly, the pathways upstream of FOXP2 promise to increase our understanding of the 
molecular mechanisms underlying speech and language. Consequently, my aim was to 
investigate the regulation of FOXP2 expression in the brain and how the regulatory 
mechanisms may contribute to human cognitive traits.  
One of my aims, which is detailed in chapter 2, was to identify enhancers, which may have 
contributed to the aetiology of delayed speech development in a child with a complex 
chromosomal rearrangement (Moralli et al., 2015). The chromosomal rearrangement included 
an inversion, with a breakpoint near the FOXP2 gene, suggesting this gene was involved in 
the aetiology of the child’s speech phenotype. Using public data and molecular experiments I 
located an enhancer just downstream of the inversion breakpoint, which would not be able to 
regulate the FOXP2 gene in the child. This rare genetic variant allowed me to locate an 
enhancer, which may regulate FOXP2 in healthy individuals. 
In order for enhancers to regulate their target promoters they get into physical contact with the 
promoter. Consequently, my aim in chapter 3 was to identify physical interactions of the 
FOXP2 promoter with putative enhancers in FOXP2 expressing cells. I identified a number of 
putative enhancers in the vicinity of FOXP2, as well as chromatin interactions to the 
neighbouring gene promoter and the 3’UTR of FOXP2.  
Enhancers, like promoters, are the integrative hubs for molecular mechanisms to control gene 
expression during development or in response to environmental stimuli. Thus, my aim in 
chapter 4 was to investigate the genetic pathways that regulate the FOXP2 enhancers. TFs, 
as the effector proteins of signalling pathways, bind to promoters and enhancers. In a reporter 
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gene expression assay I determined the effect of TFs on the enhancers and promoters of 
FOXP2.  
The aim of chapter 5 was to characterize the activity of the most promising enhancers in 
developing and adult brains. I created transgenic mice, carrying the human enhancers to 
investigate the enhancers’ target brain regions and time of activity. In combination with the 
previous chapters, the results combine aspects of the enhancer’s location, the enhancer-
interacting proteins, the brain structure in which these interactions may occur and the change 
in enhancer activity during embryonic and post-natal development. 
Following the results obtained in the earlier chapters, my aim in chapter 6 was to determine 
how the effect of genetic variation within enhancers relates to normal variation in human traits. 
To increase the statistical power of the analysis in this chapter, I analysed 296 
neurodevelopmental enhancers from a public database, which were characterized with the 
same method that I used to study the FOXP2 enhancers in chapter 5. In contrast to the 
approach in chapter 2, where I investigated the rare genetic variation of a single case, chapter 
6 investigated common genetic variants in 13,000 healthy individuals.  
In chapter 7 I will summarize the findings from chapter 2 to 6 and put the results from each 
chapter into relation to each other. The studies of FOXP2 enhancers shed light on the 
upstream mechanism that control this gene and may contribute to the development of FOXP2 
positive neurons and neuronal networks. The combination of the individual chapters enabled 
me to generate new testable hypotheses on the regulation of human FOXP2. 
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Abstract 
Mutations of FOXP2 in 7q31 cause a rare disorder involving speech apraxia, accompanied by 
expressive and receptive language impairments. A recent report described a child with speech 
and language deficits, and a genomic rearrangement affecting chromosomes 7 and 11. One 
breakpoint mapped to 7q31 and, although outside its coding region, was hypothesised to 
disrupt FOXP2 expression. We identified an element 2kb downstream of this breakpoint with 
epigenetic characteristics of an enhancer. We show that this element drives reporter gene 
expression in human cell-lines. Thus, displacement of this element by translocation may 
disturb gene expression, contributing to the observed language phenotype. 
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Mutations and chromosomal rearrangements that disrupt the FOXP2 coding sequence cause 
childhood apraxia of speech (CAS) [also known as developmental verbal dyspraxia (DVD)], as 
well as expressive and receptive deficits in both spoken and written language (Lai et al., 2001; 
MacDermot et al., 2005; Feuk et al., 2006; Shriberg et al., 2006; Zeesman et al., 2006; Laffin 
et al., 2012; Palka et al., 2012; Rice et al., 2012; Zilina et al., 2012; Turner et al., 2013). Moralli 
et al. recently described a child with a complex chromosomal rearrangement affecting 
chromosome 7 and 11, showing severe speech and language problems, similar to the profile 
typically seen for FOXP2 mutation cases (Moralli et al., 2015). For a detailed description of the 
phenotype we refer to the original clinical report (Moralli et al., 2015). 
The rearrangement in this child consists of a pericentric inversion of chromosome 7 (involving 
7p15 and 7q31) and a translocation between chromosomes 7 and 11 (involving 7q21 and 
11p12) (Moralli et al., 2015). The inversion and translocation breakpoints do not interrupt the 
sequence of any protein-coding genes (Moralli et al., 2015). It is therefore likely that the 
observed phenotype is caused by altered expression of nearby genes. FOXP2 was considered 
the most promising candidate gene, given that haploinsufficency of this gene is known to cause 
speech and language disorders with a similar phenotype (Rice et al., 2012). The chromosome 
7q31 breakpoint was mapped to a position 205 kb downstream of the FOXP2 locus and 22 kb 
upstream of the MDFIC gene (Figure 1A). MDFIC expression was not significantly different in 
fibroblasts taken from the proband as compared to those from unaffected relatives. However, 
Moralli et al. were not able to reliably determine if the breakpoint affected FOXP2 regulation, 
because this gene shows very low expression in fibroblasts. 
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We hypothesized that the inversion in the Moralli et al. case would physically separate the 
FOXP2 coding region from a genomic element with the potential to regulate expression of this 
gene. In this letter we identify and characterize a functional regulatory element located >205 
kb downstream of FOXP2. Our findings suggest a mechanism by which the breakpoint could 
disrupt regulation of FOXP2 expression and provide support for the causative nature of this 
rearrangement. 
 
To determine if the 7q31 breakpoint disrupted a regulatory element we used functional 
genomics data from the ENCODE project (ENCODE, 2012) to predict possible enhancer 
regions that would drive gene expression. Although the reported breakpoint did not directly 
disrupt any predicted enhancers, we identified two possible enhancers that are in close 
proximity. One element, located 2.5 kb downstream of the breakpoint (Element 1), includes a 
region of open chromatin (demonstrated via DNase hypersensitivity across multiple cell lines) 
and carries histone modifications characteristic of an enhancer (H3K4Me1)(Hon et al., 2009; 
Shlyueva et al., 2014) (Figure 1B). This genomic site has been shown to bind several 
transcription factors (TF) in a colorectal carcinoma cell line (TF ChIP; Figure 1B), including 
RNA polymerase II, which is found at transcriptional start sites and active enhancers (Louie et 
al., 2003; Bonn et al., 2012). A second candidate region, located 12 kb downstream of the 
breakpoint (Element 2), shows DNase hypersensitivity and TF binding, but no H3K4Me1 
modifications (Figure 1B). 
 
To test whether these regions could act as enhancer elements we cloned them into a reporter 
construct in front of a minimal promoter and luciferase reporter gene (Figure 1C). The resulting 
constructs were used to measure the ability of each element to drive increased expression of 
the reporter gene in two human cell-lines; HEK293 and SK-N-MC (Materials and Methods see 
Chapter 5). Since both cell lines endogenously express FOXP2 (Schroeder and Myers, 2008) 
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they likely express TFs that are able to regulate this gene. Element 1, which had multiple 
chromatin signatures characteristic of an enhancer, was able to act as a functional enhancer 
in both cell-lines (Figure 1D). In HEK293 cells we observed a 3 fold increase of luciferase 
expression in comparison to the empty vector control. In SK-N-MC cells the luciferase 
expression increased nearly 7 fold as compared to the control. Element 2, which lacked histone 
modifications characteristic of an enhancer, was not able to drive expression in either cell line. 
Therefore, Element 1 is a functional enhancer capable of driving increased gene expression 
in both human cell lines.  
 
Thus, following fine-mapping of the breakpoint by Moralli et al. (Moralli et al., 2015), we were 
able to identify an active enhancer that is displaced by the chromosome 7 inversion. Genome 
wide structural mapping has shown that there are topological boundaries that regulatory 
elements are unlikely to cross (Dixon et al., 2012). Enhancers usually regulate genes that lie 
within the same topological domain, suggesting 4 genes to be potentially regulated by Element 
1; PPP1R3A, FOXP2, MDFIC and TFEC. The inversion separates Element 1 from PPP1R3A 
and FOXP2. Given that PPP1R3A is a muscle specific gene not thought to be expressed in 
the brain (Tang et al., 1991), we consider the disrupted regulatory control of FOXP2 likely to 
be a contributing factor to the phenotype found in this proband.  
 
In sum, our functional data provide experimental support to the theory posited in Moralli et al. 
(Moralli et al., 2015) that the chromosome 7 breakpoint carried by this patient contributed to 
the speech and language phenotype by disrupting the regulation of FOXP2.  
Chapter 2: A chromosomal rearrangement separates FOXP2 from a functional enhancer 
 
37 
 
References 
Bonn S, Zinzen RP, Girardot C, Gustafson EH, Perez-Gonzalez A, Delhomme N, Ghavi-Helm Y, 
Wilczynski B, Riddell A, Furlong EE (2012) Tissue-specific analysis of chromatin state identifies 
temporal signatures of enhancer activity during embryonic development. Nat Genet 44:148-156. 
Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, Hu M, Liu JS, Ren B (2012) Topological domains in 
mammalian genomes identified by analysis of chromatin interactions. Nature 485:376-380. 
ENCODE (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489:57-
74. 
Feuk L et al. (2006) Absence of a paternally inherited FOXP2 gene in developmental verbal dyspraxia. 
Am J Hum Genet 79:965-972. 
Hon GC, Hawkins RD, Ren B (2009) Predictive chromatin signatures in the mammalian genome. Human 
molecular genetics 18:R195-201. 
Laffin JJ, Raca G, Jackson CA, Strand EA, Jakielski KJ, Shriberg LD (2012) Novel candidate genes and 
regions for childhood apraxia of speech identified by array comparative genomic hybridization. 
Genetics in medicine : official journal of the American College of Medical Genetics 14:928-936. 
Lai CS, Fisher SE, Hurst JA, Vargha-Khadem F, Monaco AP (2001) A forkhead-domain gene is mutated 
in a severe speech and language disorder. Nature 413:519-523. 
Louie MC, Yang HQ, Ma AH, Xu W, Zou JX, Kung HJ, Chen HW (2003) Androgen-induced recruitment 
of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci U S 
A 100:2226-2230. 
MacDermot KD, Bonora E, Sykes N, Coupe AM, Lai CS, Vernes SC, Vargha-Khadem F, McKenzie F, 
Smith RL, Monaco AP, Fisher SE (2005) Identification of FOXP2 truncation as a novel cause of 
developmental speech and language deficits. Am J Hum Genet 76:1074-1080. 
Moralli D, Nudel R, Chan MT, Green CM, Volpi EV, Benitez-Burraco A, Newbury DF, Garcia-Bellido P 
(2015) Language impairment in a case of a complex chromosomal rearrangement with a 
breakpoint downstream of FOXP2. Molecular cytogenetics 8:36. 
Palka C, Alfonsi M, Mohn A, Cerbo R, Guanciali Franchi P, Fantasia D, Morizio E, Stuppia L, Calabrese 
G, Zori R, Chiarelli F, Palka G (2012) Mosaic 7q31 deletion involving FOXP2 gene associated 
with language impairment. Pediatrics 129:e183-188. 
Rice GM, Raca G, Jakielski KJ, Laffin JJ, Iyama-Kurtycz CM, Hartley SL, Sprague RE, Heintzelman AT, 
Shriberg LD (2012) Phenotype of FOXP2 haploinsufficiency in a mother and son. American 
journal of medical genetics Part A 158A:174-181. 
Schroeder DI, Myers RM (2008) Multiple transcription start sites for FOXP2 with varying cellular 
specificities. Gene 413:42-48. 
Shlyueva D, Stampfel G, Stark A (2014) Transcriptional enhancers: from properties to genome-wide 
predictions. Nat Rev Genet 15:272-286. 
Shriberg LD, Ballard KJ, Tomblin JB, Duffy JR, Odell KH, Williams CA (2006) Speech, prosody, and 
voice characteristics of a mother and daughter with a 7;13 translocation affecting FOXP2. 
Journal of speech, language, and hearing research : JSLHR 49:500-525. 
Tang PM, Bondor JA, Swiderek KM, DePaoli-Roach AA (1991) Molecular cloning and expression of the 
regulatory (RG1) subunit of the glycogen-associated protein phosphatase. J Biol Chem 
266:15782-15789. 
Turner SJ, Hildebrand MS, Block S, Damiano J, Fahey M, Reilly S, Bahlo M, Scheffer IE, Morgan AT 
(2013) Small intragenic deletion in FOXP2 associated with childhood apraxia of speech and 
dysarthria. American journal of medical genetics Part A 161A:2321-2326. 
Zeesman S, Nowaczyk MJ, Teshima I, Roberts W, Cardy JO, Brian J, Senman L, Feuk L, Osborne LR, 
Scherer SW (2006) Speech and language impairment and oromotor dyspraxia due to deletion 
of 7q31 that involves FOXP2. American journal of medical genetics Part A 140:509-514. 
Zilina O, Reimand T, Zjablovskaja P, Mannik K, Mannamaa M, Traat A, Puusepp-Benazzouz H, Kurg 
A, Ounap K (2012) Maternally and paternally inherited deletion of 7q31 involving the FOXP2 
gene in two families. American journal of medical genetics Part A 158A:254-256. 
 
Chapter 3: Identification of neuronal FOXP2 enhancer contacts 
 
38 
 
Chapter 3 
 
Identification of neuronal FOXP2 enhancer 
contacts in human cell lines  
Chapter 3: Identification of neuronal FOXP2 enhancer contacts 
 
39 
 
Abstract 
Mutations in the FOXP2 gene cause a speech and language disorder, involving developmental 
verbal dyspraxia. The gene is expressed in distinct brain structures, some of which show 
functional and structural aberrations in individuals with FOXP2 mutations. In general, gene 
expression is regulated by genomic elements, such as enhancers, but in the case of FOXP2 
gene, these are mostly unknown.  
In this chapter, I describe the identification of enhancers of FOXP2. To accomplish this, I used 
chromatin conformation capture (3C) in human neuronal-like cell lines. I measured the 
chromatin interactions of the active promoter to distant genomic regions and detected contacts 
to several genomic regions in cells with and without endogenous FOXP2 expression. 
Quantitative analysis revealed that the majority of chromatin interactions were stronger in 
FOXP2 positive neuronal-like cell lines. Using epigenetic data from the Roadmap 
Epigenomics Project, I localized candidate enhancer elements with enhancer specific histone 
marks in neuronal-derived tissue and cell-samples. 
The chromatin interactions of the FOXP2 promoter strongly indicate that the expression of 
FOXP2 is controlled by a number of regulatory genomic regions. I detected promoter-promoter 
contacts to the MDFIC promoter, which suggest that this gene is co-regulated with FOXP2. 
Increased interaction frequencies to the putative enhancers in FOXP2 expressing cell-lines 
suggest that the interactions positively influence the FOXP2 expression. The molecular 
mechanisms that regulate the putative enhancers and their activity in the brain were 
investigated in the subsequent chapters. 
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Introduction 
The basic elements of transcription 
The human diploid genome carries two copies of each gene, one on each autosomal 
chromosome. Yet, the cell may contain thousands of RNA copies of each gene, which are 
further translated into proteins. To achieve this, the genetic information is first converted from 
DNA to RNA in the process of transcription. This process is tightly controlled to determine 
precise levels of gene expression during development and in response to environmental cues. 
In the previous chapter I have identified one enhancer, which may contribute to the expression 
of FOXP2. I have noted that the detection of chromatin interactions between the identified 
enhancer and the FOXP2 promoter would be required to validate this link. The focus of this 
chapter lies on the identification of novel human enhancers of FOXP2, using a technique that 
captures the three-dimensional interactions of chromatin. 
In living eukaryotic cells, the genome is packaged in the form of chromatin, which is a complex 
of DNA associated with proteins and RNA (Cairns, 2009). The functions of chromatin are to 
condense the DNA molecule so that the genome fits into the cell nucleus, to stabilize and 
protect the DNA from damage and to control gene expression (Berger, 2007; Bell et al., 2011). 
At transcriptionally inactive genomic regions the chromatin is tightly packed so that the DNA 
is inaccessible to the transcription machinery. For transcription to be initiated the chromatin 
has to be in an open and accessible state. The exposed DNA sequence allows transcription 
factors (TF), transcription initiation factors and RNA polymerases to bind to the nucleotides 
(Cairns, 2009; Jiang and Pugh, 2009; Spitz and Furlong, 2012). Transcription is initiated at 
gene promoters and the first nucleotide that is transcribed into RNA is called the transcriptional 
start site (TSS). General transcription initiation factors bind to promoter sequences and 
position the RNA polymerase at the TSS (Coulon et al., 2013). Promoter sequences typically 
span 2kb around the TSS (Cairns, 2009). The promoters are bound by TFs, which in turn 
recruit the transcription preinitiation complex and facilitate the positioning of RNA-polymerase 
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at the TSS. This finally results in an increased transcription rate of the target gene (Coulon et 
al., 2013).  
The FOXP2 gene is located on the long arm of chromosome 7 on band q31 and is transcribed 
from the telomeric to the centromeric side of the positive DNA strand (Lai et al., 2001). Four 
TSSs were previously described for FOXP2 (Figure 1), which were experimentally identified 
in human FOXP2 expressing cell lines and tissues (Bruce and Margolis, 2002; Schroeder and 
Myers, 2008). The most distal TSS is located at exon S1, the second TSS is 329 kb 
downstream at exon 1, followed by the third TSS 1.3 kb downstream at exon 1b. The fourth 
TSS is located another 10kb downstream of TSS3 at exon 2. TSS2 and TSS3 show a tissue-
specific activity pattern, with strong activity in the colon, trachea and cervix (Schroeder and 
Myers, 2008). TSS1 and TSS4 were ubiquitously active in FOXP2 expressing cell lines and 
primary human tissue including neuronal tissue (Bruce and Margolis, 2002; Schroeder and 
Myers, 2008). 
 
Enhancers, like promoters, are regulatory sequences that are bound by TFs and increase the 
transcription rate of their target genes, but may be located up to 1 million base pairs distant to 
the promoter (Shlyueva et al., 2014). Enhancers facilitate the assembly of the transcription 
complex by establishing physical contacts with the promoter, which creates a loop of 
Figure 1: Schematic representation of the FOXP2 promoter structure. FOXP2 has four promoter regions, 
each containing one transcriptional start site (TSS). The promoters are indicated by arrows. The distal promoter 
1 contains TSS1 and is located at the start of exon S1 at nucleotide 113,726,365 of chromosome 7 (hg19). The 
middle promoters 2 and 3 are located at exon 2 and exon 1b, respectively. Promoter 4 contains TSS4 and is 
located at exon 2. The distance between neighbouring promoters is given in kilobases (kb). Exon 2 contains the 
first translation start codon. 
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interspacing DNA (Visel et al., 2009; Ong and Corces, 2011). Enhancer contacts to FOXP2 
promoters have not been described in the literature. Following in silico predictions, two studies 
report the identification of enhancer regions near Foxp2/foxp2 in zebrafish (Bonkowsky et al., 
2008; Coutinho et al., 2011) and mouse (Coutinho et al., 2011). In addition, I have identified a 
human enhancer near FOXP2 in the previous chapter 2 (Becker et al., 2015). However, it has 
not been shown that these enhancers make contact with FOXP2.  
Challenges and possibilities to identify regulatory enhancer elements  
The identification of enhancer elements is challenging for several reasons. Enhancer elements 
are relatively small with a size of a hundred to a few thousand base pairs. TFs bind to short 
sequence motifs of about 6-10 nucleotides within the enhancer sequence (Shlyueva et al., 
2014). The TF binding site (TFBS) for an individual TF is degenerate and usually represented 
by one consensus motif. Therefore random sequence motifs that match a TFBS occur 
frequently in the genome without being functional (Wasserman and Sandelin, 2004). The 
functionality of any one enhancer is dependent on the combination of TFBSs. Thus, enhancers 
consist of clusters of short redundant binding motifs, of unknown combinatorial complexity. 
Additionally, enhancers can be distant from the genes that they regulate and the spacing DNA 
between enhancer and gene can be of magnitudes bigger than the size of the enhancer 
sequence itself (Ong and Corces, 2011; Spitz and Furlong, 2012). In short, the problem in 
predicting enhancer sequences is that they are short, redundant and complex clusters of 
sequence motifs, located at unknown distances from the protein-coding gene that they 
regulate. Finally, enhancers are highly context-specific, being active in specific tissues, 
developmental periods and in response to specific environmental stimuli. Therefore, the 
prediction of enhancers is error prone and relies substantially on the incorporation of additional 
data from molecular experiments or evolutionary conservation (Hardison and Taylor, 2012). 
For example, an algorithm for whole-genome identification of enhancers incorporated 
evolutionary constrained and clustered motif occurrence to achieve a predictive rate of only 
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13% (Blanchette et al., 2006). As a consequence, functional molecular data are critical to 
robustly identify enhancer elements. 
Distinctive molecular properties enable the experimental identification of active enhancers. 
One property is that active enhancer regions are in an open chromatin state and accessible 
to TFs and chromatin remodelling complexes (Bell et al., 2011). Because these regions are 
open, they are accessible to DNA degrading enzymes and can be identified as DNase 
hypersensitivity sites (DHS). Another property of active enhancers is that the surrounding 
chromatin is marked by specific histone modifications. Different chemical histone 
modifications mark chromatin with specific functions, such as active enhancers, promoters or 
transcribed regions (Roh et al., 2005; Heintzman et al., 2009; Hardison and Taylor, 2012). 
Thus, genome-wide identification of enhancer-specific histone marks can be used to predict 
enhancer regions. The third property is that active enhancers are in physical contact with the 
promoter of their target genes. The genome-wide identification of active enhancers 
incorporating these experimental data achieves a predictive power of 40 to 80% (Roh et al., 
2005; Heintzman et al., 2009; Cao et al., 2010; Hardison and Taylor, 2012). To reliably define 
regulatory elements of FOXP2 I determined the physical contact of the FOXP2 promoter to 
distant genomic regions as a proxy to identify enhancers.  
Chromatin conformation at the FOXP2 gene locus 
The interaction of distant genomic regions can be measured by chromatin conformation 
capture (3C) (Figure 2) (Dekker et al., 2002). With this technique, the chromatin is chemically 
fixated in its native state in living cells (Figure 2B). Interactions of distant genomic regions are 
cross-linked via intermediate proteins. The chromatin is then isolated from the cells and 
digested with restriction enzymes that recognize short cleavage sites (Figure 2C). The 
digested chromatin is re-ligated within an increased volume to favour proximity ligation of DNA 
strands within one chromatin complex (Figure 2D). The enhancer and promoter sequences 
will form one linear strand of DNA (Figure 2E). As a consequence of this procedure the 
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enhancer and promoter are spaced only by a few nucleotides instead of thousands of 
kilobases. The sequence of the ligation products can be predicted to design specific PCR 
primers, which anneal to the enhancer and promoter sequences. The ligation product can 
finally be detected by regular PCR (Figure 2A, E). In this chapter, I described the use of 3C to 
screen non-coding regions at the FOXP2 locus to identify long-distant enhancer loops at this 
gene.  
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The aims in this chapter were to i) measure the FOXP2 expression status in human neuronal-
like cell lines, ii) determine, which active FOXP2 promoter should act as the anchor point for 
the 3C design, iii) analyse long-range chromatin interactions of this promoter and iv) narrow 
down enhancer elements that can be further studied for their regulatory roles (as described in 
Figure 2: Overview of chromatin conformation capture (3C). A) Regulatory enhancer elements (blue block) 
are distant to their target promoters (red block and arrow) on the linear genome. Specific target primers (black 
arrows) are designed at BglII restriction sites (black dotted lines). B) In the living cells the genome is folded by 
proteins (brown spheres) and active enhancers contact their target promoters. The chromatin packed genome 
is cross-linked in this state and digested with BglII restriction enzymes. B) The genomic fragments and DNA 
overhangs remain in physical proximity. The DNA is diluted to favor proximity ligations between these genomic 
fragments. D) Genomic fragments that were distant in the linear genome are ligated to form one short DNA 
ligation product. E) The primers that were distant in genome amplify from the ligation product. 
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chapters 4 and 5). The enhancer elements are the regulatory hubs that determine when, 
where and how FOXP2 is expressed in the living organism. The identification of FOXP2 
enhancers enabled me to study the genetic pathways that regulate FOXP2 expression 
(Chapter 4), as well as the brain structures and developmental periods in which these 
enhancers may act (Chapter 5). 
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Materials and Methods 
Cell Culture 
HEK293, SH-SY5Y, IMR-32, SK-N-AS and KELLY cell lines were purchased from HPA 
Culture Collections, SK-N-MC and PFSK-1 were purchased from ATCC. GM22647, 
GM22671, GM22731 and GM22737 were obtained from Coriell Cell Repositories. 
HEK293 cells were grown in DMEM (Invitrogen), supplemented with 10% fetal bovine serum 
(FBS; Invitrogen) and 1% penicillin/streptavidin (P/S; Invitrogen). SK-N-MC and IMR-32 cells 
were grown in MEM (Invitrogen), supplemented with 10% FBS, 1% P/S and 2 mM L-glutamine 
(Invitrogen). SH-SY5Y and SK-N-AS were grown in DMEM:F12 (Invitrogen) supplemented 
with 10% FBS, 1% P/S, 2 mM L-glutamine and 1% non-essential amino acids (NEAA; 
Invitrogen). KELLY and PFSK-1 cell lines were grown in RPMI-160 (Invitrogen) medium 
supplemented with 10% FBS and 1% P/S and 2mM glutamine. EBV-cell lines GM22647, 
GM22671, GM22731 and GM22737 were grown in RPMI 1640 supplemented with 15% FBS, 
1% P/S and 2mM L-glutamine. 
Cells were cultured at 5% CO2 and 37°C. The adherent cells HEK293, SK-N-MC, PFSK-1, 
SH-SY5Y, KELLY, IMR-32 and SK-N-AS were passaged at 90-100% confluency. To passage 
cells, they were washed with PBS (Invitrogen) and detached from the cell culture surface using 
trypsin (Invitrogen). Cells were spun at 300g for 4 min to remove the old medium and re-
suspended in fresh medium. Cells were routinely seeded into culture flasks for passaging or 
culture dishes for experiments.  
 
Expression analysis 
Cells were grown to 80-90 % confluency in 6 cm cell culture dishes and lysed in 1 ml of cold 
TRIzol (Life technologies). After repeatedly pipetting the TRIzol over the plate, the solution 
was transferred into Eppendorf tubes and 200 μl of chloroform was added. The mixture was 
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shaken vigorously for 2 min at RT and spun at 12,000g for 5 min at 4°C to separate the 
aqueous from the organic phase. The aqueous phase was transferred to a clean Eppendorf 
tube and mixed with 600 μl of 70% ethanol. The solution was then transferred to an RNeasy 
Spin Column (Qiagen) and the RNA cleaned according to the Qiagen RNeasy Spin Colum 
protocol. To remove genomic DNA on-column DNase digestion (Qiagen) was performed first, 
followed by a membrane washing step and elution in 30 μl of RNase-free water. The amount 
of RNA was quantified using Nanodrop (ThermoScientific) and the RNA quality determined on 
a 1% agarose gel.  
The reverse transcription PCR was performed on 2000ng of RNA using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). In short, the Master Mix (2 μl RT buffer, 
0.8 μl 25x dNTP, 2 μl RT random primer, 1 μl MultiScribe reverse transcriptase and 4.2 μl 
water) was prepared, 2000 ng of RNA added and the volume filled to 20 μl with RNase-free 
water. The used RT-PCR program was 10 min at 25°C followed by 120 min at 37°C and 5 min 
at 85°C. 
To determine the relative amount of cDNA using real-time quantitative PCR (qPCR) the 
sample was diluted 1:10. 2 μl of the cDNA solution (approx. 20 ng of cDNA) was added to 18 
μl of SYBR green (BioRad) Master Mix (10 μl 2x SYBR green, 8.3 μl water, 0.6 μl 10 μM 
forward primer, 0.6 μl 10 μM reverse primer). The primer sequences and coordinates are listed 
in appendix 1, table 1. The 2-step real-time PCR protocol consisted of an initial 3 min 95°C 
denaturation and enzyme activation step, followed by 40 cycles of 95°C denaturation for 15 
sec and annealing/extension at 60°C for 30 sec. After 40 cycles the melt curve was recorded 
in a range from 55°C to 95°C in 0.5°C increments of 10 sec each. The PCR reaction was 
performed in the CFX96 PCR thermocycler (BioRad) and the fluorescence produced by the 
PCR amplification was recorded using the CFX manager software (BioRad). All real-time PCR 
reactions were performed in duplicate. The software automatically corrected for the 
background fluorescence and determined the threshold fluorescence value to derive the 
threshold cycle (Ct), at which logarithmic amplification was reached. The Ct values were 
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recorded for each sample and the Ct values of a GAPDH control PCR were subtracted to 
derive the delta Ct values. 
 
Chromatin immunoprecipitation  
Cells were grown to 80-90% confluency in T-75 cell culture flasks and trypsinized for 1-2 min. 
The living cells were counted (Biorad TC-10) and diluted to 2.5 x 106 cells per ml to a total 
volume of 10 ml (25 x 106 cells total) using fresh medium. 135 μl of 37% formaldehyde was 
added to cross-link cells for 10 min using 0.5% final formaldehyde concentration. The cells 
were shaken for 10 min at room temperature (RT), after which the cross-linking reaction was 
quenched by adding 125 mM freshly dissolved glycine. The solution was shaken for another 
2 min to fully stop the reaction. The cells were spun down at 1600 rpm for 5 min at 4°C and 
the supernatant removed. To clean the cell pellet, 10 ml of cold PBS were added and the 
cross-linked cells re-suspended. The cells were spun again at 1600 rpm for 5 min at 4°C and 
the supernatant decanted afterwards. The pellet was re-suspended in 10 ml lysis buffer (20 
mM HEPES pH7.6; 10 mM EDTA; 0.5 mM EGTA, 0.5% triton-x100) and the solution shaken 
for 10 min at 4°C. Following lysis, the cells were spun down at 1800 rpm for 5 min at 4°C and 
the suspension was decanted. The cell pellet was re-suspended in 10 ml of stop buffer solution 
(50 mM HEPES pH7.6; 150 mM NaCl; 1 mM EDTA; 0.5 mM EGTA) and shaken for 10 min at 
4°C. The solution was spun down again at 1800 rpm for 5 min at 4°C and the suspension was 
carefully removed. The pellet was finally resuspended in 2.1 ml of incubation buffer (10 mM 
Tris pH8.0; 150 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 0.15% SDS; 1% Triton X-100) and 
pipetted into aliquots of 300 μl. The aliquots were sonicated in 1.5 ml Eppendorf tubes in the 
Bioruptor (Diagenode) set to “High” frequency power with cycles of 30 sec on and 30 sec off. 
The number of sonication cycles was determined for each cell type to result in fragments of 
300-800 bp in size. 
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Before setting up the chromatin immunoprecipitation, 30 μl of protein G magnetic beads 
(Invitrogen) were washed three times with incubation buffer, using magnetic racks. After 
removing the supernatant of the third washing step, 40 μl of 5 x incubation buffer was added 
to the beads. To block for unspecific binding 3 μl of a 10mg/μl bovine serum albumin solution 
and to avoid protein degradation 10 μl protease inhibitor complex was added. 2 μl of Pol2RA 
(Diagenode, AC-055-100) and molecular grade water was added to a final volume of 200 μl. 
After adding 100 μl of sonicated chromatin, the immunoprecipitation was rotated overnight at 
4°C.  
The following day the samples were washed six times in total, using each 500 μl of different 
washing buffers; two times using wash buffer 1 (10 mM Tris pH 8.0; 150 mM NaCl; 1 mM 
EDTA; 0.5 mM EGTA; 0.1% SDS; 0.1% DOC; 1% Triton X-100), once using wash buffer 2 (10 
mM Tris pH 8.0; 500 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 0.1% SDS; 0.1% DOC; 1% Triton 
X-100), once using wash buffer 3 (10 mM Tris pH 8.0; 1 mM EDTA; 0.5 mM EGTA; 0.25 M 
LiCl; 0.5% DOC; 0.5% NP-40) and two times using wash buffer 4 (10 mM Tris pH 8.0; 1 mM 
EDTA; 0.5 mM EGTA). To elute the remaining DNA from the magnetic beads, 200 μl of fresh 
elution buffer (1% SDS, 0.1 M NaHCO3) was added and the samples were rotated for 20 min 
at RT. The eluate was taken off the magnetic beads and phenol extracted using 200 μl of 
phenol: chloroform: isoamyl alcohol (SigmaAldrich). The DNA was further purified using 
ethanol precipitation.  
Target DNA fragments were amplified using the iQ SYBR Green Supermix (BioRad). 2 μl of 
the pulled-down DNA sample was added to 18 μl of SYBR Green (BioRad) Master Mix (10 μl 
2x SYBR Green, 8.3 μl water, 0.6 μl 10 μM forward primer, 0.6 μl 10 μM reverse primer). 
Primer sequences for each target fragment are listed in appendix 1, table 2. The 2-step real-
time PCR protocol consisted of an initial 3 min 95°C denaturation and enzyme activation step, 
followed by 40 cycles of 95°C denaturation for 15 sec and annealing/extension at 60°C for 30 
sec. After 40 cycles the melt curve was recorded in a range from 55°C to 95°C in 0.5°C 
increments of each 10 sec. The PCR reaction was performed in the CFX96 PCR thermocycler 
Chapter 3: Identification of neuronal FOXP2 enhancer contacts 
 
51 
 
(BioRad) and the fluorescence produced by the PCR amplification was recorded using the 
CFX manager software (BioRad). All real-time PCR reactions were performed in duplicate. 
The delta Ct values were derived as described before. Input DNA samples were taken from 
the sonicated aliquots, left at 4°C during the chromatin immunoprecipitation and included 
again in the elution step. The delta Ct values were normalized to the promoter region of the 
GAPDH housekeeping gene. 
 
Chromatin conformation capture 
The anchor point primer and TaqMan probe were designed to match the restriction fragment 
that contains the first transcriptional start site (TSS) of the FOXP2 gene. Detection primers 
were designed to be complementary to the 5’ end of restriction fragments so that the 
amplicons of the ligation products were not bigger than 250 bp. Primers were designed to 
match genomic fragments up to 106 kb upstream of TSS1 and 1,391 kb downstream of TSS1, 
spanning a total of 1,497 kb around the FOXP2 gene locus. Within this genomic region, there 
are 428 restriction fragments produced by BglII digestion. Primers were designed for 50 
fragments. The quality of the primers was assessed using standard curves of the PCR reaction 
on 3C samples with standardized concentrations (50ng, 125ng, 250ng, 500ng, 750ng and 
1,000ng). 45 primers passed this quality control step, and they covered fragments of a total 
size of 218 kb. All primers are listed in appendix 1, table 3. 
Cells were grown to 80-90% confluency in T175 cell culture flasks. Cells were trypsinized and 
the number of living cells was determined using TC-10 (BioRad) cell counter. 106 cells were 
transferred into a clean 50 ml falcon tube and fresh medium was added to a total volume of 
10 ml. 135 μl of 37% formaldehyde was added to cross-link cells at a final concentration of 
0.5% formaldehyde. The cross-linking reaction was set to RT. After 10 min the reaction was 
quenched by adding 1.41 ml of freshly dissolved 1 M glycine. The solution was inverted six 
times. The cells were spun down at 1600 rpm for 5 min at 4°C and the supernatant decanted. 
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The cell pellet was re-suspended in 2 ml of cold lysis buffer (50 mM tris, 150 mM NaCl, 5 mM 
EDTA, 0.5% NP-40, 1% triton X-100 and 1x protease inhibitor complex) and set to shake for 
10 min at 4°C. To improve cell lysis the cell solution was transferred to a dounce tissue grinder 
and homogenized on ice with 2 times 15 piston strokes. The cell solution was again transferred 
to a 50 ml falcon tube and pelleted at 1800 rpm for 5 min at 4°C. The supernatant was carefully 
removed and the cell nuclei resuspended in 500 μl 1x restriction buffer 3 (NEB). The solution 
was transferred to 1.5 ml Eppendorf tubes and spun at 600g, for 5 min at 4°C. The supernatant 
was carefully removed and the pellet dissolved in 360 μl H2O and 60 μl of 10x restriction buffer 
3. To loosen the chromatin structure, 15 μl of 10% was added and incubated for 10 min at 
65°C, shaking at 900 rpm on a Thermomixer (Eppendorf). The SDS was quenched by adding 
150 μl of 10% triton X-100 and incubated for 1h at 37°C, shaking at 900 rpm. To control the 
digestion efficiency, 5 μl of the solution was separated as undigested control. To digest the 
chromatin, 400 units of BglII (8 μl of 50,000 U/ml; NEB) were added and the digestion reaction 
was incubated overnight at 37°C, shaking at 900 rpm. The next morning, another 200 units of 
BglII restriction enzyme were added for another incubation period of 1h at 37°C to guarantee 
proper digestion. Digestion efficiency was controlled on a 0.6% agarose gel. A barely visible 
genomic band and high molecular weight smear were indicative of proper genomic digestion. 
Before starting the re-ligation of genomic fragments, the restriction enzyme was inhibited by 
adding 80 μl of 10% SDS and incubating for 30 min at 37°C. The solution was transferred to 
a 50 ml tube and 4,860 μl of H2O and 700 μl of 10X ligation buffer were added. The ligation 
reaction was done in a 10X higher volume to favour ligation events between cross-linked DNA 
strands. The SDS was quenched with 750 μl of 10% triton X-100 and incubated for 30 min at 
37°C. Finally, 50 Units of T4 Ligase (10 μl of 5 U/μl; Roche) were added and incubated at 
16°C overnight. 
To de-crosslink the samples 30μl Prot K (10 mg/ml) was added and incubated overnight at 
65°C. The next morning, remaining RNA was digested by adding 30 μl of 10 mg/ml RNAse A 
(Invitrogen) and incubating for 45 min at 37°C. The DNA was subsequently purified by phenol 
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extraction using 50 ml PhaseLock Tubes (5 Prime). After ethanol precipitation, the DNA pellets 
were recovered in 500 μl TE to give the final 3C library DNA. To determine the concentration 
of the samples, a quantitative real-time PCR was performed, using SYBR green (BioRad). 
The calibration curve was made using human genomic DNA in a range of concentrations from 
0.5 to 250 ng per PCR reaction. The amplified region in the calibration curve is a genomic 
fragment in the promoter region of GAPDH that does not contain a BglII restriction site. 
The TaqMan real-time PCR of 3C ligation products was done using SsoFast Probes Supermix 
(BioRad). Each PCR reaction mixture contained 2,000 ng of 3C library DNA, 1.5 μM TaqMan 
probe, 0.5 μM anchor-point primer and 0.5 μM test primer in a 20 μl total reaction volume. All 
real-time PCR reactions were performed in triplicates. Primer sequences are listed in appendix 
1, table 3. The sequence of the MGB-TaqMan probe is 5’-
GATCTCTTAAACCACTGGGAATTCA-3’ and matches the sequence on chromosome 7 from 
nucleotide 113,732,166 to 113,732,190 (reference genome hg19). The probe was ordered 
from Applied Biosystems. The 2-step real-time PCR protocol consisted of an initial 3 min 95°C 
denaturation and enzyme activation step, followed by 50 cycles of 95°C denaturation for 15sec 
and annealing/extension at 60°C for 30 sec. The PCR reaction was performed in the CFX96 
PCR thermocycler (BioRad) and the fluorescence produced by the PCR amplification was 
recorded using the CFX manager software (BioRad).  
The software automatically corrected for the background fluorescence and determined the 
threshold fluorescence value to derive Ct. The Ct values were recorded for all ligation 
products. The delta Ct value for each ligation product was calculated by subtracting the Ct 
value from the average Ct value of same ligation product in the EBV-lymphocytes. In case that 
the ligation product could not be detected in the EBV cell lines I subtracted a value of 40, 
which is equal to the lowest detected ligation product in the EBV cell lines. From the Ct values, 
I calculated the relative amount of starting ligation products by raising the negative Ct value to 
the power of two, which is a measure of the interaction frequency. To normalize across the 
different cell lines, I determined the ligation product with the lowest variation across all cell 
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lines (primer at -10,574 bp) and normalized to the interaction frequency of this ligation product. 
The final value is the relative interaction frequency. 
Statistical analysis 
Statistical analysis was performed using SPSS software. Statistical significance of the RNA 
polymerase II ChIP-qPCR was assessed using pairwise ANOVA and posthoc Tukey test. 
Statistical significance of the difference of 3C crosslinking frequencies to LBV-lymphoblast cell 
crosslinking frequencies was assessed using two-tailed student t-test. P-values were 
corrected for the amount of investigated interactions (45) using Bonferroni correction. To 
determine interactions with statistically significantly increased crosslinking frequency in 
FOXP2(+) cell lines, pairwise ANOVA was used between neuronal-like cell lines followed by 
post-hoc LSD test.  
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Results 
FOXP2 is expressed in neuronal-like cell lines 
Enhancers positively influence the expression of their target genes. Therefore, I expected to 
FOXP2 enhancers to be active in cells that express this gene. I determined the expression of 
this gene in human neuronal-like cell lines. Human cell lines were used to study enhancers in 
the human genome. Also, cell lines were required to obtain sufficient amounts of chromatin 
for subsequent 3C analysis. I used neuronal-like cells to identify enhancer elements that are 
likely active in neuronal tissue, as enhancer interactions have been shown to be retained in 
cell lines derived from the corresponding tissue (Jager et al., 2015). I screened seven cell lines 
(SK-N-MC, PFSK-1, KELLY, IMR-32, SK-N-AS, SH-SY5Y and HEK293 cells), which are 
commonly used in molecular studies of neuronal genes (Vernes et al., 2007; Schroeder and 
Myers, 2008; Deriziotis et al., 2014). SK-N-AS, SH-SY5Y, IMR-32 and KELLY are 
neuroblastoma cell lines that were derived from different sites of metastasis. SK-N-AS and 
SH-SY5Y were isolated from the bone marrow; IMR-32 from an abdominal mass and for 
KELLY the site of isolation is unpublished (Schwab et al., 1983). SK-N-MC and PFSK-1 are 
malignant primitive neuroectodermal cancer cell lines. SK-N-MC was derived from the supra-
orbital area of a patient with neuroepithelioma (Biedler et al., 1973; Biedler et al., 1978; Dunn 
et al., 1994) and PFSK-1 from a cerebral hemisphere (Fults et al., 1992). HEK293 cells have 
been obtained from human embryonic kidney tissue using adenovirus infection (Graham et 
al., 1977) and have previously been used for the study of FOXP2 and other related neuronal 
genes (Vernes et al., 2006; Schroeder and Myers, 2008; Deriziotis et al., 2014). HEK293, SK-
N-MC and PFSK-1 cells have previously been shown to express FOXP2 (Schroeder and 
Myers, 2008).  
To measure endogenous FOXP2 expression, I harvested RNA from cultured cells and 
performed reverse transcription using an oligo-d(T) primer. The produced cDNA was amplified 
by quantitative PCR. The expression levels were first normalized to GAPDH and compared to 
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expression levels in HEK293, as this cell lined was repeatedly shown to express FOXP2 
(Bruce and Margolis, 2002; Schroeder and Myers, 2008). SK-N-MC cells show comparable 
FOXP2 expression levels to HEK293, whereas the expression in PFSK-1 is significantly lower 
(Figure 3). No mRNA could be detected in KELLY, IMR-32, SK-N-AS and SH-S-Y5Y cells. 
This result shows that three cell lines, which have previously been shown to express FOXP2, 
are indeed FOXP2 positive (FOXP2(+)). The other four cell lines are FOXP2 negative 
(FOXP2(-)). Enhancer regions that increase FOXP2 expression are expected to be active in 
the FOXP2(+) cell lines. 
The promoter at TSS1 is active in FOXP2(+) cell lines 
The FOXP2 gene has four promoter regions (Figure 1), which could be transcriptionally active 
(Schroeder and Myers, 2008). In order to determine the promoter, to which I would measure 
the physical contacts in the 3C experiment, I first investigated the transcriptional activity of the 
four promoters. RNA Polymerase II (PolII) binding occurs at transcriptionally active promoters 
(Bonn et al., 2012; Core et al., 2012; Le Martelot et al., 2012). Therefore, I measured the PolII 
binding at the promoters, using chromatin immunoprecipitation (ChIP). Three primer pairs 
Figure 3: Endogenous FOXP2 expression. Endogenous FOXP2 mRNA expression levels in HEK, 
SK-N-MC, PFSK-1, KELLY, IMR-32, SK-N-AS and SH-SY5Y cells as determined by RT-qPCR. All 
expression levels have been normalized to HEK, which has been repeatedly shown to express FOXP2. 
NTC: no template control.  
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were designed around promoter 1 (Figure4A: Primer 1-3) and promoter 4 (Figure4A: Primer 
8-10) and four pairs around promoter 2 and 3 (Figure 4A: Primer 4-7). The primers were 
designed to anneal just upstream of the TSS as well as 1-2 kb upstream and downstream. At 
active TSSs, the strongest PolII binding can be detected a few nucleotides upstream of the 
TSS (Core et al., 2012). Thus, using multiple primer pairs per promoter I expected a peak 
shape signal around an active TSS.  
 
Figure 4: RNA polymerase occupancy at FOXP2 promoters. A) Schematic representation of the FOXP2 
promoter regions and transcriptional start sites (TSS). The relative location of the qPCR primer pairs is 
indicated by blue lines. The primer coordinates are listed with the primer sequences in appendix1. B) RNA 
polymerase II (PolII) occupancy at the promoter regions of FOXP2 measured by ChIP-qPCR. The relative 
PolII occupancy in HEK293 cells is shown for each primer pair 1-10 and the myoglobin exon 2, which is 
used as a negative control. The RNA-PolII occupancy is normalized to the positive control region at the 
GAPDH promoter. C) The normalized PolII occupancy is shown for the cell lines HEK293, SK-N-MC, IMR32 
and KELLY for TSS1 (primer pair 2), TSS4 (primer pair 9) and myoglobin exon 2. The qPCR was performed 
in duplicate. Significance was determined in comparison to the negative control by an ANOVA followed by 
post-hoc Tukey test.*p < 0.05. 
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First, I mapped the PolII binding at the promoter regions in the FOXP2(+) HEK293 cells. I used 
the promoter region of the GAPDH housekeeping gene, which is active across different cell-
types to normalize the PolII signal between cell lines (Carter et al., 2010). As a negative control 
I included a region at exon 2 of the myoglobin gene, which is inactive in tissue other than 
muscle cells (Paschos et al., 2012; Tarrant-Elorza et al., 2014). I detected significant 
enrichment of PolII with primer pair 2 and 3 (Figure 4B), which are located 130 bp upstream 
and 1094 bp downstream of TSS1, respectively. No primer pair at TSS 2 or 3 was enriched 
for PolII (Figure 4B: primers 4-7). I also observed enriched PolII binding at primer pair 9, which 
is located 152bp upstream of TSS4 (Figure 4B). Thus, polymerase enrichment was detected 
just upstream of TSS 1 and TSS 4, which indicates that they are active in HEK293. I further 
determined PolII binding at promoter 1 and 4 in additional FOXP2(+) and FOXP2(-) cell lines, 
using the primer pairs 2 and 9 as proxy for TSS1 and 4, respectively. At TSS1 -primer 2- the 
two FOXP2(+) cell lines HEK293 and SKNMC showed, compared to the negative myoglobin 
control, 9x and 12x enrichment of PolII binding, respectively (Figure 4C). The FOXP2(-) cell 
lines IMR-32 and KELLY were not enriched for PolII at this promoter. At promoter 4, I detected 
significant PolII enrichment in HEK293 and KELLY. Thus, PolII binding occurs at promoter 4 
in both FOXP2(+) and FOXP2(-) cell lines. PolII occupancy at promoter 1 was only detected 
in FOXP2(+) cells. This finding is in agreement with previous studies, which detected 
expression from this promoter in HEK293 and SK-N-MC (Schroeder and Myers, 2008). In 
conclusion, two FOXP2(+) cell lines show transcriptional activity at promoter 1. Therefore, I 
examined the chromatin interactions to this promoter in the following 3C experiment. 
 
The FOXP2 promoter is in contact with coding and non-coding regions in HEK293 cells 
I designed the 3C experiment to capture chromatin contacts of promoter 1 –the anchor-point- 
to distant genomic regions and thus determine enhancers that interact with this promoter. In 
the 3C protocol, the chromatin is chemically fixed in living cells and subsequently digested 
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with a site-specific restriction enzyme to produce genomic fragments (Figure 2). In silico 
digestion of the genome predicts the produced restriction fragments, including their size and 
sequence. Digestion sites within known functional elements could introduce a bias in the 
digestion and ligation reactions (Naumova et al., 2012). Therefore, I chose the restriction 
enzyme BglII, which produces a digestion fragment on which promoter 1 is located centrally. 
I designed one primer, further referred to as anchor-point primer, to the 3’end of the promoter-
containing fragment (Figure 5B). In addition, I designed a TaqMan probe to match the 
sequence between the anchor primer and the BglII digestion site. Thus, both the anchor-point 
primer and TaqMan probe anneal on the promoter-containing restriction fragment. The use of 
a fluorescent TaqMan probe allowed me to perform high sensitive PCR reactions (Navarro et 
al., 2015).  
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Target primers were designed to match the 3’ ends of the predicted restriction fragments. To 
enable primer design with specific sequence recognition, the 3’ sequence was required to be 
unique. On a genome-wide scale, the frequency of enhancer occurrences declines with the 
distance to gene promoters in a symmetrical distribution (Stranger et al., 2007; Mifsud et al., 
2015). Therefore, I targeted candidate regions around the FOXP2 promoters and the adjacent 
MDFIC promoter and designed several target primers to the genomic regions. One cluster of 
target primers was designed in a 200kb window around promoter 1, spanning the intergenic 
region between PPP1R3A and the first intron of FOXP2 (Figure 5A). The second cluster of 
Figure 5: 3C design at the FOXP2 gene locus. A) The genomic location of the FOXP2 gene. The gene 
structure of FOXP2 and the neighboring genes PPP13RA and MDFIC are shown in dark blue. The anchor point 
primer is located at the distal promoter 1 and shown in red. The 3C target primers, depicted in light blue, were 
designed to cluster at four locations of the gene locus: 1. around the anchor point promoter 1; 2. clustered 
around the downstream promoters 2-4; 3. at the downstream intergenic region between the FOXP2 3’UTR and 
MDFIC, 4. far downstream of the MDFIC gene. B) FOXP2 TSS1 is located at nucleotide 113,726,365 of the 
human genome (hg19). The BglII restriction sites are depicted as black bars. The 3C primers (blue bars) have 
been designed just upstream of the restriction sites. The viewpoint primer (red) is located on the restriction 
fragment that contains TSS1. Note that not all BglII restriction sites are tagged by a 3C primer.  
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target primers was designed in a 100kb window around the three downstream promoters of 
FOXP2. The third cluster was designed to the intergenic region between FOXP2 and MDFIC, 
including the 3’-end of FOXP2. This cluster includes the functional enhancer that I have 
identified in the previous chapter (Chapter 2). In addition, two target primers were designed to 
an intronic region 460kb downstream of the MDFIC gene, targeting an unpublished deletion 
detected in a child with speech problems (personal communication). This patient has problems 
in expressive and receptive language, shows delays in communication skills and carries a 
430kb deletion at the tagged genomic site, which does not overlap coding genes. In total, I 
designed primers that successfully target 45 digestion fragments (Figure 5A). 
To normalize the interactions between cell lines I used lymphoblast cell lines as a control. In 
contrast to neuronal cells, which are derived from the ectoderm, these cells originate from the 
mesoderm (Seremetis et al., 1989). Therefore, I did not expect neuronal enhancer contacts 
within lymphoblast cells. First, I investigated the interaction landscape in HEK293 cells. In 
HEK293 cells I detected nine genomic fragments with significantly increased cross-linking 
frequencies compared to EBV lymphoblast cells (Figure 6B). Eight of nine significant 
interactions were found at local maxima, where the genomic target fragment has a higher 
cross-linking frequency than the neighbouring target fragments. The fragment at the local 
maximum likely contains the enhancer element that mediated the chromatin interaction. The 
eight local maxima in HEK293 cells are located at -37, 70, 330, 346, 604, 706, 772 and 843 
kb relative to FOXP2 promoter 1. This result shows that there are chromatin interactions 
between these regions and the FOXP2 promoter in HEK293 cells, which are not present in 
lymphoblast cells. 
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Figure 6: 3C interaction landscape at the FOXP2 gene locus. Chromatin interactions at the FOXP2 gene 
measured by chromatin conformation capture (3C). A) Schematic representation of the genomic locus of 
PPP1R3A, FOXP2 and MDFIC. The indicated promoters (arrows) and 3’UTR (black bar) align with the data 
points of the following 3C graphs. B-D) The relative interaction frequencies of genomic fragments to the 
promoter viewpoint are shown according to their distance to the TSS. B) Chromatin interactions in HEK293 
and EBV cell lines. C) Interactions in neuronal-like FOXP2(+) cell lines SK-N-MC and PFSK1. D) Interactions 
in neuronal-like FOXP2(-) cell lines KELLY, IMR32, SH-SY5Y and SKNAS. The cross-linking frequencies for 
each target primer were normalized to the cross-linking frequency of the target primer at –11kb (internal 
normalization). The cross-linking frequency for each target primer was normalized to the average cross-linking 
frequency of three measurements each in two EBV lymphoblast cell lines (between sample normalization). All 
interactions were determined in triplicate. Significance was calculated using two-tailed student t-test. P-values 
were corrected for the amount of tested genomic fragments using Bonferroni correction. * p-value < 0.05; ** p-
value < 0.001 
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FOXP2(+) and (-) neuronal-like cells share regions of increased chromatin conformation 
HEK293 cells were derived by viral transformation of embryonic kidney tissue, but their 
morphology and transcriptome suggest a neuronal cell of origin (Shaw et al., 2002). They are 
commonly used as a cellular system to study the function of neuronal genes. To obtain the 
interaction landscape of additional FOXP2(+) cell lines, which originate from neuronal tissue, 
I analysed the chromatin conformation in SK-N-MC and PFSK-1. In SK-N-MC cells I detected 
ten genomic fragments with significantly increased cross-linking frequencies, of which five 
mark local maxima at -39, 13, 53, 330, 706 and 843 kb (Figure 6C). All but one maximum at 
13 kb were previously detected in HEK293 cells. The other significantly increased interactions 
occur at the slope of these peaks at neighbouring genomic regions. Additionally, I detected a 
significantly decreased cross-linking frequency at 604 kb, which showed increased interaction 
in HEK293. In PFSK1 cells I detected four genomic regions with a significant increase in cross-
linking frequency (Figure 6B). Two of these mark local maxima that were detected in SK-N-
MC and HEK293 at 53 and 843 kb. The genomic region at 604 kb, which was significantly 
decreased in SK-N-MC, is significantly increased in PFSK-1. I detected suggestive local 
maxima at genomic regions that were significant in the other two FOXP2(+) cell lines. No 
chromatin interaction was detected between promoter 1 and the gnomic fragment at 823kb 
distance, which contains a previously identified enhancer (Chapter 2).  
To determine differences in chromatin conformation between neuronal-like cells of different 
FOXP2 expression status I measured the chromatin conformation in FOXP2(-) neuronal-like 
cell lines KELLY, IM32, SH-SY5Y and SK-N-AS (Figure 6C). Eleven target fragments show 
significantly increased cross-linking frequencies to the anchor-point fragment in one or several 
cell lines. Eight of these interactions are located at local maxima and three interactions at 
neighbouring genomic fragments. The maxima were located at -39, -37, 70, 346, 604, 706, 
772 and 843 kb. This result shows that chromatin contacts between these regions and the 
FOXP2 promoter are present in the absence of active transcription. The interactions of these 
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regions were previously detected in FOXP2(+) cells, which indicates that chromatin contacts 
are shared between FOXP2(+) and (-) neuronal-like cell lines. 
 
Chromatin interactions are stronger in FOXP2 expressing cell lines 
In total I identified eleven local maxima at which genomic regions contact the FOXP2 promoter 
(Figure 7M). Two maxima, at 13 and 330 kb, were exclusively detected in FOXP2(+) cells and 
nine were not shared with FOXP2(-) cell lines. To determine differences in chromatin 
interactions between FOXP2(+) and (-) cells I compared the relative crosslinking frequencies 
between the neuronal-like cell lines (Figure 7A-L). For each local maximum I calculated the 
pairwise difference between cell lines and determined maxima that were significantly stronger 
in FOXP2(+) cell lines. As expected, the cross-linking frequency at 13 kb is significantly 
stronger in SK-N-MC cells than in any of the FOXP2(-) cells (Figure 7C). Similarly, the 
interaction at region 330 kb is significantly stronger in HEK293 and SK-N-MC (Figure 7F). In 
total, this analysis identified eight genomic regions at -37, 13, 53, 330, 604, 706, 772 and 843 
kb with significantly increased chromatin interactions in at least one FOXP2 expressing cell 
line (Figure 7M). These genomic fragments likely contain FOXP2 regulatory elements with 
enhancer functions. 
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Figure 7: Chromatin interactions at single peak regions. The chromatin interactions of the FOXP2 promoter 
to the local maxima were re-plotted from figure 7B-D. The graphs compare the cross-linking frequencies for 
individual maxima across the investigated cell lines. The cross-linking frequencies for EBV lymphoblast cells are 
shown as black bars. The FOXP2(+) cell lines are shown as blue bars and the FOXP2(-) cell lines as white bars. 
Peak regions are labelled according to their distance to promoter 1: A) -37 kb, B) -39 kb, C) 13 kb, D) 68 kb, E) 
70 kb, F) 330 kb, G) 346 kb, H) 604 kb, I) 706 kb, K) 772 kb, L) 843 kb. Pairwise statistical difference was 
determined using univariate ANOVA followed by post-hoc LSD test. Statistical significant local maxima show 
stronger interaction in one FOXP2(+) cell lines compared to all FOXP2(-) cell lines. The reported p-value 
represents the least significant difference between a FOXP2(+) and FOXP2(-) cell line.  * p-value < 0.05; ** p-
value < 0.001. M) The peak regions are depicted in a schematic representation of the FOXP2 genomic locus. 
Red: Regions with significantly higher interaction frequency in one or more FOXP2(+) cell lines.  
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Local maxima map to regions with neuronal epigenetic marks  
I detected eight chromatin interactions with increased cross-linking frequencies in FOXP2 
expressing cell lines. The interactions occurred between promoter 1 and genomic fragments 
located at a distance of -37, 13, 53, 330, 604, 706, 772 and 843 kb (Figure 7M). The restriction 
digestion in the 3C method produced genomic fragments of 1 to 10 kb. The fragments likely 
contain enhancer sequences, which have a size of several hundred nucleotides. To follow up 
the enhancer function in molecular assays, it was necessary to define candidate enhancer 
elements on the genomic fragments. The next step was to narrow down the enhancer 
elements using histone marks.  
The Roadmap Epigenomics Project mapped histone modifications in human tissue, including 
samples from seven adult brain regions, two foetal brains (male and female), the foetal brain 
germinal matrix, two neurosphere cultures derived from embryonic tissue (cortex and 
ganglionic eminence), two neuronal progenitor cultures (derived from H1 and H9 embryonic 
stem cells) and one neuron culture (derived from H9 embryonic stem cells). Twelve types of 
epigenetic mark (eleven histone modifications and DNase hypersensitivity) were analysed 
genome-wide and the combination of marks was used to predict the function of genomic 
regions in the respective tissue. I used the predicted states in neuronal tissues to analyse the 
genomic fragments with increased interaction frequencies and looked specifically for enhancer 
marks. This allowed me to link the predictive properties of neuron-specific histone marks to 
the enhancer interactions at the FOXP2 promoter.  
I analysed the genomic regions that potentially contain enhancer elements (Figure 11-15). 
The genomic fragment at -37 kb contains a site that is predicted to exert different functions in 
the 15 analysed neuronal samples. In cultured neurospheres, derived from the ganglionic 
eminence and tissue derived from the cingulate gyrus, angular gyrus and dorsolateral 
prefrontal cortex this site was predicted to function as an enhancer (Figure 8: GE derived 
neurosphere, cingulate gyrus, angular gyrus, dorsolateral prefrontal cortex). All predictions 
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overlap at one site, which is located at the 5’-digestion site of the -37kb genomic fragment. 
Hence, this region is located on the restriction fragment that was tagged by the 3C primer 
located at -37 kb. The marked region potentially mediated the observed interaction and was 
regarded as a candidate enhancer for follow-up experiments (Table 1).  
Table 1: Candidate enhancer elements  
Target 3C 
primer Element Size Start (hg19) End (hg19) 
Mean 
PhastCons 
-37 -37 774 113,688,009 113,688,782 0.023
13 13 886 113,732,364 113,733,250 0.203
53 53 1,094 113,781,175 113,782,269 0.045
330 330 1,801 114,056,845 114,058,646 0.891
604 604 2,779 114,327,034 114,329,813 0.692
706 700 3,645 114,424,203 114,427,847 0.146
706 704 4,087 114,427,887 114,431,974 0.192
772 772 2,243 114,495,963 114,498,206 0.048
843 843 3,958 114,568,454 114,572,411 0.111 
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Figure 8: Detail of -39 to -37 kb peak region. The top panel shows the chromatin interactions in EBV-
lymphoblast and the representative SK-N-MC cell line. The alternative grey and white fields indicate the location 
of genomic fragments produced by BglII digestion. The individual data points represent the interactions of 
whole genomic fragments, as meassured with the respective target primers. The x-axis shows the distance of 
the region to the FOXP2 TSS1. Below the graph are annotations aligned to the genomic position 
(chr7:113,684,653-113,691,878 [hg19]). The BglII digestion sites (black lines) and 3C target primers (blue 
lines) are shwon in the first two rows. The predicted functional states from the Epigenome Roadmaps are 
shown for 5 human derived primary neuronal cell-types and 10 neuronal tissues. (light red = poised promoter, 
red = active TSS,  yellow = enhancer activity). The PhastCons Primate track shows the evolutionary 
conservation between 10 primate genomes. The candidate enhancer annotation (black box) shows the 
suggested enhancer element at this peak region.  
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In total, I analysed eight genomic fragments for the presence of enhancer elements (Figure 8-
15) and identified nine candidate enhancers (Table 1). In addition to candidate enhancer 
elements, two interacting fragments contained elements of known function. The genomic 
region at 604 kb contains the 3’-UTR of FOXP2 (Figure 12) and the fragment at 843 kb spans 
the promoter of the adjacent MDFIC gene (Figure 15). Therefore, the FOXP2 promoter seems 
to interact with gene elements that typically function in transctiption initiation and mRNA 
stability, but may also contribute to transcription regulation via long-distance interactions (Jash 
et al., 2012; Sahlen et al., 2015). The evolutionary conservation, which may indicate functional 
importance, of the candidate enhancers varies. The enhancer at 330kb is highly conserved 
(Mean Primate PhastConservation Score: 0.891, Figure 11, Table 1) and may be functional in 
a wide range of related species. The enhancer at -37kb shows low conservation (Mean 
Primate Phast Cons: 0.023, Figure 8, Table 1) and the function may be more specific to 
humans or primates. Thus, the 3C genomic fragments contain promising candidate enhancers 
of variable evolutionary conservation, which may regulate the expression of FOXP2.  
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Figure 9: Detail of 13 kb peak region. See figure 8. Genomic position (chr7:113731832-113743326 [hg19]).  
 
Figure 10: Detail of 53 kb peak region. See figure 8. Genomic position (chr7:113,772,159-113,785,107 
[hg19]).  
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Figure 11: Detail of 330 kb peak region. See figure 8. Genomic position (chr7:114,053,511-114,061,726 
[hg19]). The structure FOXP2 transcripts are shown below, indicating exon 1 at promoter 2 at which the 
transcription of a short isoform starts. 
Figure 12: Detail of 604 kb peak region. See figure 8. The crosslinking frequencies of the representative 
HEK293 cell lines are shown. Genomic position (chr7:114320782-114348266 [hg19]). The structure of the 
FOXP2 transcript is shown below, indicating the 3’-UTR at exon 17. 
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Figure 14: Detail of 772 kb peak region. See figure 8. The crosslinking frequencies of the representative 
HEK293 cell lines are shown. Genomic position (chr7:114,489,942-114,505,170 [hg19]).  
Figure 13: Detail of 706 kb peak region. See figure 8. Genomic position (chr7:114,423,163-114,435,725 
[hg19]).  
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In summary, I detected eleven long-distance interactions to the FOXP2 promoter 1, which is 
active in FOXP2 expressing neuronal-like cell lines. Eight interactions were significantly 
stronger in FOXP2 expressing cells, suggesting that the underlying mechanisms increase 
FOXP2 expression. Finally, I identified nine candidate FOXP2 enhancer elements on these 
genomic fragments, which show typical histone marks of enhancers in neuronal tissue. To 
validate the enhancer function, it is necessary to test elements in molecular assays, as 
described in chapter 4 of this thesis.  
Figure 15: Detail of 843 kb peak region. See figure 8. Genomic position (chr7:114,548,138-114,592,061 
[hg19]). The structure of the MDFIC transcript is shown below.  
Chapter 3: Identification of neuronal FOXP2 enhancer contacts 
 
74 
 
Discussion 
Four transcriptional start sites have been identified for FOXP2 and their activity has been 
determined by a set of human cell lines and tissue samples (Schroeder and Myers, 2008). 
Transcription from TSS1 and TSS4 was shown to be active in neuronal-like cell lines and 
primary neuronal tissue, whereas TSS2 and TSS3 were active in the colon, trachea and cervix 
(Schroeder and Myers, 2008). In agreement with this, I detected PolII occupancy at TSS1 
and/or TSS4 in neuronal-like cell lines. PolII enrichment at TSS4 was detected in HEK293 
cells, as well as in the FOXP2(-) KELLY cells. The PolII enrichment in FOXP2(-) cells could 
indicate a poised polymerase, which may become active in response to external stimuli 
(Gaertner et al., 2012). The published neuronal activity and potentially poised polymerase 
make TSS4 an interesting target for future 3C studies. The promoter of TSS1 was occupied 
exclusively in the investigated FOXP2 expressing cell lines. Therefore, I expected clear 
differences for this promoter between FOXP2(+) and (-) cell lines and prioritized the 
identification of long-range interactions with this promoter. 
I detected an interaction between the FOXP2 promoter and a genomic fragment in the 
proximity of the MDFIC promoter. Promoter-promoter interactions have been identified 
between a substantial amount of co-regulated neighbouring genes in prior genome-wide 
studies (Li et al., 2012; Sahlen et al., 2015). Thus, the promoter-promoter interaction to the 
MDFIC gene suggests that this gene could be co-regulated with FOXP2. The MDFIC gene 
encodes the MyoD family inhibitor domain containing protein, which modulates the 
transcriptional regulation of the WNT and JNK/SAPK pathways (Kusano and Raab-Traub, 
2002; Reiss-Sklan et al., 2009). Strong expression of this gene was described in T-cells 
(Thebault et al., 2000), but the expression of this gene has not been studied in other tissues. 
The Allen Brain Atlas indicates ubiquitous expression of Mdfic in adult mouse brains (Lein et 
al., 2007) and the gene likely overlaps Foxp2 expression, which shows strong expression in 
the basal ganglia, thalamus, cerebellum and neocortex (Chapter 1). Detailed studies of 
MDFIC/Mdfic expression in adult and developing brain tissue would be required to identify 
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neuronal co-regulation with FOXP2/Foxp2 in mouse or human. The co-regulation of genes 
can be investigated in published weighted gene co-expression network analysis (WGCNA) 
data. WGCNA data summarizes the co-regulation of genes across many samples of the same 
origin (Fuller et al., 2007). One WGCNA study indicated that MDFIC and FOXP2 are co-
regulated in the human and primate frontal lobe (Konopka et al., 2012), which may suggest a 
functional interaction in this tissue. MDFIC has established roles in WNT-signalling and prior 
research has shown that downstream target genes of FOXP2 are enriched for function in the 
WNT-signalling pathway (Vernes et al., 2007; Vernes et al., 2011). In addition, foxp2 in 
zebrafish is likely regulated by lef1, a TF that regulates target gene expression in response to 
activation of WNT-signalling. Thus, the co-regulation could further implicate FOXP2 in this 
pathway. 
In this chapter I described how the chromatin interactions were investigated in cell lines of 
neuronal origin. Enhancer interactions have been shown to be retained in cell lines derived 
from the corresponding tissue (Jager et al., 2015). This suggests that the identified interactions 
occur in neuronal tissue. The interactions occurred between genomic elements that show 
histone marks of active enhancers in one or several neuronal tissues (Roadmap Epigenomics 
et al., 2015), further indicating that the identified enhancers show neuronal activity. The target 
tissue and developmental period of the enhancer activity remain to be determined. 
The Roadmap Epigenomics Consortium determined the histone marks in human derived 
cultured neuronal progenitors, derived neurons, neurospheres, whole foetal brains and adult 
neuronal tissue (Ernst and Kellis, 2015). I used these marks to determine regions of 
overlapping function in several neuronal tissues. The example of the region at -37 kb (Figure 
8) shows that histone marks overlap at one narrow region at this locus. Follow-up experiments 
are important to validate the enhancers’ function and to determine tissue-specificity, as 
discussed in subsequent chapters of this thesis. Transgenic mice are commonly used to study 
tissue-specificity during development (Visel et al., 2007; Boyd et al., 2015) and in chapter 5 I 
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used this approach to determine the developmental pattern and adult tissue-specificity of the 
enhancer elements at -37 kb and 330 kb. 
The evolutionary conservation of the candidate enhancers varies from an element that is well 
conserved across vertebrates (Figure 11: 330 kb) to an element that shows low conservation 
even across primates (Figure 8: -37 kb). The presence of conservation at a genomic site can 
be regarded as the result of evolutionary constraint on sequence variety due to its functional 
impact (Ureta-Vidal et al., 2003; Miller et al., 2004). Hence, highly conserved enhancers likely 
drive target gene expression across related species. High conservation of FOXP2 enhancers 
is in agreement with the conserved expression pattern of this gene across different vertebrate 
species (Enard et al., 2002; Ferland et al., 2003; Lai et al., 2003; Teramitsu et al., 2004; Li et 
al., 2007; Campbell et al., 2009). However, I also identified an evolutionary non-conserved 
enhancer in the human gene locus, which may suggest that humans gained regulatory control 
mechanisms. This may indicate that additional brain structures gained FOXP2 expression or 
that the spatio-temporal dynamics of FOXP2 regulation in evolutionarily shared brain 
structures has changed. The evolutionary conserved expression pattern would suggest that 
regulation is more likely to change within shared structures. To explore this possibility, the 
temporal expression changes of FOXP2 need to be studied in more detail across species. 
Examples of dynamic adult expression changes have been found in the thalamus of mice 
(Horng et al., 2009) and striatum of songbirds (Teramitsu and White, 2006). The evolutionary 
conservation of these dynamic expression changes may indicate the presence of absence of 
species-dependent regulatory enhancers. 
On a molecular level, enhancer elements consist of nucleotide sequences that are bound by 
TFs. Knowing the location and sequence of the potential enhancer elements, it is possible to 
investigate TFs that bind to these enhancers. I investigated TF binding in chapter 4 and 
discuss this aspect of the identified enhancer there. 
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The aim of the current chapter was to identify long-distance interactions, which may exert an 
enhancing effect on FOXP2 expression. However, in some cases long-distance interactions 
have been reported to exert a repressive effect (Ogbourne and Antalis, 1998; Maston et al., 
2006). Therefore, the 3C approach could potentially also detect repressing elements, called 
silencers. In comparison to enhancers, I would expect these elements to show strong 
interaction in FOXP2(-) cell lines. However, I did not detect chromatin interactions that were 
stronger in the absence of FOXP2 expression. Silencers may overlap with enhancer 
sequences and the composition of TF binding determines the effect on transcription (Perissi 
et al., 2004). I can therefore not exclude that the identified elements may repress transcription 
under certain conditions. The interaction of the chromatin fragment at 604 kb was significantly 
weaker in the FOXP2(+) SK-N-MC cells compared to the control EBV-lymphoblast cells. As 
SK-N-MC cells express FOXP2, one explanation for the reduced interaction of this region 
could be that a silencing element was actively repelled from the active promoter. However, 
the same interaction was significantly increased in the FOXP2(+) HEK293 cells. Thus, the 
expression status does not distinguish the presence or depletion of this interaction. The 
fragment at 604 kb covers parts of the FOXP2 3’-UTR. At the RNA level, 3’-UTRs are known 
to mediate mRNA transcript stability and translational efficiency (He and Hannon, 2004). 
However, on the DNA level, 3’UTRs have also been found to establish long-distance 
interactions with their gene promoter. The effect of this interaction on gene expression can be 
repressive (Le Cam and Legraverend, 1995; Paul et al., 1998) or activating (Salerno et al., 
2000; Jash et al., 2012). My 3C results show that the 3’-UTR of FOXP2 interacts with the 
promoter both in the absence and presence of expression. To determine the function of this 
element on transcription, it will be necessary to study this element in isolation, using reporter 
gene assays. 
3C is a low-throughput method that requires the manual design for every investigated 
interaction. Therefore, only a limited amount of genomic fragments at the FOXP2 gene locus 
could be studied. As a consequence, long-range interactions to additional enhancers might 
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have been missed. Recent research has shown that the genome is partitioned into topological 
domains (TD) (Dixon et al., 2012). Dynamic enhancer contacts have been shown to occur 
within TDs and not across the topological borders (TB). TBs are reported to be evolutionarily 
conserved (Vietri Rudan et al., 2015) and stable during development (Dixon et al., 2012). 
Therefore, the TBs determined in one cell-type limit enhancer interactions in all or most 
differentiated tissues. All investigated genomic fragments and identified interactions were 
located within the TD that contains the FOXP2 gene. However, the TD of FOXP2 further 
covers the upstream PPP1R3A gene and the downstream genes MDFIC and TFIC. An 
extension of the 3C design, which covers the complete TD of FOXP2, may identify further 
enhancer elements.  
Currently, a broad variety of 3C-based technologies are being developed to identify enhancer 
interactions with higher specificity and sensitivity on a genome-wide scale (Dostie et al., 2006; 
Dekker et al., 2013; Jin et al., 2013; Lefebvre et al., 2013; Nagano et al., 2013). For example, 
capture Hi-C combines high-throughput sequencing technologies with the sensitivity of 
targeted 3C approaches (Jager et al., 2015; Mifsud et al., 2015). Future experiments 
investigating FOXP2 chromatin contacts could aim to identify additional or indeed all long-
distance enhancer contacts within a tissue. Additionally, one 3C based method is capable of 
determining the genome-wide chromatin interaction landscape of single cells (Nagano et al., 
2013). This circumvents the requirement to use cultured cell lines, which I used to obtain 
sufficient amount of chromatin. These approaches have so far focused on animal tissue, or 
non-neuronal human tissue (Dekker et al., 2013; Jin et al., 2013; Nagano et al., 2013; Jager 
et al., 2015; Mifsud et al., 2015; Vietri Rudan et al., 2015). Thus, future studies may identify 
all enhancers of FOXP2 in a cell type-specific manner. 
Enhancer elements have been shown to contain genetic variants that cause, or increase the 
susceptibility to, human disease. For example, rare genetics variants in regulatory regions 
have been linked to autism spectrum disorders (Poitras et al., 2010; Chen et al., 2014). The 
investigation of the here identified enhancer sequences in people with speech and language 
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disorders may reveal rare genetic variants underlying their deficits. In addition, common 
genetic variants within these enhancers may be linked to normal variation in brain structure 
and function (Chapter 6, (Becker et al.)). The catalogue of published genome-wide association 
studies (GWAS) of the National Human Genome Research Institute (NHGRI) collects 
genome-wide associations of common variants from published studies (Welter et al., 2014). 
According to this catalogue associations have been found near the FOXP2 gene locus for 
traits such as smoking behaviour (Argos et al., 2014; Sung et al., 2015), N-glycosylation of 
immunoglobin (Lauc et al., 2013), Crohn’s disease (Julia et al., 2013), lymphoblast cell viability 
(de With et al., 2015) and obesity (Kim et al., 2013). The associated single-nucleotide 
polymorphisms (SNPs), however, are not located within the candidate FOXP2 enhancers or 
the tagged genomic fragments. Thus, so far, no trait-associated SNP has been detected within 
the enhancers. However, the identified enhancers are candidate regions for future association 
studies of common genetic variants in language-related traits. 
This chapter represents the first study investigating long-distance enhancer interactions at the 
FOXP2 gene locus. The identified interactions occurred in neuronal-like cell lines and may 
provide information about the regulatory mechanisms contributing to FOXP2 expression in the 
human brain. The interactions occur between the active FOXP2 promoter to the 3’-UTR of 
FOXP2, the promoter of MDFIC and candidate enhancer elements. The identification of 
candidate enhancers facilitates the study of FOXP2 regulation and enables the identification 
of regulatory genetic variants underlying normal or pathogenic variation. 
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Abstract 
Enhancers and promoters of FOXP2 control the expression of this gene during development 
and in adult tissue. Transcription factors (TF) bind to such enhancers and promoters and 
consequently regulate their activity. Thus, the TFs acting upstream of FOXP2 determine the 
developmental and tissue-specific expression patterns of the gene. However, the TFs that 
regulate the promoters and enhancers of human FOXP2 are largely unknown.  
In this chapter I investigated the in vitro activity of FOXP2 promoters and candidate enhancers 
in human cell lines using a reporter gene assay. One promoter and three enhancers increased 
reporter gene expression in human neuronal-like cell lines. I further tested the effect of TFs 
that had been linked to FOXP2 in prior literature. Using overexpression plasmids in 
combination with the promoter and enhancer reporter constructs I detected regulation by 
FOXP1, FOXP4, POU3F2, LEF1, PAX6, SOX5 and TBR1, as well as auto-regulation by 
FOXP2.  
The presented results demonstrate that FOXP2 is regulated by known TFs and suggest 
upstream regulatory pathways. Auto-regulation of FOXP2 may explain the haploinsuficiency 
effect observed for mono-allelic gene mutations and gives new insight into possible disease 
mechanisms. One enhancer of interest (enhancer 330) is the target of TFs important for 
cortical development and may contribute to FOXP2 expression during cortical development.  
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Introduction 
Transcription factors (TFs) bind to gene promoters and enhancers to activate target gene 
expression. Promoters and enhancers of FOXP2 have been identified (as described in 
Chapter 3), but the TFs that bind to them are unknown. Importantly, TFs are known to be 
effector proteins of signalling pathways and modulate target gene expression in response to 
developmental stimuli or environmental signals. Thus, the response of FOXP2 expression to 
developmental programs and cellular processes is mediated by TFs. The aim of the current 
chapter was validate candidate enhancers identified in the previous chapter 3 and to identify 
TFs that regulate the enhancers and promoters of FOXP2 to help reveal the genetic pathways 
acting upstream of this gene 
Promoters and enhancers of FOXP2 are the target sites for transcription factor binding 
Two promoters of FOXP2, promoter 1 and 4, are active in neuronal cell lines and neuronal 
tissue (Bruce and Margolis, 2002; Schroeder and Myers, 2008) (Chapter 3, Figure 1). In the 
prior work of this thesis I identified one enhancer downstream of an inversion breakpoint of a 
complex chromosomal rearrangement in a child with speech and language problems matching 
those seen in cases of FOXP2 mutation (Moralli et al., 2015). As described in Chapter 2, the 
inversion separates the enhancer from the rest of the FOXP2 locus, suggesting that disrupted 
regulation by this enhancer contributes to the observed phenotype in the affected child (Becker 
et al., 2015) (Chapter 2). In addition, in Chapter 3 I used chromatin confirmation capture to 
identify genomic regions, which interacted with promoter 1 in neuronal-like cell lines, and could 
thus be considered as candidates for novel enhancers (Chapter 3). Enhancers and promoters 
function independently from their genomic context. Their activity does not depend on their 
orientation, distance to the target promoter and are thus able to regulate the expression of 
reporter genes in vitro (Pennacchio et al., 2013). The activity of these elements can therefore 
be studied in cultured cell lines (Deriziotis et al., 2014). 
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Prioritizing putative upstream TFs of FOXP2 
The study of enhancers in cell cultures further allows the investigation of their response to 
transcription factors (TFs). TFs are expressed or activated under specific conditions and fulfil 
varying functions. A group of TFs function in the general regulatory machinery of the cell, such 
as EP300 (Chan and La Thangue, 2001) or CTCF (Ong and Corces, 2014). In contrast, some 
TFs are expressed at specific developmental periods and regulate, for example, the body 
patterning during embryonic development (Wellik, 2007). Other TFs are active in response to 
environmental cues (Sheng and Greenberg, 1990) or environmental stress (DiDomenico et 
al., 1982; Kothary et al., 1989) and regulate the rapid response to the changed conditions. 
Certain TFs are expressed in a cell-type specific manner to establish the identity of 
differentiated cells. The TFs that regulate FOXP2 can therefore shed light on the 
developmental programs upstream of FOXP2 expression. However, the prediction of TFs that 
regulate a gene is challenging, as the genome encodes about a thousand TFs, of which 
approximately 300 are expressed in each foetal and neuronal tissue (Fulton et al., 2009; 
Vaquerizas et al., 2009). The combination of TFs found in every cell is variable and determines 
the final regulatory output. In the same way, the promoter and enhancer activity depends on 
the combination of binding TFs. The co-expression of TFs with FOXP2 is a limiting factor for 
positive regulatory interactions and has been described for a number of TFs (Introduction: 
Figure 1: Schematic of FOXP2 promoter and potential enhancer elements. Schematic representation 
of the FOXP2 promoters and enhancers in the human genome on chromosome 7 band q31.1. The figure 
shows position 113,500,000 to 114,600,000 in reference human genome (build hg19). The candidate 
enhancers, identified in Chapter 2 and 3 of this thesis, are depicted as red blocks and the promoters are 
shown in blue. The FOXP2 and MDFIC genes are shown in black.  
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Table1). I selected a number of TFs that were linked to FOXP2 in the literature to test their 
regulation of the promoters and enhancers that I had identified. 
Regulatory TFs described in the literature 
In zebrafish embryos lef1 is co-expressed with foxp2 in the tectum, mid-hindbrain boundary 
and hindbrain (Bonkowsky et al., 2008). Bonkowsky et al. further showed that knock down of 
lef1 abolishes foxp2 expression in the tectum and mid-hindbrain boundary, suggesting that 
foxp2 is regulated by lef1. LEF1 is the effector TF of the WNT-signalling pathway, which is 
involved in neurogenesis and regulates neural differentiation in the neocortex, cerebral cortex, 
hippocampus, olfactory bulb (OB) and thalamus (Oliva et al., 2013). In mouse embryos Lef1 
is expressed in the mesencephalon and diencephalon and involved in brain patterning (van 
Genderen et al., 1994). Strong adult expression of Lef1 is detected in the thalamus, 
hypothalamus, hippocampus and OB (Shimogori et al., 2004; Oliva et al., 2013). If human 
FOXP2 enhancers are regulated by LEF1, this could indicate the regulation of FOXP2 by 
WNT-signalling pathways and associated biological processes. In addition, prior studies in 
human and mouse foetal tissue indicate that FOXP2/Foxp2 regulates gene if the WNT-
signalling pathway (Spiteri et al., 2007; Vernes et al., 2011). Thus, the expression of FOXP2 
may regulate the balance of WNT-signalling pathway.  
Pax6 co-expression with Foxp2 was described in the amygdala and striatum of non-human 
primates and rats (Kaoru et al., 2010). In zebrafish pax6 is co-expressed with foxp2 in the 
embryonic telencephalon and knock-down of pax6 reduces levels of foxp2 in this brain region 
(Coutinho et al., 2011). In addition, Coutinho et al. detected reduced Foxp2 expression in the 
telencephalon of mouse embryos carrying a Pax6 null mutation, suggesting that this regulatory 
interaction is evolutionary preserved. PAX6 has a dual role in maintaining neural stem cell 
identity and promoting neural differentiation (Osumi, 2001; Osumi et al., 2008) and is 
expressed in the developing and adult neocortex, amygdala, basal ganglia, thalamus, OB and 
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cerebellum (Duan et al., 2013). In humans, PAX6 promotes the transition from embryonic stem 
cells to the neuronal lineage (Zhang et al., 2010).  
Another TF has been proposed to directly regulate FOXP2 expression in humans: POU3F2. 
The regulation of FOXP2 by POU3F2 was tested on a putative regulatory element of FOXP2. 
This element is located in an intron, within a bigger genomic region that carries a significant 
excess of genetic variants that arose in the human genome after the split from a common 
ancestor with Neanderthals (Maricic et al., 2013). The element did not show in vitro activity in 
human cell lines or in vivo activity in transgenic mouse embryos (Chapter 1). However, a 
human-specific genetic variant, which is conserved among vertebrates, was predicted to 
decrease the binding of POU3F2. In agreement with the prediction, the human variant 
decreased enhancer activity in response to POU3F2 overexpression, in comparison to the 
Neanderthal variant. Thus, the study by Maricic et al. suggests that vertebrate FOXP2/Foxp2, 
including that of the Neanderthals, was regulated by POU3F2 and this regulatory interaction 
is reduced in humans. POU3F2 has been shown to regulate other TFs in retinoic acid-treated 
embryonic stem cells and was suggested to be an upstream effector of the retinoic acid 
signalling pathway (Urban et al., 2015). Similarly, FOXP2 can promotes neural differentiation 
in combination with retinoic acid signalling in human cell lines (Devanna et al., 2014). Thus, it 
is conceivable that FOXP2 could be one of the POU3F2 target genes that promote retinoic 
acid induced neural differentiation. 
Another candidate TF, which may regulate FOXP2, is TBR1. This TF has been shown to either 
activate or repress the expression of its target genes (Hevner et al., 2001; Bedogni et al., 
2010; Han et al., 2011). TBR1 expression overlaps with FOXP2 expression in post-migratory 
neurons of the embryonic cortical plate in humans (Willsey et al., 2013) and mice (Hisaoka et 
al., 2010). In the adult mouse cortex Tbr1 is co-expressed with Foxp2 in cortical layer VI 
(Hevner et al., 2001; Bedogni et al., 2010; Hisaoka et al., 2010). FOXP2 and TBR1 physically 
interact with each other and may co-regulate target genes in a cooperative manner (Deriziotis 
et al., 2014). In the cortex of Tbr1 knock-out mice the expression of Foxp2 is significantly 
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decreased in the caudal area of layer VI (Bedogni et al., 2010). This could suggest that TBR1 
enhances FOXP2 expression in the cortex. Another TF that is co-expressed with TBR1 in the 
cortex is SOX5 (Rouaux and Arlotta, 2010). During embryonic development SOX5 is 
expressed in the ganglionic eminence and cortical plate and regulates cortical neuron subtype 
specification (Lai et al., 2008; Rouaux and Arlotta, 2010). Similar to TBR1, SOX5 can both 
repress (Kwan et al., 2008) and activate target gene expression (Hao et al., 2014). SOX5 and 
TBR1 together determine the subtype-specification of cortico-fugal neurons of cortical layer 
VI (Lai et al., 2008; Greig et al., 2013). TBR1 and SOX5 are therefore promising candidates 
for contributing to the layer specific expression of FOXP2. 
FOXP2 autoregulation and overlapping expression with FOXP family members 
The persistent expression of FOXP2 in adult tissue could suggest that FOXP2 positively 
regulates its expression in a direct auto-regulatory loop (Takahashi et al., 2003; Alon, 2007). 
Direct positive autoregulation is a common mechanism for TFs that maintain cellular identity 
of differentiated cells (Crews and Pearson, 2009). Aberrant auto-regulation in a heterozygous 
mutant could contribute to haploinsufficiency effects (Cook et al., 1998; Bhatia et al., 2013), 
which is interesting in light of suggestions that FOXP2-associated language disorder may be 
a haploinsufficiency syndrome (Zeesman et al., 2006; Palka et al., 2012; Rice et al., 2012).  
The FOXP2 protein forms hetero-dimers with FOXP1 and FOXP4 proteins (Li et al., 2004; Sin 
et al., 2015) and the combination of FOXPs may determine the directionality of the regulatory 
output (Sin et al., 2015). Co-expression of FOXP1 and FOXP2 is well described in the 
thalamus, hypothalamus and basal ganglia of mice, rats, songbirds and monkeys (Skidmore 
et al., 2008; Takahashi et al., 2008b; Kaoru et al., 2010; Mendoza et al., 2015). In the cortex, 
FOXP1 shows strong expression in layer III to layer V, whereas FOXP2 is most strongly 
expressed in cortical layer VI (Ferland et al., 2003). However, some neurons at the transition 
zone express both TFs in mice (Hisaoka et al., 2010). FOXP4 expression is strong during 
development and overlaps with FOXP2 in the ganglionic eminence, cortical plate and 
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thalamus of rats (Takahashi et al., 2008a). In the adult brain the co-expression between 
FOXP2 and FOXP4 was described in Purkinje cells, thalamus, the inferior olive and the 
striatum of rats and songbirds (Takahashi et al., 2008a; Mendoza et al., 2015). Thus, in 
addition to the hypothesis that FOXP2 may autoregulate its own expression, I hypothesize 
that the co-expressed FOXP family members also influence FOXP2 expression. 
In silico prediction of TF motifs in enhancer and promoter sequences  
TFs typically recognize motifs of 6 to 10 nucleotides via their DNA-binding domains (Shlyueva 
et al., 2014). The DNA-binding domain has the capacity to bind motifs of variable sequence 
compositions. Therefore, a TF binds to a range of short motifs of similar nucleotide sequence 
composition. The set of sequence motifs and the frequency of each nucleotide per position 
can be experimentally determined, often by genome-wide binding assays using chromatin 
immunoprecipitation based techniques (Heinz et al., 2010; Zambelli et al., 2013). The TF 
motifs can then be depicted as a consensus motif or position-weight matrix (PWM). The 
consensus motif contains the most frequent nucleotide per nucleotide position. The PWM 
provides a more informative representation of the redundant motif, because it includes the 
frequencies of the four DNA nucleotides A, T, G and C per nucleotide position (Stormo, 2000). 
In experimental studies, TF binding sites (TFBS) are commonly detected at hundreds to 
thousands of regions in the genome. The high number of binding sites enables computational 
algorithms to detect statistically significant motifs, which are represented as PWMs (Heinz et 
al., 2010). The motifs of hundreds of TFs have been characterized in molecular experiments 
and the PWMs are collected in databases, such as Transfac (Wingender et al., 2001), 
HOCOMOCO (Kulakovskiy et al., 2013), Jaspar (Mathelier et al., 2014) and HT-SELEX (Jolma 
et al., 2013). 
The prediction of TFBS in the promoters and enhancers of FOXP2 may validate the presence 
of TF motifs or identify novel TFBS. A number of computational methods aim to predict TF 
motifs in DNA sequences (Wasserman and Sandelin, 2004; Hardison and Taylor, 2012). 
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However, it is estimated that in a genome-wide scan 1,000 false positive predictions would 
occur for every 1 functional TF binding event (Wasserman and Sandelin, 2004) and the 
predictive power of these methods is dependent on additional information, such as epigenetic 
marks (Roh et al., 2005; Visel et al., 2009), evolutionary conservation (Woolfe et al., 2005; 
Stark et al., 2007; Visel et al., 2008) or prior molecular experiments (Grice et al., 2005; 
Hardison and Taylor, 2012). The enhancers that I identified at the FOXP2 locus were narrowed 
down by chromatin conformation capture and histone marks, such that the real positive 
prediction rate is expected to be increased in these sequences. However, it remains crucial to 
determine the direct interaction of the TF and the sequences. 
The aim of this chapter was to identify the upstream regulatory TFs and pathways that regulate 
FOXP2. To achieve this i) I characterized the basal in vitro activity of promoters and candidate 
enhancers, defined in prior chapters, ii) tested the regulation of selected TFs from the 
literature, and iii) and identified TF motifs in the enhancer and promoter sequences. 
Chapter 4: Upstream regulatory mechanisms at the promoters and enhancers of FOXP2 
 
93 
 
Materials and Methods 
Molecular cloning of FOXP2 regulatory sequences 
I designed primers to amplify the regulatory sequences of FOXP2, as indicated in chapter 3. 
Primer sequences are listed in appendix 2, table 1. The position and size of the cloned 
sequences are listed in table 1 and table 2. For a detailed description of the included 
sequences, conservation and functional annotations, see chapter 3. All primers were designed 
using the Primer 3 software (Untergasser et al., 2012) and the hg19 reference genome 
sequence. Promoter sequences were designed around the transcriptional start sites. 
Downstream of the transcription start site (TSS), I included the 5’untranslated region of the 
adjacent exon excluding the annotated start codon or splicing site. Upstream of the TSS, I 
included evolutionarily conserved stretches, as a proxy for promoter proximal regulatory 
sequences. . 
The regulatory sequences were cloned from healthy human genomic DNA (Novagen) using 
Advantage 2 Polymerase kit (Clontech). The PCR program started with a 95˚C activation step 
and was followed by 10 cycles of denaturation (95˚C – 15 sec) and annealing/elongation 
(64˚C) and another 25 cycles of denaturation (95˚C – 15 sec) and annealing/elongation (68˚C). 
The annealing/elongation times were calculated and changed for each PCR product (1min 
extension per 1 kb). The PCR program included a final elongation step of 68˚C for 7 min. The 
PCR samples were run on a 1% agarose gel to identify the sizes of the products. PCR products 
that had the correct nucleotide size were excised from the gel and extracted using the Wizard 
SV Gel and PCR Clean-Up System (Promega). The DNA was eluted in 20 μl water and 1 μl 
of the product was subsequently used in the TOPO TA Cloning Kit (Invitrogen) to insert the 
PCR product into the pCR2.1-TOPO vector. After leaving the TOPO reaction for 1h at room 
temperature, the plasmids were transformed into subcloning-efficient DH5α competent cells 
(Invitrogen). The cells were incubated over night at 37˚C. Individual clones were picked the 
next day and grown in liquid cultures for at last 12 h at 37˚C. The plasmids were harvested 
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from the liquid cultures using the PureYield Plasmid MiniPrep System (Promega). At this stage 
all inserts were sequenced, using the Sanger method, to confirm the sequence identity and to 
select clones without amplification errors. 
The primers were designed to add KpnI and XhoI restriction enzyme sites to the 5’ and 3’ends 
of each PCR product, respectively. The regulatory sequence-containing pCR2.1-TOPO 
plasmids and the pGL4.23 destination vector (Promega) were double-digested with KpnI and 
XhoI high-fidelity digestion enzymes (New England Biolabs) for 1 h at 37˚C. The digestion 
reactions were run on a 1% agarose gel to identify the DNA fragments with the desired product 
sizes. The fragments were excised from the gel and extracted using the Wizard SV Gel and 
PCR Clean-Up System (Promega). The digested destination vector and genomic fragments 
were mixed for a ligation reaction using 25 ng of the destination plasmid and the insert 
fragment in a 1:3 or 1:6 ratio. For the ligation I used 0.5 μl of 5U/μl T4 ligase (Fermentas) and 
incubated the reaction over night at 16˚C. The next day 1 μl of ligation product was used to 
transform subcloning-efficient DH5α cells (Invitrogen). The cells were incubated on LB agar 
plates overnight at 37˚C and the next day single clones were picked and transferred into liquid 
LB medium. The liquid cultures were incubated for at least 12 h at 37˚C and subsequently 
harvested. Small liquid cultures (2ml) were harvested using the PureYield Plasmid MiniPrep 
System (Promega) and big cultures (125 ml) were harvested using the PureYield Plasmid 
MaxiPrep System (Promega). The eluates of each mini and maxi prep were sequenced to 
confirm the sequence identity of the pGL4.23-cis-regulatory-element plasmids. 
Luciferase assay of enhancer and promoter elements 
HEK293 or SK-N-MC cells were seeded in 96-well cell-culture plates. Cell-culture conditions 
and growth medium for both cell lines were as described in chapter 2. One day after seeding 
the cells in the 96-well plates were transfected using Genejuice transfection reagent (Merck 
Millipore). Each well was transfected with 48 ng of pGL4.23-CRE construct and 6 ng of pGL4-
hRLuc-TK control plasmid (Promega), which expresses renilla luciferase under the control of 
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a herpes-simplex-virus thymidine kinase promoter element. After 2 days the cells were 
washed once with PBS and lysed in 20 μl Passive Lysis buffer (Promega) and shaken for 20 
min at room temperature. Luciferase enzymatic activity reactions and fluorescence recordings 
were performed in a TECAN Infinite 2002 (TECAN) coupled with two software controlled 
injector pumps using the iControl (TECAN) software package. The program was set up to 
inject 50 μl of freshly prepared luciferase reaction reagent II (Promega), shake for 1 sec, wait 
for 1 sec and then measure firefly luciferase fluorescence for 10 sec. To measure the control 
renilla fluorescence the program was set up to inject 50 μl of freshly prepared Stop & Glo 
reagent (Promega), shake for 1 sec, wait for 1 sec and measure fluorescence for 10 sec. The 
automated filter settings of the software program were used to avoid detection overflow. The 
fluorescence of the firefly luciferase was divided by the fluorescence of the renilla luciferase 
to normalize the measurement and derive the relative luciferase activity. The promoter and 
enhancer activities were each detected in triplicate. 
Co-transfection experiments of pGL4.23-CRE and transcription factor over-expression 
plasmids were done in HEK cells according to the above described protocol. Each well was 
transfected with 2 ng of pGL4.23-CRE construct, 2 ng of pGL4-hRLuc-TK control plasmid 
(Promega) and 10 ng of the individual TF plasmid. SOX5 was cloned into pcDNA4. pcYFP-
POU3F2, pcDNA4-TBR1 and pYFP-CASK plasmids were kindly made available by Pelagia 
Deriziotis. pcDNA4-PAX6 was kindly made available by Dario Gajewski. pcDNA4-FOXP2, 
pcDNA4-KE, pcDN4-FOXP1 and pcDNA4-FOXP4 were kindly made available by Sonja 
Vernes (Vernes et al., 2006). pBABE-LEF1 was obtained from Addgene (Nguyen et al., 2009). 
In silico motif scanning 
I downloaded the PWMs from HOCOMOCO (Kulakovskiy et al., 2013), Transfac (Wingender 
et al., 2000; Wingender et al., 2001), Jaspar (Mathelier et al., 2014) and HT-SELEX (Jolma et 
al., 2013) and filtered those that were annotated to exist in humans. I retrieved the regulatory 
sequences from the UCSC genome browser and loaded them into the MotifLab program 
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environment (Klepper and Drablos, 2013). I scanned the regulatory sequences using 
MotifScanner (Coessens et al., 2003). This algorithm was developed to identify TFBS in single 
sequences. The algorithm calculates the probability that a TF motif is present above a 
sequence background model. I used nucleotide-triplet frequencies generated from all human 
promoter sequences as background model. Hence, I penalized motifs that bind frequently at 
unrelated regulatory regions and favoured motifs that occur infrequently. The motif scan was 
run, using a prior of 0.1 to allow for some degeneracy in the retrieved motifs. The prior can be 
set between 0 and 1, where 0 does not allow for any variation from the consensus motif. The 
predicted binding sites, including the motif short name, binding score and binding position 
within the regulatory elements were extracted for analysis. 
Statistical analysis 
Statistical analysis was performed in SPSS software. To determine the basal activities, the 
relative luciferase activities of the promoter/enhancer elements were compared to the 
luciferase activity of the empty (minP) construct within the same cell lines. Statistical 
significance of the basal enhancer and promoter activities was assessed using pairwise 
ANOVA and posthoc LSD test. The luciferase activity after TF overexpression was compared 
to luciferase activity after co-transfection with the empty pcDNA4 overexpression vector. The 
difference between empty plasmid and TF overexpression was assessed per individual 
element and the statistical significance was assessed using two-way ANOVA and post-hoc 
LSD test.  
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Results 
Promoter 1 drives reporter gene expression in neuronal-like cell lines 
To study the activity of FOXP2 promoters, I cloned the promoter sequences into reporter gene 
plasmids directly upstream of the firefly luciferase reporter gene (Figure 2). The cloning 
strategy included promoter sequences up- and downstream of each TSS. Downstream of each 
TSS, I included the 5’-untranslated region excluding the following start codon or splice site. 
Upstream of each TSS, I cloned 2-4 kb to include regions of high evolutionarily conservation 
(primate PhastCons >0.9). I could not obtain promoter 4 as amplification was unsuccessful. 
The cloned elements are listed in table 1.  
 
Table 1: Cloned promoter sequences
Element Size [bp] Start (hg19) End (hg19)
Promoter 1 1,791 113,724,817 113,726,609
Promoter 2 4,104 114,051,220 114,055,324
Promoter 3 1,006 114,055,454 114,056,459
 
The promoter-luciferase constructs were transfected into HEK293 and SK-N-MC cell lines. 
Both cell lines endogenously express FOXP2 and show RNA-polymerase II binding at 
promoter 1, which is an indicator of transcriptional activity (Chapter 3). Therefore I expected 
promoter 1 to be active. Two days after transfection, I quantified the firefly luciferase 
expression using a dual-luciferase system. The relative luciferase expression was normalized 
to the expression from a minimal TATA-box containing promoter. Promoter 2 and 3 did not 
Figure 2: Cloning strategy for promoter and enhancer luciferase constructs. The promoter elements 
were cloned to replace the minimal promoter (minP) of the luciferase construct. The enhancer elements 
were cloned upstream of the minimal promoter.  
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show increased luciferase activity in HEK293 or SK-N-MC (Figure 3A), suggesting they are 
inactive. This is in line with previous PolII binding assays (Chapter3: Figure 4). Promoter 1 
significantly increased luciferase expression in HEK293 (5-fold) and in SK-N-MC cells (80-
fold). The stronger signal in SK-N-MC cells is in agreement with the earlier finding that PolII 
binding at promoter 1 was more enriched in SK-N-MC (Chapter 3: Figure 4). Thus, the 
luciferase results demonstrate that promoter 1 is active in both cell lines and may be more 
active in SK-N-MC. 
 
  
Figure 3: Basal promoter and enhancer activity in HEK293 and SK-N-MC. Relative luciferase activity 
of A) promoter and B) enhancer elements driving firefly luciferase gene expression in HEK293 and SK-N-
MC cells. The promoter and enhancer constructs were each transfected with a control element expressing 
the renilla luciferase under the control of a viral promoter. The firefly luciferase signal was divided by the 
renilla signal to derive the relative luciferase activity. The activity for each luciferase construct was 
normalized for the activity observed for the minimal promoter (minP). The constructs were measured in two 
independent experiments in a total of six biological replicates, with the exception of elements 346, 700, 704 
and 843 in SK-N-MC cells, which were measured in one experiment in three biological replicates. The 
significance of the difference between each construct and minP was determined with two-way ANOVA and 
post-hoc LSD testing. *p<0.05, ** p< 0.001. The significance in HEK293 is labeled with red asterisks; the 
significance in SK-N-MC is labeled with blue asterisks.   
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Enhancer elements increase luciferase reporter gene expression 
To test the candidate enhancers of FOXP2 in the dual-luciferase assay I cloned the candidate 
enhancer sequences upstream of the minimal promoter (Figure 2, Table 2). I cloned the 
candidate enhancers located 37, 330, 700, 704 and 843 kb distance from promoter 1 (Chapter 
3). Due to time restrictions, the candidate enhancers at 13, 53, 604 and 772 kb were not 
included. Element 815 was defined in chapter 2 and there referred to as “enhancer 1”. The 
data for enhancer 815 were collected in the experiments for chapter 2 and are also included 
here to enable direct comparison of enhancer activities. The plasmids were transfected into 
HEK293 and SK-N-MC cells and reporter gene expression was measured. In HEK293 cells 
the enhancers at 37, 330 and 815 kb significantly increased the reporter gene expression, 
compared to the minimal promoter (Figure 3B). The other elements did not show significant 
effects. In the SK-N-MC cell line I detected increased reporter gene expression for the 
elements at 37 and 815 kb. The luciferase results demonstrate that elements at 37, 330 and 
815 kb are functional enhancers that drive gene expression in vitro. The elements 700, 704 
and 843 show no enhancer activity in HEK293 and SK-N-MC. The activities of elements at 13, 
53, 604 and 772 kb remain to be determined. 
 
Table 2: Cloned enhancer sequences
Elementa Size [bp] Start (hg19) End (hg19)
Enhancer 37 774 113,688,009 113,688,782
Enhancer 330 1,801 114,056,845 114,058,646
Enhancer 700 3,645 114,424,203 114,427,847
Enhancer 704 4,087 114,427,887 114,431,974
Enhancer 815 832 114,541,370 114,542,201
Enhancer 843 3,958 114,568,454 114,572,411
aThe Name of the enhancer element indicates the distance to P1 in kb
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FOXP2 overexpression indicates autoregulation at promoters and enhancers 
To test the autoregulation of FOXP2, I co-transfected the luciferase constructs with a plasmid 
overexpressing the FOXP2 gene. As a control, the luciferase plasmids were co-transfected 
with an empty pcDNA4 plasmid. Co-transfection experiments were conducted in HEK293 cells 
because the transfection efficiency rate in SK-N-MC was below 20%, which did not guarantee 
co-transfection of luciferase and expression plasmids in the same cells. FOXP2 
overexpression increased the activity of promoter1, element 37 and 815 (Figure 4). Also, the 
previously inactive promoter 2 and element 700 show significant increases of luciferase 
expression. To determine if the increased enhancer activity is mediated by the direct binding 
of FOXP2 to DNA, I tested two aetiological variants of FOXP2 that have been found in families 
with monogenic forms of speech and language disorder (Lai et al., 2001; MacDermot et al., 
2005). The R553H variant of FOXP2 was found in the large multigenerational KE family and 
has an amino-acid substitution in the DNA-binding domain (Lai et al., 2001). The R553H 
variant is unable to bind to the consensus binding motif (Vernes et al., 2006). The other variant 
is R328X, which was found in a smaller family and lacks the DNA-binding FOX domain due to 
a premature stop codon (MacDermot et al., 2005) and cannot bind to DNA (Vernes et al., 
2006). As expected, the two variants fail to increase the activity of promoter 1, promoter 2 and 
enhancers 37, 700, 815. The effects at promoter 1 and enhancer 37 are severely reduced for 
the R328X variant, but remain significant in comparison to control. The reduced promoter and 
enhancer activities suggest that the enhancing effects observed for wild-type FOXP2 were 
mediated by direct DNA-binding. In agreement with this finding, a FOXP2 binding site within 
promoter 1 has been detected by chromatin immunoprecipitation in human neuronal-like cell 
lines SK-N-MC and PFSK-1 (Nelson et al., 2013). The aetiological variants increased the 
activity of enhancer 330. The increase could be mediated by protein-protein interactions to 
other DNA-binding factors, which in turn regulate the enhancer. In sum the luciferase results 
suggest that FOXP2 is capable to auto-regulate via direct DNA-binding to its regulatory 
elements.  
Chapter 4: Upstream regulatory mechanisms at the promoters and enhancers of FOXP2 
 
101 
 
 
The FOXP family members regulate FOXP2 enhancers and promoters 
FOXP2 can form hetero-dimers with the family members FOXP1 and FOXP4 to regulate target 
gene expression (Li et al., 2004; Sin et al., 2015). Because FOXP2 regulates its enhancers 
and promoters, it is conceivable that FOXP1 and FOXP4 have similar effects at the same 
elements. After co-transfection of the luciferase constructs with a pcDNA4-FOXP1 
overexpression plasmid, I detected increased activity for promoter 1, enhancer 37 and element 
815 (Figure 5), which were also up-regulated by FOXP2 (Figure 4). Overexpression of FOXP4 
increased the activity of enhancer 37 and decreased enhancer 330 (Figure 5). Thus, the three 
FOXP family members increase enhancer 37. Promoter 1 and enhancer 815 are up-regulated 
by both FOXP1 and FOXP2. The activity of enhancer 330, which was increased by the 
aetiological FOXP2 variants, was repressed by FOXP4. The results suggest that the FOXPs 
show regulatory effects at the same set of enhancers and the promoter 1. 
Figure 4: Assessing auto-regulation of FOXP2 via promoter and enhancer constructs. Relative 
luciferase activity of promoter and enhancer elements after co-transfection with FOXP2, FOXP2-R553H or 
FOXP2-R328X in HEK293. The promoter and enhancer constructs were co-transfected with a control 
construct expressing the renilla luciferase. The cells were additionally co-transfected with an empty pcDNA4 
control, or FOXP2 overexpression plasmid. The firefly luciferase signal was divided by the renilla signal to 
derive the relative luciferase activity. The activity for each luciferase construct was normalized for the activity 
observed for the minimal promoter (minP). Each combination was tested in three biological replicates. The 
statistical significant of the TF overexpression effect was determined with two-way ANOVA and post-hoc 
LSD testing for each construct. P-value: *<0.05, ** < 0.001.  
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The transcription factors LEF1 and PAX6, but not POU3F2, regulate human FOXP2 
promoter and enhancers in vitro 
I tested the promoter and enhancer constructs in combination with an overexpression vector 
of LEF1. The WNT-signalling pathway is active under normal culture conditions in HEK293 
cells (Oloumi et al., 2006). Therefore, I expected LEF1 to be active in the absence of further 
stimulation of the WNT-pathway. I co-transfected the regulatory elements with a pBABE-LEF1 
overexpression plasmid and determined the luciferase activity. I observed significantly 
increased activity of promoter1, promoter 3, enhancer 37 and enhancer 330 (Figure 6). Thus, 
LEF1 activates regulatory elements of FOXP2. Since LEF1 is the downstream effector of the 
WNT-signalling pathway, these findings suggest that the promoter and enhancer activities 
might be controlled by WNT-signalling.  
Figure 5: Regulatory effect of FOXP1 and FOXP4 on promoter and enhancer constructs. Relative 
luciferase activity of promoter and enhancer elements in HEK293 cells. The promoter and enhancer 
constructs were each transfected with a control construct expressing the renilla luciferase under the control 
of a viral promoter. The cells were also transfected with a control, FOXP1 or FOXP4 overexpression 
plasmid. The firefly luciferase signal was divided for the renilla signal to derive the relative luciferase activity. 
The activity for each luciferase construct was normalized for the activity observed for the minimal promoter 
(minP). Each combination was tested in three biological replicates. The statistical significant of the TF 
overexpression effect was determined with two-way ANOVA and post-hoc LSD testing for each construct. 
P-value: *<0.05, ** < 0.001.  
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Next, I tested the overexpression of PAX6, which reduced the activity of promoter 1 and 
element 815 (Figure 7A). The luciferase activity remained stable for the other regulatory 
elements. The luciferase results of promoter 1 and element 815 indicate a repressive effect of 
PAX6 on FOXP2 expression. This is inconsistent with published results from mouse and 
zebrafish embryos, where Pax6/pax6 increased Foxp2/foxp2 expression (Coutinho et al., 
2011). Despite the difference in direction of effect, my luciferase findings do support the 
hypothesis that FOXP2 is under control of PAX6 in humans.  
I went on to investigate a prior suggested link between POU3F2 and FOXP2 by testing the 
regulatory elements that I had identified, in combination with POU3F2 overexpression. I co-
transfected the luciferase constructs with pYFP-POU3F2 and an empty pcDNA4 plasmid as 
Figure 6: Regulatory effect of the WNT-signalling TF LEF1 on promoter and enhancer constructs. 
Relative luciferase activity of promoter and enhancer elements in HEK293 cells. The promoter and 
enhancer constructs were each transfected with a control construct expressing the renilla luciferase under 
the control of a viral promoter. The cells were also transfected with a pcDNA4, or LEF1 overexpression 
plasmid. The firefly luciferase signal was divided by the renilla signal to derive the relative luciferase activity. 
The activity for each luciferase construct was normalized for the activity observed for the minimal promoter 
(minP). Each combination was tested in three biological replicates. The statistical significance of the TF 
overexpression effect was determined with two-way ANOVA and post-hoc LSD testing for each construct. 
P-value: *p<0.05, **p< 0.001.  
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control. The in vitro activity of all promoters and enhancers remained constant (Figure 7B), 
indicating that POU3F2 does not regulate the tested FOXP2 enhancers and promoters. 
 
SOX5 and combinations of TBR1 with CASK regulate FOXP2 promoter and enhancer 
activity  
Next, I tested the regulation of the FOXP2 regulatory elements by TBR1. Co-transfection with 
TBR1 reduced the activity of enhancer 330 and 37. TBR1 has been shown to exert both 
Figure 7: Testing regulatory effects of PAX6 and POU3F2 on promoter and enhancer constructs.  
Relative luciferase activity of promoter and enhancer elements in HEK293 cells for experiments with A) 
PAX6, and B) POU3F2. The promoter and enhancer constructs were each transfected with a control 
construct expressing the renilla luciferase under the control of a viral promoter and the relevant TF 
overexpression construct or a pcDNA4 control plasmid. The firefly luciferase signal was divided by the 
renilla signal to derive the relative luciferase activity. The activity for each luciferase construct was 
normalized for the activity observed for the minimal promoter (minP). Each combination was tested in three 
biological replicates. The statistical significance for each construct was assessed using two-way ANOVA 
and post-hoc LSD testing. P-value: * p<0.05, ** p< 0.001.  
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activating and repressive effects on target gene expression (Bedogni et al., 2010; Han et al., 
2011), which may dependent on the co-activator CASK (Hsueh et al., 2000; Wang et al., 
2004). I therefore co-transfected the promoter and enhancer constructs with TBR1, CASK or 
a combination of both. The combination increased the activity of the enhancer 37 and promoter 
1 (Figure 7). Overexpression of CASK alone had a repressive effect on enhancer 37. As 
predicted, the activating effect of TBR1 was detectable at promoter 1 and enhancer 37 only in 
combination with the co-activator CASK. As CASK does not bind DNA, the repressive effect, 
observed in the absence of TBR1, must be mediated via protein-protein interactions to another 
DNA-binding factor. 
Finally, I tested the regulatory elements in combination with a pcDNA4-SOX5 overexpression 
plasmid. Promoter 1, elements 37 and 704 increased luciferase gene expression in response 
to SOX5 overexpression (Figure 5C). The activity of enhancer 330 however decreased. Thus, 
SOX5 exerts repressive and activating effects. Repressive and activating effects of SOX5 
have been reported before (Kwan et al., 2008; Aza-Carmona et al., 2011). This suggests that 
SOX5 may enhance or decrease FOXP2 expression levels, depending on the regulatory 
element. To my best knowledge, opposing regulatory effects of single TFs at regulatory 
elements of the same target gene have not been reported.  
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The motif scan locates motifs of tested TFs and predicts neuronal TF motifs  
To identify TF binding motifs I scanned the cloned sequences for the presence of published 
PWMs. This allowed me to locate the binding motifs of the tested TFs, as well as to predict 
the binding of untested TFs. I obtained 2,161 PWMs from the four databases Transfac 
Figure 7: Regulatory effect of TBR1 and SOX5 on promoter and enhancer constructs. A, B) Relative 
luciferase activity of promoter and enhancer elements in HEK293 cells. The promoter and enhancer 
constructs were each transfected with a control construct expressing the renilla luciferase under the control 
of a viral promoter. The cells were also transfected with a control, A) TBR1, CASK or a combination of TBR1 
and CASK overexpression plasmids and B) a SOX5 overexpression plasmid. The firefly luciferase signal 
was divided by the renilla signal to derive the relative luciferase activity. The activity for each luciferase 
construct was normalized for the activity observed for the minimal promoter (minP). Each combination was 
tested in three biological replicates. The statistical significance of the TF overexpression effect was 
determined with two-way ANOVA and post-hoc LSD testing for each construct. P-value: *p<0.05, **p< 
0.001.  
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(Wingender et al., 2000), HOCOMOCO (Kulakovskiy et al., 2013), HT-Selex (Jolma et al., 
2013) and Jaspar (Mathelier et al., 2014). These PWMs were used within the MotifScanner 
algorithm to scan the cloned sequences (Aerts et al., 2003; Coessens et al., 2003). The 
databases included the PWMs for all investigated TFs (FOXP1, FOXP2, LEF1, PAX6, 
POU3F2, TBR1 and SOX5), except FOXP4. Therefore, I could not identify potential FOXP4 
binding sites in the enhancer and promoter sequences.  
The motif scan predicted between 373 (Enhancer 815) to 855 (Enhancer 330) motifs in the 9 
analysed sequences (3 promoters, 6 enhancers) (Table 3, Appendix 2: Table S2). The 
predictions located putative motifs of the previously tested TFs (Table 4). FOXP2 motifs were 
predicted within seven cloned elements (promoter 1-3, enhancer 330, enhancer 700, 
enhancer 815 and enhancer 843). However, in response to FOXP2 overexpression, I only 
detected changes in reporter gene expression at five regulatory elements (Promoter 1, 
promoter 2, enhancer 37, enhancer 700 and enhancer 815). Therefore, the results of the motif 
prediction and luciferase are concordant at four elements (Promoter1, promoter 2, enhancer 
700 and enhancer 815). The FOXP2 motifs at promoter 3, enhancer 330 and enhancer 843 
represent false positive predictions, possibly caused by non-functional binding sites. In 
addition, no FOXP2 motif was predicted for enhancer 37. Explanations for the false negative 
prediction may be a too stringent detection threshold in the motif scan or that the observed 
regulation is due to an indirect interaction. In total I identified 19 TF motifs at concordant 
promoters and enhancers (Table 5). To verify that changes in luciferase expression were 
mediated by direct TF - DNA interactions it would be necessary to mutate or delete the 
predicted TF motifs.  
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Table3: Summary of predicted TFs  
Element Length [bp] # of predicted motifs motifs/bp 
Promoter 1 1,791 444 0.25
Promoter 2 4,104 741 0.18
Promoter 3 1,006 428 0.43
Enhancer 37 774 384 0.50
Enhancer 330 1,801 855 0.47
Enhancer 700 4,087 449 0.11
Enhancer 704 832 520 0.63
Enhancer 815 3,645 373 0.10
Enhancer 843 3,958 493 0.12
Total 21,998 4,687 0.21
 
Table 4: Predicted TF motifs per promoter/enhancer           
Elements FOXP2 FOXP2-R328X 
FOXP2-
R553H FOXP1 FOXP4 LEF1 PAX6 POU3F2 TBR1 
TBR1/   
CASK
CASK SOX5 
  
ob
se
rv
ed
 e
ffe
ct
a  
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
ob
se
rv
ed
 e
ffe
ct
a  
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
ob
se
rv
ed
 e
ffe
ct
a  
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
ob
se
rv
ed
 e
ffe
ct
 
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
ob
se
rv
ed
 e
ffe
ct
 
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
ob
se
rv
ed
 e
ffe
ct
 
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
ob
se
rv
ed
 e
ffe
ct
 
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
ob
se
rv
ed
 e
ffe
ct
 
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
ob
se
rv
ed
 e
ffe
ct
 
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
ob
se
rv
ed
 e
ffe
ct
 
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
ob
se
rv
ed
 e
ffe
ct
 
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
ob
se
rv
ed
 e
ffe
ct
 
# 
of
 p
re
di
ct
ed
 m
ot
ifs
 
P1 + 1 + NA  NA + 0  NA + 0 - 0  0  0 + NA  NA + 1 
P2 + 2  NA  NA  2  NA  4  1  3  0  NA  NA  2 
P3  1  NA  NA  1  NA + 3  1  2  1  NA  NA  0 
E37 + 0 + NA  NA + 0 + NA + 1  0  1 - 0 + NA - NA + 2 
E330  1 + NA + NA  1 - NA + 2  3  4 - 0  NA  NA - 1 
E700 + 1  NA  NA  0  NA  0  0  4  1  NA  NA  2 
E704  0  NA  NA  0  NA  5  0  1  0  NA  NA + 3 
E815 + 2  NA  NA + 1  NA  0 - 0  2  0  NA  NA  1 
E843  1  NA  NA  0  NA  4  1  2  0  NA  NA  0 
green = concordant luciferase and prediction; yellow = false negative prediction; red = false positive prediction 
a
+ = increase of luciferase expression; -  = decrease of luciferase expression 
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Table 5: Location of concordant TF motifs   
Element TF Start [hg18] End [hg18] PWM ID Motif
Promoter 1 FOXP2 113,513,165 113,513,175 MA0593  GTTGTTTACAT
Promoter 1 SOX5 113,513,220 113,513,227 HM00343  GAACAATA
Promoter 2 FOXP2 113,841,749 113,841,759 MA0593  ATTGTTTACTT
Promoter 2 FOXP2 113,840,403 113,840,413 MA0593  ATGTAAACAGA
Promoter 3 LEF1 113,843,051 113,843,056 M00805  GTTTGA
Promoter 3 LEF1 113,843,147 113,843,161 HT00135  AAACATGAAAGGAGT
Promoter 3 LEF1 113,843,177 113,843,183 HM00191  CTTTGTA
Enhancer 37 LEF1 113,475,432 113,475,438 HM00191  CTTTGAT
Enhancer 37 SOX5 113,475,604 113,475,611 HM00343  CATTGTTG
Enhancer 300 LEF1 113,844,283 113,844,289 HM00191  CTTTGTA
Enhancer 300 LEF1 113,844,761 113,844,770 M01022  CACTTTGAAA
Enhancer 300 LEF1 113,844,980 113,844,994 HT00135  AGTGCTTTCATCTTT
Enhancer 300 SOX5 113,844,505 113,844,512 HM00343  CATTGTTC
Enhancer 704 SOX5 114,215,241 114,215,250 M00042  TTAACAATAT
Enhancer 704 SOX5 114,216,589 114,216,598 M00042  CAATTGTTAG
Enhancer 704 SOX5 113,513,220 113,513,227 HM00343  GAACAATA
Enhancer 815 FOXP2 114,328,727 114,328,737 MA0593  CAGTAAACACA
Enhancer 815 FOXP2 114,328,816 114,328,824 HM00111  ATGTTTACT
Enhancer 815 FOXP1 114,328,724 114,328,738 MA0481  TATCAGTAAACACAC
 
A promising approach to select novel TFs that may regulate FOXP2 is to prioritize TFs that 
are expressed in the brain. Therefore, I filtered the list of predicted TFs using the DAVID 
bioinformatics web tool to filter for TFs within the brain expressed category (UniProt_Tissue: 
brain) (Huang da et al., 2009) and detected 145 TFs within the brain expressed category 
(Appendix 2: Table S3). As a complementary alternative, I prioritized TFs that are collected in 
the gene ontology category of neuron differentiation (Appendix 2: Table S4) because FOXP2 
function in neuron differentiation is well established (Vernes et al., 2006; Vernes et al., 2011; 
Tsui et al., 2013; Devanna et al., 2014). The “neuron differentiation” list contained 86 TFs, of 
which 54 overlap with the “brain expressed” category. The absence of some “neuron 
differentiation” genes from the “brain expressed” list may be caused by incorrect manual 
annotation of the GO-terms. An alternative explanation may be the absence of TFs, which are 
expressed during brain development in the “brain expressed” list. Both lists include several 
TFs that I studied experimentally in this chapter, such as SOX5, POU3F2, and PAX6. In 
addition the neuron differentiation list includes TFs which have been shown to be co-
expressed with FOXP2, such as ATOH1, DLX5, EMX1, LMX1B (as described in Chapter 1). 
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The motif scan could be used to prioritize additional TFs for further luciferase experiments to 
investigate the regulation of FOXP2 by these TFs. 
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Discussion 
FOXP2 enhancer and promoters are active in neuronal-like cell lines 
Promoter 1 is transcriptionally active in HEK293 and SK-N-MC cells, which is in agreement 
with the report that endogenous FOXP2 expression is driven by this promoter in these cell 
lines (Schroeder and Myers, 2008). HEK293 and SK-N-MC cells express comparable levels 
of FOXP2 mRNA, yet the promoter activity in HEK293 cells was substantially lower than in 
SK-N-MC. Similarly, I previously detected lower RNA polymerase II binding at this promoter 
in the HEK293 cell line (Chapter 3). These findings suggest that regulation of the promoter 
does not solely determine endogenous FOXP2 expression in HEK293 and that enhancers 
increase expression levels. In accordance with this hypothesis, three enhancers were active 
in HEK293 cells. One of the enhancers, enhancer 330, was inactive in SK-N-MC, which may 
contribute to the similarity in expression levels of FOXP2 in HEK293 and SK-N-MC. However, 
additional regulatory elements, such as promoter 4 and four untested candidate enhancers, 
may further contribute to the total endogenous FOXP2 expression (Chapter 3). 
Promoter 2 and 3 did not drive luciferase expression in SK-N-MC or HEK293 cells, which is in 
accordance with the previous observation that these promoters are not bound by RNA 
polymerase II in these cells (Chapter 3). In addition, this is in agreement with a previous study, 
which did not detect mRNA transcripts originating from promoter 2 or 3 in these cell lines 
(Schroeder and Myers, 2008). However, Schroeder and Myers detected tissue-specific 
expression in non-neuronal tissue, such as the cervix, liver and trachea. Luciferase 
experiments in cell lines derived from these tissues may reveal promoter 2 and/or promoter 3 
activities. Because I wanted to gain insight into the neuronal function of FOXP2, its regulation 
in non-neuronal tissue was outside the scope of this thesis. 
I demonstrated that the enhancers at 37 and 330 kb increase reporter gene expression in 
vitro. The results support the hypothesis that the measured chromatin interactions represent 
functional promoter-enhancer loops (Chapter3). The basal activity of the elements was tested 
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in the same FOXP2(+) cell lines which had been used to study the chromatin interactions. The 
activity of enhancer 330 was detected in HEK293 and absent in SK-N-MC. However, the 
chromatin interactions were comparable between both cell lines (see Chapter 3: Figure 5). 
The chromatin interaction is therefore not proportional to the in vitro activity of the enhancer 
element. The absence of enhancer 330 activity in SK-N-MC cells suggests that the enhancer 
may be “poised” in this cell line. Poised enhancers regulate rapid changes in target gene 
expression in response to developmental or environmental stimuli (Zentner et al., 2011; Jin et 
al., 2013; Shlyueva et al., 2014). As I observed repressing effects on enhancer 330 by TBR1, 
SOX5 and FOXP4, the inactivity of this enhancer in SK-N-MC could be caused by the 
presence of these TFs. The knock-down of these TFs in SK-N-MC cells might potentially 
activate enhancer 330. An alternative explanation could be the absence of an activating TF. 
A promising candidate could be LEF1, which increased enhancer 330 activity in HEK293 cells. 
As LEF1 activity is dependent on WNT-signalling, this hypothesis could be tested by activation 
of this pathway in SK-N-MC cells.  
Positive direct auto-regulation of FOXP2 likely contributes to neuronal expression 
I hypothesized that FOXP2 could auto-regulate via its promoters or enhancers, and detected 
increased activity of five regulatory elements in response to FOXP2 overexpression. Positive 
auto-regulatory loops enable rapid amplification of the TF and to maintain expression at stable 
plateau levels (Bateman, 1998). Auto-regulation has been described for developmental 
(Bateman, 1998; di Gennaro et al., 2013; Mead et al., 2013) and neurodevelopmental TFs 
(Meredith et al., 2009). Heterozygous mutations in positive auto-regulatory TFs could 
decrease the expression of the wildtype protein from the healthy allele. Consequently, the 
expression of wildtype protein would be severely reduced and below 50% compared to the 
non-mutated situation. Thus, heterogeneous mutations of positive auto-regulatory TFs may 
lead to haploinsufficiency, where the absence of one healthy allele is sufficient to cause a 
disease phenotype (Lamb et al., 2012; di Gennaro et al., 2013; Mead et al., 2013). Mutations 
of FOXP2 or the loss of one FOXP2 allele would be predicted to result in reduced activation 
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of FOXP2 expression and subsequently reduce the expression of the healthy allele. Indeed, 
heterogeneous whole-gene deletions of FOXP2 have been detected in people with speech 
impairments, strongly indicating that haploinsufficiency underlies the molecular aetiology of 
the FOXP2-related speech phenotype in some cases (Zeesman et al., 2006; Palka et al., 
2012; Rice et al., 2012). In addition, studies in mouse models of aetiological FOXP2 mutations 
indicate that heterozygous mice are overtly normal with specific effects on cortico-striatal 
neural networks (Groszer et al., 2008; Gaub et al., 2016). Positive auto-regulation could 
explain the occurrence of the haploinsufficiency effect in a subset of FOXP2-positive tissues, 
as this effect would be present only in target tissue of the enhancers.  
I have shown that both FOXP1 and FOXP4 can regulate the enhancers and promoters of 
FOXP2 in vitro, suggesting that they may also enhance FOXP2 expression in vivo. The FOXP 
family members have been shown to form functional hetero-dimers (Li et al., 2004; Sin et al., 
2015; Spaeth et al., 2015) and hetero-dimerization could influence the regulation of FOXP2. 
HEK293 cells do express FOXP1, FOXP2 and FOXP4 (Gierman et al., 2007; Uhlen et al., 
2015). It is thus possible that endogenous expression of these TFs influenced the luciferase 
results and that the observed effects are caused by FOXP dimers. Co-transfection of FOXP 
family members may further investigate the role of hetero- and homodimers in the regulation 
of FOXP2 enhancers. 
Regulatory TFs of promoters/enhancers suggest upstream pathways for FOXP2 expression 
I detected that LEF1 is capable of increasing the activity of promoter 1, promoter 3 and two 
enhancer elements. In prior work LEF1 has been shown to activate expression of target genes 
(Arce et al., 2006), which is consistent with the observed effects in my experiments. Moreover, 
the increase of enhancer and promoter activity after LEF1 overexpression is consistent with 
previously described effects of Lef1 in zebrafish, where knockdown of lef1 abolishes foxp2 
expression in the tectum, mid-hindbrain boundary and hindbrain (Bonkowsky et al., 2008). 
Thus, the luciferase results indicate that LEF1 regulates FOXP2 also in human cells. It remains 
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to be determined if regulation by LEF1 occurs in the same regions as observed for the 
zebrafish. The activities of promoter 1, promoter 3, enhancer 37 and enhancer 330 during 
development and adulthood should be characterized to address this question. As the protein 
structures of TFs are evolutionary more stable than enhancer sequences (Domene et al., 
2013; Rubinstein and de Souza, 2013) the human enhancers are likely recognized by 
orthologous TFs in related species. Thus, the human enhancer activities could be tested in 
transgenic mice (Visel et al., 2008), which I did for the most promising enhancers in chapter 
5. 
I found that in human cells PAX6 overexpression decreased promoter 1 and enhancer 815 
activity. A previous report showed in zebrafish that pax6 knockdown reduced foxp2 expression 
in the developing telencephalon, suggesting that it activates foxp2 expression (Coutinho et al., 
2011). The conflicting results between my data and the study by Coutinho et al. could be 
caused by inter-species differences. Also, my data was obtained within neuronal-like cell lines, 
which are unlikely to resemble the transcriptional program of embryonic telencephalon. 
However, my luciferase data indicates that FOXP2 is a target gene of PAX6 in humans. Co-
expression of both TFs was shown in the amygdala and striatum of non-human primates and 
rats (Kaoru et al., 2010) and the embryonic (E12) cortical plate of mice (Tsui et al., 2013). In 
the developing cortex of Pax6 knock-out mice, cortico-fugal axons show aberrant migratory 
pathways (Jones et al., 2002). FOXP2 is expressed specifically in cortico-fugal neurons of 
cortical layer VI (Hisaoka et al., 2010) and regulates neurite outgrowth (Vernes et al., 2011). 
Thus, aberrant Foxp2 regulation in Pax6 knock-out mice may contribute to the defect in axon 
pathfinding.  
In a previous report, POU3F2 has been suggested to regulate the expression of FOXP2 via a 
putative enhancer element in intron 8 (Maricic et al., 2013). Maricic et al. suggested that the 
regulation by POU3F2 was reduced in modern humans, due to a genetic variant that arose in 
humans after the split from a common ancestor with Neanderthals. However, the element 
proposed by Maricic et al. did not show independent in vitro or in vivo activity in their study 
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and was not included here. In my experiments, POU3F2 did not increase or decrease the 
activity of the promoters and enhancers that I tested. The presented results cannot exclude 
the possibility that POU3F2 is capable of regulating FOXP2 expression via untested regulatory 
elements or indirect interactions. 
TF important for cortical neuron subtype specification may contribute to FOXP2 expression 
I identified regulatory effects on FOXP2 promoters and enhancers by SOX5, which is 
expressed in post-migratory neurons of the developing cortex and is involved in subtype 
specification (Kwan et al., 2008; Lai et al., 2008). Similar to SOX5, TBR1 is involved in the 
development and maturation of cortical neurons (Hevner et al., 2001; Han et al., 2011). FOXP2 
is involved in embryonic cortical development (Tsui et al., 2013) and restricted to cortical layer 
VI (Lai et al., 2003). Thus, in the adult cortex expression of TBR1 and SOX5 overlaps with 
FOXP2 expression in cortical layer VI. I showed that TBR1, in absence of the co-activator 
CASK, represses the activity of enhancer 330, while in presence of CASK it promotes activity 
of enhancer 37 and promoter 1. CASK is expressed throughout the cortex with the highest 
expression in cortical layers III and IV (Kristiansen et al., 2010). SOX5 and TBR1 in 
combination with CASK increase the activity of enhancer 37. This could indicate that enhancer 
37 is active in cortical layer VI, where FOXP2 is co-expressed with these TFs. However, 
enhancer 330 activity is decreased by TBR1 and SOX5. It is therefore unlikely that both 
enhancer 37 and 330 are active in the same neurons. The enhancer activity pattern and an 
assessment of the overlap with FOXP2 in the brain are thus important to fully evaluate the 
effects observed in my experiments. As there are no methods to study enhancer activity in 
human brains it is required to test the enhancers in transgenic animals (Visel et al., 2007). 
 
 
Mutations in components of the upstream regulatory network reported in disease phenotypes 
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Some TFs that regulate the FOXP2 enhancers and promoters may cause disease phenotypes 
if mutated. Rare de novo mutations of TBR1 have been implicated in the aetiology of autism 
spectrum disorder (ASD) (O'Roak et al., 2012b; O'Roak et al., 2012a). Patients with ASD have 
impaired communication skills and language disruption is a common phenotype shared 
between patients with TBR1 and FOXP2 mutations (Deriziotis et al., 2014). Haploinsufficiency 
of SOX5 causes intellectual disability with prominent speech delay (Lamb et al., 2012; 
Schanze et al., 2013). Mutations of PAX6 and chromosomal rearrangements at the PAX6 
gene have been shown to cause aniridia, a disorder that is characterized by the absence of 
the iris in affected cases (Prosser and van Heyningen, 1998). In rare cases mutations of PAX6 
have been found in patients with intellectual disability (ID) and autism (Ticho et al., 2006; 
Graziano et al., 2007; Davis et al., 2008). The possibility of an underlying molecular link 
between language phenotypes observed in for mutations in FOXP2, PAX6, TBR1 or SOX5 
need to be addressed in future studies.  
In this chapter, I included enhancer 815, which I have identified in chapter 2 downstream of a 
de novo inversion breakpoint found in a child with a complex rearrangement and language 
deficits (Becker et al., 2015; Moralli et al., 2015). The proximity to FOXP2 suggested that the 
de-regulation of this gene might contribute to the observed phenotype in this child. In the 
present chapter, I determined that this element is responsive to the overexpression of PAX6, 
FOXP1 and FOXP2. FOXP1 mutations have been found in cases of autism spectrum 
disorders (Bacon et al., 2015), which are partly characterized by communication problems. 
The language problems of people with FOXP1 and PAX6 mutations could be secondary to 
major problems in unrelated molecular pathways. PAX6 mutations commonly cause 
developmental problems, which are unrelated to cognition and behaviour (Prosser and van 
Heyningen, 1998). It will be important to identify the patterns of tissue activity of element 815 
to determine whether and how these overlap with sites of expression of FOXP1 and PAX6. 
The brain regions that are affected in the child described by Moralli et al. have not been 
reported. The overlap of affected brain regions and the expression of FOXP1 or PAX6, as well 
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as the activity of element 815 could provide an explanation for the molecular aetiology of the 
observed phenotype. 
HEK293 cells have been shown to express FOXP1, FOXP4, SOX5, CASK, LEF1 and PAX6 
(Gierman et al., 2007; Uhlen et al., 2015). In an alternative experiment the endogenous TF 
levels could be knocked down, using RNA silencing techniques, to assess the effects on 
promoters and enhancers. Ideally, follow-up experiments should employ cells obtained from 
tissue and developmental periods in which the regulatory effect is expected to occur. It will be 
useful to switch to more advanced cellular systems, such as primary neurons from mouse 
embryos or induced pluripotent stem (iPS) cells. In developmental protocols of iPS cells, 
FOXP2 is used as a marker for development stages (Molina-Hernandez et al., 2013; Belinsky 
et al., 2014). Therefore the longitudinal expression pattern of FOXP2 has been described for 
this system (Belinsky et al., 2014). This makes iPS cells an ideal system to manipulate the 
expression of potential regulatory TFs and to analyse the effect on FOXP2 expression during 
their development. 
In this chapter I demonstrated the in vitro activity of previously identified enhancer elements 
and one promoter of FOXP2. The enhancer and promoter activities respond to the 
overexpression of several TFs that had previously been linked to FOXP2 in the literature. 
However, changes of endogenous FOXP2 mRNA in response to TFs still need to be 
determined. In silico motif scan partially predicted the DNA binding motifs in the responding 
regulatory sequences and suggested additional TFs that may regulate the 
enhancers/promoters. The activity patterns of the enhancer and promoter elements need to 
be characterized to address the developmental period and target tissue of the observed 
regulatory effects, which I describe in the following chapter. Overall, the results of the current 
chapter indicated the influence of known developmental programs and signalling pathways on 
the expression of FOXP2 and open new directions to investigate the biological role of this TF 
in normal and pathogenic development.  
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Abstract 
Mutations in FOXP2 affect the structure and function of the striatum, cortex and cerebellum. 
During development FOXP2 is expressed in these brain areas, as well as other neural sites, 
and it remains expressed during adulthood. The mechanisms that initiate developmental 
FOXP2 expression in these different brain structures are unknown. Enhancers of FOXP2 and 
their upstream regulatory processes have been identified (as described in prior chapters of this 
thesis), but their tissue-specific activity has not been investigated. 
In this chapter I aimed to characterize the neural sites of action of a number of human FOXP2 
enhancer elements defined from my earlier work. I created transgenic mice that expresses the 
LacZ reporter gene under control of the enhancer 37 and enhancer 330, and analysed the 
reporter gene expression in embryonic and adult mouse brains. Adult mice carrying enhancer 
37 showed LacZ expression in the hippocampus, the ventricles and the olfactory bulb (OB). 
The ventricular expression of LacZ started at early post-natal age (P7) and remained during 
adulthood. Expression in OB began during late embryogenesis (E18.5) and faded in adult 
animals (P280+). By contrast, activity of enhancer 330 in adulthood was detected in the cortex 
and the Purkinje cell (PC) layer of the cerebellum. The enhancer activity in the cortex started 
in the ventricular zone during embryonic development and was found in all cortical layers at 
early post-natal ages (P8) and early adult ages (P88). During adulthood the enhancer activity 
weakened in the deeper cortical layers (P150). 
The tissue-specific activity of enhancer 37 may link FOXP2 to adult neurogenesis. The in vivo 
activity of enhancer 330 suggests that it activates FOXP2 early during cortical development. 
The regulatory mechanisms of this enhancer may contribute to the cortical layer specific 
expression of FOXP2.  
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Introduction 
The expression of human and mouse FOXP2/Foxp2 starts during embryonic development in 
sub-structures of the forebrain, midbrain and hindbrain, including the thalamus, basal ganglia, 
cortex and cerebellum (Ferland et al., 2003; Lai et al., 2003). This complex expression pattern 
persists into adulthood within developed brain structures (Ferland et al., 2003). I have identified 
enhancer elements which may regulate the expression of human FOXP2 during development 
or adulthood (Becker et al., 2015) (Chapter 3). However, the tissue-specific activity of the 
enhancers needs to be identified, and this is the focus of the current chapter. 
To characterize enhancer tissue-specific activity, transgenic mice can be created that carry a 
certain enhancer sequence and express a reporter gene under the control of the enhancer 
(Visel et al., 2007; Boyd et al., 2015). The enhancer sequence is commonly cloned upstream 
of a minimal promoter and a reporter such as the beta-galactosidase (LacZ) gene (Kothary et 
al., 1989), which can be visualized by enzymatic staining in tissue samples to identify the 
tissue-specific activity of the enhancer (Visel et al., 2007). The preferred minimal promoter for 
these studies is typically derived from the mouse heat-shock 68 (Hsp68) gene and inactive 
under normal conditions (Kothary et al., 1989). Therefore, the reporter gene expression is 
dependent on the upstream enhancer and induced in endogenous tissue relevant for the 
activity of the enhancer (Visel et al., 2007; Visel et al., 2008; Visel et al., 2009; Visel et al., 
2013). 
The study of human FOXP2 enhancers in mice is a promising approach to characterize human 
enhancer activity in homologous mammalian brain regions (Visel et al., 2013; Boyd et al., 
2015). Comparative studies of TFs and enhancers strongly suggest that enhancers are subject 
to evolutionary changes whereas the protein structure of TFs and their binding motifs remain 
more stable during evolution (Rubinstein and de Souza, 2013; Villar et al., 2015). Furthermore, 
the expression patterns of many TFs also tend to change little during evolution (Rubinstein and 
de Souza, 2013). Similarly, the expression pattern of FOXP2/Foxp2 is conserved between 
humans and mice (Ferland et al., 2003; Lai et al., 2003). One example of the cross-species 
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activity of gene enhancers can be seen for two mouse enhancers of the Pomc gene, which 
drive gene expression in the hypothalamus (Young et al., 1998). The Pomc enhancer 
sequences evolved de novo in mammals, but are capable to drive reporter gene expression in 
the hypothalamus of zebrafish (Domene et al., 2013). Thus, the tissue-specific activity of 
enhancers can be conserved across species and the activity of human enhancers in transgenic 
mice is assumed to mimic the activity pattern in humans.  
The hypothesis for the work carried out in this chapter was that the FOXP2 enhancers would 
drive gene expression within known regions of FOXP2/Foxp2 expression. The expression of 
human and mouse FOXP2/Foxp2 is detailed in the general introduction (Chapter 1). In short, 
FOXP2/Foxp2 is mainly expressed in the neocortex, thalamus, hypothalamus, basal ganglia, 
amygdala, olfactory system, midbrain, cerebellum and medulla oblongata (Figure 1, 2) (Shu et 
al., 2001; Ferland et al., 2003; Lai et al., 2003). The expression in the cortex of mice starts at 
embryonic day 12.5 (E12.5) (Shu et al., 2001). In the developed cortex the Foxp2 expression 
is mostly restricted to the deep layer VI (Figure 2) (Ferland et al., 2003) with some expression 
extending into layer V (Campbell et al., 2009; Hisaoka et al., 2010). The expression in the 
thalamus and hypothalamus was detected at E13.5 in mice and Carnegie Stage (CS) 23 in 
human (Figure 1C) (Lai et al., 2003). The ganglionic eminence, the developmental origin of the 
basal ganglia, expresses FOXP2/Foxp2 at E12.5 in mice (Ferland et al., 2003) and CS23 in 
human (Figure 1D) (Lai et al., 2003). Midbrain expression of FOXP2/Foxp2 is detected in the 
superior and inferior colliculi of the tectum and substantia nigra of mice (Ferland et al., 2003) 
and human (Figure 1B) (Lai et al., 2003). The cerebellar primordium shows FOXP2/Foxp2 
expression at CS23/E14.5  (Figure 1E, F) and the precursor of the medulla oblongata shows 
the first expression of Foxp2 at E11.5 in mice and CS18 in human (Figure 1C) (Lai et al., 2003). 
Adult cerebellar expression is restricted to the Purkinje cells (PCs) and weak expression is 
detected in some cerebellar nuclei in mice (Ferland et al., 2003; Fujita and Sugihara, 2012). 
Expression in the medulla oblongata is specific to the inferior olive (Figure 1G, H) (Lai et al., 
2003; Fujita et al., 2012). I focused on the neuronal expression, as mutations in FOXP2 affect 
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the structure and function of neurons and neuronal networks, yielding disorders of speech and 
language (Vargha-Khadem et al., 1998; Watkins et al., 2002; Lai et al., 2003; Vernes et al., 
2011).  
 
Figure 1: Reproduced from Lai et al. 2003, Brain. FOXP2 mRNA expression in the developing human 
brain. In situ hybridization to FOXP2 mRNA in transverse sections of human fetal brain slices (~9 weeks post-
fertilization). Boxed areas B, C, D, F and H in pictures A, E and G are magnified in adjacent pictures. FOXP2 
expression is shown in the tectum (B), thalamus (C), caudate nucleus (D), cerebellum (F) and inferior olives (H). 
CN: caudate nucleus, Th: thalamus, CB: cerebellum, IO: inferior olivary complex, Tm: tectum, CT-f: cortico-
thalamic tract. Scale bars: (A,E and G) 1mm, (B-D, F and H) 0.5 mm. 
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In earlier work described in this thesis, I identified enhancer elements of the human FOXP2 
gene (Chapter 3) and TFs that may regulate the activity of these enhancers (Chapter 4). The 
enhancer elements were identified based on the demonstration that they contact the active 
FOXP2 promoter in neuronal-like cells using chromatin conformation capture (3C). In addition 
two of the enhancers, enhancer 37 and enhancer 330, activated the expression of a luciferase 
reporter gene in vitro (Chapter 4). Activity of enhancer 37 was increased by overexpression of 
LEF1, SOX5, FOXP1, FOXP2, FOXP4 and TBR1 in the presence of the CASK co-activator. 
Enhancer 330 was increased by LEF1 and repressed by TBR1 alone, SOX5 and FOXP4. 
Figure 2: Reproduced from Ferland et al. 2003, J Comp Neurol. Post-natal expression of Foxp2 mRNA in 
the mouse brain. Representative photomicrographs of in situ hybridizations to Foxp2 mRNA in mouse brain 
slices at different postnatal time points (P1.5, P3.5, P6.5, P9.5, P15.5 and adult). Foxp2 expression is visualized 
as dark staining and series of photomicrographs are shown for the cortex, striatum, hippocampus and cerebellum. 
L1-6: cortical layer 1-6, MZ: marginal zone, STR: striatum, V.STR: ventral striatum, THAL: thalamus. 
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However, the enhancer’s tissue-specific activities (i.e. the sites where they are active) are 
unknown. The in vivo characterization can therefore link the previously identified regulatory 
interactions to the brain regions and developmental periods they occur in. 
In a genome-wide analysis of ultra-conserved non-coding regions, defined by long stretches 
(>200 bp) of identical nucleotide sequences between human and mouse, the tissue activity of 
hundreds of human enhancers were characterized in transgenic mice and the data made 
publicly available in the VISTA Enhancer Browser (Visel et al., 2008). The tissue activity was 
determined in E11.5 mouse embryos using the Hsp68-LacZ reporter gene construct (Visel et 
al., 2008), the same construct I used for analyses in this chapter. The regions that were tested 
in the VISTA project included enhancer 330 (VISTA ID: hs218), because of the high 
evolutionary conservation across vertebrate species (Figure 3A). Enhancer 330 is annotated 
in the VISTA Browser as being active in the forebrain. Here I followed the activity between 
early post-natal (P8) and adult mice (P200). 
The aim of this chapter was to characterize the neural regions of FOXP2 enhancer 330 (Figure 
3A) and enhancer 37 activity (Figure 3B). First, I determined the tissue-specificity activity of 
the enhancers in brains of adult animals. The aim was to then follow the enhancer activity 
during late embryonic and early post-natal development. In combination with the previously 
described FOXP2/Foxp2 expression pattern, these results will help us understand the 
regulatory mechanisms that guide expression of FOXP2 in specific brain regions.  
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Figure 3: Evolutionary and common human genetic variation of FOXP2 enhancer elements. The alignment of 
human genomic sequences to primate, mammal and genomes of evolutionary more distant species is shown in 
the below the enhancer. Evolutionary conservation of each nucleotide across primate species is shown within the 
Primate Conservation by PhastCons track. In addition, common single/simple nucleotide polymorphisms (SNPs), 
which are found in more than 1% of the human population, are shown in the last track. The A) Genomic position 
of enhancer 330 (chr7: 114056845-114058646, hg19) and 1kb of flanking sequences. The enhancer sequence is 
highly conserved across vertebrates.  The enhancer, including the flanking sequences contains 12 common human 
SNPs B) Genomic position of enhancer 37 (ch7: 113688009- 113688782, hg19) and 1kb of flanking sequence. The 
enhancer sequence shows low conservation across primates and is mostly absent from non-primate vertebrates. 
The enhancer, including flanking sequences contains 8 common human SNPs. 
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Materials and Methods 
Molecular cloning of LacZ constructs 
I created DNA constructs that contain the enhancer sequence in a cassette with a minimal 
promoter (Hsp68) and the beta-galactosidase (LacZ) gene (Kothary et al., 1989). Enhancer 37 
and 330 were amplified from genomic DNA of a healthy individual and inserted into TOPO 
vectors, as described before (Chapter 3). The enhancer sequences were further amplified 
using primers, tagged with attB gateway-cloning sequences. The resulting PCR products were 
run on a 1% agarose gel and extracted from the gel using Wizard SV Geld and PCR Clean-
Up System (Promega). The attB-tagged PCR product together with pDONR 221 vector was 
mixed with a BP clonase to insert the PCR product into the plasmid (Gateway BP cloning 
reaction). The resulting pDONR/Enhancer plasmids were incubated with pHsp68-
LacZ.Gateway and an LR clonase to produce the final pHsp68-LacZ.Enhancer37 and pHsp68-
LacZ.Enhancer330 plasmids (Gateway LR cloning reaction). 
Pronuclear injection of enhancer constructs 
The Enhancer constructs were linearized using SalI restriction enzymes (NEB) in 2h digestion 
at 37˚C. The digestion sample was run on a 0.6% agarose gel (TAE buffer), loading 200 ng of 
product on individual lanes. The gel was run in TAE buffer and the desired product was 
extracted from the gel using QIAEX II (QIAGEN). This was necessary to remove the plasmid 
backbone, which reduces the success rate of the genomic integration. The final products were 
eluted and stored at 4˚C.  
The transgenic mice were generated in the laboratory of Friedemann Kiefer, Max Planck 
Institute for Molecular Biomedicine, Münster, Germany using the C57BL/6 mouse strain. 
Pronuclear injection (PNI) was done as described before (Ittner and Gotz, 2007). With this 
technique the enhancer-hsp68-LacZ construct is injected into fertilized mouse oocytes at the 
one-cell stage where it integrates randomly into the mouse genome. Upon successful 
integration, the enhancer-reporter cassette is present in all cells of the developing mouse.  
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To validate genomic integration, I genotyped the mouse pups for the presence of the LacZ 
reporter gene. Mouse tails were lysed in 100 μl lysis buffer containing 50 μg/ml fresh 
Proteinase K for 10 min at 100˚C. The samples were constantly shaken at 1000RPM and 
vortexed for several seconds after 5 min of incubation and at the end of the incubation. The 
samples were spun down for 5 min at 12,000g. The supernatant was transferred to a clean 
Eppendorf tube and the eluted DNA precipitated with ice-cold ethanol. After ethanol 
precipitation the pelleted DNA was dissolved in 20 μl water. To amplify the LacZ gene, 1μl was 
used in a standard titanium PCR reaction (Clontech) and a LacZ specific primer pair (Forward: 
5’- CGATGAGCGTGGTGGTTATGCC-3’; Reverse: 5’- GACGATTCATTGGCACCATGC-3’). 
The band pattern was analysed in a 1% agarose gel. The expected band size for presence of 
the LacZ reporter gene was 440 bp. 
Positively genotyped mice were transported from the Max Planck Institute for Molecular 
Biomedicine in Münster, Germany to the central animal facility (Centraal Dierenlaboratorium) 
in Nijmegen, The Netherlands according to regulations. The mice were housed for 1-2 months 
in quarantine to ensure that the mice were pathogen free. 
Staining of mouse brain tissue 
Whole brains were dissected from sacrificed mice and washed in PBS. The brains were first 
incubated in 4% formalin (4% formaldehyde, 10% methanol) for 30 min at RT and then cut. All 
brains were cut at the sagittal midline. Embryonic day 14 brains were not cut further. One 
hemisphere of embryonic day 18/19 and early post-natal brains were cut at two coronal planes; 
one cut through the frontal cortex and ganglionic eminences and another cut at the dorsal end 
of the cortex. Adult (P15+) brains were cut at an additional coronal plane at the medial cortical 
line. The brain blocks were incubated in 4% formalin for another 30 min at RT to further fixate 
the tissue. The brain was then transferred into staining buffer (10 mM phosphate buffer pH 7, 
150 mM NaCl, 1 mM MgCl2, 0.1 % deoxycholate, 0.02% Igepal and 0.01 % SDS) with fresh 
added 50 mg/ml X-Gal, 200 mM ferrocyanide and 200 mM ferricyanide. The tissue was 
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incubated over night at 37˚C. The protein product of LacZ, beta-galactosidase, is enzymatically 
active and able to hydrolyze X-Gal (5-Brom-4-chlor-3-indoxyl-β-D-galactopyranosid) to 
galactose and a blue water-insoluble indigo-dye (Juers et al., 2012). The next morning the 
tissue was washed three times in PBS and further fixed in 4% formaldehyde for 1 day. Finally 
the tissue was transferred to 0.05% azine in PBS solution and stored at 4˚C. The staining was 
analysed under the S2000C (Zeiss) stereo microscope and documented using the powershot 
G7 (Canon) digital camera at 3.2x magnification. 
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Results 
Enhancer 330 drives cortical and cerebellar expression 
In order to investigate the in vivo activity of the enhancer elements I cloned the sequences 
previously used in chapter 4, into a plasmid that contains the E.coli derived LacZ gene 
downstream of the Hsp68 minimal promoter. The enhancer constructs integrated randomly 
into the mouse genome (Ittner and Gotz, 2007). I generated several mice to search for 
reproducible reporter gene expression across random insertion events. According to the 
VISTA enhancer browser, a brain structure with reporter gene expression can be defined as 
“reproducibly staining brain region” if it is found in at least three founder animals (Visel et al., 
2007). In addition to this criterion, I defined a region as reproducibly staining if it is found in 
50% or more of the analysed founder animals. Reproducible staining is believed to represent 
the endogenous enhancer activity.  
Pronuclear injections (PNI) of enhancer 330 yielded 108 mice, of which seven mice were 
positively genotyped for LacZ. One of the seven mice was excluded from the analysis because 
it showed staining across the whole brain, which is a potential source of false-positive 
replication. The initial assessment of reporter gene expression was done on adult brains, 
because, the transgenic mice were generated in a separate institute and for ethical reasons, 
the pregnant foster mothers could not be transported to our facility. In the adult (P108+) mice 
I detected reproducible staining in the cortex (4 of 6 mice) and cerebellum (3 of 6 mice) (Figure 
4). I further detected non-reproducible staining in the thalamus (2 of 6 mice). Two founder mice 
did not show any staining. The cortical staining was distributed in patches with no recurrent 
pattern (Figure 5). The staining was detectable in all cortical layers and the brain with the 
strongest overall staining showed strong staining in the upper layers and weak staining in the 
deeper layers (Figure 5 E, F; Figure 4A, B). Prior work has established that FOXP2/Foxp2 
cortical expression is largely limited to the deeper cortical layer VI. Therefore, it is surprising 
that the enhancer shows a tendency to stain the upper cortical layers. Positive LacZ staining 
was strong within the cell bodies of the PC layer (Figure 4C, D; Figure 6). One brain showed 
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strong staining within all lobules (Figure 6A), whereas two brains showed more prominent 
staining in the lobules VIII-X (Figure 6A, C). FOXP2/Foxp2 shows strong expression in PCs 
within most lobules, with moderate to weak expression in lobule X of the mouse cerebellum 
(Fujita and Sugihara, 2012). The observed enhancer activity thus overlaps known expression 
patterns for FOXP2/Foxp2 in the cerebellum. Immunohistochemistry (IHC) and/or in situ 
hybridization (ISH) experiments would be necessary to determine the exact overlap. The 
reporter gene expression suggests that enhancer 330 regulates human FOXP2 expression in 
the cortex and PCs.  
 
Figure 4: Tissue activity of enhancer 330 in adult mouse brain. Representative stereomicroscopic 
pictures of adult (P108) mouse brains stained for LacZ expression. Boxed areas B and D in pictures 
A and C are manual zooms of adjacent pictures. A,B) The upper cortical layers of the neocortex show 
strong staining and scattered positive cells are visible in the lower layers; C-E) The Purkinje cell layer 
in the cerebellum shows strong and specific staining. CC: corpus callosum, Ctx: cortex, I-VI: cortical 
layer I-VI, Str: striatum, Cb: cerebellum, gl: granular layer, PC: Purkinje cell layer, ml: molecular layer. 
Scale bars: 1 mm. 
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Figure 5: Cortical staining of 
enhancer 330. Stereomicroscopic 
pictures of cortical sliced tissue blocks 
of mouse brains stained for LacZ 
expression. A,B) Mouse #64 (P200+) 
with patchy staining across the cortex. 
C,D) Mouse #112 (P108) shows weak 
patchy staining. E,F) Mouse #113 
(P108) with strong cortical staining in 
the upper cortical layers and weak 
uneven staining in the rest of the 
cortex. This mouse also showed 
strong thalamic staining. G,H) #117 
(P108) shows weak and patchy 
staining in the upper cortical layers. 
Ctx: cortex, CC: corpus callosum, Str: 
Striatum, TH: thalamus, HPF: 
hippocampal formation, CP: caudate-
putamen, HY: hypothalamus. Scale 
bar: 1 mm.  
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Cortical activity of enhancer 330 during development overlaps published FOXP2 expression 
sites 
The most reproducible staining for enhancer 330 was detected in the neocortex, which is in 
agreement with data from the VISTA enhancer browser (Visel et al., 2007). According to the 
prior VISTA data, enhancer 330 is active in the neocortex of the forebrain at E11.5 (Figure 7A-
C). In the cortical sections from the VISTA project the staining was present in the ventricular 
zone of the pallium, which is the developmental precursor of the neocortex, (Figure 7B, C) 
along the anterior to posterior line (Figure 7A). These findings are consistent with the 
hypothesis that the enhancer activates Foxp2 in the embryonic cortex. However, the VISTA 
enhancer data is limited to the early embryonic development and further enhancer mapping 
was necessary to determine the activity in post-natal and adult cortices.  
Figure 6: Cerebellar staining of enhancer 330. Stereomicroscopic pictures of the cerebellum mouse brains 
stained for LacZ expression. A) Mouse #112 shows specific staining in the cell body of the PCs. The majority of 
stained PCs are located in lobule IX. B) Mouse #113 shows strong staining in the PC layer of the whole 
cerebellum, C) Mouse #117 shows weak staining in lobules X and IX. gl: granular layer, ml: molecular layer, PC: 
Purkinje cell layer. Scale bar: 1 mm. 
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Figure 7: Embryonic, neo-natal and adult cortical staining of enhancer 330. Enhancer 330 tissue activity in mouse brains, 
visualized by LacZ staining. Pictures C,F,I ,L and O are manual zooms of the adjacent pictures. A-C) Reproduced and adapted 
pictures of enhancer 330 in E11.5 mouse embryos downloaded from the VISTA Enhancer Browser 
(http://enhancer.lbl.gov/cgi-bin/imagedb3.pl?form=presentation&show=1&experiment_id=218&organism_id=1). A) Lateral 
view of the embryo and B-C) Microscopic picture of LacZ staining in cortical slices of the same embryo. D-O) Mouse brains 
from mouse line #64. (D, G, J, M) lateral view of mouse brains, showing intense staining across the forebrain and (E, F, H, I, K, 
L, N, O) cortical sliced brain tissue blocks, showing LacZ staining across the cortical layers. HB: hindbrain, MB: midbrain, FB: 
forebrain, Pal: pallium, LGE: lateral ganglionic eminence: MGE: medial ganglionic eminence, PallV: ventricular zone of pallium, 
PallM: mantle zone of pallium, Ctx: cortex, OB: olfactory bulb, HPF: hippocampal formation, I-VI: cortical layer I-VI.  Scale bar: 
1mm, no scale bars available for pictures A-C. 
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I established a mouse line of founder mouse #64, chosen because it showed strongest 
neocortical staining. To establish this mouse line, I crossed the founder mouse with a WT 
C57BL/6 mouse to produce heterozygote offspring. The heterozygotes were further crossed 
with WT or heterozygote offspring of the same founder animal. I did not observe differences in 
staining intensity or staining pattern for the homozygous of heterozygotes state. Due to limited 
access to the experimental mice, timed mating was not possible and I determined only post-
natal reporter gene expression of this mouse line. I analysed enhancer activity at post-natal 
day 8 (P8), in adult mice (P88 and P150) and at a late adult time point (P200). At P8 the cortical 
layers of the neocortex are established and the enhancer activity in all layers appeared equally 
strong (Figure 7E, F). In the coronal plane the cortical staining was present along the rostral-
ventral line in the medial and lateral parts of cortex. At age P150 the staining decreased in the 
deeper layers of the cortex (Figure 7J-L) and at age P200 the staining intensities further 
decreased in both the deeper and upper cortical layers (Figure 7M-O). The activity pattern 
along the rostral-ventral line remained stable through adulthood, for the different ages that I 
studied. Some patches of weaker staining were visible within the stained cortical structures, 
but the location of these patches was inconsistent across post-natal time points. At all 
developmental stages the reporter gene staining was absent from the dorsal side of the cortex, 
which forms the three-layered paleocortex. In summary, enhancer 330 is activated in the 
ventricular zone of the pallium, remains active across the cortical plate in early post-natal mice 
and in adult mice the enhancer activity decreases. I could not study the cerebellar activity of 
enhancer 330, as the mouse line did not show cerebellar staining. 
Enhancer 37 is active in regions both with and without known FOXP2 expression 
PNI of the enhancer 37 construct yielded 87 mice, of which 13 mice had positive genotypes 
for the reporter gene. The mice were sacrificed at adult age (P145+) and the brains were 
dissected for LacZ staining. Two mice showed unspecific whole-brain staining and were 
excluded from the analysis as potential source for false-positive replication. In sum, I analysed 
the brain staining pattern of eleven mice (Mouse #2, 49, 41, 38, 45, 48, 57 58, 59, 32 and 33). 
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I detected LacZ staining in six brain regions. Reproducible staining was observed in only two 
regions the hippocampus (7/11) and ventricles (6/11). In the hippocampus I observed staining 
in the pyramidal neurons of the dentate gyrus and CA1 (Figure 8A, B; Figure 9). Expression 
was visible in the dentate gyrus of 5 brains (Figure 9A, D-G), whereas weak CA1 expression 
was detected only in three brains. Thus, according to my definition the staining in individual 
pyramidal regions of the hippocampus is not reproducible. The ventricular staining was found 
in a thin layer of the lateral ventricles (Figure 8C, D; Figure 10) and the third ventricle (Figure 
8C, E). The staining seems to appear in the outermost cell layer, which consist of specialist 
ependymal cells. IHC of ISH for cell-type specific markers would be required to validate the 
cell identity. The staining pattern in hippocampus and ventricles was surprising as FOXP2 has 
not been reported to be expressed in these regions in either the mouse or human.  
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Figure 8: Tissue activity of enhancer 37 in adult mouse brain at P200+. Representative stereomicroscopic pictures of 
mouse brains stained for LacZ expression. Boxed areas B, D, E, G, I and J in pictures A, C, F and H are manual zooms of 
adjacent pictures. LacZ staining shown A,B) in the pyramidal neurons of the hippocampus; C-E) in the ventricular system of 
the left (D) and third ventricle (E); E,G) in the olfactory bulb and H-J) in the neocortex. DG: dentate gyrus; CA1: cornu 
ammonis area 1; LV: left ventricle; 3rdV; third ventricle; OB: olfactory bulb, Str: striatum, CC: corpus callosum, I-VI: cortical 
layer I-VI. 
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Figure 9: Hippocampal staining of enhancer 37 mouse lines. A-G) 
Stereomicroscopic pictures of mouse brains stained for LacZ 
expression. All mice carried the enhancer 37 construct at random 
genomic positions. Mice A) #32 (P145), D) #45 (P200+) and G) #58 
(P200+) show intense staining in the DG. Mice B) #33 (P145), C) #41 
(P200+), E) #48 (P200+) and F) #49 (P200+) show various degrees of 
staining intensities in the pyramidal cells of the HPF. Ctx: cortex, HPF: 
hippocampal formation, TH: thalamus. Scale bar: 1 mm. 
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The OB and neocortex stained positive in five out of eleven founder mice (Figure 11 and 12). 
These staining meet the criteria of being stained in more or equal to 3 mice, but do not meet 
the strict criteria for reproducible staining in 50% of the analysed animals. Because 
FOXP2/Foxp2 is expressed in these regions I determined their activity pattern. In the OB I saw 
consistent staining in a lateral region (Figure 8F, G; Figure 11), which does not overlap with a 
defined region from the Allen Brain Reference Atlas (Hawrylycz et al., 2012). The OB staining 
could suggest overlap with FOXP2 expression. The cortical staining was distributed in clusters 
with dense staining in the upper cortical layers and 4 brains showed staining in the allocortex 
(Figure 8 H-J). However, the allocortex, as well as the upper layers of the neocortex, do not 
express Foxp2 (Ferland et al., 2003). The staining therefore suggests that the activity of the 
enhancer does not overlap with known FOXP2 expression patterns in the cortex.  
Figure 10: Lateral ventricle staining of enhancer 37 mouse lines. A-F) Stereomicroscopic pictures of mouse brains stained 
for LacZ expression. All mice carried the enhancer 37 construct at random genomic positions. Mouse A) #2 (P129), B) #32 
(P145), C) #33 (P145), D) #45 (P200+), E) #48 (P200+) and F) #57 (P200+). A,B,E) Strong staining in the LV. C,D,F) weak 
staining in the LV. CC: corpus callosum, Ctx: cortex, Str: striatum, LV: lateral ventricle. Scale bar: 1 mm 
 
Chapter 5: Activity of FOXP2 enhancers during development and in adult brains 
 
145 
 
 
Figure 11: Olfactory bulb staining of enhancer 37 mouse lines. A-E) Stereomicroscopic pictures of mouse brains stained 
for LacZ expression. All mice carried the enhancer 37 construct at random genomic positions. Mice A) #2 (P200+), B) #32 
(P145), C) #33 (P135), D) #41 (P200+) and E) #49 (P200+) show staining of a ventral region in the olfactory bulb. Ctx: cortex, 
OB: olfactory bulb. Scale bars: 1 mm 
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Enhancer 37 activity changes during embryonic and adult development 
The most promising overlap of known FOXP2 expression patterns and enhancer 37 activity 
was in the OB. Therefore, I established a stable mouse line of founder mouse #2, which 
showed staining in the adult ventricles and OB. I harvested mice at embryonic stages (E13.5, 
E18.5), neo-natal (P5, P7), juvenile (P18), late adolescent (P39), adult (P129) and late adult 
age (P218). In the early embryo (E13.5) I did not detect LacZ staining (Figure 13A). At E18.5 
I observed staining in the OB (Figure 13B), which was also observed in adolescent mice (P39) 
(Figure 13C). The late adult individual (P281) did not show OB staining (Figure 13D). 
Figure 12: Neocortical staining of enhancer 37 mouse lines. A-E) Stereomicroscopic pictures of mouse brains stained for 
LacZ expression. All mice carried the enhancer 37 construct at random genomic positions. A) Mouse #38 (P200+) shows 
scattered positive stained cells across the cortex. B) Mouse #49 (P200+) shows patchy staining across the cortex and OB. 
C) Mouse #57 (P200+), D) #58 (P200+) and E) #59 (P200+) with weak and patchy staining across the cortex. CC: corpus 
callosum, Ctx: cortex, Str: striatum, OB: olfactory bulb. Scale bar: 1 mm. 
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Ventricular staining was first visible at post-natal age P7 (Figure 14A). In late adolescent (P39) 
and late adult (P281) mice, I observed staining in the lateral and third ventricles (Figure 14B, 
C). Similar to the adult, the staining is observable in a thin lining of the ventricular walls. The 
regulatory control of enhancer 37 in the ventricular system seems to start after birth and 
remains throughout adulthood. In the OB, the enhancer becomes active during late embryonic 
development and declines in late adult stages. To determine the overlap of this enhancer with 
Foxp2 expression it will be crucial to determine the Foxp2 mRNA and protein levels at these 
sites.  
  
Figure 13: Development of olfactory bulb staining of enhancer 37 in mouse line 2. Stereomicroscopic pictures of mouse 
brains stained for LacZ expression. All mice are offspring of the same founder mouse. (A) LacZ staining shown in a sagittal 
section along the midbrain line at embryonic day 13.5 is not present; (B). OB staining is first visible at age E18.5; (C) OB 
staining continues to be present in late adolescent mice at P39; (D) No OB staining is not detectable in mature adult mice. 
A-D) are lateral views of the olfactory bulb of a tissue block that was cut along the frontal cortex. HB: hindbrain, MB: 
midbrain, Di: diencephalon, Tel: Telencephalon, Ctx: cortex, OB: olfactory bulb. Scale bars: 1 mm 
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Figure 14: Development of ventricular staining of enhancer 37 in mouse line 2. Stereomicroscopic pictures of mouse brains 
stained for LacZ expression. All mice are offspring of the same founder animal. The staining of the lateral ventricle is first 
visible at age P7 (A) and is present in late adolescent mice (B). The staining remains intense in mature adult mice (C). fi: 
fimbria, LV: lateral ventricle, CC: corpus callosum, Ctx: cortex, Str: striatum, 3rdV: third ventricle, HPF: hippocampal 
formation, TH: thalamus. Scale bar: 1 mm.  
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Discussion 
In this chapter I analysed the activity patterns of two putative FOXP2 enhancers in the 
developing and adult central nervous system. I used PNI to insert enhancer-reporter gene 
constructs into fertilized mouse oocytes. With this method the transgene inserts randomly into 
the genome. It was therefore crucial to use criteria that distinguish endogenous enhancer 
activity from spurious activity caused by positional effects (i.e. the impact of neighbouring 
regulatory regions at the points of genomic insertion). The VISTA enhancer browser collects 
the results for thousands of enhancers tested with the same PNI-based method (Visel et al., 
2007). In the VISTA method, at least five transgenic mice were generated for each enhancer, 
carrying the sequence at different genomic positions. The staining pattern was analysed in 
every animal and endogenous activity was defined for staining that is observed in the same 
tissue in at least three animals (Visel et al., 2007). Both enhancers drive expression in two or 
more distinct brain regions. The finding that enhancers are active in multiple tissues is in line 
with data from previously reported enhancers (Visel et al., 2007; Bonn et al., 2012). As both 
enhancers have been shown to physically contact the transcriptionally active FOXP2 promoter 
in human cell lines (Chapter 3) and drive gene expression in reporter assays, they could 
contribute to FOXP2 expression in the detected brain regions. 
Enhancer 37 activity is present in the OB, which has been reported to express FOXP2. The 
enhancer activity was detected in the outer layers of the OB, but did not overlap with a defined 
anatomical region. FOXP2 has been previously found in glomerular and granular cells of the 
OB (Campbell et al., 2009; Zegary, 2009), of which the glomerular cells form the external 
neuronal layer. Therefore, enhancer 37 activity and FOXP2 expression likely overlap in this 
layer. In the glomerular cells, FOXP2 expression marks one of three defined subtypes (Zegary, 
2009). Thus, enhancer 37 may contribute to the expression of FOXP2 in the OB. Co-
localization of enhancer 37 activity with Foxp2 expression in the transgenic mice is necessary 
to determine the exact overlap of targeted cell types. 
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Enhancer 37 was also active in the hippocampus and ventricles, which do not show FOXP2 
expression according to prior research. Enhancers may regulate more than one gene. Thus, 
enhancer 37 could regulate another gene that is expressed in these structures (Bonn et al., 
2012). Enhancer contacts are dynamic between different cell types, but limited to genes within 
a topological domain (Dixon et al., 2012). Therefore, genes of the same topological domain as 
FOXP2 may be targeted by enhancer 37. Next to FOXP2, the surrounding topological domain 
contains the MDFIC, TFEC and PPP1R3A genes (Dixon et al., 2012). In neuronal-like cell lines 
the enhancer interacted with the FOXP2 promoter (Chapter3). The promoter was in contact 
with additional genomic regions, including the promoter of the MDFIC gene. It is therefore 
possible that enhancer 37 interacts with the MDFIC promoter and regulates the expression of 
this gene. MDFIC encodes the MyoD family inhibitor domain-containing protein, which 
regulates the WNT and JNK pathways (Kusano and Raab-Traub, 2002). The Allen Brain Atlas 
suggests strong expression of MDFIC in the CA1 and dentate gyrus, which matches the 
observed enhancer activity in the hippocampus (Lein et al., 2007). To further assess the 
hypothesis that enhancer 37 regulates MDFIC, it would be required to determine the direct 
interaction of enhancer 37 to the MDFIC promoter. In addition, co-localization of enhancer 37 
with Mdfic and Foxp2 in transgenic mice could further indicate the target gene of this enhancer 
in the hippocampus. 
The tissue, in which enhancer 37 is active has been linked to adult neurogenesis in prior 
studies (Eriksson et al., 1998; Jessberger and Gage, 2014). Adult neurogenesis occurs in the 
hippocampus and is involved in memory formation in mammals and humans (Eriksson et al., 
1998; Jessberger and Gage, 2014; Ernst and Frisen, 2015). A second site of adult 
neurogenesis is the subventricular zone (SVZ) of the ventricles. In rodents, the new-born 
neurons migrate from the SVZ towards the OB, where they differentiate into interneurons and 
integrate in the existing cellular architecture (Lois et al., 1996; Bergmann et al., 2015). To 
demonstrate a link between enhancer 37 and neurogenesis it would be necessary to co-label 
enhancer 37 reporter staining with markers of neurogenesis (Young et al., 2007). Mouse Foxp2 
Chapter 5: Activity of FOXP2 enhancers during development and in adult brains 
 
151 
 
has been implicated in embryonic neurogenesis and contributes to the transformation from 
neural progenitor to differentiated neurons (Tsui et al., 2013). Targets of FOXP2 in human 
neuronal-like cells and mouse embryonic brain are enriched for genes involved in 
neurogenesis (Spiteri et al., 2007; Vernes et al., 2007; Vernes et al., 2011). In adult zebra 
finch, FoxP2 expression has been detected in new-born neurons, originating from the SVZ 
(Rochefort et al., 2007). In zebra finches the SVZ born neurons migrated to and integrated into 
the striatal nucleus area X. FOXP2 expression was not observed in the SVZ itself, suggesting 
that FOXP2 expression is activated in post-migratory neurons (Rochefort et al., 2007). 
However, it remains to be shown whether or not FOXP2 is involved in adult neurogenesis in 
mammals. Research shows that, in humans, SVZ born neurons migrate and integrate into the 
striatum (Ernst et al., 2014; Ernst and Frisen, 2015), suggesting that the neurons from the 
rostral migratory stream could migrate towards the striatum. Enhancer 37 shows low 
evolutionary conservation across primates and is absent from non-primate species (Figure 
3A), suggesting that the function of this enhancer was obtained during more recent 
evolutionary events. Species-specific genetic variation in enhancers has been shown to 
contribute to human-specific neuronal changes (Boyd et al., 2015). However, from the 
presented data it remains speculative whether or not this enhancer could be linked to the 
human specific traits, such as a changed migratory pathway of new-born neurons. Migration 
of SVZ neurons to the striatum can be induced in mice after blocking the Notch-signalling 
pathway (Magnusson et al., 2014). Inducing this pathway in enhancer transgenic mice could 
be used to assess whether enhancer 37 is active in SVZ-to-striatal migratory neurons. 
The other investigated enhancer, enhancer 330, was previously shown to drive forebrain 
expression at embryonic day E11.5 (Visel et al., 2007). In other studies, Foxp2 mRNA 
expression in the ventricular zone and cortical plate has been detected at E14.5 (Ferland et 
al., 2003). Indeed, after knock-out of the Dicer gene, which encodes the enzyme responsible 
for processing immature micro RNAs (miRNA), cortical expression of Foxp2 can be detected 
at E13.5 (Clovis et al., 2012). In the early post-natal cortex, I detected activity of enhancer 330 
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in all cortical layers, at a time when Foxp2 is expression is mostly restricted to the deeper 
cortical layer VI (Ferland et al., 2003). In the post-natal brain the activity of enhancer 330 
overlaps FOXP2 expression in the deeper cortical layers. Thus, enhancer330 activity and 
FOXP2 expression could overlap in the embryonic and post-natal cortex suggesting that this 
enhancer activates FOXP2 expression during cortical development. Enhancer 330 activity was 
specific to the six-layered neocortex and absent in the three-layered paleocortex. This is in 
agreement with the absence of FOXP2 expression in the paleocortex (Ferland et al., 2003). 
In adult brain tissue, enhancer 330 is active in the upper cortical layers, whereas FOXP2 is 
expressed specifically in the deeper cortical layer VI (Ferland et al., 2003; Hisaoka et al., 2010). 
The difference in enhancer 330 activity and FOXP2 expression may be explained by post-
transcriptional and/or post-translational regulation. At the post-transcriptional level FOXP2 
mRNA has been shown to be a target of miRNAs (Clovis et al., 2012; Fu et al., 2014). The 
miRNAs miR-9 and miR-132 repress FOXP2 expression specifically in the upper cortical layers 
(Clovis et al., 2012). In addition, the FOXP2 protein is post-translationally modified and may 
be targeted for protein degradation. For example, the post-translational addition of a SUMO 
protein to FOXP2 has been shown, but this modification has not been shown to target FOXP2 
for degradation (Meredith et al., 2015; Estruch et al., 2016). The LacZ reporter gene does not 
contain the FOXP2 amino-acid sequences required for protein degradation or 3’-UTR for 
miRNA-mediated silencing. Therefore, it is likely that staining positive for the reporter gene is 
observed in cells which endogenously reduce FOXP2 protein levels via post-transcriptional 
and post-translational mechanisms. 
People with mutations of FOXP2 show structural and functional abnormalities in some cortical 
areas, such as the classical language associated Wenicke’s and Broca’s area, the angular 
gyrus and the precentral gyrus (Vargha-Khadem et al., 1998; Watkins et al., 2002; Belton et 
al., 2003; Liegeois et al., 2003; Liegeois et al., 2011). Genetic variation of enhancer 330 could 
in principle impact on enhancer function and affect the cortical expression of FOXP2. To my 
best knowledge, no case has been described with a selective deletion or mutation of this 
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element and high-throughput sequencing studies of clinical cases commonly focus on genetic 
variants within the exonic part of the genome and would not detect variation in the enhancer 
(Rabbani et al., 2014). The common single nucleotide polymorphism (SNP) rs12533005, which 
is located within 1kb of the upstream flanking sequence (Figure 3A), showed association to 
human traits in candidate association studies. One study investigated 12 SNPs and detected 
an association of this SNP to ADHD in a German cohort, which did not replicate in a Spanish 
cohort (Ribases et al., 2012). Another study investigated the association of 9 SNPs with 
dyslexia and detected a nominal association to rs12533005 (Wilcke et al., 2012). Wilcke et al. 
further conducted functional magnetic resonance imaging in 25 individuals carrying the risk-
conferring minor allele and 8 non-carrier individuals. They detected that carriers of the minor 
allele showed reduced activity in the angular gyrus and supramarginal gyri during phonological 
processing tasks. Thus, enhancer 330 activity and genetic effects of rs12533005 coincide at 
cortical areas that show anomalies in patients with FOXP2 mutations. This could suggest that 
rs12533005 influences the activity of enhancer 330 or tags another functional variant within 
this enhancer. A third study detected an association of rs12533005 (out of 6 tested variants) 
to increased left-hemispheric speech perception in healthy individuals (Ocklenburg et al., 
2013), further indicating that this SNP may affect cortical functioning. However, the link 
between this SNP and enhancer 330 requires additional evidence. For example, genotyping 
of additional SNPs within this enhancer may show that rs12533005 is a proxy of an association 
to a variant within enhancer 330. Alternatively, a longer version of enhancer 330 could be 
investigated in reporter gene studies to determine if the sequence at rs12533005 contributes 
to enhancer function. In addition, the screening of enhancer 330 for mutations in cohorts of 
people with speech/language disorders is a promising approach to detect pathological 
variation. 
FOXP2 has been recognized as a marker gene for cortical differentiation of cultured neuronal 
stem cells (Bickenbach et al., 2013; Espuny-Camacho et al., 2013; Belinsky et al., 2014; 
Raitano et al., 2015). During the in vitro differentiation of induced pluripotent stem cells (iPSC) 
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to cortical neurons, endogenous FOXP2 expression is switched on (Espuny-Camacho et al., 
2013; Belinsky et al., 2014). The activity of the FOXP2 enhancer 330 in developing cortex 
could suggest that this enhancer would be activated in the cultured neurons. Chromatin 
conformation (Chapter 3) and reporter gene experiments (Chapter 4) in cultured stem cells 
would help to test this hypothesis. Human iPSCs and derived neurons are promising systems 
to study the neurodevelopmental function of enhancer 330 in human genetic background.  
I also detected enhancer 330 activity in the adult cerebellum. The cerebellum develops after 
E11.5 and enhancer activity at this time may be undetected by the analysis performed for the 
VISTA enhancer browser. The cerebellar anlage is formed at E12.5 and the cerebellar 
hemisphere can be distinguished from other anatomical regions at embryonic day E14 (Millen 
et al., 1994; Fujita and Sugihara, 2012). FOXP2 is expressed in the majority of neuronal nuclei 
of the cerebellar hemisphere at E14.5 (Fujita and Sugihara, 2012). The founder mouse and 
subsequent mice of the established mouse line, which were used to study the longitudinal 
activity of enhancer 330 did not show cerebellar staining. Therefore, it remains to be 
determined at what developmental stage FOXP2 expression and enhancer 330 activity start 
in the cerebellar anlage/cerebellar hemisphere. 
Several FOXP2 positive brain structures did not show enhancer activity for either enhancer 37 
or 330. I therefore expect that additional enhancers regulate the expression of FOXP2. In the 
previous chapters I identified enhancers that were not tested in this chapter and could be 
promising candidates for recapitulating further parts of the FOXP2 expression pattern. 
In summary, in this chapter I characterized the pattern of activity of two FOXP2 enhancers in 
the brain and followed this activity during development. The enhancers recapitulated some 
parts of the complex FOXP2 expression pattern. Enhancer 37 is active in the OB, a known 
region of FOXP2 expression, and coincides with sites of adult neurogenesis. Enhancer 330 
may be involved in modulating FOXP2 expression in the cortex and PCs. In addition, the 
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proximity of enhancer 330 to rs12533005 may explain the observed associations of this SNP 
to language-related traits.  
  
Chapter 5: Activity of FOXP2 enhancers during development and in adult brains 
 
156 
 
References 
Becker M, Devanna P, Fisher SE, Vernes SC (2015) A chromosomal rearrangement in a child with 
severe speech and language disorder separates FOXP2 from a functional enhancer. Molecular 
cytogenetics 8:69. 
Belinsky GS, Rich MT, Sirois CL, Short SM, Pedrosa E, Lachman HM, Antic SD (2014) Patch-clamp 
recordings and calcium imaging followed by single-cell PCR reveal the developmental profile of 
13 genes in iPSC-derived human neurons. Stem cell research 12:101-118. 
Belton E, Salmond CH, Watkins KE, Vargha-Khadem F, Gadian DG (2003) Bilateral brain abnormalities 
associated with dominantly inherited verbal and orofacial dyspraxia. Human brain mapping 
18:194-200. 
Bergmann O, Spalding KL, Frisen J (2015) Adult Neurogenesis in Humans. Cold Spring Harbor 
perspectives in biology 7. 
Bickenbach JR, Tomanek-Chalkley A, Wiechert S, Winter MC (2013) Human skin keratinocytes can be 
reprogrammed to express neuronal genes and proteins after a single treatment with decitabine. 
BioResearch open access 2:217-221. 
Bonn S, Zinzen RP, Girardot C, Gustafson EH, Perez-Gonzalez A, Delhomme N, Ghavi-Helm Y, 
Wilczynski B, Riddell A, Furlong EE (2012) Tissue-specific analysis of chromatin state identifies 
temporal signatures of enhancer activity during embryonic development. Nat Genet 44:148-156. 
Boyd JL, Skove SL, Rouanet JP, Pilaz LJ, Bepler T, Gordan R, Wray GA, Silver DL (2015) Human-
Chimpanzee Differences in a FZD8 Enhancer Alter Cell-Cycle Dynamics in the Developing 
Neocortex. Current biology : CB. 
Campbell P, Reep RL, Stoll ML, Ophir AG, Phelps SM (2009) Conservation and diversity of Foxp2 
expression in muroid rodents: functional implications. The Journal of comparative neurology 
512:84-100. 
Clovis YM, Enard W, Marinaro F, Huttner WB, De Pietri Tonelli D (2012) Convergent repression of Foxp2 
3'UTR by miR-9 and miR-132 in embryonic mouse neocortex: implications for radial migration 
of neurons. Development 139:3332-3342. 
Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, Hu M, Liu JS, Ren B (2012) Topological domains in 
mammalian genomes identified by analysis of chromatin interactions. Nature 485:376-380. 
Domene S, Bumaschny VF, de Souza FS, Franchini LF, Nasif S, Low MJ, Rubinstein M (2013) Enhancer 
turnover and conserved regulatory function in vertebrate evolution. Philosophical transactions 
of the Royal Society of London Series B, Biological sciences 368:20130027. 
Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH (1998) 
Neurogenesis in the adult human hippocampus. Nature medicine 4:1313-1317. 
Ernst A, Frisen J (2015) Adult neurogenesis in humans- common and unique traits in mammals. PLoS 
biology 13:e1002045. 
Ernst A, Alkass K, Bernard S, Salehpour M, Perl S, Tisdale J, Possnert G, Druid H, Frisen J (2014) 
Neurogenesis in the striatum of the adult human brain. Cell 156:1072-1083. 
Espuny-Camacho I, Michelsen KA, Gall D, Linaro D, Hasche A, Bonnefont J, Bali C, Orduz D, Bilheu A, 
Herpoel A, Lambert N, Gaspard N, Peron S, Schiffmann SN, Giugliano M, Gaillard A, 
Vanderhaeghen P (2013) Pyramidal neurons derived from human pluripotent stem cells 
integrate efficiently into mouse brain circuits in vivo. Neuron 77:440-456. 
Estruch SB, Graham SA, Deriziotis P, Fisher SE (2016) The language-related transcription factor 
FOXP2 is post-translationally modified with small ubiquitin-like modifiers. Sci Rep 6. 
Ferland RJ, Cherry TJ, Preware PO, Morrisey EE, Walsh CA (2003) Characterization of Foxp2 and 
Foxp1 mRNA and protein in the developing and mature brain. The Journal of comparative 
neurology 460:266-279. 
Fu LJ, Shi ZM, Luo GZ, Tu WH, Wang XJ, Fang ZD, Li XC (2014) Multiple microRNAs regulate human 
FOXP2 gene expression by targeting sequences in its 3 ' untranslated region. Molecular brain 
7. 
Fujita E, Tanabe Y, Momoi MY, Momoi T (2012) Cntnap2 expression in the cerebellum of Foxp2(R552H) 
mice, with a mutation related to speech-language disorder. Neuroscience letters 506:277-280. 
Fujita H, Sugihara I (2012) FoxP2 expression in the cerebellum and inferior olive: development of the 
transverse stripe-shaped expression pattern in the mouse cerebellar cortex. The Journal of 
comparative neurology 520:656-677. 
Hawrylycz MJ et al. (2012) An anatomically comprehensive atlas of the adult human brain transcriptome. 
Nature 489:391-399. 
Chapter 5: Activity of FOXP2 enhancers during development and in adult brains 
 
157 
 
Hisaoka T, Nakamura Y, Senba E, Morikawa Y (2010) The forkhead transcription factors, Foxp1 and 
Foxp2, identify different subpopulations of projection neurons in the mouse cerebral cortex. 
Neuroscience 166:551-563. 
Ittner LM, Gotz J (2007) Pronuclear injection for the production of transgenic mice. Nature protocols 
2:1206-1215. 
Jessberger S, Gage FH (2014) Adult neurogenesis: bridging the gap between mice and humans. Trends 
Cell Biol 24:558-563. 
Juers DH, Matthews BW, Huber RE (2012) LacZ beta-galactosidase: structure and function of an 
enzyme of historical and molecular biological importance. Protein science : a publication of the 
Protein Society 21:1792-1807. 
Kothary R, Clapoff S, Darling S, Perry MD, Moran LA, Rossant J (1989) Inducible expression of an 
hsp68-lacZ hybrid gene in transgenic mice. Development 105:707-714. 
Kusano S, Raab-Traub N (2002) I-mfa domain proteins interact with Axin and affect its regulation of the 
Wnt and c-Jun N-terminal kinase signaling pathways. Molecular and cellular biology 22:6393-
6405. 
Lai CS, Gerrelli D, Monaco AP, Fisher SE, Copp AJ (2003) FOXP2 expression during brain development 
coincides with adult sites of pathology in a severe speech and language disorder. Brain : a 
journal of neurology 126:2455-2462. 
Lein ES et al. (2007) Genome-wide atlas of gene expression in the adult mouse brain. Nature 445:168-
176. 
Liegeois F, Morgan AT, Connelly A, Vargha-Khadem F (2011) Endophenotypes of FOXP2: dysfunction 
within the human articulatory network. European journal of paediatric neurology : EJPN : official 
journal of the European Paediatric Neurology Society 15:283-288. 
Liegeois F, Baldeweg T, Connelly A, Gadian DG, Mishkin M, Vargha-Khadem F (2003) Language fMRI 
abnormalities associated with FOXP2 gene mutation. Nat Neurosci 6:1230-1237. 
Lois C, Garcia-Verdugo JM, Alvarez-Buylla A (1996) Chain migration of neuronal precursors. Science 
271:978-981. 
Magnusson JP, Goritz C, Tatarishvili J, Dias DO, Smith EM, Lindvall O, Kokaia Z, Frisen J (2014) A 
latent neurogenic program in astrocytes regulated by Notch signaling in the mouse. Science 
346:237-241. 
Meredith LJ, Wang CM, Nascimento L, Liu R, Wang L, Yang WH (2015) The Key Regulator for 
Language and Speech Development, FOXP2, is a Novel Substrate for SUMOylation. Journal of 
cellular biochemistry. 
Millen KJ, Wurst W, Herrup K, Joyner AL (1994) Abnormal embryonic cerebellar development and 
patterning of postnatal foliation in two mouse Engrailed-2 mutants. Development 120:695-706. 
Ocklenburg S, Arning L, Gerding WM, Epplen JT, Gunturkun O, Beste C (2013) FOXP2 variation 
modulates functional hemispheric asymmetries for speech perception. Brain Lang 126:279-284. 
Rabbani B, Tekin M, Mahdieh N (2014) The promise of whole-exome sequencing in medical genetics. 
J Hum Genet 59:5-15. 
Raitano S, Ordovas L, De Muynck L, Guo W, Espuny-Camacho I, Geraerts M, Khurana S, Vanuytsel K, 
Toth BI, Voets T, Vandenberghe R, Cathomen T, Van Den Bosch L, Vanderhaeghen P, Van 
Damme P, Verfaillie CM (2015) Restoration of progranulin expression rescues cortical neuron 
generation in an induced pluripotent stem cell model of frontotemporal dementia. Stem cell 
reports 4:16-24. 
Ribases M, Sanchez-Mora C, Ramos-Quiroga JA, Bosch R, Gomez N, Nogueira M, Corrales M, 
Palomar G, Jacob CP, Gross-Lesch S, Kreiker S, Reif A, Lesch KP, Cormand B, Casas M, 
Bayes M (2012) An association study of sequence variants in the forkhead box P2 (FOXP2) 
gene and adulthood attention-deficit/hyperactivity disorder in two European samples. 
Psychiatric genetics 22:155-160. 
Rochefort C, He X, Scotto-Lomassese S, Scharff C (2007) Recruitment of FoxP2-expressing neurons 
to area X varies during song development. Developmental neurobiology 67:809-817. 
Rubinstein M, de Souza FS (2013) Evolution of transcriptional enhancers and animal diversity. 
Philosophical transactions of the Royal Society of London Series B, Biological sciences 
368:20130017. 
Shu W, Yang H, Zhang L, Lu MM, Morrisey EE (2001) Characterization of a new subfamily of winged-
helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. 
J Biol Chem 276:27488-27497. 
Spiteri E, Konopka G, Coppola G, Bomar J, Oldham M, Ou J, Vernes SC, Fisher SE, Ren B, Geschwind 
DH (2007) Identification of the transcriptional targets of FOXP2, a gene linked to speech and 
language, in developing human brain. Am J Hum Genet 81:1144-1157. 
Chapter 5: Activity of FOXP2 enhancers during development and in adult brains 
 
158 
 
Tsui D, Vessey JP, Tomita H, Kaplan DR, Miller FD (2013) FoxP2 regulates neurogenesis during 
embryonic cortical development. The Journal of neuroscience : the official journal of the Society 
for Neuroscience 33:244-258. 
Vargha-Khadem F, Watkins KE, Price CJ, Ashburner J, Alcock KJ, Connelly A, Frackowiak RS, Friston 
KJ, Pembrey ME, Mishkin M, Gadian DG, Passingham RE (1998) Neural basis of an inherited 
speech and language disorder. Proc Natl Acad Sci U S A 95:12695-12700. 
Vernes SC, Spiteri E, Nicod J, Groszer M, Taylor JM, Davies KE, Geschwind DH, Fisher SE (2007) 
High-throughput analysis of promoter occupancy reveals direct neural targets of FOXP2, a gene 
mutated in speech and language disorders. Am J Hum Genet 81:1232-1250. 
Vernes SC, Oliver PL, Spiteri E, Lockstone HE, Puliyadi R, Taylor JM, Ho J, Mombereau C, Brewer A, 
Lowy E, Nicod J, Groszer M, Baban D, Sahgal N, Cazier JB, Ragoussis J, Davies KE, 
Geschwind DH, Fisher SE (2011) Foxp2 regulates gene networks implicated in neurite 
outgrowth in the developing brain. PLoS Genet 7:e1002145. 
Villar D, Berthelot C, Aldridge S, Rayner TF, Lukk M, Pignatelli M, Park TJ, Deaville R, Erichsen JT, 
Jasinska AJ, Turner JM, Bertelsen MF, Murchison EP, Flicek P, Odom DT (2015) Enhancer 
evolution across 20 mammalian species. Cell 160:554-566. 
Visel A, Minovitsky S, Dubchak I, Pennacchio LA (2007) VISTA Enhancer Browser--a database of 
tissue-specific human enhancers. Nucleic Acids Res 35:D88-92. 
Visel A, Prabhakar S, Akiyama JA, Shoukry M, Lewis KD, Holt A, Plajzer-Frick I, Afzal V, Rubin EM, 
Pennacchio LA (2008) Ultraconservation identifies a small subset of extremely constrained 
developmental enhancers. Nat Genet 40:158-160. 
Visel A, Blow MJ, Li Z, Zhang T, Akiyama JA, Holt A, Plajzer-Frick I, Shoukry M, Wright C, Chen F, Afzal 
V, Ren B, Rubin EM, Pennacchio LA (2009) ChIP-seq accurately predicts tissue-specific activity 
of enhancers. Nature 457:854-858. 
Visel A et al. (2013) A high-resolution enhancer atlas of the developing telencephalon. Cell 152:895-
908. 
Watkins KE, Vargha-Khadem F, Ashburner J, Passingham RE, Connelly A, Friston KJ, Frackowiak RS, 
Mishkin M, Gadian DG (2002) MRI analysis of an inherited speech and language disorder: 
structural brain abnormalities. Brain : a journal of neurology 125:465-478. 
Wilcke A, Ligges C, Burkhardt J, Alexander M, Wolf C, Quente E, Ahnert P, Hoffmann P, Becker A, 
Muller-Myhsok B, Cichon S, Boltze J, Kirsten H (2012) Imaging genetics of FOXP2 in dyslexia. 
European journal of human genetics : EJHG 20:224-229. 
Young JI, Otero V, Cerdan MG, Falzone TL, Chan EC, Low MJ, Rubinstein M (1998) Authentic cell-
specific and developmentally regulated expression of pro-opiomelanocortin genomic fragments 
in hypothalamic and hindbrain neurons of transgenic mice. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 18:6631-6640. 
Young KM, Fogarty M, Kessaris N, Richardson WD (2007) Subventricular zone stem cells are 
heterogeneous with respect to their embryonic origins and neurogenic fates in the adult olfactory 
bulb. The Journal of neuroscience : the official journal of the Society for Neuroscience 27:8286-
8296. 
Zegary JA (2009) Transcription Factor Regulation of Olfactory Bulb Interneuron Heterogeneity. Doctoral 
dissertation of the College of Medicine at the University of Cincinnati  
 
Chapter 6: Gene enhancers affect subcortical volumes in the adult human brain 
 
159  
Chapter 6 
 
Early developmental gene enhancers affect 
subcortical volumes in the adult human brain 
 
 
This chapter has been published in 
Becker M, Guadalupe T, Franke B, Hibar DP, Renteria ME, Stein JL, Thompson PM, 
Francks C, Vernes SC, Fisher SE (2016) Early developmental gene enhancers affect 
subcortical volumes in the adult human brain. Human Brain Mapping 37:1788-1800. 
The supplementary information is available online on the website of the Human Brain 
Mapping journal. 
 
  
Chapter 6: Gene enhancers affect subcortical volumes in the adult human brain 
 
160  
Abstract 
Genome-wide association screens (GWAS) aim to identify common genetic variants 
contributing to the phenotypic variability of complex traits, such as human height or brain 
morphology. The identified genetic variants are mostly within non-coding genomic regions and 
the biology of the genotype-phenotype association typically remains unclear. In this paper, we 
propose a complementary targeted strategy to reveal the genetic underpinnings of variability 
in subcortical brain volumes, by specifically selecting genomic loci that are experimentally 
validated forebrain enhancers, active in early embryonic development. We hypothesized that 
genetic variation within these enhancers may affect the development and ultimately the 
structure of subcortical brain regions in adults. We tested whether variants in forebrain 
enhancer regions showed an overall enrichment of association with volumetric variation in 
subcortical structures of >13,000 healthy adults. We observed significant enrichment of 
genomic loci that affect the volume of the hippocampus within forebrain enhancers (empirical 
p = 0.0015), a finding which robustly passed the adjusted threshold for testing of multiple brain 
phenotypes (cut-off of p < 0.0083 at an alpha of 0.05). In analyses of individual SNPs, we 
identified an association upstream of the ID2 gene with rs7588305 and variation in 
hippocampal volume. This SNP-based association survived multiple-testing correction for the 
number of SNPs analyzed but not for the number of subcortical structures. Targeting known 
regulatory regions offers a way to understand the underlying biology that connects genotypes 
to phenotypes, particularly in the context of neuroimaging genetics. This biology-driven 
approach generates testable hypotheses regarding the functional biology of identified 
associations.  
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Introduction 
Global research efforts are underway to determine how genomic variants contribute to 
variation in brain volume in the general population. Altered volumes of brain regions are 
associated with neurodegenerative (Jack et al., 2011) and neuropsychiatric disorders 
(Videbech and Ravnkilde, 2004; van Erp et al., 2015). Current GWAS studies connect 
common genetic variants known as single nucleotide polymorphisms (SNPs) with phenotypic 
variations in brain imaging data in cohorts of normal individuals (Bis et al., 2012; Stein et al., 
2012; Cai et al., 2014; Guadalupe et al., 2014b). However, most SNPs identified by GWAS 
are within non-coding regions and their biological functions remain unclear. We employed a 
hypothesis-driven strategy involving pre-selection of SNPs within genomic regions of 
experimentally defined biological function. We found that the selected SNPs are significantly 
enriched for association with hippocampal volume. This approach can help to generate 
testable follow-up hypotheses about the underlying genotype-phenotype correlation. 
It is challenging to predict and test the consequences of single nucleotide changes in genomic 
regions that do not encode protein-coding genes or regulatory RNA molecules (Visel et al., 
2009a). Nevertheless, a vast amount of non-coding DNA is thought to play some functional 
role, for example by regulating gene expression as promoters or enhancers. These regions 
are bound by regulatory proteins such as transcription factors (TFs) to directly influence gene 
expression and single nucleotide changes within these regions can affect gene expression 
(Spitz and Furlong, 2012). 
A complementary strategy to genome-wide association screening is to look specifically for 
association within genomic regions that are predicted to be functional; for example by targeting 
regions known to be bound by a particular TF or marked by a given epigenetic modification. 
The approach was adopted in a study focusing on the genomic distribution of cell-type specific 
regulatory regions in hematopoietic cells. These regions were enriched for the presence of 
genetic variants associated with hematological traits such as platelet count, while no enriched 
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association was detected for unrelated traits such as body-mass index (BMI) (Paul et al., 
2013). Another study applied a similar approach to publicly available functional datasets and 
found enriched association across a range of human traits and disorders, including Crohn’s 
disease and height (Pickrell, 2014). Thus, a priori knowledge of the functional characteristics 
of genomic regions may help in selecting subsets of genomic variants for association testing. 
To our knowledge, no prior study has systematically integrated information about functional 
brain enhancers with genetic data in human individuals. In the current study, we analyzed 
publicly available data from the ENIGMA (Enhancing Neuroimaging Genetics through Meta-
analysis) consortium, a neuroimaging genetics initiative that combines GWAS statistics from 
50 cohorts spread world-wide, with a total combined sample size of 30,717 individuals 
(Thompson et al., 2014). The ENIGMA consortium recently presented GWAS findings on 
seven subcortical volumes and intracranial volume (Hibar et al., 2015). Five genetic variants 
were significantly associated with the volumes of the hippocampus and putamen. These SNPs 
mapped within non-coding regions of the genome and their functional roles are largely 
unknown. We hypothesized that polymorphisms located within experimentally validated brain 
enhancers, with established impacts on early neural development may be enriched for 
association with volumetric changes in subcortical brain structures. A valuable source of 
enhancers is the VISTA browser, which reports the tissue-specificity of about two thousand 
potential enhancers. Genomic elements tested in VISTA were chosen for their conservation 
across species and/or enhancer-specific chromatin marks in brain tissue (Visel et al., 2008; 
Visel et al., 2009b). Their potential to reproducibly drive expression of a reporter gene was 
tested at an early developmental timepoint in the mouse brain (Visel et al., 2007). VISTA 
contains 309 enhancers that drive expression in the embryonic forebrain; the developmental 
origin of the subcortical regions analyzed in adults by the ENIGMA consortium. Here, we 
integrate ENIGMA meta-analysis data with information on VISTA forebrain enhancer regions 
to assess for genetic effects on normal variation in subcortical brain volumes, using gene-set 
and SNP-based approaches.  
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Methods and Materials 
VISTA enhancer browser of experimentally validated enhancer fragments 
The VISTA enhancer browser is a collection of experimentally validated non-coding fragments 
of the human and mouse genomes that exhibit enhancer activity (Visel et al., 2007). Potential 
enhancers were predicted based on ChIP-seq experiments or evolutionary conservation. The 
selected non-coding fragments were cloned in front of a minimal promoter and the LacZ 
reporter gene. The resulting constructs were injected into the pro-nucleus of mouse embryos 
and re-implanted into foster mothers. Developing embryos were stained for reporter gene 
expression at embryonic day 11.5 (E11.5). Non-coding fragments that drive reproducible 
reporter gene expression in multiple (≥5) embryos are defined as positive enhancers. If no 
reproducible staining was detected in seven individual embryos, the non-coding fragment was 
regarded as negative. Thus, the database represents a collection of functional enhancers and 
their tissue of activity in developing embryos. 
 
ENIGMA meta-analyzed neuroimaging GWAS of subcortical brain volumes 
The ENIGMA consortium conducts harmonized analyses that combine neuroimaging genetics 
data from over 50 cohorts world-wide to search for common gene variants that are associated 
with brain structure and function. ENIGMA2 describes the second project of this consortium, 
which tested associations of 8.5 million SNPs with the variance in volumes of the nucleus 
accumbens, amygdala, caudate nucleus, hippocampus, pallidum, putamen, thalamus, and the 
intracranial volume, measured from brain MRI (Hibar et al., 2015). The discovery sample for 
ENIGMA2 consisted of 13,171 subjects of European ancestry. The ENIGMA consortium also 
had access to a replication set of 17,546 subjects and reported on a total of 30,717 individuals. 
Subjects were scanned at the individual sites using brain MRI and the resulting images were 
processed in a standard way across all sites. The volumetric measures of all subcortical 
structures were corrected for age, sex, genetic homogeneity and intracranial volume. At each 
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site, genotypes were obtained from commercially available platforms and imputed to the 
reference panel 1000genomes v1.3 using scripts provided by the ENIGMA working group. 
GWAS was performed at each site, and the meta-analysis of all 50 cohorts was performed 
centrally using the software package METAL (Willer et al., 2010). Here, we use the meta-
analyzed summary p-values of the 13,171 subjects obtained from the discovery sample. The 
remaining 17,000 subjects from ENIGMA2 lack meta-analyzed genome-wide statistics and 
were thus unavailable for use in the present study. 
 
Selecting SNPs within human enhancers 
A list of enhancers, including their genomic coordinates (human genome build hg19) and their 
tissue of activity, was downloaded from the VISTA enhancer browser (Version 19.Sept 2014) 
(Visel et al., 2007). We filtered all human enhancer elements with a reproducible forebrain 
activity at embryonic stage E11.5. The forebrain is the developmental origin of the subcortical 
regions analyzed by ENIGMA. We removed nine enhancer elements located on chromosome 
X, as this chromosome was not included in the ENIGMA2 data. Four enhancers (hs322, 
hs1354, hs998, and hs1597) contained within larger enhancers were deleted to obtain a non-
redundant list of 296 loci with a mean size of 1936 bp (standard deviation of 941 bp). Enhancer 
boundaries are not well defined, and flanking regions can be critical for the stability of an 
enhancers activity (Ludwig et al., 2011). We intersected the genomic enhancer regions, 
including 500 bp flanking regions with the genomic positions of all markers present in the 
meta-analyzed GWAS files of ICV-adjusted subcortical volumes (nucleus accumbens, 
amygdala, caudate nucleus, hippocampus, pallidum, putamen, and thalamus) from ENIGMA2. 
From this, we derived a list of 2082 SNPs and indels, which represent non-coding genetic 
variants with a potential impact on enhancer activity. We refer to these variants as enhancer 
SNPs.  
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Testing enrichment of association with subcortical volumes 
ENIGMA2 tested for the association of 8.5 million genome-wide markers against volumes of 
7 subcortical brain structures. 2,082 of these markers were located within forebrain enhancer 
regions. For each of these markers we converted their association p-values into z-scores. 
Note that we could not specify a priori whether a particular allele of a SNP within an enhancer 
should lead to an increase or decrease in the activity of the relevant enhancer. Moreover, 
increases in gene expression may be correlated with either an increase or decrease in volume 
of a structure, depending on the nature of the gene product; both directions of effect are 
possible in principle, given what is known about mechanisms by which genes influence brain 
morphology. Thus, because we did not have prior hypotheses regarding direction of effect, we 
converted the p-values to right-tailed z-scores. These z-scores were then summed to calculate 
a "forebrain enhancer" test statistic. This was repeated for each of the tested brain 
phenotypes.  
The probability of observing a similar (or greater) test statistic was determined by sampling 
2,082 markers from 296 random genomic regions from the rest of the ENIGMA2 results. For 
each of the 296 forebrain enhancer regions, a randomly sampled genomic region of similar 
length was selected (with a difference no greater than 1000 bp), which included at least the 
same number of markers as the original one. We chose the generated regions to be of similar 
size to avoid repetitive parts of the genome, such as telomeres or centromeres. We note that 
since the ENIGMA results are obtained via a large-scale meta-analysis of GWAS statistics 
from many different populations, we are unable to determine the precise LD structure that 
would most appropriately match the enrichment analyses. Thus, our permutation approach 
assumes that the LD structure of the enhancer regions is broadly characteristic of the rest of 
the genome. From this set of new selected regions, 2,082 markers were used to calculate the 
new randomly-generated set statistic. This was repeated ten thousand times. The p-value for 
the enrichment is the result of dividing the number of randomly-generated test statistics that 
are higher than the observed test statistic by the number of permutations (10,000). The seven 
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phenotypes are correlated, and we determined that the effective number of independent 
phenotypes is six, using the Matrix Spectral Decomposition, matSpD software. We accounted 
for multiple testing by Bonferroni correction for this effective number of independent 
phenotypes. Thus, at an alpha of 0.05, the p-value threshold for significant enrichment was 
0.0083. 
 
Testing enrichment of association with unrelated human traits as a control 
As noted above, our permutation approach for assessing enrichment assumes that enhancer 
regions do not deviate substantially in LD structure, as compared to the rest of the genome. 
Therefore, we performed additional control experiments to discount the possibility that 
evidence of enrichment might be an artefact of unusual LD patterns. We downloaded the 
meta-analyzed GWAS summary statistics for BMI (Speliotes et al., 2010), height (Lango Allen 
et al., 2010) and waist-to-hip ratio (WHR) (Heid et al., 2010) from the Genetic Investigation of 
Anthropometric Traits (GIANT) consortium. We used the Galaxy web-based platform 
(Giardine et al., 2005; Blankenberg et al., 2010; Goecks et al., 2010) to add the SNP’s genomic 
locations (hg19) and carried out enrichment analysis as described above. Based on Bonferroni 
correction for use of three control phenotypes, at an alpha of 0.05 the p-value threshold for 
significant enrichment in these analyses was 0.017. 
 
Association of individual enhancer SNPs with subcortical volumes 
SNPs within the same enhancer are in close proximity, and often in linkage disequilibrium 
(LD), so not independent from each other. We therefore wanted to determine the effective 
number of independent SNPs in the SNP-based association tests. Since the original 
genotypes for all subjects were not centrally collected by ENIGMA they were unavailable for 
the present study. Therefore, we calculated the effective number of tested SNPs from a large 
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subset of ENIGMA for which genotypes were available to us: the Brain Imaging Genetics (BIG) 
cohort of the Cognomics initiative (Guadalupe et al., 2014a). This cohort contributed 
approximately 10% of the subjects to the ENIGMA2 discovery sample and consists of healthy 
subjects of European ancestry. Using the Genetic Type I Error Calculator (Li et al., 2012), we 
determined that the number of effectively independent tests performed when assessing 
associations for the 2,082 enhancer SNPs was 770. 
We evaluated the evidence for association between enhancer SNPs (spread across 296 
enhancers) and variation in the seven subcortical volumes analyzed in ENIGMA2. As noted 
above, analyses with matSpD (Nyholt, 2004) indicated that the effective number of 
independent phenotypes is six. We derived an appropriate significance threshold based on 
Bonferroni correction, taking into consideration both the effective number of tested SNPs and 
the effective number of independent phenotypes. At an alpha of 0.05, the significance 
threshold for a SNP was 1.08x10-5. 
 
Analysis of eQTL effects in adult brain samples 
We used the BRAINEAC eQTL database (Ramasamy et al., 2014) to investigate if rs7588305 
is associated with expression changes in adult human hippocampal samples. Using the 
webtool we obtained eQTL association p-values for the queried SNP to expression probes of 
surrounding genes in different brain areas. We corrected the p-values for the number of probes 
that the rs7588305 SNP was correlated with to determine if the SNP represents an eQTL for 
one of the surrounding genes. 
 
Predicting transcription factor binding events 
To predict the effect of rs7588305 alleles on TF binding events, we performed a motif analysis 
using the MATCH algorithm, set to minimize false positives (Kel et al., 2003). As the source 
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for position weight matrices we used the commercially available Transfac2014.4 motif library. 
We predicted the binding events for a 51-nucleotide long genomic fragment centered on 
rs7588305, which was downloaded from the UCSC Genome Browser human genome version 
19 (hg19). We predicted binding events for both the major and minor alleles. 
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Results 
Developmental brain enhancers are significantly enriched for association with hippocampal 
volume 
The a priori selection of functional genomic regions (Figure 1, Supporting table 1) allowed us 
to test for enriched genetic association among all enhancer elements as a group. We 
hypothesized that the group of enhancers contains a significant number of SNPs with sub-
threshold associations, which we could detect by comparing the enhancer regions to random 
genomic regions. Using a permutation approach, we detected significantly enriched 
association of the enhancer region set with hippocampal volume (empirical p = 0.0015, 
passing our predesignated threshold of p < 0.0083 based on Bonferroni correction for multiple 
brain phenotypes). Additionally, we detected nominally significant enrichment in the nucleus 
accumbens, putamen, and thalamus (p = 0.016, p=0.048, p=0.016, respectively) that did not 
pass multiple testing correction for the number of subcortical volumes that were analyzed 
(Table 1). This result supports the hypothesis that experimentally validated forebrain enhancer 
regions from early developmental timepoints contain a significant number of genetic variants 
associated with the size of adult subcortical brain structures. 
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Figure 1: Overview of enhancer SNP association study. In this study we used two independent datasets. (A) 
Genomic regions of forebrain enhancers as determined in transgenic E11.5 mouse embryos and (B) association 
of common genetic variants with the volumetric variation of subcortical brain structures, determined by MRI. (C) 
Preselecting SNPs within enhancer regions allowed us to investigate associations that do not pass genome-wide 
significance. We used two complementary strategies testing for enriched occurrence of association signals within 
the group of enhancer regions, and looking for association of individual enhancer SNPs. 
Table 1: Enrichment of enhancer SNP 
association 
Brain structure Enrichment p-value 
Accumbens 0.016 
Amygdala 0.068 
Caudate 0.076 
Hippocampus 0.0015 
Pallidum 0.075 
Putamen 0.048 
Thalamus 0.016 
 
Within each permutation the SNPs were randomly generated, but had to be located in genomic 
regions of similar SNP density to the enhancer regions. Genomic regions with low SNP density 
may have a different overall LD structure from that of the enhancer regions and may skew the 
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observed enrichment. Indeed, if we did not limit the genomic distribution of the randomly 
generated SNPs, we detect a more significant enrichment for the forebrain enhancer regions 
within the hippocampus (p < 0.0006).  
Our hypothesis was that specifically forebrain enhancers are enriched for association with 
subcortical volumes. To assess if the detected enrichment could instead be due to a more 
general enrichment in enhancer regions, we generated a list of VISTA enhancers that are 
active in tissues other than the brain. We obtained a comparable number of non-brain 
enhancers (320 enhancers, Supporting table 2). We calculated the enrichment of association 
with hippocampal volume using the same approach as for the forebrain enhancer set and 
found that the control enhancer regions were not significantly enriched for association with 
hippocampal volume (p = 0.95). These findings suggest that the enrichment we detected 
within forebrain enhancers reflect functional links between these enhancer sequences and 
their tissue of activity. 
Enhancers may function in more than one tissue and many of the forebrain enhancers are 
also active in other parts of the developing embryo, such as the neural tube (79/296 enhancer 
regions), limbs (33/296), eye (19/296) or heart (5/296) (Supporting table 3). However, we 
wanted to determine if the forebrain enhancers are specifically enriched for neuronal traits and 
exclude that the enrichment is caused by factors other than the biological link. We downloaded 
GWAS summary statistics for BMI, height and WHR from the GIANT consortium and repeated 
the enrichment analysis. We detected no enrichment for BMI, height or WHR (p = 0.06, p = 
0.99, p = 0.97 respectively, none approaching predesignated threshold of p < 0.017 for control 
phenotypes). This finding supports the view that the significant enrichment of forebrain 
enhancers with hippocampal volume reflects specific effects, rather than being an artefact e.g. 
of the particular LD structure of the regions being studied. 
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Suggestive association of an enhancer SNP upstream of ID2 with variation in hippocampal 
volume 
In parallel we analyzed the individual enhancer SNPs for association with the seven 
subcortical volumes. After adjusting our significance threshold for the effective number of 
tested SNPs and the effective number of independent phenotypes, no individual SNP met the 
strictest significant threshold (Table 2, Supporting table 4). Nonetheless, the strongest 
evidence of association was between hippocampus volume and SNP rs7588305, which had 
an unadjusted p-value of 2.9x10-5 (Figure 2a, Table 2). This association remained significant 
after correcting for the effective number of tested SNPs (p = 0.022 after Bonferroni correction), 
but not after further correction for the number of subcortical brain regions investigated 
(adjusted p = 0.13). Rs7588305 has a minor allele frequency (MAF) of 0.45. The SNP is 
located in the enhancer hs1527, which according to the VISTA enhancer browser is active in 
the forebrain, hindbrain, midbrain, and neural tube (Figure 2b). In the genome this enhancer 
is approximately 38 kb upstream of the closest gene ID2 (Figure 2d), which is involved in 
transcriptional regulation (Ferrer-Vicens et al., 2014). ID2 expression overlaps hs1527 
enhancer activity in the forebrain and midbrain at the same embryonic period (Figure 2c). 
However, we could not find supportive expression quantitative trait loci (eQTL) association 
between rs7588305 and ID2 in a dataset of human adult hippocampal expression data 
(Ramasamy et al., 2014). 
Table 2: Most significant individual SNP associations in each subcortical brain structure  
Brain 
structure 
Enhancer 
ID 
Enhancer 
SNP 
Allele 1 
[A1] 
Allele 2 
[A2] P-value 
Effect of A2 
[mm3/allele] 
StdErr 
effect 
Accumbens hs1578 rs139118507 A C 5.65E-04 -18.16 5.27 
Amygdala hs1300 rs149826134 A G 9.50E-04 -31.75 9.61 
Caudate hs1362 rs17710617 T C 8.79E-05 20.66 5.27 
Hippocampus hs1527 rs7588305 C G 2.88E-05 -21.73 5.20 
Pallidum hs1636 rs36058915 - T 1.18E-04 7.73 2.01 
Putamen hs1300 rs149826134 A G 1.33E-04 -88.06 23.04 
Thalamus hs200 rs34415491 A - 1.29E-04 -26.76 6.99 
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Figure 2: The enhancer SNP rs7588305 is associated with reduced hippocampal volume and is located 
upstream of the ID2 gene. Plot (A) shows association P-values with hippocampal volume. Plotted are all enhancer 
SNPs within hs1527 according to their position on human chromosome 2. The rs7588305 SNP is at position 
8,780,959 and has a P-value of 2.88 3 1025. (B) Representative transgenic mouse embryo injected with the hs1527 
construct. Picture downloaded from the VISTA enhancer database (http://enhancer.lbl.gov/cgi-bin/ 
imagedb3.pl?form=presentation&show=1&experiment_id=1527&organism_id=1) (Visel et al., 2007). The hs1527 
enhancer activity is detected at embryonic stage E11.5 in parts of the forebrain, midbrain and neural tube as shown 
by the blue reporter gene staining. (C) ID2 gene expression in a mouse embryo at stage E11.5, detected with in 
situ hybridization. Picture downloaded from the Allen Developing Mouse Brain Atlas (http://developing mouse.brain-
map.org/experiment/siv?id=100072835&imageId=101217794&initImage=ish, Website: VC 2015 Allen Institute for 
Brain Science.). ID2 expression overlaps hs1527 enhancer activity in the forebrain and midbrain (red arrows in b 
and c). (D) UCSC genome browser (https://genome.ucsc.edu) showing the genomic location of the hs1527 
enhancer upstream of the ID2 gene. 
 
Using the prior knowledge that rs7588305 is located within a forebrain enhancer, we identified 
a suggestive association of this SNP with hippocampal volume. If this SNP itself (rather than 
others in LD) is mediating this association, then complementary data should support a 
functional role. For example, the alternative allele of this SNP might affect the activity of the 
surrounding enhancer caused by differential binding of TFs. In order to assess such 
possibilities, we used in silico analyses to test if the change from major to minor allele would 
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affect known TF binding sites. The differential motif analysis of the surrounding genomic 
fragment predicted a gain of six new motifs and a loss of five motifs for the minor allele 
(Supporting table 5). Among these predicted differences we found two ubiquitously expressed 
general TFs that are involved in chromatin structure and looping, CTCF and p300 (Supporting 
figure 1). The minor allele of rs7588305 gained a binding motif for CTCF - a general TF that 
stabilizes chromatin loops and is generally found in structural chromatin loops that either block 
enhancer promoter interactions or are active enhancer loops (Ong and Corces, 2014). The 
second change for the minor allele was the loss of a p300-binding motif. P300 is a 
transcriptional coactivator that is found at active enhancer-promoter loops and increases 
transcription of the target gene (Chan and La Thangue, 2001). The motif analysis of the 
rs7588305 SNP is thus consistent with the view that the allelic state of this SNP could be 
associated with changed activity of the enhancer. The variant could potentially decrease the 
activity of the enhancer, given that the binding site for the co-activator p300 is lost. However, 
CTCF function is highly dependent on context, and the effect of a gained CTCF binding site is 
difficult to predict. Thus, to determine the direction of effect of the minor allele would require 
future experiments, for example using cellular models. 
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Discussion 
The advent of GWAS has allowed for the high-throughput characterization of genetic variants 
in large cohorts of human subjects. In a comprehensive resource of SNP-trait association data 
from multiple GWAS studies, collated by the National Institutes of Health (NIH), more than 
90% of SNP associations map to non-coding regions (Welter et al., 2014). A substantial 
number of these SNPs are in genomic regions with regulatory functions, such as enhancers. 
Thus, pre-selecting functionally tested enhancers may help to detect biological links between 
genetic variants and phenotypic traits. Here we investigated the association of common 
variation in well-defined developmental forebrain enhancers with volumetric measures of 
subcortical regions in a meta-analyzed study of 13,000 adult subjects. For hippocampus 
volume, we found a significant overall enrichment of association within enhancer regions that 
was robust to multiple-testing, as well as suggestive individual association of one enhancer 
SNP. Therefore, this study shows how functional data can help to detect trait-associated 
genetic variants. Our approach also generates testable hypotheses relating non-coding SNPs 
to an observed trait of interest. 
High-throughput studies have documented the functions of non-coding DNA across a range 
of tissues and cell lines by characterizing genome-wide distribution of chromatin modifications 
and/or TF interactions (ENCODE, 2012; Barrett et al., 2013). The resulting public databases 
allow predictions to be made regarding the regulatory activity of a genomic fragment. They 
thus provide useful tools to determine the functionality of trait-associated non-coding SNPs, 
and how they relate to the phenotype of interest (Boyle et al., 2012; Ward and Kellis, 2012). 
Crucially, in most GWAS efforts these data are only exploited in a post-hoc manner, to assess 
SNP associations that meet genome-wide significance. Our method is unbiased with respect 
to the functional regions and our results therefore include sub-threshold associations of SNPs 
with smaller effect sizes. 
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Targeted studies of single genomic regions indicate that variants in non-coding DNA are 
related to variation in normal brain volume and risk for psychiatric illness. For example, a rare 
variant implicated in autism was found in an enhancer that is active during forebrain 
development. The variant that may increase risk for autism alters binding of regulatory TFs 
and reduces enhancer activity in the developing forebrain (Poitras et al., 2010). Another study 
focused on an enhancer that underwent accelerated evolution on the human lineage, after 
splitting from that of chimpanzees. In mouse models, the human version of this enhancer 
prolongs forebrain growth and increases the size of the developing neocortex (Boyd et al., 
2015). This supports our finding that human gene enhancers help explain how non-coding 
SNPs contribute to variation in brain volume. 
We identified an enhancer SNP that has a within-phenotype significant association with 
hippocampal volume. The SNP is contained within the enhancer hs1527 and positioned 
upstream of the inhibitor of DNA binding 2 (ID2) gene. ID2 is expressed in the embryonic 
mouse forebrain and in regions of adult rat brain, including the hippocampus (Kitajima et al., 
2006). The expression pattern of ID2 overlaps with the regions of hs1527 enhancer activity 
(Figure 2b-c). ID2 enhances cell proliferation (Iavarone et al., 1994) and promotes axon growth 
in primary rat neurons (Lasorella et al., 2006). In human neuronal cell lines, ID2 is directly 
regulated by MECP2. Disruptions of the MECP2 gene cause Rett syndrome, a 
neurodevelopmental disorder characterized by severe intellectual disability and microcephaly 
(Amir et al., 1999). Accordingly, ID2 expression was higher in post-mortem brain samples from 
subjects with Rett Syndrome (Peddada et al., 2006). The absence of association between 
rs7588305 and ID2 expression in adult human hippocampal samples, as measured by the 
Braineac eQTL database, does not discount an effect on enhancer activity in embryonic tissue. 
Differential ID2 expression during embryonic development may be sufficient to lead to 
volumetric changes in the adult, which agrees with the role of the gene in cell-proliferation and 
neurogenesis. Future studies of ID2 function in neurodevelopment may link this gene to 
hippocampal development. 
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A benefit of pre-selecting genetic variants based on functional information is that specific 
testable hypotheses are generated for follow-up studies. For example, motif analysis using 
the major and minor alleles of rs7588305 predicted differential binding of CTCF and p300, two 
ubiquitously expressed proteins involved in chromatin loop formation and transcriptional 
regulation. The minor allele lacks the motif for p300, a general mediator for enhancer activity, 
and gains a motif for CTCF, which may affect enhancer loop formation. The shifted binding of 
these two general chromatin associated factors could conceivably alter the activity of the 
hs1527 enhancer, a hypothesis that can be tested with future experiments in cellular models, 
which would also enable the direction of effect to be determined. 
Here, we determined if a set of functionally validated enhancers, active during early brain 
development, was enriched for association with volumetric differences in subcortical brain 
structures in human adults. We found significant enrichment with hippocampal volume and 
nominal significance for the nucleus accumbens, pallidum, and thalamus. The selected 
forebrain enhancers contained an increased number of common genetic variants with sub-
threshold associations. The observed enrichment in the hippocampus was found with 
forebrain enhancers, but was not detectable for non-brain enhancers. In order to exclude that 
the effects reflected unusual LD structure of the forebrain enhancers, or some other artefact, 
we performed additional control analyses of other human traits, including BMI, height and 
WHR, and did not observe enrichment. This finding implies that early developmental enhancer 
activity has an impact on adult hippocampal volume. During the human lifespan more than 
80% of all genes (≥ 20,000) are expressed in the developing and adult human brain (Kang et 
al., 2011), and each active gene promoter is in contact with several enhancers (Sanyal et al., 
2012; Jin et al., 2013). Tens of thousands of enhancers may guide the coordinated expression 
of genes during development. Indeed, more than 80,000 non-coding genomic regions show 
histone marks indicative of active enhancers in brain tissue (Vermunt et al., 2014). The VISTA 
enhancer database likely represents only a fraction of enhancers that act during human brain 
development, and genetic variants in unsampled enhancers may also contribute to subcortical 
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volumes. This could likely have limited our ability to detect enrichment beyond the 
hippocampus. Future testing of all existing brain enhancers may increase the power to identify 
enrichment of associations. 
Another current limitation is that the VISTA database characterizes enhancer activity at E11.5 
and anatomically annotates this activity only to the general forebrain region. An annotation 
with respect to specific adult subcortical areas is not possible at this early embryonic period. 
It is crucial to look at the most relevant tissue for association studies of enhancers, so more 
detailed anatomical annotations of enhancer activities at later time points would improve the 
approach. This may enable mapping of more direct connections from enhancer activity to adult 
neuroimaging data.  
In this study we focused on experimentally validated enhancer elements, because these give 
a robust set of regions with clear functional links to defined human tissues. The method we 
have employed may be expanded to study tissue-specific histone modifications as they 
become more readily available (Vermunt et al., 2014; Roadmap Epigenomics et al., 2015). A 
benefit of these datasets may be their more fine-grained anatomical description and sampling 
across several developmental time points. 
In summary, we demonstrated genotype-phenotype connections between early 
neurodevelopmental enhancers and the volumes of adult subcortical brain regions in a dataset 
of over 13,000 people. As with all genetic association studies, replication of these findings 
should be sought in independent samples of a similar size where matched genome-wide 
genotyping and brain measures are available. Comparable analyses of enhancer SNPs in 
cohorts of patients with neurodevelopmental disorders has the potential to link early embryonic 
enhancer activity to disease processes. Our study illustrates a novel method for integrating 
functional genomic and phenotypic data to identify the biological underpinnings of highly 
heterogeneous traits, including neuropsychological traits. Our method can be applied to other 
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sets of functional non-coding genomic elements, to connect the function of the regions to 
studied phenotypes of interest. 
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Summary 
DNA sequence variants affecting protein-coding genes may cause Mendelian disorders or 
increase the likelihood to develop a certain phenotype. FOXP2 mutations cause a condition 
that is characterized by severe difficulties in performing the oral motor movements required for 
speech (developmental verbal dyspraxia), as well as reduced receptive and expressive 
language skills. The expression pattern of FOXP2 in the brain suggests that this gene supports 
the development of neuronal circuits involved in sensorimotor integration and learning of motor 
skills. Thus, the upstream pathways that determine this complex expression pattern are key 
for understanding its biological effects. In this dissertation, I investigated the regulation of the 
FOXP2 gene, from the molecular level, through cultured cell-lines, to the whole organism. I 
identified regulatory elements of FOXP2 implicated in disorder (Chapter2), as well as novel 
enhancers that make direct contact with promoters of the gene (Chapter3). I studied the 
upstream mechanisms that regulate these elements (Chapter 4) and characterized the tissue 
activity of the most promising enhancers in the developing mouse brain (Chapter 5). Finally I 
demonstrated how this type of enhancer information can generate novel insights into the 
underlying biology of genotype-phenotype associations in relation to human brain development 
(Chapter 6). 
The aim of this thesis was to shed light on the mechanisms of neuronal FOXP2 regulation in 
humans and to investigate the contribution of regulatory genetic variants to phenotypic 
variation in health and disease. In this final chapter, I will summarize the findings of each 
experimental chapter and highlight the different levels at which I approached the overarching 
aims of this dissertation. I will combine the results from the single chapters and discuss the 
findings in a bigger picture. Furthermore, I will discuss follow-up strategies to gain further 
insight into the genetics and biology of speech and language.  
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What can we learn from the genome? 
Variability in neurodevelopmental enhancers are known to contribute to both normal variation 
and disease phenotypes (Visel et al., 2013; Ramasamy et al., 2014; Boyd et al., 2015). In 
chapter 2, I identified an enhancer near the FOXP2 gene that is displaced in a child with 
delayed speech development (Becker et al., 2015). The affected individual carries a complex 
chromosomal rearrangement, including an inversion of chromosome 7. One breakpoint of the 
inversion is located downstream of FOXP2 and was mapped to the exact nucleotide position 
by Moralli et al. (Moralli et al., 2015). The published information, in combination with predicted 
functional states of the genome, was necessary and sufficient to locate the functional 
enhancer. The phenotype overlaps that of people with high-penetrance FOXP2 mutations, 
which suggested that misregulation of this gene could be involved in the aetiology of the 
disorder. Thus, the displacement of the identified enhancer could cause aberrant FOXP2 
expression and consequently disrupt speech development. 
Moving beyond the linear sequence of the genome, I used the three-dimensional folding of the 
DNA molecule to help uncover further novel regulatory elements that might regulate FOXP2 
expression. In chapter 3, my approach to identify enhancers was to investigate chromosomal 
interactions of the FOXP2 promoter. To achieve this, I identified the transcriptionally active 
promoter in neuronal-like cells and then measured the chromatin interactions of this promoter 
with genomic elements located upstream and downstream of the FOXP2 locus. In total, I 
identified eleven genomic regions that interacted with the promoter in neuronal-like cells 
(Figure 1). Promoter-promoter interactions between FOXP2 and MDFIC suggested that these 
genes could be co-regulated. Indeed, transcriptome sequencing studies of primate forebrain 
clustered both genes in one group of co-regulated genes (Konopka et al., 2012). However, not 
much is known about MDIFC function and expression. Follow-up studies of this gene with 
respect to FOXP2 function may further establish a link between FOXP2 and the WNT-
signalling pathway. I also detected an interaction of the FOXP2 promoter with the 3’-UTR of 
the FOXP2. Similar interactions have been described for other genes and were reported to 
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both decrease (Le Cam and Legraverend, 1995; Paul et al., 1998) and increase gene 
expression (Salerno et al., 2000; Jash et al., 2012). The interaction to the 3’-UTR in FOXP2 
expressing cells was either increased or depleted and thus, the influence of this interaction on 
FOXP2 expression remains unclear. Within the eleven interacting regions I detected nine 
candidate enhancer elements that were characterized by enhancer-specific histone marks in 
neuronal tissue and increased chromatin interactions in FOXP2 expressing cell lines. 
 
 
What can we learn from enhancers? 
The candidate enhancers of FOXP2 enabled me to study the regulatory mechanism of this 
gene at different levels. On the molecular level, enhancers are active within genetic networks 
and respond to specific signaling pathways. On the cellular level, enhancers are active in 
specific tissues and at developmental periods. On the human population level, variation in 
enhancer sequences may contribute to the variation in structure and function of the target 
Figure 1: Chromatin interactions at the FOXP2 promoter. I detected chromatin interactions of the active 
FOXP2 promoter in human neuronal-like cells (Chapter 3). The distal FOXP2 promoter interacts with the MDFIC 
promoter, the 3’-UTR and neurodevelopmental enhancers. Interactions to two representative enhancers (red) are 
depicted. Promoter-promoter interactions, 3’-UTR and enhancer contacts may regulate the expression of FOXP2 
in response to developmental or environmental cues. 
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tissue. In the following section I summarized what I have learned from studying enhancers on 
the different levels. 
Upstream regulatory networks of FOXP2 identified in molecular studies 
In chapter 4 I determined the basal activity of the FOXP2 promoters and enhancers in human 
neuronal-like cells. I detected the activity of promoter 1 and demonstrated the in vitro enhancer 
function of three enhancer elements. In combination with the enhancers, I studied the 
regulatory potential of eight TFs: LEF1, POU3F2, PAX6, TBR1, SOX5, FOXP1, FOXP2 and 
FOXP4. All TFs except POU3F2 modulated the activity of one or more regulatory element.  
I demonstrated an enhancing effect of FOXP2 on its regulatory elements, which suggested a 
positive auto-regulatory loop. Auto-regulation is found for TFs that function to maintain the 
cellular identity of differentiated cells (Bateman, 1998; Meredith et al., 2009) and for some TFs 
has been suggested as a mechanism to explain haploinsufficiency in disorders (Kleinjan et al., 
2004). I detected WNT-signalling TF motifs in all active regulatory elements and consequently 
determined regulation by the WNT effector LEF1 (Figure 2). The effects of this experiment 
suggested that FOXP2 might be actively regulated in response to WNT-signalling. This 
pathway is important in neurodevelopment and adult neurogenesis (Piccin and Morshead, 
2011; Dickins and Salinas, 2013; Oliva et al., 2013). It will be important to determine the 
developmental period and brain tissue in which FOXP2 could be regulated by WNT signalling. 
Additionally, I demonstrated the regulation of the candidate elements by SOX5 and TBR1, 
which overlap FOXP2 expression in cortico-fugal interneurons of the cortical layer VI and 
regulate subtype specification in post-mitotic neurons (Kwan et al., 2008; Lai et al., 2008; 
Bedogni et al., 2010; Hisaoka et al., 2010; Han et al., 2011; McKenna et al., 2011; Hao et al., 
2014). Both TFs increased promoter 1 and enhancer 37 activity, which suggest an activating 
effect on FOXP2 expression in cortical layer VI. 
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FOXP2 enhancers drive in vivo expression in specific neuronal tissue 
In chapter 5, I mapped the activity of two FOXP2 enhancers in the developing mouse brain. I 
created transgenic mice that expressed a reporter gene under the control of these enhancers 
and visualized reporter gene expression in embryonic, postnatal and adult brains. Enhancer 
37 activated reporter gene expression in the hippocampus, ventricles and olfactory bulb (OB). 
The activity of enhancer 37 overlapped known FOXP2 expression sites only in the OB. The 
ventricular activity of this enhancer started after birth and remained stable throughout 
adulthood, whereas the LacZ expression in OB was detectable at embryonic day 18.5 and 
decreased in adult mice. The activity pattern of this enhancer could suggest that it is activated 
in adult new-born neurons in the ventricles and hippocampus, and remains active in neurons 
that migrate to the OB (Doetsch and Alvarez-Buylla, 1996; Lois et al., 1996). In humans and 
songbirds, the ventricular born neurons have been shown to migrate into the striatum (Alvarez-
Buylla et al., 1994; Bergmann et al., 2015; Ernst and Frisen, 2015). In songbirds, these neurons 
Figure 2: Promoter and enhancers are regulated by transcription factors. Co-transfection luciferase 
experiments reveal regulatory interactions of the regulatory elements in human neuronal-like cell lines (Chapter 
4). The schematic shows effect of LEF1 (blue) on promoter 1, enhancer 37 and enhancer 330. Enhancer 815 
activity was not affected by LEF1. In chapter 4 I additionally studied the effects of PAX6, POU3F2, FOXP1, 
FOXP2, FOXP4, SOX5 and TBR1. 
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express FoxP2 and migrate into in the striatal nucleus area X (Rochefort et al., 2007). The 
increased expression of FoxP2 in area X was linked to singing behaviour in adult zebra finches 
(Haesler et al., 2004; Teramitsu and White, 2006; Haesler et al., 2007). It remains to be shown 
whether or not this gene is active during adult neurogenesis in a mammalian model system. In 
particular, it is unknown if FOXP2 is expressed in the migratory stream of adult new-born 
neurons in humans. 
The transgenic mice carrying enhancer 330 showed reporter gene expression in the neocortex 
and Purkinje Cells (PCs) of the cerebellum (Figure 3). The enhancer was active in the 
ventricular zone of the embryo and cortex of neonatal brains. Thus, enhancer 330 activity 
overlaps with known sites of FOXP2 expression during development. These results suggest 
that enhancer 330 might be involved in driving early cortical expression of FOXP2. In adult 
mice, the activity of enhancer 330 decreased in deeper cortical layers, but remained active in 
the upper layers. Interestingly, prior studies have shown that FOXP2 expression is localized 
specifically to the deeper cortical layer VI (Ferland et al., 2003). The absence of FOXP2 mRNA 
in the upper layers can be explained by micro RNA mediated down-regulation, as the two micro 
RNAs mir-9 and mir-132 have been shown to repress FOXP2 expression specifically in the 
upper cortical layers (Clovis et al., 2012). The lack of enhancer 330 activity in the adult deeper 
cortical layers indicates that FOXP2 transcription in this layer is maintained by regulatory 
mechanisms that only act on the promoter or on other enhancers. In summary, the enhancer 
330 activity overlapped FOXP2 expression in the adult PCs and developing neocortex, which 
strongly suggests that this enhancer contributes to FOXP2 expression in these structures. 
Chapter 7: Summary and General Discussion 
 
190 
 
 
Genetic variants in neurodevelopmental enhancers explain structural variation in brain tissue 
In chapter 6 I studied common genetic variants in a set of neurodevelopmental enhancers. The 
hypothesis was that genetic variants in enhancers affect the structure of the enhancer’s target 
tissue in the adult brain. To test this hypothesis I selected common genetic variants located 
within experimentally validated regulatory elements. Because I expected subtle effects for 
single genetic enhancer variants, I analysed a set of 296 enhancers of the prior VISTA study, 
publically available through the VISTA enhancer browser (Visel et al., 2007). The results of 
this chapter are therefore not specific to the FOXP2 enhancers. I focused on enhancers that 
had been shown to be active in the embryonic forebrain, which develops into the cortex and 
most of the subcortical brain regions. I hypothesized that variants in these enhancers influence 
the enhancer activity and consequently the expression of their target genes. Differential 
expression of neural genes could potentially alter the function and/or structure of the forebrain. 
I selected the enhancer variants from the summary data of the ENIGMA2 genome-wide 
Figure 3: Neurodevelopmental enhancers drive tissue-specific expression in vivo. I determined the in vivo 
enhancer activity of two elements in transgenic mice expressing the LacZ reporter gene under control of the 
enhancer elements. In the schematic, enhancer 330 is depicted as active enhancer in the endogenous genomic 
loci controlling FOXP2 in the cortex and PCs. 
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association study (GWAS) (Hibar et al., 2015). The ENIMGA2 study aimed to identify 
associations between genetic variants and variation in subcortical brain volumes of 30,000 
healthy human adults, of which I analysed the discovery sample (13,000) in chapter 6. Within 
the group of forebrain enhancer variants I detected significant enrichment for variants 
associated with hippocampal volume. This enrichment was specific to subcortical phenotypes 
and not detectable in control phenotypes, such as body-mass index. The results of this chapter 
demonstrate how targeting experimentally-defined enhancers may help identify the underlying 
molecular aetiology of genotype-phenotype associations.  
 
Integration of results across the chapters 
Point mutations in FOXP2 cause a developmental speech and language disorder (Lai et al., 
2001). People with FOXP2 mutations show functional and structural differences in brain 
structures related to motor control and language (Vargha-Khadem et al., 2005; Liegeois et al., 
2011). The aim of this thesis was to identify the upstream regulatory networks that control 
FOXP2 expression, which might help shed further light on genetic pathways involved in the 
development of neuronal circuits supporting human speech and language. Each chapter 
produced independent results and provided insight into components of the regulatory 
mechanisms. I obtained results on the molecular, cellular, tissue and human population levels. 
In order to understand the complex regulatory mechanisms and their possible implications for 
pathogenic and normal variation it is important to discuss the results across the chapters.  
 
Purkinje cells maintenance mediated by WNT-signalling 
In this thesis, I demonstrated that enhancer 330 is a neurodevelopmental enhancer and active 
in the PCs of the cerebellum (Chapter 5). The enhancer activity could be increased by LEF1 
(Chapter 4), which is known to be expressed in the developing cerebellum and in adult PCs 
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(Wisniewska et al., 2010). LEF1 is the effector TF of the WNT-signalling pathway, which is 
active in a subset of adult PCs (Selvadurai and Mason, 2011). Thus, my findings raise the 
possibility that LEF1 might regulate FOXP2 expression during cerebellar development and in 
adult PCs (Figure 4). However, I did not study the embryonic activity pattern of enhancer 330 
in the cerebellum, which is necessary to determine the overlap with WNT-signalling. In a prior 
study of zebrafish embryos, lef1 knock-down was reported to abolish foxp2 expression in the 
hindbrain (Bonkowsky et al., 2008), which is the developmental origin of the cerebellum. It has 
been established that WNT-signalling in the cerebellum controls axon maintenance and 
synapse formation (Salinas, 1999; Dickins and Salinas, 2013) and that PCs express different 
components of the WNT-signalling pathway (Salinas et al., 1994; Patapoutian and Reichardt, 
2000). Mouse Foxp2 has been shown to promote neuronal differentiation, neurite formation 
and axon guidance in the striatum (Vernes et al., 2011). It can therefore be hypothesized that 
LEF1 may potentially control FOXP2 expression to regulate aspects of axon growth and 
synapse plasticity in the developing cerebellum (Figure 1), something that could be specifically 
tested with future functional investigations. Notably, mice homozygous for aetiological Foxp2 
mutations develop a smaller cerebellum (Groszer et al., 2008). The hypothesis that a Lef1-
Foxp2 pathway is important for normal cerebellar development could be followed up by 
conditional knock-out of Foxp2 or Lef1 in PCs. Homozygous knock-out mice of Lef1 die before 
weening, whereas heterozygotes appear normal with no effect on cerebellar development 
(Vangenderen et al., 1994; Galceran et al., 2000). Conditional knock-outs of Lef1, where the 
gene is disrupted specifically in the PCs, may be required to determine subtle effects on 
cerebellar development, which cannot be detected with conventional knock-out. In conclusion, 
Foxp2 is important for normal cerebellar development and my findings suggest that its 
cerebellar expression may be regulated by enhancer 330. The human enhancer 330 is itself 
regulated by LEF1, which may indicate a LEF1-FOXP2 pathway in the developing cerebellum. 
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Is cortical neuron subtype specificity mediated by enhancer 330? 
I detected reproducible activity of enhancer 330 in the developing and adult neocortex (Chapter 
5). This enhancer was previously shown to reproducibly drive cortical expression in mouse 
embryos at day E11.5 (Visel et al., 2007). In earlier studies, cortical Foxp2 mRNA expression 
has been detected as early as E14.5 in the ventricular zone and in the postnatal cortex (Ferland 
et al., 2003). In the cortex of neonatal mice, enhancer 330 is active in all cortical layers. FOXP2 
expression is known to be primarily limited to the cortical layer VI in the adult cortex, whereas 
I found that enhancer 330 showed the strongest activity in the higher cortical layers (Chapter 
5). Thus, enhancer 330 and FOXP2 overlap in embryonic and neonatal brains, but not in the 
adult cortex.  
Figure 4: Integration of FOXP2 in cell-specific signaling pathways. Enhancer 330 (red) is located within the 
FOXP2 gene body. This enhancer contacts the FOXP2 promoter (Chapter 3) and increases gene expression 
(Chapter 4). The enhancer is, among others, active in developing and adult PCs (Chapter 5). PCs express LEF1 
(blue), which is the transcription factor downstream of the WNT-signaling pathway and activates genes 
responsible for synapse development and axon maintenance. LEF1 increases the activity of enhancer 330 
(Chapter 4). The hypothesis is that WNT-signaling via LEF1 regulates FOXP2 expression in the PCs to control 
axon and synapse plasticity.  
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I detected reduced enhancer 330 activity in response to TBR1 and SOX5 overexpression in 
human neuronal-like cell lines (Chapter 4) and enhancer 330 activity in the deeper cortical 
layers of adult brains (Figure 5). The results from both chapters together suggest that TBR1 
and SOX5 downregulate the expression of FOXP2 in the developing cortex. The expression 
of SOX5 and TBR1 is present in the developing cortical subplate and cortical layer VI (Kwan 
et al., 2008; McKenna et al., 2011). Enhancer 330 activity, SOX5 and TBR1 expression thus 
likely overlap in embryonic and prenatal neurons. Immunohistochemistry or in situ hybridization 
of SOX5/TBR1 with FOXP2 is required to determine the exact expression overlap of these 
TFs. Cortical development of cortico-thalamic projection neurons is regulated by SOX5 and 
TBR1, which establish the cellular-identity by repressing TFs that are found in other cortical 
subtypes, such as FEZF2 and CTIP (Kwan et al., 2008; Lai et al., 2008; McKenna et al., 2011; 
Greig et al., 2013). In the adult cortex, SOX5 and TBR1 expression is limited to layer VI (Lai 
et al., 2008) and enhancer 330 activity in this layer decreases in adult animals. This suggests 
that SOX5 and TBR1 may repress enhancer 330 in adult cortical layer VI. However, FOXP2 
remains expressed in adult cortical layer VI neurons and all FOXP2 positive cortical neurons 
in the postnatal cortex have been reported to be TBR1 positive (Hisaoka et al., 2010). Thus, 
the adult activity of enhancer 330 cannot explain adult FOXP2 expression in the cortical layers.  
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Downregulation of FOXP2 in upper cortical layers by post-transcriptional mechanisms may 
explain the missing FOXP2 expression in these layers. Indeed, mir-9 and mir-132 have been 
shown to specifically repress FOXP2 mRNA in the upper cortical layers (Clovis et al., 2012). 
Thus, enhancer 330 may activate expression in all cortical progenitor cells and the layer VI 
specificity is achieved by the post-transcriptional down-regulation. The expression in the 
deeper cortical layers could potentially be maintained by FOXP2 itself, via autoregulation at 
other regulatory elements (Chapter 4). Thus, enhancer 330 may only be required for embryonic 
and early postnatal expression of FOXP2. In conclusion, my data suggest that FOXP2 
expression in the cortex could be initiated by enhancer 330. SOX5 and TBR1 could be involved 
in the regulation of enhancer 330, but the timing of the regulatory interaction will have to be 
investigated in model systems of neural development.  
 
Figure 5: Integration of FOXP2 in cortical laminar development. Enhancer 330 (red) is located within the 
FOXP2 gene body. This enhancer contacts the FOXP2 promoter (Chapter 3) and increases gene expression 
(Chapter 4). The enhancer is active in the developing cortex and upper cortical layers in the adult (Chapter 
5). FOXP2 expression overlaps enhancer 330 activity in the developing cortex. In the adult cortex FOXP2 is 
specifically expressed in the deeper cortical layer VI. TBR1 and SOX5 are expressed in the cortical layer VI 
and decrease the activity of enhancer 330 (Chapter 4).  
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Could enhancer 37 regulate the expression of FOXP2 in adult neurogenesis? 
I mapped the in vivo activity of enhancer 37 to the hippocampus, ventricles and OB. Adult 
neurogenesis occurs in the hippocampus and ventricles (Eriksson et al., 1998; Ernst et al., 
2014; Bergmann et al., 2015). In mice, the ventricular born neurons migrate to the OB in the 
rostral migratory stream (Doetsch and Alvarez-Buylla, 1996; Wichterle et al., 1997). The 
ventricular and OB activity of enhancer 37 could suggest that this enhancer is active in neurons 
that migrate in the rostral migratory stream. I also detected that TF motifs of the WNT-signalling 
pathway are located in enhancer 37 and that it is upregulated by LEF1 (Chapter 4). LEF1 in 
complex with TCF-1 regulates the expression of WNT-signalling target genes (Dickins and 
Salinas, 2013; Oliva et al., 2013). WNT signalling has been shown to regulate neurogenesis 
in the ventricles (Piccin and Morshead, 2011), the hippocampus (Lie et al., 2005) and OB 
(Booker-Dwyer et al., 2008). Enhancer 37 could thus be a target regulatory element of WNT-
signalling during adult neurodevelopment (Figure 6).  
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In humans, the ventricular born neurons do not migrate to the OB but have been shown to 
migrate into the striatum, where they differentiate into interneurons (Ernst et al., 2014; Ernst 
and Frisen, 2015). Similarly, in songbirds ventricular born neurons migrate into the striatal 
song-learning nucleus called Area X, where they differentiate and integrate into the existing 
neuronal architecture (Alvarez-Buylla et al., 1994). The regulation of FoxP2 in Area X has been 
shown to be linked to singing behaviour in the songbirds (Chen et al., 2013; Mendoza et al., 
2015). The increase of FoxP2 expression is partly due to new-born neurons in adult animals 
that migrated into the striatum (Rochefort et al., 2007). Thus, adult neurogenesis may be linked 
to FoxP2 expression and singing behaviour in songbirds (Schulz et al., 2010). However, in 
songbirds, the new-born neurons form medium spiny neurons, whereas in humans they form 
interneurons (Ernst and Frisen, 2015). The new-born human interneurons are DARPP32 
Figure 6: Integration of FOXP2 in adult neurogenesis. Enhancer 37 (red) is located upstream of the FOXP2 
gene. This enhancer and the promoter region of MDFIC contact the FOXP2 promoter (Chapter 3). Enhancer 37 
increases gene expression (Chapter 4). The enhancer is active in the OB, the outer layer of the ventricles, the 
dentate gyrus and CA1 neurons of the hippocampus (Chapter 5). Ventricular born neurons migrate to OB in 
mice; and to the striatum in human and songbirds. The canonical WNT-signaling pathway, with the downstream 
activators LEF1 and TCF-1 regulate neural differentiation in adult new-born neurons. LEF1 increases the activity 
of enhancer 37. The hypothesis is that WNT-signaling via LEF1 regulates FOXP2 expression in adult new-born 
neurons in the ventricles and the neurons migrate to the species-specific target tissue. 
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negative and express parvalbumin and calbindin. The co-expression of FOXP2 with these 
marker genes in striatal interneurons would, therefore, be crucial to determine a possible 
relation between FOXP2 and human adult neurogenesis. Molecular studies of adult 
neurogenesis in humans are not feasible, because of the lack of neuronal tissue for 
experimental investigations. As new-born neurons in mice migrate into the OB, this animal is 
not a suitable system to study the link between FOXP2 and neurogenesis. Possibly, this link 
could be studied in other mammals, such as bats. Recently bats obtained attention as a model 
system for mammalian vocal and communication system (Rodenas-Cuadrado et al., 2015). 
Ventricular born neurons in bats at least partially migrate towards the OB (Amrein et al., 2007), 
but the migratory route to the striatum has not yet been investigated.  
 
Signalling pathways involved in language-related phenotypes 
I identified enhancer 815 based on the information about a child with delayed speech 
development, described in the literature (Chapter 2). The child carries an inversion that 
separates FOXP2 from this enhancer, suggesting that misregulation of the gene contributes 
to the disorder. My in vitro experiments suggested that activity of enhancer 815 may be 
regulated by PAX6, FOXP1 and FOXP2 (Chapter 4), which suggests that, in the affected child, 
the FOXP2 gene lacks enhancer 815 mediated regulatory input from these TFs. Similarly, loss-
of-function mutations in these TFs could affect the regulation of FOXP2 in other clinical cases. 
The study of phenotypes associated with PAX6 and FOXP1 mutations and their overlap with 
phenotypes seen for people with FOXP2 mutations may shed light on an overlapping molecular 
aetiology. Genetic disruptions of FOXP1 can cause autism spectrum disorder, intellectual 
disability, motor delay and expressive language problems (Pariani et al., 2009; Carr et al., 
2010; Hamdan et al., 2010; Horn et al., 2010; O'Roak et al., 2011; Bacon and Rappold, 2012; 
Talkowski et al., 2012). The phenotypic spectra associated with FOXP1 and FOXP2 
disruptions were previously described in a review and show overlap for language problems 
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(Bacon and Rappold, 2012). PAX6 mutations generally cause aniridia and other malformations 
of the eye (Hanson, 2003). A splice site mutation in PAX6 was linked to Gillespie syndrome, 
which among other problems includes impairments in orofacial motor control and dysarthric 
speech (Ticho et al., 2006). While dysarthria has been suggested to be a phenotype associated 
with FOXP2 disruptions at least in some cases (Shriberg et al., 2006), it was not reported for 
the child with the chromosomal rearrangement that separates FOXP2 from enhancer 815 
(Moralli et al., 2015). Another patient carrying a de novo nonsense mutation in PAX6 presented 
with the typical aniridia phenotype, but further included coordination impairment, general 
dyspraxia, intellectual disability and poor speech (Graziano et al., 2007). Detailed comparisons 
between people with PAX6 and FOXP2 mutations would be required to determine a possible 
common overlapping phenotype.  
Co-expression of FOXP2 with FOXP1 has been described in the basal ganglia, thalamus and 
inferior olive (Teramitsu et al., 2004; Takahashi et al., 2008; Kaoru et al., 2010; Mendoza et 
al., 2015) and with PAX6 in the amygdala and striatum (Kaoru et al., 2010). Notably, co-
expression of all three TFs has been seen in the striatum of monkeys and rats (Kaoru et al., 
2010). Thus, the observed regulation of enhancer 815 by FOXP1 and PAX6 could suggest that 
this enhancer is active in the striatum (Figure 7). Perhaps the overlap in speech/language-
related phenotypes between cases of PAX6, FOXP1 and FOXP2 mutation can be partially 
explained by regulatory interactions in the striatum. Overlapping functional or structural 
aberrations in the striatum of the child that led to the discovery of enhancer 815 would further 
support this hypothesis. Brain imaging studies of this child have not been reported, and 
comparison to findings in additional clinical cases would be required to thoroughly evaluate 
this hypothesis. 
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Future direction 
In the previous section, I presented models of FOXP2 regulation that emerged from analysing 
results across the individual chapters and suggested follow-up strategies to investigate these. 
In the following section, I address additional future directions that follow from my results.  
Enhancers as tools to study FOXP2 
The experiments in each chapter investigated a limited amount of the possible search space. 
Future findings on FOXP2 regulation may highlight the importance of genomic regions which 
have not been tested in chapter 3, and TFs which have not been investigated in chapter 4. 
Clinically relevant copy number variants near FOXP2 may justify the extension of the chromatin 
conformation capture design to more distant genomic regions. My in silico analyses detected 
hundreds of TF motifs in the putative regulatory elements that I identified. Many of the relevant 
Figure 7: Disruption of enhancer 815 regulation in language development. Enhancer 815 (red) is located 
downstream of the FOXP2 gene. This enhancer is separated from FOXP2 in a patient with language problems 
(Chapter 2). Enhancer 815 is repressed by PAX6 and activated by FOXP1 and FOXP2 (Chapter 4). Mutations 
in PAX6 and FOXP2 can cause language problems. The hypothesis is that the language phenotypes caused by 
mutations of FOXP1, FOXP2 and PAX6 are the result of aberrant FOXP2 regulation. This regulatory interaction 
possibly occurs in the developing striatum. 
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TFs are expressed in the brain and known to be involved in neuronal development (chapter 
4). For example, the overlapping expression of foxp2 with emx1 in the zebrafish forebrain could 
be an interesting link to follow up (Shah et al., 2006). Also retinoic acid binding receptor alpha 
was detected in the motif analysis and accumulating evidence shows that retinoic acid 
signalling is linked to FOXP2 function (Devanna et al., 2014) and language-related neural 
networks (van Rhijn and Vernes, 2015). Furthermore, I selected the most promising enhancers 
to map the in vivo activity (Chapter 5) and did not investigate enhancer 815 using these 
techniques. As previously discussed, this enhancer is likely involved in the pathogenesis of a 
child with delayed speech development. Uncovering the tissue-specific activity of this enhancer 
will be important to determine the molecular aetiology underlying the phenotype of this case. 
Genetic variation underlying language-related phenotypes 
The identification of FOXP2 mutations in speech and language disorders has sparked 
speculations on the potential contributions of this gene to other pathological and normal human 
cognitive phenotypes. Consequently, researchers have investigated the FOXP2 gene locus for 
genetic association to various traits. Such studies investigated the association of common 
variants within the FOXP2 gene to auditory-visual hallucinations (Sanjuan et al., 2006; 
McCarthy-Jones et al., 2014), schizophrenia (Tolosa et al., 2010; Spaniel et al., 2011), ADHD 
(Ribases et al., 2012), autism (Park et al., 2014), enhanced language skills (Chandrasekaran 
et al., 2015) or brain volumes (Hoogman et al., 2014). However, most of these studies report 
negative findings or have not been replicated. Genetic variants that affect the identified 
regulatory elements from this thesis could potentially alter FOXP2 expression and disrupting 
the development of FOXP2 positive neuronal circuits. According to this hypothesis, in chapter 
6 I demonstrated on a broader scale that neurodevelopmental enhancers are enriched for 
association to subtle common phenotypes. Thus future candidate gene association studies of 
FOXP2 would benefit from targeting genetic variants within the identified regulatory enhancer 
elements from this thesis. Similarly, next generation sequencing of samples of people with 
speech- and language-related disorders has been limited to the exome, focusing on coding 
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sequences (Villanueva et al., 2015). The regulatory regions of FOXP2 are promising candidate 
regions to contain rare variants, which would remain undetected with exome-sequencing. As 
the field of clinical genetics moves rapidly from exome-sequencing to whole-genome 
sequencing it will be crucial to filter the variants in a justified and meaningful way. Thus, the 
incorporation of enhancer and other regulatory sequences will be necessary for all genes. The 
field of language genetics is well equipped to identify genetic variants that may affect the 
regulation of FOXP2 and contribute to language-related traits. 
Conclusion 
In my thesis, I investigated the regulation of FOXP2 at the molecular, cellular, tissue and 
phenotypic level. I identified the first human enhancers of the FOXP2 gene, which led to the 
identification of upstream signalling pathways of FOXP2. I mapped the enhancer activity in the 
developing and adult brain, which relates the identified upstream pathways to the neuronal 
tissue in which they regulate FOXP2. I linked a set of neurodevelopmental enhancers, 
unrelated to FOXP2, to normal variation in brain structure and pathologic variation of language 
skills. The integration of results across these levels created new hypotheses regarding the 
mechanisms underlying the neurobiology of FOXP2. 
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Appendix 1 
Appendix table 1: Expression primer 
Gene Exon Direction Sequence 
FOXP2 5 Forward ACAGCATCCTGGAAAGCAAG 
FOXP2 6 Reverse ATGGAGATGAGTCCCTGACG 
GAPDH 2 Forward AAGGTGAAGGTCGGAGTCAAC 
GAPDH 3 Reverse GGGGTCATTGATGGCAACAATA 
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Forw
ard Prim
er 
R
everse Prim
er 
  
C
hrom
os
om
e 
ID
 
Start [hg19] 
End [hg19] 
Sequence 
Start 
[hg19] 
End [hg19] 
Sequence 
A
m
plicon 
Size 
chr7 
1 
113724817 
113724837 
G
TTC
A
A
G
TTG
G
C
C
G
TTC
TTTC
 
113724901 
113724923 
TG
A
A
A
C
TTTC
C
TC
C
A
A
ATA
G
C
TG
 
106 
chr7 
2 
113726213 
113726234 
G
C
G
A
G
C
A
G
TG
TG
TG
TA
C
A
G
TTC
 
113726290 
113726306 
G
TG
TG
TC
TG
TG
TG
TG
TG
A
A
TG
TG
 
93 
chr7 
3 
113727436 
113727458 
TG
G
C
C
TG
G
TTTTA
C
TTTTA
TTC
C
 
113727572 
113727593 
A
G
G
TA
A
C
A
G
C
C
A
A
G
TG
A
G
A
A
G
C
 
157 
chr7 
4 
114053697 
114053719 
A
A
G
G
TG
A
A
A
TG
TG
A
A
A
TTTG
C
TG
 
114053820 
114053842 
A
C
A
TC
TG
C
C
A
C
TA
C
TTTTG
TTG
C
 
145 
chr7 
5 
114054910 
114054932 
TG
G
TG
C
TTTTG
TC
TC
TC
TC
TC
TC
 
114055046 
114055068 
G
G
TG
A
C
A
A
A
G
G
TTC
A
A
G
A
C
TG
A
G
 
158 
chr7 
6 
114056133 
114056155 
A
G
C
TTG
G
C
TG
G
G
C
TA
TA
A
A
TTA
C
 
114056230 
114056252 
G
TC
A
TC
A
G
G
C
A
A
TTA
C
TG
TA
G
C
C
 
119 
chr7 
7 
114057557 
114057579 
TTG
C
A
A
G
TC
C
TG
TA
A
TG
A
TG
A
TG
 
114057648 
114057670 
G
TG
A
TA
TTG
A
A
A
C
A
G
C
C
C
A
A
TTC
 
113 
chr7 
8 
114065128 
114065151 
TG
TA
TTTA
G
TG
TTTG
TG
TG
C
A
TC
G
 
114065193 
114065215 
A
A
TG
C
A
A
G
C
TTC
C
TA
TC
TC
TTC
C
 
87 
chr7 
9 
114066378 
114066400 
G
A
TTA
G
C
A
TC
TG
G
A
TG
A
A
A
G
C
TG
 
114066505 
114066527 
A
C
A
C
G
TTA
C
A
C
C
TTC
A
C
A
C
TTC
C
 
149 
chr7 
10 
114067773 
114067794 
A
A
G
TTA
A
A
G
C
A
A
A
TG
C
C
C
A
C
A
C
 
114067874 
114067900 
G
A
TTA
TTC
TTG
A
A
A
A
C
A
A
TG
C
C
TA
A
AG
 
127 
chr12 
G
A
P
D
H
 
prom
oter 
6643535 
6643554 
C
G
G
C
TA
C
TA
G
C
G
G
TTTTA
C
G
 
6643653 
6643672 
G
C
TG
C
G
G
G
C
TC
A
A
TTTA
TA
G
 
137 
chr22 
M
yoglobin 
E
xon2  
36013261 
36013280 
C
A
G
A
C
G
TTC
A
G
C
A
C
C
A
A
C
TG
 
36013332 
36013351 
A
C
C
C
A
G
TG
A
G
C
C
C
A
TA
C
TTG
 
90 
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Appendix table 3: 3C target and anchor primer  
Chromosome 
Start 
[hg19] 
End 
[hg19] 
ID [distance to 
TSS1] Sequence  
chr7 113619659 113619682 -106682 TTCTTTCAGTACCACTGCTAGGTG  
chr7 113652257 113652276 -74088 TTCTCTCCCCTCCCCATATC  
chr7 113658218 113658234 -68130 CCACATGGGAGGAGCAAG   
chr7 113667023 113667041 -59323 CCCCATTAAATGCTTGCAG  
chr7 113686885 113686904 -39460 GTTCCTTTTCTGGCAGGATG  
chr7 113688356 113688375 -37989 CAATGCCTTGGTCATTGTTG  
chr7 113689702 113689721 -36643 CACACTGATGGATGGCTCAC  
chr7 113706877 113706896 -19468 GCAAGCCAAAATTCCAAATC  
chr7 113708164 113708186 -18178 TTGCTCATAGACACAAATCAAGG  
chr7 113710846 113710867 -15497 AAAACCAGGAAACTGACATTGG  
chr7 113715771 113715790 -10574 GGGTCTGCTTCCAAGTTCAG  
chr7 113721054 113721074 -5290 TCTTGCATCAGGAAATTCCAC  
chr7 113732140 113732161 Anchor 5797 TGAAAAGCACATTGCTGTGAAG  
chr7 113739754 113739773 13409 CTCCCTTGGACACCAGAATC  
chr7 113743011 113743032 16668 TTGTTCAGTGCTTGACTTTTGG  
chr7 113755630 113755649 29285 GCCAGGAATATTGGCTGTTG  
chr7 113764551 113764570 38206 TCCAATGGTGCTCACAAAAG  
chr7 113772692 113772711 46347 TAGATGGAATGGCCAGGAAG  
chr7 113779379 113779407 53043 GTTGTTTTCGGGGAGGTTG  
chr7 113792245 113792265 65901 TGTGTGGCACAATGATGAAAC  
chr7 113796607 113796626 70262 CCACCTTTCAAGACCAGACC  
chr7 113803849 113803870 77506 CTGGAATGTTACCTAGGGCATC  
chr7 113815841 113815863 89499 CGATTCTCTTCCCTGTAGAATCC  
chr7 113978968 113978990 252626 TTCCATGCTCTGGAGATTAAAAC  
chr7 113988151 113988176 261812 GAGAATTACGTGGTAAATCACAGTTG  
chr7 113998725 113998744 272380 AGAGACTGGAGGCATTTTGC  
chr7 114034128 114034148 307784 TCCAAAAGCAATTAGCACACC  
chr7 114055582 114055601 329237 GGGAGACCAGACACAGGAAC  
chr7 114056404 114056423 330059 TTCCCAGTGACATGAGCAAG  
chr7 114061389 114061413 335049 TTTCATTGGCTTTACTTATGTTTCC  
chr7 114068822 114068845 342481 TGATGCAGTTATTGCCTTTAATTC  
chr7 114072519 114072541 346177 AACTAAGGTTTTGCAGCTGACTG  
chr7 114079808 114079827 353463 ATGTGGAGACAGGGTTTTGG  
chr7 114329855 114329874 603510 GGAAGAGCCAGTGATTGCAG  
chr7 114329855 114329874 603510 TTGGAAAGGGCTACAGTGACA  
chr7 114329855 114329874 603510 CACCCATTTCCTCTTTTTCCA  
chr7 114408672 114408691 682327 GTCGTCTTGAGAGGCAGCAC  
chr7 114432476 114432495 706131 GAAGTTGACCCACCACTCCA  
chr7 114449271 114449290 722926 ACAGCACAGTCAAGGCCACT  
chr7 114463228 114463247 736883 TGGGCCTCTGTTGTCTCAGT  
chr7 114478670 114478689 752325 GCAGAACAAGGGTGGACAAA  
chr7 114498528 114498547 772183 AGCTTTTCTGGGGAGCTGAC  
chr7 114508327 114508347 781983 TAAACCTGGGAGGTGGAGGT  
chr7 114535036 114535055 808691 TCCTTTAGCGCTGCTCTGAT  
chr7 114549286 114549307 822943 CAAGCATTTGTCCTTTCTTTGA  
chr7 114559396 114559415 833051 CAGTGGCCCACATAGCTCAC  
chr7 114568978 114568997 842633 CAGCTGTGAGAACCCCTGAG  
chr7 114590707 114590726 864362 CAGGGGAGGTAAAGGCTCAA  
chr7 115112801 115112820 1386456 CACAAGGGCCCAAGTTACAA  
chr7 115117519 115117538 1391174 GGAGATCCCGAGAAAAGCTC  
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R
eg. Elem
ent 
O
rientation 
Start [hg19] 
End [hg19] 
Sequence 
Size 
E
lem
ent 37 
Forw
ard 
113688009 
113688029 
A
TC
A
G
G
TA
C
C
C
A
C
A
G
G
G
G
A
A
C
C
TC
TG
C
A
AA
A
C
TG
C
 
20 
E
lem
ent 37 
R
everse 
113475999 
113476018 
A
TC
A
C
TC
G
A
G
C
A
C
A
ATTTG
TG
G
TG
G
G
TG
G
G
TG
G
G
 
19 
E
lem
ent 330 
Forw
ard 
114056847 
114056867 
A
TC
A
G
G
TA
C
C
G
G
TTTTC
A
C
G
G
AA
A
G
C
A
G
A
G
T 
20 
E
lem
ent 330 
R
everse 
114058626 
114058647 
A
TC
A
G
A
G
C
TC
G
A
C
G
TC
TG
TTC
TG
TG
A
G
TTTC
C
 
21 
E
lem
ent 815 
Forw
ard 
114541369 
114541389 
A
TC
A
G
G
TA
C
C
A
G
TATTG
G
C
A
C
AC
C
C
A
G
C
A
A
 
20 
E
lem
ent 815 
R
everse 
114542182 
114542201 
A
TC
A
G
A
G
C
TC
TG
TTC
C
TAG
G
C
G
TG
TC
TG
TG
 
19 
E
lem
ent 700 
Forw
ard 
114424203 
114424224 
A
TC
A
G
A
G
C
TC
A
C
C
A
G
AG
G
AA
AC
C
C
TTC
TTA
C
C
 
21 
E
lem
ent 700 
R
everse 
114427828 
114427847 
A
TC
A
C
TC
G
A
G
A
G
AA
G
C
ATG
TC
C
C
A
G
AA
A
G
C
 
19 
E
lem
ent 704 
Forw
ard 
114427887 
114427907 
A
TC
A
G
G
TA
C
C
TC
A
G
A
C
A
C
AA
C
C
G
A
C
A
TTC
C
 
20 
E
lem
ent 704 
R
everse 
114431955 
114431974 
A
TC
A
C
TC
G
A
G
A
C
C
TC
G
A
G
C
A
C
A
TG
TTTTC
C
 
19 
E
lem
ent 843 
Forw
ard 
114568454 
114568473 
A
TC
A
G
G
TA
C
C
A
G
TG
TG
A
TG
G
C
A
G
AA
C
A
TG
G
 
19 
E
lem
ent 843 
R
everse 
114572392 
114572411 
A
TC
A
C
TC
G
A
G
A
C
A
A
C
TC
C
C
C
A
ATTTC
TC
G
C
 
19 
P
rom
oter 1 
Forw
ard 
113724817 
113724838 
A
TC
A
G
A
G
C
TC
G
TTC
AA
G
TTG
G
C
C
G
TTC
TTTC
C
 
21 
P
rom
oter 1 
R
everse 
113726588 
113726609 
A
TC
A
C
TC
G
A
G
A
A
G
C
C
C
C
C
A
AAC
A
A
C
A
C
A
C
C
 
21 
P
rom
oter 2 
Forw
ard 
114051220 
114051242 
A
TC
A
G
A
G
C
TC
C
TC
A
C
A
TC
G
C
C
AA
A
G
G
TA
TA
C
C
 
22 
P
rom
oter 2 
R
everse 
114055298 
114055324 
A
TC
A
C
TC
G
A
G
G
C
A
C
A
G
A
AA
A
C
AG
TA
TA
AA
AA
G
A
A
G
G
G
 
26 
P
rom
oter 3 
Forw
ard 
114055454 
114055475 
A
TC
A
G
A
G
C
TC
TA
G
AG
A
G
G
G
G
TG
G
G
A
TTTTA
C
G
 
21 
P
rom
oter 3 
R
everse 
114056438 
114056459 
A
TC
A
C
TC
G
A
G
G
G
TC
A
G
A
G
G
AAA
AA
G
C
TG
TTG
G
 
21 
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Table S2: Predicted TF motifs         
Enhancer 37, 330 and 700  Enhancer 704, 815 and 843  Promoter 1, 2 and 3 
Reg. Element 
Transcription 
Factor 
# of 
motifs/ 
element  Reg. Element 
Transcription 
Factor 
# of 
motifs/ 
element  
Reg. 
Element 
Transcription 
Factor 
# of 
motifs/ 
element 
Enhancer 37 AML 1  Enhancer 704 ALX3 4  Promoter 1 AHR 2 
Enhancer 37 AML1 7  Enhancer 704 AML1 4  Promoter 1 AHRHIF 1 
Enhancer 37 AP1 24  Enhancer 704 AP1 18  Promoter 1 AML 1 
Enhancer 37 AP1FJ 3  Enhancer 704 AP1FJ 2  Promoter 1 AP2 5 
Enhancer 37 AP2A 1  Enhancer 704 ARI3A 1  Promoter 1 AP2ALPHA 4 
Enhancer 37 AP2C 1  Enhancer 704 ARX 6  Promoter 1 AP2B 1 
Enhancer 37 AP3 1  Enhancer 704 Atoh1 2  Promoter 1 AP2D 1 
Enhancer 37 AP4 3  Enhancer 704 BARHL1 1  Promoter 1 AP2GAMMA 1 
Enhancer 37 ARP1 1  Enhancer 704 BARX1 1  Promoter 1 AREB6 1 
Enhancer 37 ATF3 1  Enhancer 704 BARX2 2  Promoter 1 ARNT2 1 
Enhancer 37 BACH1 1  Enhancer 704 BATF 2  Promoter 1 Ascl2 1 
Enhancer 37 BACH2 1  Enhancer 704 BCL6 5  Promoter 1 ATF 2 
Enhancer 37 BARX1 3  Enhancer 704 BHLHA15 2  Promoter 1 ATF1 3 
Enhancer 37 BARX2 4  Enhancer 704 BHLHE23 1  Promoter 1 ATF2+ATF4 2 
Enhancer 37 BATF 2  Enhancer 704 BPTF 1  Promoter 1 ATF3 1 
Enhancer 37 BATF::JUN 2  Enhancer 704 BRCA1 1  Promoter 1 ATF4 2 
Enhancer 37 BCL6 9  Enhancer 704 CART1 4  Promoter 1 BHLHE22 1 
Enhancer 37 BLIMP1 2  Enhancer 704 CDP 2  Promoter 1 BHLHE23 2 
Enhancer 37 CART1 4  Enhancer 704 CDX2 3  Promoter 1 BPTF 3 
Enhancer 37 CEBP 4  Enhancer 704 CEBPGAMMA 1  Promoter 1 BRCA 1 
Enhancer 37 CEBPA 3  Enhancer 704 CEBPZ 1  Promoter 1 BRCA1 1 
Enhancer 37 CEBPB 5  Enhancer 704 COT2 2  Promoter 1 CEBPZ 1 
Enhancer 37 CEBPD 1  Enhancer 704 COUP 1  Promoter 1 CETS1P54 1 
Enhancer 37 CEBPDELTA 2  Enhancer 704 COUPTF 1  Promoter 1 CHCH 1 
Enhancer 37 CEBPE 1  Enhancer 704 CPEB1 2  Promoter 1 CKROX 2 
Enhancer 37 CEBPG 1  Enhancer 704 CTCF 1  Promoter 1 COE1 1 
Enhancer 37 
CEBPGAMM
A 2  Enhancer 704 DEC 1  Promoter 1 CP2 5 
Enhancer 37 CMYB 1  Enhancer 704 DLX1 2  Promoter 1 CREB 10 
Enhancer 37 COUPTF 2  Enhancer 704 DLX2 2  Promoter 1 CREB1 4 
Enhancer 37 CP2 2  Enhancer 704 DLX3 2  Promoter 1 CREB3 1 
Enhancer 37 CPEB1 5  Enhancer 704 DLX7 1  Promoter 1 CREBATF 2 
Enhancer 37 DBP 2  Enhancer 704 DR1 1  Promoter 1 CREBP1 2 
Enhancer 37 EBOX 1  Enhancer 704 DR3 1  Promoter 1 CREBP1CJUN 2 
Enhancer 37 EGR2 4  Enhancer 704 EAR2 1  Promoter 1 CREM 2 
Enhancer 37 EHF 2  Enhancer 704 EFC 1  Promoter 1 CXXC1 1 
Enhancer 37 ELF1 6  Enhancer 704 EHF 1  Promoter 1 E12 1 
Enhancer 37 ELF3 2  Enhancer 704 ELF1 1  Promoter 1 E2A 1 
Enhancer 37 Elf5 3  Enhancer 704 EMX2 1  Promoter 1 E2F 4 
Enhancer 37 ELK3 2  Enhancer 704 EN1 2  Promoter 1 E2F1 6 
Enhancer 37 EPAS1 1  Enhancer 704 EN2 2  Promoter 1 E2F6 1 
Enhancer 37 ERR3 1  Enhancer 704 ERR1 2  Promoter 1 E47 1 
Enhancer 37 ESE1 2  Enhancer 704 ERR2 1  Promoter 1 EBF 1 
Enhancer 37 ESR1 2  Enhancer 704 ESX1 3  Promoter 1 EBF1 1 
Enhancer 37 ESR2 4  Enhancer 704 EVI1 3  Promoter 1 EGR 1 
Enhancer 37 ESRRA 1  Enhancer 704 EVX1 1  Promoter 1 EGR1 1 
Enhancer 37 ESRRG 1  Enhancer 704 FEV 1  Promoter 1 EGR2 2 
Enhancer 37 ETS 2  Enhancer 704 FOS 3  Promoter 1 EGR3 2 
Enhancer 37 ETS1 3  Enhancer 704 FOSB 3  Promoter 1 EGR4 2 
Enhancer 37 ETS2 2  Enhancer 704 FOSL1 2  Promoter 1 EHF 1 
Enhancer 37 ETV4 1  Enhancer 704 FOSL2 6  Promoter 1 ELF2 1 
Enhancer 37 ETV5 1  Enhancer 704 FOXB1 7  Promoter 1 ELF5 2 
Enhancer 37 FEV 5  Enhancer 704 FOXC1 5  Promoter 1 ELK1 3 
Enhancer 37 FOS 5  Enhancer 704 FOXC2 3  Promoter 1 ELK3 1 
Enhancer 37 FOSB 2  Enhancer 704 FOXI1 3  Promoter 1 ELK4 1 
Enhancer 37 FOSL1 5  Enhancer 704 FOXJ2 8  Promoter 1 EPAS1 2 
Enhancer 37 FOSL2 5  Enhancer 704 Foxj3 6  Promoter 1 ER 1 
Enhancer 37 FOXH1 1  Enhancer 704 FOXL1 6  Promoter 1 ERF 1 
Enhancer 37 Foxj3 7  Enhancer 704 FOXM1 4  Promoter 1 ERG 2 
Enhancer 37 FOXO4 1  Enhancer 704 FOXO1 5  Promoter 1 ESR2 1 
Enhancer 37 FRA1 3  Enhancer 704 FOXO3 4  Promoter 1 ETF 2 
Enhancer 37 
GABP1+GAB
P2 1  Enhancer 704 FRA1 2  Promoter 1 ETS 1 
Enhancer 37 GATA3 6  Enhancer 704 GATA1 2  Promoter 1 ETS1 2 
Enhancer 37 GCM1 5  Enhancer 704 GATA3 5  Promoter 1 ETV1 1 
Enhancer 37 GLI1 1  Enhancer 704 GATA4 2  Promoter 1 ETV2 1 
Enhancer 37 GLI3 2  Enhancer 704 GATA5 2  Promoter 1 ETV4 1 
Enhancer 37 HBP1 3  Enhancer 704 GATA6 2  Promoter 1 ETV5 2 
Enhancer 37 HELIOSA 2  Enhancer 704 GBX1 1  Promoter 1 EVI1 4 
Enhancer 37 HES1 2  Enhancer 704 GBX2 4  Promoter 1 FAC1 2 
Enhancer 37 HLTF 1  Enhancer 704 GCR 1  Promoter 1 FEV 1 
Enhancer 37 HMGA2 1  Enhancer 704 GFI1 2  Promoter 1 FIGLA 2 
Enhancer 37 HMGIY 2  Enhancer 704 GFI1B 1  Promoter 1 FLI1 2 
Enhancer 37 HNF1 3  Enhancer 704 GKLF 2  Promoter 1 FOS 3 
Enhancer 37 HNF4 2  Enhancer 704 GLI 1  Promoter 1 FOXA1 7 
Enhancer 37 HNF4G 1  Enhancer 704 GLI3 6  Promoter 1 FOXA2 4 
Enhancer 37 HOXA4 1  Enhancer 704 GR 1  Promoter 1 FOXA3 4 
Enhancer 37 HOXA5 1  Enhancer 704 GSX1 1  Promoter 1 FOXB1 6 
Enhancer 37 HOXD8 1  Enhancer 704 HAND1 2  Promoter 1 FOXC1 12 
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Enhancer 37 HXD4 1  Enhancer 704 HAND1E47 2  Promoter 1 FOXC2 6 
Enhancer 37 HXD9 3  Enhancer 704 HB9 1  Promoter 1 FOXD1 6 
Enhancer 37 ICSBP 2  Enhancer 704 HESX1 3  Promoter 1 FOXD3 9 
Enhancer 37 IRF 3  Enhancer 704 Hic1 3  Promoter 1 FOXF1 4 
Enhancer 37 IRF1 5  Enhancer 704 HINFP 1  Promoter 1 FOXF2 4 
Enhancer 37 IRF2 2  Enhancer 704 HLF 2  Promoter 1 Foxg1 3 
Enhancer 37 IRF3 5  Enhancer 704 HLTF 1  Promoter 1 FOXI1 6 
Enhancer 37 IRF4 2  Enhancer 704 HMBOX1 2  Promoter 1 FOXJ2 12 
Enhancer 37 IRF5 2  Enhancer 704 HMGA1 2  Promoter 1 Foxj3 12 
Enhancer 37 IRF7 3  Enhancer 704 HMGIY 2  Promoter 1 FOXL1 4 
Enhancer 37 IRF8 5  Enhancer 704 HMX2 1  Promoter 1 FOXM1 3 
Enhancer 37 IRF9 1  Enhancer 704 HMX3 1  Promoter 1 FOXO1 11 
Enhancer 37 ISL1 1  Enhancer 704 HNF1 3  Promoter 1 FOXO3 11 
Enhancer 37 Jdp2 3  Enhancer 704 HNF1A 2  Promoter 1 FOXO4 9 
Enhancer 37 JUN 3  Enhancer 704 HNF1B 4  Promoter 1 FOXO6 3 
Enhancer 37 JUN(var.2) 2  Enhancer 704 HNF3 5  Promoter 1 FOXP2 6 
Enhancer 37 JUN::FOS 2  Enhancer 704 HNF4 3  Promoter 1 FOXP3 7 
Enhancer 37 JUNB 4  Enhancer 704 HNF4ALPHA 1  Promoter 1 FPM315 2 
Enhancer 37 JUND 3  Enhancer 704 HOX13 1  Promoter 1 FREAC2 3 
Enhancer 37 KROX 1  Enhancer 704 HOXA10 1  Promoter 1 FREAC4 3 
Enhancer 37 LBX2 1  Enhancer 704 Hoxa11 1  Promoter 1 FREAC7 2 
Enhancer 37 LEF1 2  Enhancer 704 HOXA13 7  Promoter 1 FUBP1 2 
Enhancer 37 LHX2 1  Enhancer 704 HOXA2 2  Promoter 1 GABP1+GABP2 1 
Enhancer 37 LHX4 1  Enhancer 704 HOXA4 1  Promoter 1 GABPALPHA 1 
Enhancer 37 LMO2COM 2  Enhancer 704 HOXA5 3  Promoter 1 GATA 2 
Enhancer 37 MAF 1  Enhancer 704 HOXA6 1  Promoter 1 GATA3 2 
Enhancer 37 Mafb 2  Enhancer 704 HOXA7 2  Promoter 1 GFI1 3 
Enhancer 37 MAFG 3  Enhancer 704 HOXB13 2  Promoter 1 GKLF 1 
Enhancer 37 MAFK 5  Enhancer 704 HOXB5 1  Promoter 1 GLI2 1 
Enhancer 37 MATH1 1  Enhancer 704 HOXC10 2  Promoter 1 GLI3 1 
Enhancer 37 MAZ 1  Enhancer 704 HOXC12 1  Promoter 1 HEB 2 
Enhancer 37 MCR 1  Enhancer 704 HOXC13 4  Promoter 1 HES1 2 
Enhancer 37 MEF2 1  Enhancer 704 HOXC5 1  Promoter 1 HEY2 1 
Enhancer 37 MEF2C 2  Enhancer 704 HOXC8 1  Promoter 1 HFH3 3 
Enhancer 37 MITF 1  Enhancer 704 HOXD12 3  Promoter 1 HFH8 3 
Enhancer 37 MSX1 1  Enhancer 704 HOXD13 7  Promoter 1 HIC1 1 
Enhancer 37 MSX2 1  Enhancer 704 HOXD3 1  Promoter 1 HIF1 1 
Enhancer 37 Msx3 1  Enhancer 704 HOXD8 1  Promoter 1 HIF1A 1 
Enhancer 37 MYB 1  Enhancer 704 Hoxd9 2  Promoter 1 HINFP 2 
Enhancer 37 MYBL1 1  Enhancer 704 HSF1 2  Promoter 1 HINFP1 1 
Enhancer 37 MYCMAX 1  Enhancer 704 HTF4 1  Promoter 1 HNF3 5 
Enhancer 37 MYOD 1  Enhancer 704 HXA5 1  Promoter 1 HNF3A 3 
Enhancer 37 MYOG 1  Enhancer 704 HXA7 1  Promoter 1 HNF3ALPHA 4 
Enhancer 37 MZF1 2  Enhancer 704 HXD10 2  Promoter 1 HNF3B 2 
Enhancer 37 NEUROD 1  Enhancer 704 IK 1  Promoter 1 HOXA13 5 
Enhancer 37 NF2L1 1  Enhancer 704 IKZF1 1  Promoter 1 HSF1 1 
Enhancer 37 NF2L2 1  Enhancer 704 INSM1 1  Promoter 1 HSFY2 4 
Enhancer 37 NFAC2 1  Enhancer 704 IPF 1  Promoter 1 HTF4 1 
Enhancer 37 NFAC4 1  Enhancer 704 IPF1 4  Promoter 1 HXA10 1 
Enhancer 37 NFAT 3  Enhancer 704 IRF 1  Promoter 1 IRF1 5 
Enhancer 37 NFAT1 1  Enhancer 704 IRF1 4  Promoter 1 IRF4 3 
Enhancer 37 NFAT2 2  Enhancer 704 IRF3 1  Promoter 1 KLF1 1 
Enhancer 37 NFATC2 1  Enhancer 704 IRF4 1  Promoter 1 KLF15 2 
Enhancer 37 NFE2::MAF 1  Enhancer 704 IRF5 1  Promoter 1 KLF16 2 
Enhancer 37 
NFIA+NFIB+N
FIC+NFIX 2  Enhancer 704 IRF8 2  Promoter 1 KLF4 2 
Enhancer 37 NFIX 1  Enhancer 704 IRX2 2  Promoter 1 KLF5 2 
Enhancer 37 NKX2-3 4  Enhancer 704 Irx3 2  Promoter 1 KLF6 1 
Enhancer 37 NKX25 3  Enhancer 704 ISL2 1  Promoter 1 KLF8 2 
Enhancer 37 NKX28 2  Enhancer 704 ITF2 1  Promoter 1 KROX 1 
Enhancer 37 NKX2-8 4  Enhancer 704 JUN 4  Promoter 1 LBP1 2 
Enhancer 37 NKX3-1 2  Enhancer 704 JUN(var.2) 4  Promoter 1 LHX61 1 
Enhancer 37 NKX32 3  Enhancer 704 JUN::FOS 2  Promoter 1 MATH1 2 
Enhancer 37 NOTO 1  Enhancer 704 JUNB 5  Promoter 1 MAZ 4 
Enhancer 37 Nr2e1 2  Enhancer 704 JUND 5  Promoter 1 MAZR 1 
Enhancer 37 NR2F6 1  Enhancer 704 K2B 1  Promoter 1 MBD2 1 
Enhancer 37 NR4A1 1  Enhancer 704 KLF1 2  Promoter 1 MCR 1 
Enhancer 37 NR4A2 4  Enhancer 704 Klf12 1  Promoter 1 MECP2 1 
Enhancer 37 NUR77 1  Enhancer 704 KLF3 1  Promoter 1 MEF2 4 
Enhancer 37 NURR1 1  Enhancer 704 KLF8 1  Promoter 1 MEIS3 3 
Enhancer 37 OCT 5  Enhancer 704 LBX2 1  Promoter 1 MGA 1 
Enhancer 37 OCT1 14  Enhancer 704 LEF1 4  Promoter 1 MLXPL 1 
Enhancer 37 OCT2 2  Enhancer 704 LEF1TCF1 1  Promoter 1 MYCMAX 2 
Enhancer 37 OCTAMER 1  Enhancer 704 LH2 1  Promoter 1 MYF6 2 
Enhancer 37 P53 4  Enhancer 704 LHX2 2  Promoter 1 MYOD 1 
Enhancer 37 PARP 2  Enhancer 704 LHX3 1  Promoter 1 MYOD1 1 
Enhancer 37 PAX 2  Enhancer 704 LHX4 1  Promoter 1 MYOG 1 
Enhancer 37 PAX2 3  Enhancer 704 LHX6 1  Promoter 1 MYOGENIN 1 
Enhancer 37 PAX8 5  Enhancer 704 LHX61 2  Promoter 1 MZF1 10 
Enhancer 37 PEA3 1  Enhancer 704 LMO2COM 1  Promoter 1 NANOG 3 
Enhancer 37 PEBP 1  Enhancer 704 LTF 1  Promoter 1 NDF1 2 
Enhancer 37 PITX2 2  Enhancer 704 LYF1 1  Promoter 1 NEUROD 1 
Enhancer 37 PO2F1 3  Enhancer 704 MAX 1  Promoter 1 NEUROD2 2 
Enhancer 37 PO2F2 2  Enhancer 704 MEF2 4  Promoter 1 NFAT1 1 
Enhancer 37 PO3F1 2  Enhancer 704 MEF2A 5  Promoter 1 NFATC1 1 
Enhancer 37 PO3F2 2  Enhancer 704 MEF2C 3  Promoter 1 NFIA 1 
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Enhancer 37 PO4F2 1  Enhancer 704 MEF2D 2  Promoter 1 
NFIA+NFIB+NFIC+
NFIX 1 
Enhancer 37 POU1F1 5  Enhancer 704 MEIS1 1  Promoter 1 NFIC 1 
Enhancer 37 POU2F1 6  Enhancer 704 MEIS1BHOXA9 1  Promoter 1 NFIX 2 
Enhancer 37 POU2F2 8  Enhancer 704 MEIS3 1  Promoter 1 NFKB 1 
Enhancer 37 POU2F3 9  Enhancer 704 MEOX1 1  Promoter 1 NFY 1 
Enhancer 37 POU3F1 6  Enhancer 704 MEOX2 4  Promoter 1 NFYA 2 
Enhancer 37 POU3F2 5  Enhancer 704 MESP1 1  Promoter 1 NFYB 2 
Enhancer 37 POU3F3 9  Enhancer 704 MGA 1  Promoter 1 NFYC 1 
Enhancer 37 POU3F4 3  Enhancer 704 MITF 1  Promoter 1 NHLH1 2 
Enhancer 37 POU4F1 2  Enhancer 704 MMEF2 1  Promoter 1 NKX2-3 2 
Enhancer 37 POU5F1 3  Enhancer 704 MNX1 1  Promoter 1 NKX25 6 
Enhancer 37 POU5F1P1 6  Enhancer 704 MSX1 2  Promoter 1 NKX2-8 2 
Enhancer 37 PRDM1 5  Enhancer 704 MSX2 2  Promoter 1 NR0B1 2 
Enhancer 37 PRRX1 2  Enhancer 704 MYBB 1  Promoter 1 NR2F6 1 
Enhancer 37 PU1 2  Enhancer 704 NANOG 1  Promoter 1 NRF1 2 
Enhancer 37 RAX 1  Enhancer 704 NCX 2  Promoter 1 NUR77 2 
Enhancer 37 RFX5 1  Enhancer 704 NEUROD2 1  Promoter 1 OCT1 14 
Enhancer 37 Rhox11 1  Enhancer 704 NFAC1 3  Promoter 1 OLIG2 4 
Enhancer 37 RREB1 2  Enhancer 704 NFAC2 2  Promoter 1 OLIG3 2 
Enhancer 37 RUNX2 4  Enhancer 704 NFAT2 1  Promoter 1 P50P50 1 
Enhancer 37 RUNX3 1  Enhancer 704 NFAT5 2  Promoter 1 PAX3 1 
Enhancer 37 SF1 1  Enhancer 704 NFIA 1  Promoter 1 PAX4 2 
Enhancer 37 SIX4 1  Enhancer 704 NFKB1 1  Promoter 1 PAX5 3 
Enhancer 37 SMAD1 2  Enhancer 704 NFY 1  Promoter 1 PAX8 4 
Enhancer 37 SMAD2 1  Enhancer 704 NFYA 1  Promoter 1 PBX3 1 
Enhancer 37 SMAD3 2  Enhancer 704 NFYB 1  Promoter 1 PLAG1 3 
Enhancer 37 SMAD4 1  Enhancer 704 NKX22 1  Promoter 1 PPARD 1 
Enhancer 37 SMRC1 1  Enhancer 704 NKX2-3 2  Promoter 1 PURA 2 
Enhancer 37 SOX10 8  Enhancer 704 NKX25 2  Promoter 1 RARA 1 
Enhancer 37 SOX13 1  Enhancer 704 NKX2-8 2  Promoter 1 RARB 1 
Enhancer 37 SOX15 2  Enhancer 704 NKX31 2  Promoter 1 RELB 1 
Enhancer 37 SOX18 2  Enhancer 704 NKX3-1 4  Promoter 1 RFX1 1 
Enhancer 37 SOX4 2  Enhancer 704 NKX32 3  Promoter 1 RREB1 4 
Enhancer 37 SOX5 5  Enhancer 704 NKX3-2 1  Promoter 1 SMAD 1 
Enhancer 37 SOX9 3  Enhancer 704 NKX3A 4  Promoter 1 SMAD2 2 
Enhancer 37 SPIB 1  Enhancer 704 NKX61 2  Promoter 1 SNAI1 1 
Enhancer 37 SRY 7  Enhancer 704 NKX62 2  Promoter 1 SNAI2 1 
Enhancer 37 STAT1 2  Enhancer 704 NOBOX 1  Promoter 1 SOX13 1 
Enhancer 37 STAT2 1  Enhancer 704 NR1D1 1  Promoter 1 SOX15 1 
Enhancer 37 
STAT2::STAT
1 1  Enhancer 704 NR2C2 1  Promoter 1 SOX4 2 
Enhancer 37 STAT3 3  Enhancer 704 Nr2e1 3  Promoter 1 SOX5 2 
Enhancer 37 STAT4 1  Enhancer 704 NR2E3 2  Promoter 1 SOX9 1 
Enhancer 37 STAT6 1  Enhancer 704 NR2F1 1  Promoter 1 SP1 16 
Enhancer 37 STF1 1  Enhancer 704 NR4A1 1  Promoter 1 SP1SP3 1 
Enhancer 37 TF7L2 1  Enhancer 704 NR4A2 1  Promoter 1 SP2 4 
Enhancer 37 TFAP2A 4  Enhancer 704 NURR1 2  Promoter 1 SP3 4 
Enhancer 37 TFAP2C 4  Enhancer 704 OCT 3  Promoter 1 SP4 3 
Enhancer 37 TFAP4 1  Enhancer 704 OCT1 11  Promoter 1 SPDEF 2 
Enhancer 37 TFCP2 2  Enhancer 704 OCT2 1  Promoter 1 SPIB 1 
Enhancer 37 TFE3 3  Enhancer 704 OCTAMER 2  Promoter 1 SRBP2 2 
Enhancer 37 TFEB 2  Enhancer 704 OLIG2 4  Promoter 1 STAT1 2 
Enhancer 37 TFEC 2  Enhancer 704 OLIG3 2  Promoter 1 STAT3 1 
Enhancer 37 THAP1 1  Enhancer 704 OSF2 1  Promoter 1 SZF11 1 
Enhancer 37 TLX1 1  Enhancer 704 OTX2 5  Promoter 1 TAL1 3 
Enhancer 37 UBIP1 2  Enhancer 704 OVOL1 1  Promoter 1 TAL1::TCF3 2 
Enhancer 37 USF1 2  Enhancer 704 PAX 2  Promoter 1 TBX1 1 
Enhancer 37 USF2 1  Enhancer 704 PAX4 1  Promoter 1 TBX15 1 
Enhancer 330 AIRE 3  Enhancer 704 PAX5 4  Promoter 1 TBX5 2 
Enhancer 330 Alx1 4  Enhancer 704 PAX8 1  Promoter 1 TCF4 1 
Enhancer 330 ALX3 8  Enhancer 704 PBX1 2  Promoter 1 TCF7 1 
Enhancer 330 ALX4 4  Enhancer 704 PIT1 2  Promoter 1 TCF7L2 1 
Enhancer 330 AML 2  Enhancer 704 PITX2 3  Promoter 1 Tcfap2a 2 
Enhancer 330 AML1 4  Enhancer 704 PMX2A 1  Promoter 1 TEF 1 
Enhancer 330 AREB6 1  Enhancer 704 PO2F1 3  Promoter 1 TF7L2 1 
Enhancer 330 ARI3A 3  Enhancer 704 PO2F2 1  Promoter 1 TFAP2A 2 
Enhancer 330 ARI5B 1  Enhancer 704 PO3F1 1  Promoter 1 TFAP2B 1 
Enhancer 330 ARX 2  Enhancer 704 PO3F2 2  Promoter 1 TFAP4 1 
Enhancer 330 ATF4 1  Enhancer 704 PO4F2 1  Promoter 1 TFDP1 1 
Enhancer 330 ATF5 1  Enhancer 704 PO5F1 2  Promoter 1 TFE2 1 
Enhancer 330 Atoh1 1  Enhancer 704 POU1F1 4  Promoter 1 TFIII 1 
Enhancer 330 BARHL1 5  Enhancer 704 POU2F1 5  Promoter 1 THA 1 
Enhancer 330 BARHL2 10  Enhancer 704 POU2F2 6  Promoter 1 THAP1 1 
Enhancer 330 BARX1 4  Enhancer 704 POU2F3 5  Promoter 1 THB 2 
Enhancer 330 BARX2 2  Enhancer 704 POU3F1 5  Promoter 1 TLX1 1 
Enhancer 330 BCL6 2  Enhancer 704 POU3F2 4  Promoter 1 TWST1 1 
Enhancer 330 BHLHE22 1  Enhancer 704 POU3F3 5  Promoter 1 VDR 2 
Enhancer 330 BHLHE23 1  Enhancer 704 POU3F4 3  Promoter 1 WHN 1 
Enhancer 330 BRN2 2  Enhancer 704 POU4F1 2  Promoter 1 WT1 3 
Enhancer 330 BRN4 1  Enhancer 704 POU4F3 2  Promoter 1 XBP1 2 
Enhancer 330 BSX 2  Enhancer 704 POU5F1 3  Promoter 1 YBOX1 1 
Enhancer 330 CART1 5  Enhancer 704 POU5F1P1 2  Promoter 1 ZBT7B 2 
Enhancer 330 CDC5L 1  Enhancer 704 POU6F1 1  Promoter 1 ZBTB33 1 
Enhancer 330 CDP 2  Enhancer 704 PPAR 1  Promoter 1 Zfp740 1 
Enhancer 330 CDX 2  Enhancer 704 PPARA 1  Promoter 1 ZFX 3 
Enhancer 330 CDX1 4  Enhancer 704 PPARD 1  Promoter 1 ZN148 2 
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Enhancer 330 CDX2 7  Enhancer 704 PR 2  Promoter 1 ZN219 2 
Enhancer 330 CEBP 8  Enhancer 704 PRGR 1  Promoter 1 ZNF219 2 
Enhancer 330 CEBPA 3  Enhancer 704 PRRX1 2  Promoter 1 ZNF263 2 
Enhancer 330 CEBPB 1  Enhancer 704 PRRX2 1  Promoter 1 ZNF354C 1 
Enhancer 330 CEBPD 1  Enhancer 704 PU1 1  Promoter 1 ZNF740 3 
Enhancer 330 CEBPE 1  Enhancer 704 PXRRXR 2  Promoter 2 AIRE 2 
Enhancer 330 CEBPG 1  Enhancer 704 RAX 1  Promoter 2 ALX1 2 
Enhancer 330 CEBPZ 1  Enhancer 704 RBPJK 1  Promoter 2 ALX3 3 
Enhancer 330 CHX10 1  Enhancer 704 RFX1 1  Promoter 2 ALX4 2 
Enhancer 330 CREB 1  Enhancer 704 RORA 4  Promoter 2 AP2ALPHA 3 
Enhancer 330 CREBP1 1  Enhancer 704 RORA1 1  Promoter 2 AP3 1 
Enhancer 330 CRX 3  Enhancer 704 RORA2 1  Promoter 2 ARI3A 4 
Enhancer 330 CUX1 1  Enhancer 704 RORBETA 1  Promoter 2 ARI5B 1 
Enhancer 330 DBP 2  Enhancer 704 RORG 1  Promoter 2 ATF5 2 
Enhancer 330 DLX1 5  Enhancer 704 RUNX2 1  Promoter 2 Barhl1 4 
Enhancer 330 DLX2 7  Enhancer 704 RXRB 1  Promoter 2 BARHL2 7 
Enhancer 330 DLX3 4  Enhancer 704 RXRG 1  Promoter 2 BARX1 5 
Enhancer 330 DLX4 2  Enhancer 704 SATB1 1  Promoter 2 BARX2 2 
Enhancer 330 DLX5 4  Enhancer 704 SF1 3  Promoter 2 BCL6 3 
Enhancer 330 DLX6 2  Enhancer 704 SMAD1 3  Promoter 2 BPTF 1 
Enhancer 330 DMRT2 1  Enhancer 704 SMAD3 2  Promoter 2 BRN4 2 
Enhancer 330 DMRT3 1  Enhancer 704 SMAD4 2  Promoter 2 BSX 1 
Enhancer 330 DRGX 2  Enhancer 704 SMRC1 3  Promoter 2 CDC5 1 
Enhancer 330 DRI1 1  Enhancer 704 SOX 1  Promoter 2 CDC5L 1 
Enhancer 330 DUX4 1  Enhancer 704 SOX10 6  Promoter 2 CDX1 2 
Enhancer 330 E2F1 1  Enhancer 704 SOX13 1  Promoter 2 CDX2 3 
Enhancer 330 E4BP4 1  Enhancer 704 SOX15 2  Promoter 2 CEBP 2 
Enhancer 330 EGR1 1  Enhancer 704 SOX2 1  Promoter 2 CEBPA 2 
Enhancer 330 EMX1 3  Enhancer 704 SOX4 1  Promoter 2 CEBPB 1 
Enhancer 330 EMX2 6  Enhancer 704 SOX5 4  Promoter 2 CEBPGAMMA 1 
Enhancer 330 EN1 8  Enhancer 704 SOX9 4  Promoter 2 CHOP 1 
Enhancer 330 EN2 7  Enhancer 704 SOX91 1  Promoter 2 COT2 1 
Enhancer 330 ER 1  Enhancer 704 SRF 2  Promoter 2 CP2 1 
Enhancer 330 ESX1 4  Enhancer 704 SRY 6  Promoter 2 CPEB1 1 
Enhancer 330 EVX1 4  Enhancer 704 STA5A 3  Promoter 2 CRX 3 
Enhancer 330 EVX2 2  Enhancer 704 STA5B 2  Promoter 2 CUX1 1 
Enhancer 330 FOS 1  Enhancer 704 STAT 1  Promoter 2 DBP 1 
Enhancer 330 FOXA1 3  Enhancer 704 STAT1 6  Promoter 2 DLX1 3 
Enhancer 330 FOXA2 1  Enhancer 704 STAT1STAT1 1  Promoter 2 DLX2 6 
Enhancer 330 FOXA3 2  Enhancer 704 STAT2 2  Promoter 2 DLX3 3 
Enhancer 330 FOXB1 2  Enhancer 704 STAT2::STAT1 1  Promoter 2 DLX4 1 
Enhancer 330 FOXC1 6  Enhancer 704 STAT3 4  Promoter 2 DLX5 2 
Enhancer 330 FOXC2 3  Enhancer 704 STAT4 3  Promoter 2 DLX6 1 
Enhancer 330 FOXD1 2  Enhancer 704 STAT5A 3  Promoter 2 DLX7 1 
Enhancer 330 FOXD2 2  Enhancer 704 STAT5B 2  Promoter 2 DMRT1 2 
Enhancer 330 FOXD3 4  Enhancer 704 SUH 1  Promoter 2 DMRT2 1 
Enhancer 330 FOXF1 1  Enhancer 704 TAL1::TCF3 1  Promoter 2 DMRT3 1 
Enhancer 330 FOXF2 2  Enhancer 704 TBP 3  Promoter 2 DPRX 1 
Enhancer 330 Foxg1 1  Enhancer 704 TBX1 1  Promoter 2 DRI1 1 
Enhancer 330 FOXI1 3  Enhancer 704 TBX15 1  Promoter 2 EGR3 1 
Enhancer 330 FOXJ2 3  Enhancer 704 TBX20 1  Promoter 2 EMX1 2 
Enhancer 330 FOXJ3 2  Enhancer 704 TBX4 1  Promoter 2 EMX2 2 
Enhancer 330 Foxk1 1  Enhancer 704 TBX5 1  Promoter 2 EN1 6 
Enhancer 330 FOXL1 4  Enhancer 704 TCF11 1  Promoter 2 EN2 3 
Enhancer 330 FOXM1 1  Enhancer 704 TCF3 2  Promoter 2 EPAS1 1 
Enhancer 330 FOXO1 6  Enhancer 704 TCF4 1  Promoter 2 ERR1 1 
Enhancer 330 FOXO3 5  Enhancer 704 TEAD1 11  Promoter 2 ERR3 1 
Enhancer 330 FOXO3A 1  Enhancer 704 TEAD3 5  Promoter 2 ESE1 1 
Enhancer 330 FOXO4 5  Enhancer 704 TEAD4 4  Promoter 2 ESX1 2 
Enhancer 330 FOXO6 1  Enhancer 704 TEF 8  Promoter 2 ETV7 1 
Enhancer 330 FOXP1 1  Enhancer 704 TEF1 2  Promoter 2 EVI1 3 
Enhancer 330 FOXP2 2  Enhancer 704 TFE 1  Promoter 2 FAC1 1 
Enhancer 330 FOXP3 3  Enhancer 704 TFE2 2  Promoter 2 FOS 1 
Enhancer 330 FREAC7 1  Enhancer 704 TFEB 1  Promoter 2 FOX 2 
Enhancer 330 FUBP1 1  Enhancer 704 TFEC 1  Promoter 2 FOXA1 4 
Enhancer 330 GATA1 2  Enhancer 704 TGIF1 1  Promoter 2 FOXA2 2 
Enhancer 330 GATA2 2  Enhancer 704 THA 2  Promoter 2 FOXA3 2 
Enhancer 330 GATA3 2  Enhancer 704 TR4 1  Promoter 2 FOXB1 4 
Enhancer 330 GATA4 1  Enhancer 704 TWST1 1  Promoter 2 FOXC1 8 
Enhancer 330 GATA5 2  Enhancer 704 UBIP1 1  Promoter 2 FOXC2 4 
Enhancer 330 GATA6 2  Enhancer 704 Uncx 3  Promoter 2 FOXD1 4 
Enhancer 330 Gbx1 4  Enhancer 704 USF 1  Promoter 2 FOXD2 4 
Enhancer 330 GBX2 9  Enhancer 704 USF1 2  Promoter 2 FOXD3 7 
Enhancer 330 GFI1 2  Enhancer 704 USF2 1  Promoter 2 FOXF1 2 
Enhancer 330 GR 2  Enhancer 704 VAX1 1  Promoter 2 FOXF2 3 
Enhancer 330 GSC 1  Enhancer 704 VBP 2  Promoter 2 Foxg1 2 
Enhancer 330 GSX1 2  Enhancer 704 VSX1 1  Promoter 2 FOXI1 3 
Enhancer 330 GSX2 2  Enhancer 704 VSX2 1  Promoter 2 FOXJ2 7 
Enhancer 330 HAND1 1  Enhancer 704 ZABC1 2  Promoter 2 Foxj3 6 
Enhancer 330 HAND1E47 1  Enhancer 704 ZEB1 1  Promoter 2 Foxk1 2 
Enhancer 330 HB9 1  Enhancer 704 ZFHX3 1  Promoter 2 FOXL1 3 
Enhancer 330 HBP1 1  Enhancer 704 ZNF333 2  Promoter 2 FOXM1 2 
Enhancer 330 HELIOSA 1  Enhancer 704 ZNF354C 1  Promoter 2 FOXO1 6 
Enhancer 330 HESX1 2  Enhancer 815 AFP1 2  Promoter 2 FOXO3 6 
Enhancer 330 HFH3 1  Enhancer 815 Alx1 5  Promoter 2 FOXO3A 1 
Enhancer 330 HFH4 1  Enhancer 815 ALX3 3  Promoter 2 FOXO4 4 
Enhancer 330 HLF 6  Enhancer 815 ALX4 6  Promoter 2 FOXO6 2 
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Enhancer 330 HMBOX1 1  Enhancer 815 AP1 13  Promoter 2 FOXP1 2 
Enhancer 330 HMGA1 2  Enhancer 815 AP1FJ 1  Promoter 2 FOXP2 4 
Enhancer 330 HMGIY 4  Enhancer 815 AP4 1  Promoter 2 FOXP3 5 
Enhancer 330 HMX1 1  Enhancer 815 ARI5B 1  Promoter 2 FREAC2 2 
Enhancer 330 HMX2 1  Enhancer 815 ARX 4  Promoter 2 FREAC4 2 
Enhancer 330 HMX3 2  Enhancer 815 ATF3 1  Promoter 2 FREAC7 1 
Enhancer 330 HNF1 4  Enhancer 815 ATF5 3  Promoter 2 FUBP1 1 
Enhancer 330 HNF1A 1  Enhancer 815 BACH2 1  Promoter 2 GATA 1 
Enhancer 330 HNF1B 3  Enhancer 815 BARHL2 1  Promoter 2 GATA1 4 
Enhancer 330 HNF3 3  Enhancer 815 BATF 2  Promoter 2 GATA2 1 
Enhancer 330 HNF3A 1  Enhancer 815 BATF::JUN 1  Promoter 2 GATA3 1 
Enhancer 330 HNF3ALPHA 2  Enhancer 815 BCL6 4  Promoter 2 GATA4 1 
Enhancer 330 HNF3B 2  Enhancer 815 CART1 2  Promoter 2 GATA5 2 
Enhancer 330 HNF4 2  Enhancer 815 CDX 2  Promoter 2 GATA6 1 
Enhancer 330 HNF6 3  Enhancer 815 CDX1 1  Promoter 2 Gbx1 2 
Enhancer 330 HOX13 2  Enhancer 815 CDX2 3  Promoter 2 GBX2 3 
Enhancer 330 HOXA1 3  Enhancer 815 CEBP 8  Promoter 2 GFI1 2 
Enhancer 330 HOXA10 5  Enhancer 815 CEBPA 6  Promoter 2 GMEB2 1 
Enhancer 330 Hoxa11 3  Enhancer 815 CEBPB 6  Promoter 2 GR 1 
Enhancer 330 HOXA13 2  Enhancer 815 CEBPD 2  Promoter 2 GSC 1 
Enhancer 330 HOXA2 6  Enhancer 815 CEBPDELTA 1  Promoter 2 GSC2 1 
Enhancer 330 HOXA3 2  Enhancer 815 COT2 3  Promoter 2 GSX1 1 
Enhancer 330 HOXA4 4  Enhancer 815 CRX 3  Promoter 2 GSX2 1 
Enhancer 330 HOXA6 2  Enhancer 815 DBP 2  Promoter 2 HB9 1 
Enhancer 330 HOXA9 2  Enhancer 815 DMBX1 1  Promoter 2 HELIOSA 1 
Enhancer 330 HOXB2 2  Enhancer 815 DMRT3 1  Promoter 2 HESX1 2 
Enhancer 330 HOXB3 2  Enhancer 815 DPRX 1  Promoter 2 HFH3 1 
Enhancer 330 HOXB5 4  Enhancer 815 DRGX 3  Promoter 2 HFH4 1 
Enhancer 330 HOXB6 2  Enhancer 815 EPAS1 1  Promoter 2 HFH8 2 
Enhancer 330 HOXB9 1  Enhancer 815 EVI1 7  Promoter 2 HIF2A 2 
Enhancer 330 HOXC10 8  Enhancer 815 FOS 2  Promoter 2 HMGA1 1 
Enhancer 330 HOXC11 4  Enhancer 815 FOSB 3  Promoter 2 HMGIY 4 
Enhancer 330 HOXC12 2  Enhancer 815 FOSL1 1  Promoter 2 HMX1 1 
Enhancer 330 HOXC4 1  Enhancer 815 FOSL2 4  Promoter 2 HMX2 1 
Enhancer 330 HOXC5 1  Enhancer 815 FOX 3  Promoter 2 HMX3 2 
Enhancer 330 HOXC8 2  Enhancer 815 FOXA1 5  Promoter 2 HNF1 3 
Enhancer 330 HOXC9 1  Enhancer 815 FOXA2 3  Promoter 2 HNF1A 2 
Enhancer 330 HOXD11 2  Enhancer 815 FOXA3 3  Promoter 2 HNF1B 4 
Enhancer 330 HOXD12 3  Enhancer 815 FOXB1 6  Promoter 2 HNF3 3 
Enhancer 330 HOXD13 3  Enhancer 815 FOXC1 7  Promoter 2 HNF3A 2 
Enhancer 330 HOXD3 4  Enhancer 815 FOXC2 5  Promoter 2 HNF3ALPHA 2 
Enhancer 330 HOXD8 3  Enhancer 815 FOXD1 5  Promoter 2 HNF3B 1 
Enhancer 330 Hoxd9 3  Enhancer 815 FOXD2 4  Promoter 2 HOX13 1 
Enhancer 330 HSF1 2  Enhancer 815 FOXD3 8  Promoter 2 HOXA1 1 
Enhancer 330 HSF2 2  Enhancer 815 FOXF1 3  Promoter 2 HOXA10 4 
Enhancer 330 HXA10 1  Enhancer 815 FOXF2 5  Promoter 2 Hoxa11 2 
Enhancer 330 HXA13 1  Enhancer 815 Foxg1 2  Promoter 2 HOXA13 4 
Enhancer 330 HXA5 1  Enhancer 815 FOXI1 4  Promoter 2 HOXA2 2 
Enhancer 330 HXD10 1  Enhancer 815 FOXJ2 7  Promoter 2 HOXA3 2 
Enhancer 330 HXD4 3  Enhancer 815 FOXJ3 5  Promoter 2 HOXA4 1 
Enhancer 330 HXD9 3  Enhancer 815 Foxk1 2  Promoter 2 HOXA6 2 
Enhancer 330 INSM1 1  Enhancer 815 FOXL1 7  Promoter 2 HOXA7 1 
Enhancer 330 IPF 1  Enhancer 815 FOXM1 5  Promoter 2 HOXA9 1 
Enhancer 330 IPF1 14  Enhancer 815 FOXO1 5  Promoter 2 HOXB13 1 
Enhancer 330 IRF 4  Enhancer 815 FOXO3 5  Promoter 2 HOXB2 1 
Enhancer 330 IRF1 4  Enhancer 815 FOXO3A 1  Promoter 2 HOXB3 1 
Enhancer 330 IRF3 4  Enhancer 815 FOXO4 5  Promoter 2 HOXB5 2 
Enhancer 330 IRF4 4  Enhancer 815 FOXO6 2  Promoter 2 HOXB6 2 
Enhancer 330 IRF7 4  Enhancer 815 FOXP1 1  Promoter 2 HOXB9 1 
Enhancer 330 IRX2 2  Enhancer 815 FOXP2 5  Promoter 2 HOXC10 5 
Enhancer 330 IRX4 2  Enhancer 815 FOXP3 4  Promoter 2 HOXC11 4 
Enhancer 330 IRX5 2  Enhancer 815 FRA1 3  Promoter 2 HOXC12 1 
Enhancer 330 IRXB3 1  Enhancer 815 FREAC2 2  Promoter 2 HOXC13 1 
Enhancer 330 ISL1 2  Enhancer 815 FREAC3 2  Promoter 2 HOXC4 1 
Enhancer 330 ISL2 1  Enhancer 815 FUBP1 2  Promoter 2 HOXC5 2 
Enhancer 330 ISRE 1  Enhancer 815 GAF 1  Promoter 2 HOXC8 2 
Enhancer 330 ISX 4  Enhancer 815 GATA1 3  Promoter 2 HOXC9 1 
Enhancer 330 JUN 3  Enhancer 815 GATA3 7  Promoter 2 HOXD11 2 
Enhancer 330 JUND(var.2) 1  Enhancer 815 GATA5 3  Promoter 2 HOXD12 2 
Enhancer 330 K2B 1  Enhancer 815 GATA6 4  Promoter 2 HOXD13 3 
Enhancer 330 LBX2 4  Enhancer 815 GFI1 4  Promoter 2 HOXD3 3 
Enhancer 330 LEF1 6  Enhancer 815 GKLF 1  Promoter 2 Hoxd9 2 
Enhancer 330 LH2 2  Enhancer 815 GLI2 1  Promoter 2 HSF2 1 
Enhancer 330 LHX2 6  Enhancer 815 GLI3 3  Promoter 2 HXA13 1 
Enhancer 330 LHX3 1  Enhancer 815 GSC 1  Promoter 2 HXA5 1 
Enhancer 330 LHX4 5  Enhancer 815 GSC2 1  Promoter 2 HXC8 1 
Enhancer 330 LHX5 1  Enhancer 815 HESX1 2  Promoter 2 HXD10 2 
Enhancer 330 LHX6 2  Enhancer 815 HFH3 4  Promoter 2 HXD13 1 
Enhancer 330 LHX61 3  Enhancer 815 HFH8 2  Promoter 2 HXD4 2 
Enhancer 330 Lhx8 2  Enhancer 815 Hic1 3  Promoter 2 HXD9 2 
Enhancer 330 LHX9 2  Enhancer 815 HIC2 2  Promoter 2 ID4 1 
Enhancer 330 LMX1 1  Enhancer 815 HLF 1  Promoter 2 IPF 1 
Enhancer 330 LMX1A 2  Enhancer 815 HMBOX1 1  Promoter 2 IPF1 4 
Enhancer 330 LMX1B 4  Enhancer 815 HMGA1 2  Promoter 2 IRF 1 
Enhancer 330 MAFG 4  Enhancer 815 HMGIY 4  Promoter 2 IRF1 4 
Enhancer 330 MEF2A 1  Enhancer 815 HNF3 6  Promoter 2 IRF2 1 
Enhancer 330 MEF2C 2  Enhancer 815 HNF3A 3  Promoter 2 IRF4 2 
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Enhancer 330 MEIS1 1  Enhancer 815 HNF3ALPHA 4  Promoter 2 IRF7 2 
Enhancer 330 MEOX1 2  Enhancer 815 HNF3B 3  Promoter 2 IRF8 3 
Enhancer 330 MEOX2 8  Enhancer 815 HNF4 2  Promoter 2 IRF9 1 
Enhancer 330 MIXL1 2  Enhancer 815 HOXA5 1  Promoter 2 IRX2 1 
Enhancer 330 MMEF2 1  Enhancer 815 HOXA7 1  Promoter 2 Irx3 1 
Enhancer 330 MNX1 2  Enhancer 815 HOXD11 1  Promoter 2 IRX5 1 
Enhancer 330 MOX1 1  Enhancer 815 HOXD13 5  Promoter 2 ISL1 1 
Enhancer 330 MSX1 9  Enhancer 815 Hoxd9 1  Promoter 2 ISL2 1 
Enhancer 330 MSX2 9  Enhancer 815 HSF1 1  Promoter 2 ISX 2 
Enhancer 330 Msx3 5  Enhancer 815 HXD10 2  Promoter 2 ITF2 1 
Enhancer 330 MYB 2  Enhancer 815 HXD9 2  Promoter 2 JUND(var.2) 1 
Enhancer 330 NANOG 1  Enhancer 815 IRF1 2  Promoter 2 K2B 1 
Enhancer 330 NCX 2  Enhancer 815 IRX2 1  Promoter 2 KLF3 1 
Enhancer 330 NF2L1 2  Enhancer 815 Irx3 1  Promoter 2 LEF1 4 
Enhancer 330 NFAC2 2  Enhancer 815 IRX5 2  Promoter 2 LEF1TCF1 1 
Enhancer 330 NFAC3 1  Enhancer 815 IRXB3 1  Promoter 2 LHX2 2 
Enhancer 330 NFAT 5  Enhancer 815 ISL1 1  Promoter 2 LHX3 4 
Enhancer 330 NFIL3 5  Enhancer 815 ISX 1  Promoter 2 Lhx4 2 
Enhancer 330 NFKB2 1  Enhancer 815 JDP2 2  Promoter 2 LHX5 1 
Enhancer 330 NFY 4  Enhancer 815 JUN 2  Promoter 2 LHX6 1 
Enhancer 330 NFYA 2  Enhancer 815 JUN(var.2) 3  Promoter 2 Lhx8 3 
Enhancer 330 NFYB 3  Enhancer 815 JUN::FOS 1  Promoter 2 LHX9 2 
Enhancer 330 NFYC 2  Enhancer 815 JUNB 5  Promoter 2 LMX1A 2 
Enhancer 330 NKX25 3  Enhancer 815 JUND 4  Promoter 2 LMX1B 3 
Enhancer 330 NKX31 1  Enhancer 815 KLF4 1  Promoter 2 Mafb 1 
Enhancer 330 NKX3A 2  Enhancer 815 LFA1 1  Promoter 2 MAFF 1 
Enhancer 330 NKX61 4  Enhancer 815 Lhx8 1  Promoter 2 MAFK 5 
Enhancer 330 Nkx6-1 6  Enhancer 815 LRH1 1  Promoter 2 MEF2 3 
Enhancer 330 NKX62 2  Enhancer 815 MAF 1  Promoter 2 MEF2A 3 
Enhancer 330 NKX6-2 4  Enhancer 815 MEF2 4  Promoter 2 MEF2C 1 
Enhancer 330 NOBOX 2  Enhancer 815 MEF2A 4  Promoter 2 MEIS1 2 
Enhancer 330 NOTO 3  Enhancer 815 MEF2C 1  Promoter 2 MEIS1AHOXA9 1 
Enhancer 330 NR1I3 1  Enhancer 815 MRF2 1  Promoter 2 MEIS2 3 
Enhancer 330 Nr2e1 5  Enhancer 815 MYB 5  Promoter 2 MEIS3 2 
Enhancer 330 NR2E3 1  Enhancer 815 MYF6 1  Promoter 2 MEOX1 1 
Enhancer 330 NRL 1  Enhancer 815 MYOGENIN 1  Promoter 2 MEOX2 4 
Enhancer 330 OCT 6  Enhancer 815 NDF1 1  Promoter 2 MIXL1 1 
Enhancer 330 OCT1 23  Enhancer 815 NFAC2 2  Promoter 2 MNX1 1 
Enhancer 330 OCT2 3  Enhancer 815 NFAC3 1  Promoter 2 MOX1 2 
Enhancer 330 OCTAMER 4  Enhancer 815 NFAT3 2  Promoter 2 MSX1 5 
Enhancer 330 OLIG2 2  Enhancer 815 NFAT5 1  Promoter 2 MSX2 3 
Enhancer 330 OLIG3 1  Enhancer 815 NFATC2 2  Promoter 2 Msx3 2 
Enhancer 330 OTX 1  Enhancer 815 NFE2 2  Promoter 2 MYBL1 1 
Enhancer 330 OVOL1 1  Enhancer 815 
NFIA+NFIB+NFI
C+NFIX 3  Promoter 2 MYBL2 1 
Enhancer 330 PARP 2  Enhancer 815 NFIC 1  Promoter 2 MYF6 1 
Enhancer 330 PAX2 3  Enhancer 815 NFIL3 2  Promoter 2 NANOG 2 
Enhancer 330 PAX3 1  Enhancer 815 NFKAPPAB 1  Promoter 2 NCX 2 
Enhancer 330 PAX4 8  Enhancer 815 NFKB 1  Promoter 2 NDF1 1 
Enhancer 330 PAX6 3  Enhancer 815 NKX31 2  Promoter 2 NFAC1 1 
Enhancer 330 PAX7 2  Enhancer 815 NKX3-1 4  Promoter 2 NFAC2 1 
Enhancer 330 PBX1 1  Enhancer 815 NKX3A 2  Promoter 2 NFAT3 1 
Enhancer 330 PBX2 2  Enhancer 815 NKX61 1  Promoter 2 NFATC2 1 
Enhancer 330 PDX1 5  Enhancer 815 NKX62 1  Promoter 2 NFIL3 1 
Enhancer 330 PEBB 1  Enhancer 815 NR2E3 1  Promoter 2 NKX22 3 
Enhancer 330 PEBP 2  Enhancer 815 NRF2 1  Promoter 2 NKX25 2 
Enhancer 330 PHOX2A 2  Enhancer 815 OCT 4  Promoter 2 NKX31 1 
Enhancer 330 PHOX2B 4  Enhancer 815 OCT1 13  Promoter 2 Nkx3-1 2 
Enhancer 330 PIT1 2  Enhancer 815 OCTAMER 2  Promoter 2 NKX3A 3 
Enhancer 330 PITX1 1  Enhancer 815 OTX 2  Promoter 2 NKX61 3 
Enhancer 330 PITX2 3  Enhancer 815 OTX1 3  Promoter 2 Nkx6-1 3 
Enhancer 330 PITX3 1  Enhancer 815 OTX2 6  Promoter 2 NKX62 2 
Enhancer 330 PLZF 1  Enhancer 815 P50P50 1  Promoter 2 NKX6-2 2 
Enhancer 330 PMX2A 2  Enhancer 815 P53 1  Promoter 2 NOBOX 1 
Enhancer 330 PMX2B 2  Enhancer 815 P63 1  Promoter 2 NR0B1 1 
Enhancer 330 PO2F1 3  Enhancer 815 PAX 1  Promoter 2 NR1I2 1 
Enhancer 330 PO2F2 2  Enhancer 815 PAX5 3  Promoter 2 NR1I3 2 
Enhancer 330 PO3F1 3  Enhancer 815 PBX 3  Promoter 2 NR2C1 1 
Enhancer 330 PO3F2 3  Enhancer 815 PBX1 5  Promoter 2 NR2E3 1 
Enhancer 330 PO5F1 2  Enhancer 815 PHOX2A 2  Promoter 2 NR2F1 1 
Enhancer 330 POU1F1 7  Enhancer 815 PHOX2B 4  Promoter 2 NR4A1 1 
Enhancer 330 POU2F1 6  Enhancer 815 PIT1 4  Promoter 2 NR4A2 3 
Enhancer 330 POU2F2 11  Enhancer 815 PITX1 4  Promoter 2 NRL 2 
Enhancer 330 POU2F3 10  Enhancer 815 PITX2 4  Promoter 2 NUR77 1 
Enhancer 330 POU3F1 6  Enhancer 815 PITX3 2  Promoter 2 NURR1 1 
Enhancer 330 POU3F2 5  Enhancer 815 PO2F1 3  Promoter 2 OCT 2 
Enhancer 330 POU3F3 8  Enhancer 815 PO3F2 3  Promoter 2 OCT1 13 
Enhancer 330 POU3F4 4  Enhancer 815 PO5F1 1  Promoter 2 OTX 1 
Enhancer 330 POU4F1 2  Enhancer 815 POU1F1 6  Promoter 2 Otx1 2 
Enhancer 330 POU4F2 2  Enhancer 815 POU2F1 6  Promoter 2 OTX2 1 
Enhancer 330 POU4F3 1  Enhancer 815 POU2F2 9  Promoter 2 PAX 1 
Enhancer 330 POU5F1 2  Enhancer 815 POU2F3 7  Promoter 2 PAX4 1 
Enhancer 330 POU5F1P1 6  Enhancer 815 POU3F1 5  Promoter 2 PAX6 1 
Enhancer 330 POU6F1 4  Enhancer 815 POU3F2 5  Promoter 2 PAX8 2 
Enhancer 330 POU6F2 4  Enhancer 815 POU3F3 7  Promoter 2 PBX1 2 
Enhancer 330 PR 2  Enhancer 815 POU3F4 4  Promoter 2 PBX2 1 
Enhancer 330 PROP1 7  Enhancer 815 POU4F1 1  Promoter 2 PDX1 3 
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Enhancer 330 PRRX1 7  Enhancer 815 POU4F3 1  Promoter 2 PIT1 4 
Enhancer 330 PRRX2 6  Enhancer 815 POU5F1 3  Promoter 2 PITX1 3 
Enhancer 330 RAX 5  Enhancer 815 POU5F1P1 5  Promoter 2 PITX2 2 
Enhancer 330 RAXL1 2  Enhancer 815 PROP1 7  Promoter 2 PITX3 2 
Enhancer 330 RFX2 1  Enhancer 815 PRRX1 3  Promoter 2 PKNX1 1 
Enhancer 330 Rhox11 2  Enhancer 815 RHOXF1 2  Promoter 2 PO2F1 2 
Enhancer 330 RORA 1  Enhancer 815 SMAD1 3  Promoter 2 PO2F2 1 
Enhancer 330 RUNX1 1  Enhancer 815 SMAD2 1  Promoter 2 PO3F1 2 
Enhancer 330 RUNX2 5  Enhancer 815 SMAD3 1  Promoter 2 PO3F2 1 
Enhancer 330 SHOX 2  Enhancer 815 SMAD4 1  Promoter 2 POU1F1 4 
Enhancer 330 Shox2 4  Enhancer 815 SMRC1 3  Promoter 2 POU2F1 4 
Enhancer 330 SMAD1 1  Enhancer 815 SOX10 2  Promoter 2 POU2F2 8 
Enhancer 330 SOX10 4  Enhancer 815 SOX17 2  Promoter 2 POU2F3 3 
Enhancer 330 SOX13 1  Enhancer 815 SOX5 1  Promoter 2 POU3F1 4 
Enhancer 330 SOX15 2  Enhancer 815 SP1 1  Promoter 2 POU3F2 5 
Enhancer 330 SOX2 3  Enhancer 815 SRF 1  Promoter 2 POU3F3 5 
Enhancer 330 SOX5 1  Enhancer 815 SRY 4  Promoter 2 POU3F4 4 
Enhancer 330 SOX9 5  Enhancer 815 STA5A 1  Promoter 2 POU4F1 2 
Enhancer 330 SOX91 1  Enhancer 815 STAT1 1  Promoter 2 POU4F3 1 
Enhancer 330 SRF 2  Enhancer 815 STAT3 2  Promoter 2 POU5F1 1 
Enhancer 330 SRY 5  Enhancer 815 STAT4 1  Promoter 2 POU5F1P1 3 
Enhancer 330 STAT1STAT1 1  Enhancer 815 STAT5A 2  Promoter 2 POU6F2 1 
Enhancer 330 
STAT2::STAT
1 1  Enhancer 815 STAT6 2  Promoter 2 PPARA 1 
Enhancer 330 STAT3 1  Enhancer 815 TAL1::GATA1 2  Promoter 2 PPARG 1 
Enhancer 330 STAT4 1  Enhancer 815 TAL1BETAITF2 1  Promoter 2 PROP1 1 
Enhancer 330 STAT5A 1  Enhancer 815 TBP 1  Promoter 2 PRRX1 3 
Enhancer 330 STAT6 2  Enhancer 815 TCF3 1  Promoter 2 PRRX2 2 
Enhancer 330 TAL1 1  Enhancer 815 TEAD1 7  Promoter 2 PXR 1 
Enhancer 330 TATA 2  Enhancer 815 TEAD3 3  Promoter 2 PXRRXR 2 
Enhancer 330 TBP 1  Enhancer 815 TEAD4 4  Promoter 2 RARA 1 
Enhancer 330 TCF11 1  Enhancer 815 TEF 7  Promoter 2 RARG 1 
Enhancer 330 TCF3 2  Enhancer 815 TFE2 1  Promoter 2 RAX 1 
Enhancer 330 Tcf7 1  Enhancer 815 TFIII 3  Promoter 2 RAXL1 1 
Enhancer 330 TCF7L2 1  Enhancer 815 UNCX 2  Promoter 2 RFX1 2 
Enhancer 330 TEAD1 2  Enhancer 815 VBP 1  Promoter 2 RFX2 6 
Enhancer 330 TEAD3 1  Enhancer 815 YBOX1 1  Promoter 2 Rfx3 4 
Enhancer 330 TEAD4 1  Enhancer 815 ZBTB4 2  Promoter 2 RFX4 2 
Enhancer 330 TEF 3  Enhancer 815 ZN589 1  Promoter 2 RFX5 7 
Enhancer 330 TEF1 1  Enhancer 815 ZNF333 1  Promoter 2 Rhox11 1 
Enhancer 330 TGIF1 1  Enhancer 843 AFP1 1  Promoter 2 RHOXF1 3 
Enhancer 330 TITF1 1  Enhancer 843 Alx1 3  Promoter 2 RORA 1 
Enhancer 330 TLX1 1  Enhancer 843 ALX3 1  Promoter 2 RORA1 1 
Enhancer 330 UBIP1 2  Enhancer 843 ALX4 2  Promoter 2 RORBETA 1 
Enhancer 330 UNCX 8  Enhancer 843 AML 1  Promoter 2 RSRFC4 2 
Enhancer 330 VAX1 2  Enhancer 843 AML1 3  Promoter 2 RUSH1A 1 
Enhancer 330 VAX2 4  Enhancer 843 AP1 6  Promoter 2 SHOX 1 
Enhancer 330 VBP 2  Enhancer 843 AR 3  Promoter 2 SHOX2 2 
Enhancer 330 VENTX 1  Enhancer 843 AREB6 3  Promoter 2 SIX1 1 
Enhancer 330 VSX1 6  Enhancer 843 ARI3A 1  Promoter 2 SIX4 2 
Enhancer 330 VSX2 4  Enhancer 843 ATF5 2  Promoter 2 SIX6 3 
Enhancer 330 YY1 1  Enhancer 843 BATF 2  Promoter 2 SMAD 1 
Enhancer 330 ZFHX3 1  Enhancer 843 BCL6 4  Promoter 2 SMAD1 1 
Enhancer 330 ZNF333 2  Enhancer 843 BPTF 1  Promoter 2 
SMAD2::SMAD3::S
MAD4 1 
Enhancer 330 ZNF354C 1  Enhancer 843 CART1 1  Promoter 2 SNAI2 1 
Enhancer 700 AFP1 1  Enhancer 843 CDC5 2  Promoter 2 SOX10 3 
Enhancer 700 AIRE 2  Enhancer 843 CDP 3  Promoter 2 SOX13 1 
Enhancer 700 AP1 10  Enhancer 843 CDX 1  Promoter 2 SOX15 1 
Enhancer 700 AP1FJ 2  Enhancer 843 CDX2 4  Promoter 2 SOX17 1 
Enhancer 700 AP4 1  Enhancer 843 CEBP 7  Promoter 2 SOX18 1 
Enhancer 700 ARI3A 4  Enhancer 843 CEBPA 7  Promoter 2 SOX21 1 
Enhancer 700 ATF5 1  Enhancer 843 CEBPB 5  Promoter 2 SOX4 2 
Enhancer 700 Atoh1 4  Enhancer 843 CEBPD 3  Promoter 2 SOX5 2 
Enhancer 700 BARX2 3  Enhancer 843 CEBPG 3  Promoter 2 SOX9 3 
Enhancer 700 BCL6 8  Enhancer 843 CEBPGAMMA 1  Promoter 2 SOX91 1 
Enhancer 700 BEN 1  Enhancer 843 COT1 1  Promoter 2 SRF 7 
Enhancer 700 BHLHA15 4  Enhancer 843 COT2 2  Promoter 2 SRY 5 
Enhancer 700 BHLHE22 2  Enhancer 843 CPEB1 2  Promoter 2 STAT1STAT1 1 
Enhancer 700 BHLHE23 2  Enhancer 843 CTF1 1  Promoter 2 STAT2 1 
Enhancer 700 BLIMP1 1  Enhancer 843 CUX1 2  Promoter 2 STAT2::STAT1 1 
Enhancer 700 BRN2 1  Enhancer 843 CUX2 1  Promoter 2 STAT4 1 
Enhancer 700 CDX 2  Enhancer 843 DBP 3  Promoter 2 TAL1 3 
Enhancer 700 CDX2 6  Enhancer 843 DELTAEF1 1  Promoter 2 TATA 1 
Enhancer 700 CEBPDELTA 1  Enhancer 843 DLX3 3  Promoter 2 TBP 4 
Enhancer 700 CEBPZ 2  Enhancer 843 DMRT2 1  Promoter 2 TBX20 1 
Enhancer 700 CETS1P54 1  Enhancer 843 DRGX 1  Promoter 2 TBX5 1 
Enhancer 700 COT1 2  Enhancer 843 DRI1 1  Promoter 2 TCF3 2 
Enhancer 700 COT2 2  Enhancer 843 E12 1  Promoter 2 TCF4 2 
Enhancer 700 CP2 1  Enhancer 843 E2F6 2  Promoter 2 TCF7 1 
Enhancer 700 CPEB1 4  Enhancer 843 EFC 1  Promoter 2 TCF7L2 2 
Enhancer 700 CUX1 2  Enhancer 843 EHF 2  Promoter 2 Tcfap2a 2 
Enhancer 700 CUX2 1  Enhancer 843 ELF1 3  Promoter 2 TEAD1 1 
Enhancer 700 DEC 2  Enhancer 843 ELF3 3  Promoter 2 TEAD3 2 
Enhancer 700 DLX2 3  Enhancer 843 ELF4 1  Promoter 2 TEAD4 1 
Enhancer 700 DLX3 3  Enhancer 843 Elf5 3  Promoter 2 TEF 4 
Enhancer 700 DMRT3 1  Enhancer 843 ELK1 5  Promoter 2 TF7L2 2 
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Enhancer 700 DR1 2  Enhancer 843 ELK3 2  Promoter 2 TFAP2A 4 
Enhancer 700 E2F6 1  Enhancer 843 ELK4 1  Promoter 2 TFAP2B 2 
Enhancer 700 EAR2 2  Enhancer 843 ERR1 2  Promoter 2 TFAP2C 4 
Enhancer 700 EGR1 2  Enhancer 843 ERR2 3  Promoter 2 TFE2 1 
Enhancer 700 EGR2 3  Enhancer 843 ERR3 1  Promoter 2 TFIIA 1 
Enhancer 700 EGR3 2  Enhancer 843 ESE1 1  Promoter 2 TGIF1 2 
Enhancer 700 EGR4 1  Enhancer 843 Esrra 4  Promoter 2 TITF1 1 
Enhancer 700 ELF1 4  Enhancer 843 ESRRG 1  Promoter 2 UNCX 3 
Enhancer 700 ELF3 1  Enhancer 843 ETS 2  Promoter 2 VAX1 1 
Enhancer 700 ELK3 1  Enhancer 843 ETS2 2  Promoter 2 VAX2 1 
Enhancer 700 EMX2 2  Enhancer 843 ETV6 1  Promoter 2 VDR 1 
Enhancer 700 EN1 5  Enhancer 843 EVI1 6  Promoter 2 VENTX 1 
Enhancer 700 EOMES 4  Enhancer 843 EVX1 1  Promoter 2 Vsx1 2 
Enhancer 700 ER 1  Enhancer 843 FEV 1  Promoter 2 YY1 1 
Enhancer 700 ESE1 1  Enhancer 843 FLI1 2  Promoter 2 ZBTB7B 1 
Enhancer 700 ESR2 1  Enhancer 843 FOS 1  Promoter 2 ZFHX3 2 
Enhancer 700 ETS1 1  Enhancer 843 FOSB 2  Promoter 2 ZN384 1 
Enhancer 700 EVI1 3  Enhancer 843 FOX 2  Promoter 3 ALX1 1 
Enhancer 700 FEV 3  Enhancer 843 FOXA1 4  Promoter 3 AML1 1 
Enhancer 700 FOXA1 2  Enhancer 843 FOXA2 3  Promoter 3 AP1 5 
Enhancer 700 FOXA3 1  Enhancer 843 FOXA3 3  Promoter 3 AP1FJ 1 
Enhancer 700 FOXB1 6  Enhancer 843 FOXB1 5  Promoter 3 AP3 1 
Enhancer 700 FOXC1 5  Enhancer 843 FOXC1 9  Promoter 3 AR 1 
Enhancer 700 FOXC2 4  Enhancer 843 FOXC2 4  Promoter 3 AREB6 2 
Enhancer 700 FOXD1 2  Enhancer 843 FOXD1 3  Promoter 3 ATF3 2 
Enhancer 700 FOXD2 1  Enhancer 843 FOXD2 4  Promoter 3 Atf4 4 
Enhancer 700 FOXD3 2  Enhancer 843 FOXD3 5  Promoter 3 Barhl1 1 
Enhancer 700 FOXF1 1  Enhancer 843 FOXF1 4  Promoter 3 BARHL2 2 
Enhancer 700 FOXI1 3  Enhancer 843 FOXF2 5  Promoter 3 BARX1 5 
Enhancer 700 FOXJ2 6  Enhancer 843 FOXH1 2  Promoter 3 BARX2 3 
Enhancer 700 FOXJ3 6  Enhancer 843 FOXI1 3  Promoter 3 BATF 1 
Enhancer 700 FOXM1 3  Enhancer 843 FOXJ2 8  Promoter 3 BATF::JUN 1 
Enhancer 700 FOXO1 2  Enhancer 843 Foxj3 8  Promoter 3 BCL6 1 
Enhancer 700 FOXO3A 1  Enhancer 843 FOXL1 4  Promoter 3 BSX 1 
Enhancer 700 FOXP2 1  Enhancer 843 FOXM1 4  Promoter 3 CDP 1 
Enhancer 700 FOXP3 2  Enhancer 843 FOXO1 7  Promoter 3 CDX1 1 
Enhancer 700 FUBP1 1  Enhancer 843 FOXO3 4  Promoter 3 CDX2 2 
Enhancer 700 FXR 1  Enhancer 843 FOXO4 5  Promoter 3 CEBP 4 
Enhancer 700 GATA 2  Enhancer 843 FOXP2 3  Promoter 3 CEBPA 4 
Enhancer 700 GATA1 2  Enhancer 843 FPM315 1  Promoter 3 CEBPB 3 
Enhancer 700 GATA2 2  Enhancer 843 FRA1 3  Promoter 3 CEBPD 2 
Enhancer 700 GATA3 4  Enhancer 843 FREAC2 3  Promoter 3 CEBPDELTA 2 
Enhancer 700 GBX2 5  Enhancer 843 FREAC7 3  Promoter 3 CEBPG 2 
Enhancer 700 GCM1 2  Enhancer 843 FUBP1 2  Promoter 3 COUPTF 1 
Enhancer 700 GFI1B 2  Enhancer 843 GABP1+GABP2 1  Promoter 3 CREM 3 
Enhancer 700 GLI3 4  Enhancer 843 GABPA 2  Promoter 3 DBP 2 
Enhancer 700 HELIOSA 1  Enhancer 843 GABPALPHA 1  Promoter 3 DLX1 2 
Enhancer 700 HFH3 2  Enhancer 843 GADP 1  Promoter 3 DLX2 5 
Enhancer 700 HFH8 1  Enhancer 843 GATA 5  Promoter 3 DLX3 2 
Enhancer 700 Hic1 3  Enhancer 843 GATA1 2  Promoter 3 DLX4 1 
Enhancer 700 HMGA1 3  Enhancer 843 GATA3 7  Promoter 3 DLX5 3 
Enhancer 700 HMX3 2  Enhancer 843 GATA4 4  Promoter 3 DLX6 1 
Enhancer 700 HNF1 5  Enhancer 843 GATA5 4  Promoter 3 DLX7 1 
Enhancer 700 HNF1A 4  Enhancer 843 GATA6 5  Promoter 3 ELF3 1 
Enhancer 700 HNF1B 7  Enhancer 843 GCM 1  Promoter 3 EMX2 1 
Enhancer 700 HNF3 3  Enhancer 843 GFI1 5  Promoter 3 EN1 5 
Enhancer 700 HNF3ALPHA 2  Enhancer 843 GFI1B 5  Promoter 3 EOMES 1 
Enhancer 700 HNF3B 2  Enhancer 843 GRHL1 4  Promoter 3 ERR2 1 
Enhancer 700 HNF4 2  Enhancer 843 HEB 1  Promoter 3 ETS2 1 
Enhancer 700 HOXA10 2  Enhancer 843 HELIOSA 2  Promoter 3 EVI1 2 
Enhancer 700 Hoxa11 2  Enhancer 843 HESX1 2  Promoter 3 FOSB 1 
Enhancer 700 HOXA13 13  Enhancer 843 HFH3 3  Promoter 3 FOSL1 1 
Enhancer 700 HOXB13 3  Enhancer 843 HFH4 1  Promoter 3 FOSL2 2 
Enhancer 700 HOXC10 5  Enhancer 843 HFH8 3  Promoter 3 FOX 1 
Enhancer 700 HOXC11 3  Enhancer 843 Hic1 2  Promoter 3 FOXA1 6 
Enhancer 700 HOXC12 3  Enhancer 843 HIC2 1  Promoter 3 FOXA2 4 
Enhancer 700 HOXC13 7  Enhancer 843 HMGA1 1  Promoter 3 FOXA3 4 
Enhancer 700 HOXD11 1  Enhancer 843 HMGIY 6  Promoter 3 FOXB1 4 
Enhancer 700 HOXD12 5  Enhancer 843 HMX2 1  Promoter 3 FOXC1 9 
Enhancer 700 Hoxd13 8  Enhancer 843 HNF1 4  Promoter 3 FOXC2 3 
Enhancer 700 Hoxd9 2  Enhancer 843 HNF1B 1  Promoter 3 FOXD1 3 
Enhancer 700 HSF1 6  Enhancer 843 HNF3 5  Promoter 3 FOXD2 2 
Enhancer 700 HSF2 3  Enhancer 843 HNF3A 1  Promoter 3 FOXD3 4 
Enhancer 700 HSF4 1  Enhancer 843 HNF3ALPHA 4  Promoter 3 FOXF1 4 
Enhancer 700 HXD10 2  Enhancer 843 HNF3B 2  Promoter 3 FOXF2 3 
Enhancer 700 HXD9 2  Enhancer 843 HNF4ALPHA 2  Promoter 3 FOXG1 3 
Enhancer 700 ICSBP 1  Enhancer 843 HNF6 1  Promoter 3 FOXH1 1 
Enhancer 700 IPF1 7  Enhancer 843 HOXA10 1  Promoter 3 FOXI1 4 
Enhancer 700 IRF 2  Enhancer 843 HOXA13 3  Promoter 3 FOXJ2 10 
Enhancer 700 IRF1 5  Enhancer 843 HOXB13 1  Promoter 3 Foxj3 12 
Enhancer 700 IRF3 3  Enhancer 843 HOXC13 1  Promoter 3 Foxk1 2 
Enhancer 700 IRF4 2  Enhancer 843 HOXD13 4  Promoter 3 FOXL1 3 
Enhancer 700 IRF5 2  Enhancer 843 HXA7 1  Promoter 3 FOXM1 2 
Enhancer 700 IRF8 3  Enhancer 843 HXA9 3  Promoter 3 FOXO1 11 
Enhancer 700 IRX2 2  Enhancer 843 HXD10 3  Promoter 3 FOXO3 7 
Enhancer 700 Irx3 2  Enhancer 843 HXD13 3  Promoter 3 FOXO4 9 
Enhancer 700 IRX5 1  Enhancer 843 HXD4 2  Promoter 3 FOXP1 1 
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Enhancer 700 JUN 3  Enhancer 843 HXD9 2  Promoter 3 FOXP2 4 
Enhancer 700 JUNB 3  Enhancer 843 ICSBP 1  Promoter 3 FOXP3 6 
Enhancer 700 JUND(var.2) 1  Enhancer 843 IK 1  Promoter 3 FOXQ1 1 
Enhancer 700 KLF3 2  Enhancer 843 IKZF1 1  Promoter 3 FRA1 1 
Enhancer 700 KLF8 2  Enhancer 843 IPF1 5  Promoter 3 FREAC2 3 
Enhancer 700 LHX3 2  Enhancer 843 IRF 2  Promoter 3 FREAC4 2 
Enhancer 700 LHX6 2  Enhancer 843 IRF1 2  Promoter 3 FREAC7 2 
Enhancer 700 Mafb 1  Enhancer 843 IRF7 1  Promoter 3 FUBP1 2 
Enhancer 700 MAFK 3  Enhancer 843 IRF8 3  Promoter 3 GATA 2 
Enhancer 700 MAX 2  Enhancer 843 ISRE 1  Promoter 3 GATA2 2 
Enhancer 700 MEF2A 5  Enhancer 843 JUN(var.2) 2  Promoter 3 GATA3 3 
Enhancer 700 MEF2C 3  Enhancer 843 JUNB 4  Promoter 3 GATA4 2 
Enhancer 700 MEIS1 4  Enhancer 843 JUND 3  Promoter 3 GATA5 2 
Enhancer 700 Meis2 1  Enhancer 843 KAISO 1  Promoter 3 GATA6 2 
Enhancer 700 Meis3 2  Enhancer 843 KLF1 1  Promoter 3 GBX2 1 
Enhancer 700 MGA 2  Enhancer 843 KLF8 1  Promoter 3 GFI1 3 
Enhancer 700 MRF2 1  Enhancer 843 LEF1 7  Promoter 3 GFI1B 3 
Enhancer 700 MYBB 2  Enhancer 843 LHX61 1  Promoter 3 GMEB2 1 
Enhancer 700 NANOG 2  Enhancer 843 LYF1 1  Promoter 3 HBP1 2 
Enhancer 700 NCX 4  Enhancer 843 MAX 1  Promoter 3 HESX1 1 
Enhancer 700 NDF1 1  Enhancer 843 MAZ 1  Promoter 3 HFH3 3 
Enhancer 700 NEUROD2 2  Enhancer 843 MEF2 1  Promoter 3 HFH8 3 
Enhancer 700 NEUROG2 4  Enhancer 843 MEF2A 2  Promoter 3 HLF 1 
Enhancer 700 NF1 1  Enhancer 843 MEF2D 1  Promoter 3 HMGIY 3 
Enhancer 700 NFAC1 4  Enhancer 843 MEIS1 8  Promoter 3 HNF1 2 
Enhancer 700 NFAT 1  Enhancer 843 MEIS1AHOXA9 1  Promoter 3 HNF3 4 
Enhancer 700 NFAT2 2  Enhancer 843 MEIS2 6  Promoter 3 HNF3ALPHA 4 
Enhancer 700 
NFIA+NFIB+N
FIC+NFIX 1  Enhancer 843 Meis3 7  Promoter 3 HNF3B 2 
Enhancer 700 NGFIC 1  Enhancer 843 MITF 1  Promoter 3 HNF4ALPHA 1 
Enhancer 700 NKX21 1  Enhancer 843 MSX1 4  Promoter 3 HOX13 2 
Enhancer 700 NKX2-3 4  Enhancer 843 Msx3 2  Promoter 3 HOXA1 2 
Enhancer 700 NKX25 4  Enhancer 843 MYB 2  Promoter 3 HOXA13 2 
Enhancer 700 NKX28 1  Enhancer 843 MYBB 2  Promoter 3 HOXA2 1 
Enhancer 700 NKX2-8 4  Enhancer 843 NCX 1  Promoter 3 HOXA5 1 
Enhancer 700 NKX31 3  Enhancer 843 NEUROD2 1  Promoter 3 HOXA6 2 
Enhancer 700 NKX3-1 4  Enhancer 843 NF1 3  Promoter 3 HOXB5 1 
Enhancer 700 NKX32 5  Enhancer 843 NFAC2 1  Promoter 3 HOXB6 1 
Enhancer 700 NKX3-2 2  Enhancer 843 NFAC4 1  Promoter 3 HOXC10 1 
Enhancer 700 NKX3A 4  Enhancer 843 NFAT1 1  Promoter 3 HOXC8 2 
Enhancer 700 NKX61 3  Enhancer 843 NFAT2 1  Promoter 3 HOXD13 1 
Enhancer 700 NR2F1 2  Enhancer 843 NFAT3 1  Promoter 3 Hoxd9 1 
Enhancer 700 NR4A2 2  Enhancer 843 NFATC2 1  Promoter 3 HXA1 1 
Enhancer 700 NR4A3 1  Enhancer 843 NFE2 1  Promoter 3 HXA10 2 
Enhancer 700 NRF2 1  Enhancer 843 NFIA 3  Promoter 3 HXA9 2 
Enhancer 700 OCT 5  Enhancer 843 
NFIA+NFIB+NFI
C+NFIX 3  Promoter 3 HXD10 2 
Enhancer 700 OCT1 17  Enhancer 843 NFIB 1  Promoter 3 HXD13 1 
Enhancer 700 OCT2 2  Enhancer 843 NFIX 6  Promoter 3 HXD4 1 
Enhancer 700 OLIG1 2  Enhancer 843 NKX22 1  Promoter 3 HXD9 1 
Enhancer 700 OLIG2 8  Enhancer 843 NKX2-3 2  Promoter 3 IPF1 3 
Enhancer 700 OLIG3 4  Enhancer 843 NKX25 1  Promoter 3 IRF 1 
Enhancer 700 P53 3  Enhancer 843 NKX31 2  Promoter 3 IRF1 2 
Enhancer 700 P63 1  Enhancer 843 NKX3-1 4  Promoter 3 IRX2 1 
Enhancer 700 P73 2  Enhancer 843 NKX3-2 1  Promoter 3 IRX5 1 
Enhancer 700 PARP 1  Enhancer 843 NKX3A 2  Promoter 3 JUN 1 
Enhancer 700 PAX2 1  Enhancer 843 NR0B1 1  Promoter 3 JUN(var.2) 1 
Enhancer 700 PAX7 1  Enhancer 843 NR2F1 2  Promoter 3 JUN::FOS 2 
Enhancer 700 PIT1 3  Enhancer 843 NR2F6 2  Promoter 3 JUNB 2 
Enhancer 700 PLZF 1  Enhancer 843 NR4A1 1  Promoter 3 JUND 2 
Enhancer 700 PO2F1 4  Enhancer 843 NR4A2 3  Promoter 3 LEF1 3 
Enhancer 700 PO2F2 2  Enhancer 843 NUR77 1  Promoter 3 LEF1TCF1 1 
Enhancer 700 PO3F1 2  Enhancer 843 OCT 4  Promoter 3 LFA1 1 
Enhancer 700 PO3F2 2  Enhancer 843 OCT1 16  Promoter 3 LHX2 2 
Enhancer 700 PO6F1 1  Enhancer 843 OCT2 2  Promoter 3 LMX1B 1 
Enhancer 700 POU1F1 4  Enhancer 843 OCTAMER 3  Promoter 3 MAFK 1 
Enhancer 700 POU2F1 7  Enhancer 843 ONEC2 1  Promoter 3 MEIS1 6 
Enhancer 700 POU2F2 9  Enhancer 843 OTX 2  Promoter 3 Meis2 2 
Enhancer 700 POU2F3 9  Enhancer 843 OTX2 2  Promoter 3 MEIS3 4 
Enhancer 700 POU3F1 7  Enhancer 843 PAX4 4  Promoter 3 MEOX2 2 
Enhancer 700 POU3F2 5  Enhancer 843 PAX5 1  Promoter 3 MGA 2 
Enhancer 700 POU3F3 9  Enhancer 843 PAX6 2  Promoter 3 MOX1 2 
Enhancer 700 POU3F4 3  Enhancer 843 PAX7 1  Promoter 3 MSX1 3 
Enhancer 700 POU4F1 2  Enhancer 843 PAX8 2  Promoter 3 MSX2 2 
Enhancer 700 POU4F2 1  Enhancer 843 PBX 2  Promoter 3 Msx3 1 
Enhancer 700 POU4F3 2  Enhancer 843 PBX1 6  Promoter 3 MYB 1 
Enhancer 700 POU5F1 4  Enhancer 843 PBX2 3  Promoter 3 MYBB 1 
Enhancer 700 POU5F1P1 4  Enhancer 843 PBX3 1  Promoter 3 MYBL1 1 
Enhancer 700 POU6F2 4  Enhancer 843 PEA3 1  Promoter 3 NANOG 2 
Enhancer 700 PPAR 2  Enhancer 843 PEBB 2  Promoter 3 NF2L1 1 
Enhancer 700 PPARA 3  Enhancer 843 PEBP 1  Promoter 3 NFIA 2 
Enhancer 700 PPARD 2  Enhancer 843 PHOX2A 1  Promoter 3 
NFIA+NFIB+NFIC+
NFIX 2 
Enhancer 700 PPARG 1  Enhancer 843 PHOX2B 3  Promoter 3 NFIX 4 
Enhancer 700 PRDM1 2  Enhancer 843 PIT1 6  Promoter 3 NKX31 1 
Enhancer 700 PRRX1 2  Enhancer 843 PITX2 2  Promoter 3 NKX3-1 1 
Enhancer 700 PU1 2  Enhancer 843 PITX3 1  Promoter 3 NKX3A 1 
Enhancer 700 RARA 1  Enhancer 843 PO2F1 3  Promoter 3 NKX61 1 
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Enhancer 700 RARG 1  Enhancer 843 PO2F2 2  Promoter 3 Nkx6-1 1 
Enhancer 700 RBPJK 2  Enhancer 843 PO3F1 2  Promoter 3 NKX62 1 
Enhancer 700 RFX 2  Enhancer 843 PO3F2 3  Promoter 3 NKX6-2 1 
Enhancer 700 RFX1 2  Enhancer 843 POU1F1 7  Promoter 3 NOBOX 1 
Enhancer 700 RORA 5  Enhancer 843 POU2F1 6  Promoter 3 NR1I2 1 
Enhancer 700 RORA1 2  Enhancer 843 POU2F2 12  Promoter 3 NR1I3 1 
Enhancer 700 RREB1 1  Enhancer 843 POU2F3 8  Promoter 3 OCT 1 
Enhancer 700 RSRFC4 1  Enhancer 843 POU3F1 6  Promoter 3 OCT1 7 
Enhancer 700 RUSH1A 1  Enhancer 843 POU3F2 4  Promoter 3 OCTAMER 2 
Enhancer 700 RXRB 3  Enhancer 843 POU3F3 9  Promoter 3 OTX 1 
Enhancer 700 SMAD 1  Enhancer 843 POU3F4 3  Promoter 3 OTX1 1 
Enhancer 700 SMAD1 2  Enhancer 843 POU5F1 4  Promoter 3 P50RELAP65 1 
Enhancer 700 SMAD3 2  Enhancer 843 POU5F1P1 6  Promoter 3 P53 2 
Enhancer 700 SNAI1 1  Enhancer 843 PPARA 2  Promoter 3 P63 1 
Enhancer 700 SOX 2  Enhancer 843 PR 1  Promoter 3 PAX2 3 
Enhancer 700 SOX10 7  Enhancer 843 PROP1 2  Promoter 3 PAX4 4 
Enhancer 700 SOX15 3  Enhancer 843 PRRX1 2  Promoter 3 PAX6 1 
Enhancer 700 SOX18 1  Enhancer 843 PTF1A 1  Promoter 3 PBX1 2 
Enhancer 700 SOX2 2  Enhancer 843 PU1 1  Promoter 3 PBX2 1 
Enhancer 700 SOX21 3  Enhancer 843 Rarb 1  Promoter 3 PEBB 1 
Enhancer 700 SOX4 2  Enhancer 843 RARG 2  Promoter 3 PHOX2B 1 
Enhancer 700 SOX5 7  Enhancer 843 RBPJK 3  Promoter 3 PIT1 3 
Enhancer 700 SOX9 6  Enhancer 843 RORA1 1  Promoter 3 PKNX1 1 
Enhancer 700 SOX91 2  Enhancer 843 RUNX1 2  Promoter 3 PO2F1 1 
Enhancer 700 SRBP2 1  Enhancer 843 RUNX2 2  Promoter 3 PO2F2 1 
Enhancer 700 SREBF2 1  Enhancer 843 RUNX3 1  Promoter 3 PO3F1 1 
Enhancer 700 SREBP 1  Enhancer 843 RUSH1A 1  Promoter 3 PO3F2 1 
Enhancer 700 SRF 3  Enhancer 843 SF1 2  Promoter 3 PO5F1 1 
Enhancer 700 SRY 11  Enhancer 843 SIX1 1  Promoter 3 POU1F1 4 
Enhancer 700 T3R 2  Enhancer 843 SIX4 1  Promoter 3 POU2F1 2 
Enhancer 700 TAL1 1  Enhancer 843 SMAD1 3  Promoter 3 POU2F2 5 
Enhancer 700 TBP 4  Enhancer 843 SMRC1 1  Promoter 3 POU2F3 2 
Enhancer 700 TBR1 1  Enhancer 843 SOX 1  Promoter 3 POU3F1 3 
Enhancer 700 TBX1 2  Enhancer 843 SOX10 4  Promoter 3 POU3F2 2 
Enhancer 700 TBX2 2  Enhancer 843 SOX15 2  Promoter 3 POU3F3 4 
Enhancer 700 TBX20 3  Enhancer 843 SOX17 1  Promoter 3 POU3F4 1 
Enhancer 700 TBX21 2  Enhancer 843 SOX18 1  Promoter 3 POU4F1 1 
Enhancer 700 TBX3 1  Enhancer 843 SOX2 1  Promoter 3 POU4F2 1 
Enhancer 700 TBX4 4  Enhancer 843 SOX4 1  Promoter 3 POU4F3 1 
Enhancer 700 TBX5 4  Enhancer 843 SOX9 3  Promoter 3 POU5F1 2 
Enhancer 700 TCF11 2  Enhancer 843 Spic 1  Promoter 3 POU5F1P1 2 
Enhancer 700 TCF11MAFG 1  Enhancer 843 SRY 7  Promoter 3 PRRX2 1 
Enhancer 700 TCF7L1 1  Enhancer 843 STAT 2  Promoter 3 PXRRXR 1 
Enhancer 700 Tcfap2a 1  Enhancer 843 STAT1STAT1 1  Promoter 3 RUNX1 1 
Enhancer 700 TEAD1 5  Enhancer 843 STAT2 1  Promoter 3 SMAD1 2 
Enhancer 700 TERALPHA 1  Enhancer 843 STAT3 5  Promoter 3 SMAD3 1 
Enhancer 700 TFAP2A 2  Enhancer 843 STAT5A 3  Promoter 3 SMAD4 1 
Enhancer 700 TFAP2B 1  Enhancer 843 SUH 1  Promoter 3 SOX10 3 
Enhancer 700 TFAP2C 2  Enhancer 843 TAL1 2  Promoter 3 SOX15 2 
Enhancer 700 TFE 2  Enhancer 843 TAL1::GATA1 1  Promoter 3 SOX9 2 
Enhancer 700 TFIII 1  Enhancer 843 TATA 1  Promoter 3 SPZ1 1 
Enhancer 700 TGIF1 2  Enhancer 843 TBX5 5  Promoter 3 SREBP1 1 
Enhancer 700 THA 3  Enhancer 843 TCF4 3  Promoter 3 SRY 4 
Enhancer 700 TP63 1  Enhancer 843 Tcf7 2  Promoter 3 STA5A 1 
Enhancer 700 Tp73 2  Enhancer 843 TCF7L2 4  Promoter 3 STA5B 2 
Enhancer 700 TWST1 3  Enhancer 843 TEAD4 1  Promoter 3 STAT 1 
Enhancer 700 UBIP1 2  Enhancer 843 TEF 3  Promoter 3 STAT1 7 
Enhancer 700 VAX1 2  Enhancer 843 TEF1 1  Promoter 3 STAT3 5 
Enhancer 700 VAX2 1  Enhancer 843 TF7L2 3  Promoter 3 STAT4 1 
Enhancer 700 VSX2 2  Enhancer 843 TFAP2A 1  Promoter 3 STAT5A 2 
Enhancer 700 ZABC1 3  Enhancer 843 TFAP2C 1  Promoter 3 STAT5B 2 
Enhancer 700 ZBTB49 1  Enhancer 843 TFE 1  Promoter 3 TAL1 4 
Enhancer 700 ZBTB6 1  Enhancer 843 TFEB 1  Promoter 3 TAL1::TCF3 3 
Enhancer 700 ZFHX3 2  Enhancer 843 TFIII 2  Promoter 3 TAL1ALPHAE47 1 
Enhancer 700 ZN333 1  Enhancer 843 TGIF1 4  Promoter 3 TBP 3 
Enhancer 700 ZN384 1  Enhancer 843 TLX1::NFIC 1  Promoter 3 TBR1 2 
Enhancer 700 ZNF263 1  Enhancer 843 TR4 1  Promoter 3 TBX1 2 
Enhancer 700 ZSCAN4 1  Enhancer 843 TWST1 1  Promoter 3 TBX15 2 
    Enhancer 843 USF 2  Promoter 3 TBX2 1 
    Enhancer 843 USF1 2  Promoter 3 TBX20 2 
    Enhancer 843 USF2 1  Promoter 3 TBX21 2 
    Enhancer 843 VSX2 1  Promoter 3 TBX4 1 
    Enhancer 843 YY1 2  Promoter 3 TBX5 6 
    Enhancer 843 ZNF263 2  Promoter 3 TCF3 1 
    Enhancer 843 ZNF524 2  Promoter 3 TCF4 3 
        Promoter 3 Tcf7 2 
        Promoter 3 TCF7L2 3 
        Promoter 3 TEF 2 
        Promoter 3 TF7L2 3 
        Promoter 3 TFE2 2 
        Promoter 3 TFE3 1 
        Promoter 3 TGIF 3 
        Promoter 3 TGIF1 2 
        Promoter 3 TP53 1 
        Promoter 3 TP63 2 
        Promoter 3 UBIP1 1 
        Promoter 3 UNCX 1 
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        Promoter 3 WHN 2 
        Promoter 3 ZN384 1 
        Promoter 3 ZNF333 1 
        Promoter 3 ZNF75A 1 
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Table S3: Predicted Transcription factors expressed in the brain 
Gene Gene Name 
ALX1 ALX homeobox 1 
ALX3 ALX homeobox 3 
ALX4 ALX homeobox 4 
BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 
CEBPE CCAAT/enhancer binding protein (C/EBP), epsilon 
CTCF CCCTC-binding factor (zinc finger protein) 
CDC5L CDC5 cell division cycle 5-like (S. pombe) 
DBP D site of albumin promoter (albumin D-box) binding protein 
E2F1 E2F transcription factor 1 
ELK1 ELK1, member of ETS oncogene family 
ELK3 ELK3, ETS-domain protein (SRF accessory protein 2) 
ESX1 ESX homeobox 1 
ERF Ets2 repressor factor 
FOSB FBJ murine osteosarcoma viral oncogene homolog B 
FEV FEV (ETS oncogene family) 
GABPA GA binding protein transcription factor, alpha subunit 60kDa 
GATA2 GATA binding protein 2 
GLI2 GLI family zinc finger 2 
GSX2 GS homeobox 2 
HBP1 HMG-box transcription factor 1 
Klf12 Kruppel-like factor 12 
KLF5 Kruppel-like factor 5 (intestinal) 
KLF8 Kruppel-like factor 8 
LHX2 LIM homeobox 2 
MGA MAX gene associated 
MAX MYC associated factor X 
MAZ MYC-associated zinc finger protein (purine-binding transcription factor) 
Meis2 Meis homeobox 2 
Meis3 Meis homeobox 3; Meis homeobox 3 pseudogene 2 
MIXL1 Mix1 homeobox-like 1 (Xenopus laevis) 
NKX2-8 NK2 homeobox 8 
POU2F3 POU class 2 homeobox 3 
POU3F2 POU class 3 homeobox 2 
POU3F3 POU class 3 homeobox 3 
POU3F4 POU class 3 homeobox 4 
POU6F1 POU class 6 homeobox 1 
SMAD3 SMAD family member 3 
SOX15 SRY (sex determining region Y)-box 15 
SOX18 SRY (sex determining region Y)-box 18 
SOX5 SRY (sex determining region Y)-box 5 
SP1 Sp1 transcription factor 
SP2 Sp2 transcription factor 
SP3 Sp3 transcription factor 
SP4 Sp4 transcription factor 
TBX2 T-box 2 
TBX3 T-box 3 
TBR1 T-box, brain, 1 
TGIF1 TGFB-induced factor homeobox 1 
THAP1 THAP domain containing, apoptosis associated protein 1 
WT1 Wilms tumor 1 
YY1 YY1 transcription factor 
ATF3 activating transcription factor 3 
ATF5 activating transcription factor 5 
AR androgen receptor 
ARNT2 aryl-hydrocarbon receptor nuclear translocator 2 
CREB3 cAMP responsive element binding protein 3 
CREM cAMP responsive element modulator 
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CTF1 cardiotrophin 1 
CPEB1 cytoplasmic polyadenylation element binding protein 1 
DLX1 distal-less homeobox 1 
DLX2 distal-less homeobox 2 
DMRT1 doublesex and mab-3 related transcription factor 1 
EGR3 early growth response 3 
EGR4 early growth response 4 
EMX1 empty spiracles homeobox 1 
EMX2 empty spiracles homeobox 2 
EN2 engrailed homeobox 2 
EOMES eomesodermin homolog (Xenopus laevis) 
ESR1 estrogen receptor 1 
ESRRA estrogen-related receptor alpha 
ESRRG estrogen-related receptor gamma 
ETV1 ets variant 1 
ETV7 ets variant 7 
FUBP1 far upstream element (FUSE) binding protein 1 
FIGLA folliculogenesis specific basic helix-loop-helix 
Foxg1 forkhead box G1 
Foxj3 forkhead box J3 
Foxk1 forkhead box K1 
FOXP2 forkhead box P2 
GBX2 gastrulation brain homeobox 2 
GMEB2 glucocorticoid modulatory element binding protein 2 
GFI1B growth factor independent 1B transcription repressor 
HAND1 heart and neural crest derivatives expressed 1 
HSF1 heat shock transcription factor 1 
HSF2 heat shock transcription factor 2 
HLTF helicase-like transcription factor 
HLF hepatic leukemia factor 
Hoxd3 homeobox D3 
HMBOX1 homeobox containing 1 
HIC2 hypermethylated in cancer 2 
IRF3 interferon regulatory factor 3 
IRF8 interferon regulatory factor 8 
MECP2 methyl CpG binding protein 2 (Rett syndrome) 
MZF1 myeloid zinc finger 1 
MEF2A myocyte enhancer factor 2A 
MEF2D myocyte enhancer factor 2D 
NHLH1 nescient helix loop helix 1 
NF1 neurofibromin 1 
NEUROD2 neurogenic differentiation 2 
NEUROG2 neurogenin 2 
NFIA nuclear factor I/A 
NFIX nuclear factor I/X (CCAAT-binding transcription factor) 
NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive 
NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 
NR2E1 nuclear receptor subfamily 2, group E, member 1 
NR4A2 nuclear receptor subfamily 4, group A, member 2 
NFYC nuclear transcription factor Y, gamma 
OLIG2 oligodendrocyte lineage transcription factor 2 
OLIG1 oligodendrocyte transcription factor 1 
OTX1 orthodenticle homeobox 1 
PAX6 paired box 6 
PHOX2A paired-like homeobox 2a 
PHOX2B paired-like homeobox 2b 
PLAG1 pleiomorphic adenoma gene 1 
PBX1 pre-B-cell leukemia homeobox 1 
PURA purine-rich element binding protein A 
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RREB1 ras responsive element binding protein 1 
RFX4 regulatory factor X, 4 (influences HLA class II expression) 
RARA retinoic acid receptor, alpha 
RXRB retinoid X receptor, beta 
SRF serum response factor (c-fos serum response element-binding transcription factor) 
STAT1 signal transducer and activator of transcription 1, 91kDa 
STAT4 signal transducer and activator of transcription 4 
STAT5A signal transducer and activator of transcription 5A 
STAT5B signal transducer and activator of transcription 5B 
IK similar to CG18005; IK cytokine, down-regulator of HLA II 
SPZ1 spermatogenic leucine zipper 1 
SF1 splicing factor 1 
TEF thyrotrophic embryonic factor 
TFAP4 transcription factor AP-4 (activating enhancer binding protein 4) 
TFEB transcription factor EB 
TFEC transcription factor EC 
TP53 tumor protein p53 
ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 
Mafb v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) 
MAFK v-maf musculoaponeurotic fibrosarcoma oncogene homolog K (avian) 
MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 
VAX1 ventral anterior homeobox 1 
ZEB1 zinc finger E-box binding homeobox 1 
ZBTB4 zinc finger and BTB domain containing 4 
ZNF219 zinc finger protein 219 
ZNF333 zinc finger protein 333 
ZBTB49 zinc finger protein 509 
ZNF524 zinc finger protein 524 
 
  
Appendix 2 
 
225 
 
Table S4: Predicted Transcription factors in the "Neuron differentiation" category 
Gene Gene Name 
BARHL2 BarH-like homeobox 2 
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 
GATA2 GATA binding protein 2 
GLI2 GLI family zinc finger 2 
GLI3 GLI family zinc finger 3 
GSX1 GS homeobox 1 
GSX2 GS homeobox 2 
ISL1 ISL LIM homeobox 1 
ISL2 ISL LIM homeobox 2 
LHX2 LIM homeobox 2 
LHX4 LIM homeobox 4 
LHX5 LIM homeobox 5 
LHX6 LIM homeobox 6 
Lhx8 LIM homeobox 8 
LMX1A LIM homeobox transcription factor 1, alpha 
LMX1B LIM homeobox transcription factor 1, beta 
NKX2-8 NK2 homeobox 8 
NKX6-1 NK6 homeobox 1 
NKX6-2 NK6 homeobox 2 
POU3F2 POU class 3 homeobox 2 
POU3F4 POU class 3 homeobox 4 
POU4F1 POU class 4 homeobox 1 
POU4F2 POU class 4 homeobox 2 
POU4F3 POU class 4 homeobox 3 
RORA RAR-related orphan receptor A 
SMAD4 SMAD family member 4 
SOX2 SRY (sex determining region Y)-box 2 
SOX5 SRY (sex determining region Y)-box 5 
TBR1 T-box, brain, 1 
TLX1 T-cell leukemia homeobox 1 
ARX aristaless related homeobox 
Atoh1 atonal homolog 1 (Drosophila) 
BHLHE22 basic helix-loop-helix family, member e22 
CREB1 cAMP responsive element binding protein 1 
CTF1 cardiotrophin 1 
CUX1 cut-like homeobox 1 
DLX1 distal-less homeobox 1 
DLX2 distal-less homeobox 2 
DLX5 distal-less homeobox 5 
EGR2 early growth response 2 
EMX1 empty spiracles homeobox 1 
EMX2 empty spiracles homeobox 2 
EN1 engrailed homeobox 1 
EN2 engrailed homeobox 2 
ETV4 ets variant 4 
EVX1 even-skipped homeobox 1 
FOXA1 forkhead box A1 
FOXA2 forkhead box A2 
Foxg1 forkhead box G1 
GBX2 gastrulation brain homeobox 2 
GFI1 growth factor independent 1 transcription repressor 
HES1 hairy and enhancer of split 1, (Drosophila) 
HOXA1 homeobox A1 
HOXA2 homeobox A2 
HOXC10 homeobox C10 
HOXC8 homeobox C8 
Hoxd9 homeobox D9 
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ID4 inhibitor of DNA binding 4, dominant negative helix-loop-helix protein 
IRX5 iroquois homeobox 5 
MNX1 motor neuron and pancreas homeobox 1 
NRL neural retina leucine zipper 
NEUROD2 neurogenic differentiation 2 
NEUROG2 neurogenin 2 
NR2E1 nuclear receptor subfamily 2, group E, member 1 
NR2E3 nuclear receptor subfamily 2, group E, member 3 
NR2F6 nuclear receptor subfamily 2, group F, member 6 
NR4A2 nuclear receptor subfamily 4, group A, member 2 
OLIG2 oligodendrocyte lineage transcription factor 2 
OLIG1 oligodendrocyte transcription factor 1 
OTX2 orthodenticle homeobox 2 
PAX2 paired box 2 
PAX3 paired box 3 
PAX6 paired box 6 
PAX7 paired box 7 
PHOX2A paired-like homeobox 2a 
PITX3 paired-like homeodomain 3 
PTF1A pancreas specific transcription factor, 1a 
PBX3 pre-B-cell leukemia homeobox 3 
RUNX3 runt-related transcription factor 3 
SRF serum response factor (c-fos serum response element-binding transcription factor) 
STAT3 signal transducer and activator of transcription 3 (acute-phase response factor) 
Tp73 tumor protein p73 
VAX1 ventral anterior homeobox 1 
VAX2 ventral anterior homeobox 2 
VSX1 visual system homeobox 1 
VSX2 visual system homeobox 2 
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Nederlandse samenvatting 
Mutaties in het FOXP2-gen veroorzaken problemen bij de ontwikkeling van spraak en taal. 
Het gen codeert voor een eiwit uit de transcriptiefactor (TF)-familie, dat met het DNA 
interageert en daardoor honderden andere genen aan en uit kan zetten. De mutaties in 
FOXP2 zorgen ervoor dat het eiwit niet aan het DNA kan binden of niet goed geproduceerd 
kan worden. Onder normale omstandigheden wordt FOXP2 geproduceerd in de longen, het 
hart, de darm en de hersenen. In de hersenen wordt het gen aangezet in bepaalde 
structuren, zoals de hersenenschors, de kleine hersenen en de basale gangliën. De 
taalproblemen bij mensen met FOXP2-mutaties worden vooral veroorzaakt door het 
ontbreken van het normale FOXP2-eiwit in de hersenen. 
De effecten van de mutatie op moleculair en cellulair niveau zijn intensief bestudeerd en zij 
leveren veel kennis op over de rol van het gen in de ontwikkeling van neuronen en de 
formatie van neurale netwerken die de menselijke taalvaardigheden beïnvloeden. In 
hoofdstuk 1 van deze PhD-thesis beschrijf ik hoe de eerste mutaties in FOXP2 ontdekt zijn, 
wat voor aandoeningen mensen met FOXP2-mutaties precies hebben en wat er al is ontdekt 
over de functie van FOXP2 in menselijke en dierlijke hersencellen. Hoewel al veel bekend is 
over de processen die het FOXP2-eiwit reguleert, weten wij vrij weinig over de processen die 
de productie van het FOXP2-gen zelf reguleren. Daarom was het doel van dit PhD-project 
om te onderzoeken hoe het FOXP2-gen wordt aangezet, wat voor processen daar een rol bij 
spelen en wat er gebeurt als de regulatie misgaat. 
Mijn onderzoek uit hoofdstuk 2 is gebaseerd op een eerdere beschrijving van een kind met 
een vertraagde taalontwikkeling. In het genoom van het kind werd aangetoond dat sommige 
delen van  het DNA in volgorde zijn omgedraaid. Eén van de breukpunten, waar delen van 
het genoom zijn omgedraaid, ligt in de buurt van het FOXP2-gen en het gen zelf werd niet 
veranderd. Het idee is dus, dat door de omgedraaide volgorde een regulerend DNA-element 
verplaatst werd en het FOXP2-eiwit niet goed wordt aangemaakt. Ik beschrijf in hoofdstuk 2 
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hoe ik een regulerend element, enhancer genoemd, met behulp van het bovengenoemde 
breukpunt kon identificeren. Bij het bovengenoemde kind is de enhancer verplaatst en zal 
het FOXP2-gen niet kunnen reguleren, met als gevolg dat FOXP2 niet goed wordt 
aangemaakt. 
Enhancers reguleren de productie in bepaalde weefsels en cellen. Genen met een complexe 
expressie, zoals FOXP2, hebben meestal meerdere enhancers. In hoofdstuk 3 was het mijn 
doel om verdere enhancers van het gen op te sporen. Een eigenschap van enhancers is dat 
ze de productie van genen reguleren door contact te maken met het beginpunt van het gen, 
de zogenaamde promoter. Om FOXP2-enhancers op te sporen heb ik  de contacten van de 
FOXP2-promoter met andere delen van het genoom bepaald. Ik verwachtte in cellen die 
FOXP2 produceren contacten te ontdekken die afwezig -of minder sterk- zijn in cellen zonder 
FOXP2-productie. Inderdaad kon ik een aantal van deze contacten detecteren en daardoor 
potentiële enhancers ontdekken. 
De activiteit van enhancers en promoters wordt mede bepaald door TFs – waarvan FOXP2 
er éé is-, die aan specifieke DNA-motieven binden. In hoofdstuk 4 heb ik de activiteit van 
enhancers in menselijke cellen getest en vervolgens bepaald of de activiteit afhankelijk is 
van bepaalde TFs. In totaal heb ik de invloed van 8 TFs bestudeerd op basis van vermoede 
associaties uit de literatuur. Inderdaad zag ik voor 7 TFs dat ze de activiteit van de 
enhancers of promoters verhogen of verlagen. Ik kon bijvoorbeeld zien dat FOXP2 zelf de 
activiteit van zijn promoter en een enhancer verhoogt. Het gen zou dus zijn eigen productie 
positief kunnen beïnvloeden. Deze positieve autoregulatie zou een bijdrage kunnen leveren 
aan het feit dat mutaties in één van de twee FOXP2-kopieën voldoende is om de bekende 
aandoening in taalontwikkeling te veroorzaken. 
Zoals eerder genoemd, zijn enhancers slechts in bepaalde weefsels en cellen actief. Zij 
dragen dus bij aan de productie van het gen in een beperkt aantal cellen. Om te begrijpen 
waar een enhancer door TFs wordt aangestuurd is het dus noodzakelijk om de weefsel-
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specifieke activiteit van de enhancers te onderzoeken. In het vijfde hoofdstuk heb ik twee 
enhancers in transgene muizen bestudeerd. Deze muizen produceren een reportergen onder 
de controle van de ontdekte enhancer. Het reportergen is dan eenvoudig te visualiseren in 
de weefsels en cellen waar de enhancer actief is. Ik zag dat een enhancer actief was in de 
cortex, en juist rond de geboorte activiteit vertoonde in het specifieke weefsel waar ook 
FOXP2 wordt geproduceerd. Deze enhancer zal dus FOXP2 tijdens de ontwikkeling aan 
kunnen sturen. Verdere overeenstemming tussen enhanceractiviteit en FOXP2-productie 
was te zien in de cerebellum. De enhancer stuurt dus de productie van FOXP2 tijdens een 
belangrijke fase van de hersenontwikkeling. Genetische variatie in deze enhancer zou 
kunnen veroorzaken dat FOXP2 in deze weefsels minder goed wordt geproduceerd en zou 
dus problemen in taal en spraak kunnen veroorzaken. Verder onderzoek naar mutaties in 
deze enhancer bij mensen met specifieke taalproblemen zou dus een genetische verklaring 
van deze specifieke aandoeningen kunnen opleveren. 
Voor de zesde hoofdstuk was mijn doel om aan te tonen dat normale genetische 
veranderingen in enhancers de structuur van de hersenen kan beïnvloeden. Normale 
genetische veranderingen zijn variaties van enkele DNA-bouwstenen die bij iedereen 
aanwezig kunnen zijn. Er zijn miljoenen posities in het genoom bekend waar mensen van 
elkaar verschillen. De effecten van enkele variaties zullen dus heel klein zijn. Om toch een 
effect te ontdekken, heb ik zo’n 300 enhancers uit de wetenschappelijke literatuur 
onderzocht, waarvan bekend is dat ze in de hersenen actief zijn. Ik wilde weten of normale 
genetische verandering in één van de enhancers invloed op de hersenenstructuur van 
gezonde mensen heeft. Een vergelijkbare vraag werd eerder onderzocht door een 
wereldwijd consortium, Enhancing Neuro Imaging Genetics by Meta-Analysis genaamd, 
kortweg ENIGMA. Dit consortium heeft de normale genetische variatie en hersenenstructuur 
van 30,000 mensen bestudeerd en voor meer dan 8 miljoen variaties statistisch berekend 
wat de invloed op de structuren in het midden van de hersenen zou kunnen zijn. Bij 8 miljoen 
bekeken variaties is het heel moeilijk om statistisch aan te tonen dat het effect van één 
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variant echt de hersenenstructuur beïnvloedt, of dat de berekende invloed door toeval is 
ontstaan. Omdat ik niet naar het hele genoom keek, maar naar een beperkt aantal  
interessante posities, de 300 enhancers, was het mogelijk om statistische effecten in deze 
enhancers aan te tonen. In hoofdstuk zes laat ik zien dat normale genetische variatie in 
enhancers, die in de hersenen actief zijn, de normale variatie in de hersenstructuur 
beïnvloeden. Verder onderzoek naar genetische variatie in enhancers van FOXP2 zou 
mogelijk effecten op kunnen leveren in de hersendelen waar FOXP2 geproduceerd wordt of 
in de neuronale functies van deze hersengebieden. 
Samenvattend, ik heb de basiselementen van genregulatie op moleculair en cellulair niveau 
onderzocht en de mogelijke effecten van mis-regulatie bestudeerd. Mijn onderzoek was 
speciaal gericht op het FOXP2-gen, dat bekend is als veroorzaker van mogelijke 
ontwikkelingsstoornissen van taal en spraak. De resultaten van mijn project tonen genetische 
elementen aan die de productie van FOXP2 sturen en factoren die de productie verder 
kunnen versterken of verminderen. Bovendien heb ik  voor twee enhancers de activiteit in de 
hersenen zien laten zien. De afwezigheid van deze enhancers zou een 
taalontwikkelingsstoornis kunnen veroorzaken. Normale genetische variatie in deze 
enhancers zou ook een invloed kunnen hebben op de normale variatie in de hersenstructuur. 
Met behulp van mijn resultaten kunnen toekomstige studies onderzoeken hoe de productie 
van het FOXP2-gen de hersenontwikkeling verandert. 
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